patient_filename,text,t,cmem_t_is_parsed,cmem_t_rules_str,cmem_t_memory_str,cmem_t_memory_len,cmem_t_memory_str_len,cmem_t_ans_str,cmem_t_reasoning,cmem_t_edit_distance,cmem_t_is_updated
TCGA-AN-A0AS.0D1ACC76-910E-4243-A229-5F76B5A3299A,JB: Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 2a M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,1,True,"If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.","If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.",4.0,708.0,T2,"The report mentions that the patient underwent a radical mastectomy and the tumor grade is 2. The T stage for breast cancer is determined by the size of the tumor and whether it has invaded the chest wall or skin. In this case, the report does not provide specific information about the size of the tumor. However, the fact that a radical mastectomy was performed suggests that the tumor was significant in size and/or had invaded the chest wall or skin. Therefore, a reasonable prediction for the T stage would be T2, which corresponds to a tumor size of 2-5 cm or tumor of any size with direct extension to the chest wall or skin.",,
TCGA-BH-A1F8.BAA6AA92-69C5-454B-A550-246E7DB1EBE3,"proceuare wave. Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE OF LMP. DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: LEFT BREAST CANCER. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: LEFT MASTECTOMY. CLINICAL HISTORY: MATERIAL SUBMITTED: A) LEFY (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. B) LEFT AXILLA, PROCUREMENT BY SURGICAL PROCEDURE. NODES. FINAL DIAGNOSIS: FINAL DIAGNOSIS: A) LEFT BREAST, MODIFIED RADICAL MASTECTOMY: INFILTRATING DUCTAL CARCINOMA/ 4.0 BY 3.5 BY 3.0 CM. - HISTOLOGIC GRADE, POOR. - NUCLEAR CRADE, MODERATE. - NOTTINGHAM SCORE 7 (TUBULE 3, NUCLEI 2, MITOSIS 2). - TUMOR INVOLVING SUBAREOLAR AND NIPPLE LIMPHATICS. - TUMOR INVOLVING DERMIS AND DERMAL LYMPHATICS OVERLYING TUMOR AND EXTENDING INTO EPIDERMIS. - INTRADUCTAL COMPONENT, COMIDO VARIANT, COMPRISING 10% OF TUMOR. - INKED MARGINS INCLUDING SKIN MARGINS, FREE or TUMOR. (CROSS REFER. B) LEFT AXILLARY CONTENTS: - TWELVE OF THIRTEEN (12/13) LYMPH NODES CONTAINING METASTATIC TUMOR WITH PROMIMENT PERINODAL EXTENSION IN 6. NODES. - TWO (2) ADDITIONAL TUMOR NODULES ARE SEEN AS PERIVASCULAR TUMOR NODULES WITHOUT RECOGNIZABLE NODAL. FEATURES.",3,True,"If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3.
If the report mentions a radical mastectomy and the tumor has invaded the skin, then the T stage is likely to be T3.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.","If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.",4.0,708.0,T3,"The pathology report mentions a modified radical mastectomy, which suggests that the tumor is larger and requires a more extensive surgical removal. The report also mentions that the tumor involves the dermis and dermal lymphatics overlying the tumor and extending into the epidermis. This finding suggests that the tumor has invaded the skin, which is consistent with a T3 stage. The report also provides a specific tumor size of 4.0 x 3.5 x 3.0 cm, which is consistent with a T3 stage according to the AJCC's TNM Staging System.",73.0,False
TCGA-E2-A14R.0B6DCA80-3108-4D25-B095-3EC704598B23,"SPECIMENS: A. SENTINEL NODE #1 LEFT AXILLA. B. SENTINEL NODE #2 LEFT AXILLA. C. SENTINEL NODE #3 LEFT AXILLA. D. WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. E. INFERIOR MARGIN LEFT BREAST. F. LATERAL MARGIN LEFT BREAST. G. MEDIAL MARGIN LEFT BREAST. H. POSTERIOR MARGIN LEFT BREAST. I. SENTINEL NODE #4 LEFT AXILLA. J. SENTINEL NODE #5 LEFT AXILLA. K. SENTINEL NODE #6 LEFT AXILLA. SPECIMEN(S): A. SENTINEL NODE #1 LEFT AXILLA. B. SENTINEL NODE #2 LEFT AXILLA. C. SENTINEL NODE #3 LEFT AXILLA. D. WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. E. INFERIOR MARGIN LEFT BREAST. F. LATERAL MARGIN LEFT BREAST. G. MEDIAL MARGIN LEFT BREAST. H. POSTERIOR MARGIN LEFT BREAST. I. SENTINEL NODE #4 LEFT AXILLA. J. SENTINEL NODE #5 LEFT AXILLA. K. SENTINEL NODE #6 LEFT AXILLA. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA-TPC: One lymph node each part, negative for carcinoma. D: Gross assessment 2.0 cm mass >0.5 cm all margins and 1.0 cm satellite nodule at inferior margin. TPI: One lymph node, negative for carcinoma. TPJ/FSJ: 2 lymph nodes, negative for carcinoma. TPK: One lymph node, negative for carcinoma. By Dr. called to Dr. at 1. (A),. (B),. C), : (D) and. (I, JJK). GROSS DESCRIPTION: A. SENTINEL NODE #1, LEFT AXILLA. Received fresh and labeled with the patient name designated ""A - sentinel node #1, left axilla"", is a fragment of. beige-tan possible lymphoid tissue measuring 2.0 x 2.0 1.2 cm. The specimen is serially sectioned, touch prep. performed. The entire specimen is submitted in cassette A1 and A2. B. SENTINEL NODE #2, LEFT AXILLA. Received fresh and labeled with the patient name designated ""B - sentinel node #2, left axilla"", is a fragment of. beige-tan possible lymphoid tissue measuring 1.0x 1.0 x 1.3 cm. The specimen is serially sectioned, touch. prep. performed. The entire specimen is submitted in cassette B1 and B2. C. SENTINEL NODE #3, LEFT AXILLA. Received fresh and labeled with the patient name designated ""C - sentinel node #3"", is a fragment of beige-tan. possible lymphoid tissue measuring 0.7 x 0.5 x 0.3 cm. The specimen is serially sectioned, touch prep performed. The entire specimen is submitted in cassette C1. D. LEFT BREAST WIDE NEEDLE LOCALIZATION. Received in fresh state the specimen labeled with patients name and identification number and labeled as wide local. excision left breast needle localization. The specimen consists of 293 grams resected breast tissue measuring 12.5. cm from medial to lateral, 7.5 cm from anterior to posterior and 6.0 cm from superior to inferior. The margins of. specimen are oriented with sutures, single indicating anterior, double-lateral and triple-superior. There is a. localization needle coursing from the superior to the inferior aspect of the specimen and the accompanying. radiogram that shows density located in the mid portion of the specimen. The margins of specimen are color coded. as follows: Inferior-orange, superior-red, lateral-yellow, anterior-blue, medial-green and posterior-black. At mid. portion of the specimen is a firm palpable mass which on cut section shows solid firm mass with nodular and. lobulated pushing borders with a tan white cut surface with total dimensions of 4.0 x 3.0 x 0.9 cm. A metallic clip is. identified within the main portion of the tumor and the surrounding breast tissue consists mostly of fatty parenchyma. The tumor grossly 0.9 cm from the nearest inferior margin. Multiple sections are submitted and labeled as follows: D1-D8: One en bloc section of tumor with margins. D9: Cross section of tumor. D10-D18: En bloc section of tumor with margins, (block 15 section taken site of apparent previous biopsy site. wherein a clip was identified). D19: Sections of gross fat necrosis. D20: Sections from posterior and medial margins. D21: Sections from inferior and medial margins. D22-D23: Sections from the posterior margin. D24-D25: Sections from lateral margin. n26-D27: Additional medial margin. E. LEFT BREAST INFERIOR MARGIN. Stitch marks new margin. Received fresh is an oriented 17.0-gram fragment of fibrofatty tissue 6.0 x 5.0 x 2.0 cm. The new true margin is inked blue, the specimen is serially sectioned and submitted in toto in cassette E1-E11. F. LEFT BREAST LATERAL MARGIN. Stitch at new lateral margin. Received fresh is an oriented tan-pink fragment of fibrofatty tissue 5.0 x 2.0 x 1.5 cm. The new true margin is inked blue. Also separate within the container is an unoriented tan-pink fragment of fibrofatty. tissue 5.5 x 4.0 x 2.0 cm. The specimen is inked blue. The entire specimen is submitted as follows: F1-F5: Oriented tissue fragment. F6-F12: Unoriented tissue fragment. G. LEFT BREAST MEDIAL MARGIN. Irregular fragment of fibrofatty tissue measuring 3.5 x 2.0 x 1.0 cm. Submitted in toto in cassettes labeled G1-G2. H. LEFT BREAST POSTERIOR MARGIN. Received fresh is an unoriented 3.0-gram tan-pink fragment of fibrofatty tissue 4.0 x 2.0 x 1.5 cm. The specimen is. inked blue, serially sectioned and submitted in toto in cassette H1 and H2. I. SENTINEL NODE #4, LEFT AXILLA. Received fresh is a tan-pink lymph node 0.8 x 0.7 x 0.7 cm. The specimen is serially sectioned, touch preps are. taken. The specimen is submitted entirely in cassette I1. J. SENTINEL NODE #5, LEFT AXILLA. Received fresh are 2 tan-pink lymph nodes 1.5 x 1.0 x 1.0 cm and 0.8 x 0.5 x 0.5 cm. A portion of the larger lymph. node is submitted for frozen section in FSJ1. Touch preps are taken. The remainder of the lymph node is submitted. as follows: J2-J3: One lymph node. J4: One lymph node. K. SENTINEL NODE #6, LEFT AXILLA. Received fresh is a tan-pink lymph node 0.7 x 0.6 x 0.5 cm. The specimen is bisected. Touch preps are taken and. the specimen is submitted entirely in cassette K1. DIAGNOSIS: A. SENTINEL LYMPH NODE #1, LEFT AXILLA. - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). B. SENTINEL LYMPH NODE #2, LEFT AXILLA. - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). C. SENTINEL LYMPH NODE #3, LEFT AXILLA. - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). D. LEFT BREAST, NEEDLE LOCALIZATION WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA WITH AREAS OF NECROSIS, SBR GRADE III OF. LEFT BREAST. - SIZE OF TUMOR: 4.0 x 3.0 x 0.9 CM. - PREDOMINANTLY FATTY BREAST TISSUE WITH FOCAL AREAS OF COLUMNAR. CELL CHANGE. - POST BIOPSY SITE CHANGES. - MARGINS OF RESECTION-NEGATIVE FOR TUMOR. E. LEFT BREAST, INFERIOR MARGIN: - PREDOMINANTLY FATTY BREAST TISSUE-NEGATIVE FOR TUMOR. F. LEFT BREAST, LATERAL MARGIN: - FATTY BREAST TISSUE-NEGATIVE FOR TUMOR. G. LEFT BREAST, MEDIAL MARGIN: - FATTY TISSUE AND 1 MM FOCUS OF LYMPH NODE-NEGATIVE FOR TUMOR (0/1). H. LEFT BREAST, POSTERIOR MARGIN: - FATTY BREAST TISSUE INCLUDING SKELETAL MUSCLE TISSUE-NEGATIVE FOR TUMOR. I. SENTINEL LYMPH NODE #4, LEFT AXILLA: - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). J. SENTINEL LYMPH NODE, #5 LEFT AXILLA: - TWO LYMPH NODES, NEGATIVE FOR TUMOR (0/2). K. SENTINEL LYMPH NODE #6, LEFT AXILLA: - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). Note: specimen # D- grossly, of what appears clinically as two tumor is only one large tumor with lobulated and. nodulat extensions. the main bulk of the specimen consist mostly of fatty breast tissue,. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: D: WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. Specimen Type: Excision. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 4cm. Additional dimensions: 3cm x 0.9cm. Tumor Site: Central. Margins: Negative. Distance from closest margin: 1.5cm. superior. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: Indeterminate. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0/8. Non-neoplastic areas: Post biopsy site changes. DCIS not present. Pathological staging (pTN): pT 2 N 0. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimens Involved. Specimens: D: WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. Specimen: Surgical Excision. Block Number: D9. ER: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the proportion score. (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of cells staining, 4 = 31-60% of. cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak intensity of staining, 2 = intermediate. intensity of staining, 3 = strong intensity of staining), with a scoring range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of less than. or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR 136, 1:100). provided by Dako. a) following the manufacturer S instructions. This assay was not modified. Interpretation of the ER/PR immunonistochemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. CLINICAL HISTORY: -year-old Caucasian female with palpable left breast mass. Ultrasound showed 2 masses at 12 o'clock position,. largest one 2.0 cm. Core biopsy showed DCIS, here for wide local excision and sentinel node biopsy. PRE-OPERATIVE DIAGNOSIS: None given. ADDENDUM: SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: D9. Interpretation: NEGATIVE. Intensity: 1+. % Tumor Staining: 8%. Fish Ordered: No. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis. was performed using the FDA approved Dako HercepTest (TM) test kit (Dako, Carpenteria, CA) using rabbit anti-. human HER2. This assay was not modified. External kit-slides provided by the manufacturer (cell lines with high,. low and negative HER2 protein expression) and in-house known HER2 amplified control tissue were evaluated along. with the test tissue. Adequate, well preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2 immunohistochemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from ASCO and CAP. and from the NCCN HER2 testing in Breast Cancer Task Force. The Pathology Department takes full responsibility. for this test's performance. Microscopic/Diagnostic Dictation: Pathologist. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: Pathologist. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist.",1,True,"If the report mentions a lumpectomy or wide local excision, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy or wide local excision.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.","If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.",4.0,708.0,T2,"The report mentions a 'wide local excision' of the left breast, which is a surgical procedure to remove a tumor without removing the breast itself. According to the rules provided, this suggests that the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy or wide local excision. The report also provides a specific tumor size of 4.0 x 3.0 x 0.9 cm. According to the AJCC's TNM Staging System, a tumor size of greater than 2 cm but not greater than 5 cm corresponds to T2. Therefore, the predicted T stage is T2.",42.0,False
TCGA-BH-A18K.EEB515A4-4AF3-475B-B6C0-A6134C96480A,"FATIENI MISTURT: DATE of LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: LEFT BREAST CANCER. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: LEFT SEG MAST AND AXILLARY DISSECTION. CLINICAL HISTORY: MATERIAL SUBMITTED: A) LEFT AXILLA, PROCUREMENT BY SURGICAL PROCEDURE. B) LEFT BREAST BIOPSY/MASS/SEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE CONSULTATION: CONSULT: 2) left breast tissue with usual markings; 7.5 by 7.0 by 2.0 cm breast mass with specimen. radiograph. Specimen is received inked and previously sectioned by Dr. There is a medial 1.8 by 1.5. by 1.1 cm firm to hard area which is 0.4 cm from theposterior margin and 0.3cmfrom the anterior. margin;. lateral to this mass is an area of calcification on radiograph. Section thru this area shows ill defined. fibrous tissue, approximately 1.2 by 1.0 by 0.8 cm with white punctate tissue, < 0.1 cm. ADDENDA: Addendum. MACROSCOPIC DESCRIPTION: BLOCKS B3 AND B8 SUBMITTED FOR ER/PR AND HER-2/NEU. FINAL DIAGNOSIS: My signature is attestation that I have personally reviewed the submitted material(s) and the final. diagnosis reflects that `evaluation. ER/PR. IMMUNOPEROXIDASE IDENTTIFICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON BLOCKS B3 AND B8. DISTINCT INTRANUCLEAR STAINING IS IDENTIFIED FOR ESTROGEN RECEPTOR (90%) AND FOR PROGESTERONE RECEPTOR. (60%) THEREFORE, BOTH ARE INTERPRETED AS POSITIVE. HER-2/NEU. c-erbB2 (HER-2/NEU) IMMUNOSTAINING IS CARRIED OUT ON BLOCKS B3 AND 88 (BREAST CANCER) USING A 1:300 DILUTION. OF DAKO'S POLYCLONAL ANTIBODY A485 (DIRECTED AGAINST THE INTRACELLULAR DOMAIN or c-erbB2) WITHOUT ANTIGEN. RETRIEVAL. DISTINCT COMPLETE MEMBRANE STAINING IS IDENTIFIED ONLY RARELY IN 5% OF TUMOR CELLS. THEREFORE, c-. erbB2 (HER-2/NEU) IS INTERPRETED AS NEGATIVE (SCORE 1+). FINAL DIAGNOSIS: FINAL DIAGNOSIS: PREVIOUS REPORTS. A) LEET AXILLARY CONTENTS: - ELEVEN (11) LYMPH NODES, NEGATIVE FOR METASTATIC CARCINOMA. B) LEFT BREAST, SEGMENTAL MASTECTOMY: INFILTRATING MULTIFOCAL, POORLY DIFFERENTIATED. DUCT CARCINONA, 1.8 CM AND 1.2 CM (CR. 300-312,. SEE. NOTE). - NOTTINGHAM SCORE FOR BOTH TUMORS - 8/9 (TUBULES - 3, NUCLEAR ATYPIA - 3, MITOTIC INDEX. - DUCTAL CARCINOMA IN SITU, COMEDO AND NON-COMEDO TYPE, COMPRISES <5% OF EACH TUMOR. - MARGINS OF RESECTION ARE FREE OF INFILTRATING TUMOR; HOWEVER, DUCTAL CARCINOMA IN SITU EXTENDS TO INVOLVE. INKED ANTERIOR MARGIN AND INFILTRATING TUMOR EXTENDS TO WITHIN 0.3 CM OF THE ANTERIOR MARGIN. - LYMPHOVASCULAR PERMEATION IS IDENTIFIED. - TUMOR AND NON-TUMOR ASSOCIATED MICROCALCITICATIONS. - CHANGES CONSISTENT WITH PREVIOUS BIOPSY. - FIBROCYSTIC CHANGES. NOTE: Both tumor nodules have similar architectural and cytologic features NOTE: ER/PR immunoparoxidase. assay and Her-2/NEU testing will be performed on both tumors (blocks 93 and B8).",0,True,"If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.","If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.",4.0,708.0,T2,"The report mentions a 'segmental mastectomy' of the left breast, which involves removing part of the breast tissue. This suggests that the tumor is larger and requires a more extensive procedure than a lumpectomy. The report also provides a specific tumor size of 1.8 cm, which falls within the T2 stage range (2.0-5.0 cm) according to the AJCC's TNM Staging System.",76.0,False
TCGA-A8-A08I.F2077079-D683-4D18-94B9-84C760674AF6,"Diagnosis: 1. Poorly differentiated invasive ductal breast carcinoma with small areas of necrosis. and secondary inflammation (tumor diameter 3 cm, margin distances: cranial 0.6 cm,. caudal 0.4 cm, ventral 0.2 cm, dorsal 0.1 cm, medial 0.4 cm and lateral 0.8 cm). This results in the following summary tumor classification: invasive ductal breast. carcinoma, NOS, G III, pT2 NO(O/3sn)LOVORO.",1,True,"If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.
If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.","If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.",4.0,708.0,T2,"The report provides a specific tumor size of 3 cm, which falls within the T2 category of the AJCC's TNM Staging System for invasive ductal breast carcinoma. The mention of a lumpectomy is not necessary to determine the T stage in this case, as the tumor size is sufficient for staging.",20.0,False
TCGA-AN-A0FK.5F5FF3CA-2DBB-4DE1-9190-1FE36E2B5ACB,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Right breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 4 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,3,True,"If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.","If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.",4.0,708.0,T4,"The report mentions that the patient underwent a mastectomy ('Type of Procurement: surgery') and does not specify a radical mastectomy. According to the rules, this suggests a T2 or T3 stage. However, the report also indicates a T Stage of 4 ('T Stage: 4'). Although the specific details of the T4 stage are not provided, the fact that the report explicitly states a T Stage of 4 overrides the previous rule, leading to a T4 stage prediction.",76.0,False
TCGA-AR-A0TW.F832C787-3668-475F-8F67-6342DA3777F4,"Breast, right, modified radical mastectomy: Multifocal ductal carcinoma of the breast. The largest tumor. is a Nottingham grade III (of III) ductal adenocarcinoma (5.5 cm in greatest dimension). There are. multiple (3) additional tumors (all Nottingham grade II (of III) 2.0 cm 1.5 cm, and 1.0 cm in greatest. dimension. The surgical margins are negative. Metastatic adenocarcinoma is identified in multiple (3 of. 27) right axillary lymph nodes. The largest node of metastasis measures 3.5 cm in greatest dimension. No definite extracapsular extension is identified. Breast, left, simple mastectomy: Nonproliferative fibrocystic changes characterized by dense fibrosis,. cyst formation, and fibroadenomatous change. Nipples, left and right, excision: Negative for malignancy.",2,True,"If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3.
If the report mentions a radical mastectomy and the largest tumor size is greater than or equal to 5 cm, then the T stage is likely to be T3.
If the report provides a specific tumor size and it is greater than or equal to 5 cm, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.","If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.",4.0,708.0,T3,"The report mentions a modified radical mastectomy, which suggests that the tumor is larger and has invaded the lymph nodes. The largest tumor is 5.5 cm in greatest dimension, which falls under the T3 stage in the AJCC's TNM Staging System. The report also mentions metastatic adenocarcinoma in multiple right axillary lymph nodes, which supports the T3 stage.",69.0,False
TCGA-AC-A3W6.B52E150F-5B34-482A-84E7-1739B9AC09B7,"Sex: I. MRN #: SPECIMEN INE. DIAGNOSIS. DIAGNOSIS: Right modified radical mastectomy with sentinel node mapping: Invasive lobular carcinoma. Lobular carcinoma was previously confirmed by negative e cadherin expression. Size: 5.3 cm. Architectural score: 3 of 3. Nuclear score: 2 of 3. Mitotic score: 1 of 3. Total score: 6 of 9 = grade 2. Carcinoma involves sections of the nipple but does not involve the overlying epidermis and is not seen in dermal lymphatics. Prognostic panel was performed on the previous biopsy and will not be repeated unless requested. Carcinoma does not involve inked deep margin of excision. Right sentinel lymph nodes: Three lymph nodes, metastatic carcinoma in three of three nodes. Size of involvement within the node: 1 cm. Extracapsular extension of carcinoma present. Confirmed by staining with pancytokeratin. TNM: T3N1MX. CLINICAL INFORMATION. CLINICAL HISTORY: Preoperative Diagnosis: Right modified radical mastectomy with sentinel node mapping with frozen section. Invasive mammary carcinoma, ER positive,. PR positive. Postoperative Diagnosis: Symptors/Radiologic Findings: SPECIMENS: Right breast, tie marks sentinel node. SPECIMEN DATA. GROSS DESCRIPTION: The specimen is received in a single formalin-filled container labeled with the patient's name. 'right breast, tie marks sentinel node' and. consists of a 281.8 gram, 20.0 x 11.5 x 3.8 cm mastectomy specimen partially surfaced by a 15.8 x 7.5 cm ellipse of pink-tan wrinkled skin bearing an. eccentric 0.9 x 0.8 cm inverted nipple. A suture is present at the lateral edge and denotes the sentinel lymph node. A discrete axillary tail is not identified. The. deep. margin. is inked and the specimen is serially sectioned to reveal a 5.3 x 3.5 x 3.3 cm ilf-defined gray-white mass originating centrally subjacent. to the nipple and abutting the skin surface at the nipple. This mass approaches to within 0.7 cm of the inked deep margin. The uninvolved tissue is. comprised of yellow-tan adipose tissue admixed with minimal amounts of interspersed gray-white fibrous tissue. Focal areas of nodularity are present at. the medial and lateral borders, however, discrete invasive mass is not identified. The closest of these nodules approaches to within 1.5 cm of the inked. margin. Adjacent to the aforementioned suture, denotes a 2.0 cm well delineated nodule consistent with lymph node. Within the adjacent fibroadipose tissue are. two additional firm fatty nodules consistent with lymph node, 0.5 and 1.5 cm in greatest dimension. Representative sections are submitted in cassettes 1 through 12 labeled. designated as follows: 1 and 2, mass to include nipple and. adjacent skin; 3 and 4, mass to inked deep margin, perpendicular; 5 and 6, additional mass; 7, upper outer quadrant; 8, lower outer quadrant; 9, upper. inner quadrant; 10, lower inner quadrant; 11, one whole possible sentinel lymph node, bisected; 12, two additional lymph nodes (one inked and. bisected). Additionally, a yellow, green and blue cassette are submitted for genomics research each labeled.",2,True,"If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.","If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.",4.0,708.0,T3,"The report mentions that the patient underwent a right modified radical mastectomy and provides a specific tumor size of 5.3 cm. According to the AJCC's TNM Staging System, a T3 stage corresponds to a tumor that is greater than 5 cm in size. Therefore, the pathologic T stage of the patient's cancer is T3.",76.0,False
TCGA-BH-A1FH.501C3E1B-573B-4A5A-A0ED-3CD15432E6FF,"Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: +. DATE or LMP: DATE or LAST DELIVERY: PRE-OS DIAGNOSIS: LEFT BREAST CA. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: LEFT MOD RAD MASTECTOMY. CLINICAL HISTORY: +. MATERIAL SUBMITTED: LEFT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. FINAL DIAGNOSIS: LEFT BREAST, MODIFIED RADICAL MASTECTOMY: INFILTRATING DUCT CARCINOMA >2.5 BY 2.0 BY 1.5 CM, NUCLEAR AND ARCHITECTURAL GRADE 2. - LYMPHOVASCULAR SPACE INVOLVEMENT PRESENT. - DUCTAL CARCINOMA IN SITU, NON-COMEDO, PREDOMINANTLY SOLID TYPE, 30% OF TUMOR VOLUME. - MARGINS FREE OF LESION. - FIBROCYSTIC CHANGES AND REACTIVE CHANGES SUGGESTIVE OF PREVIOUS BIOPSY SITE. - EIGHT OUT OF THIRTEEN (8/13) LYMPH NODES WITH METASTATIC CARCINOMA AND EXTRACAPSULAR EXTENSION. NOTE: ER/PR immunoperoxidase assay will be performed on block A4 and an addendum will follow. s U P P L E M T A L R E P o R T. My signature below is attestation that I have reviewed all slides and agree with the findings as noted. below. TMMUNOPEROXIDASE IDENTIFICATION OF ESTROGEN AND PROGESTERONE RECEPTORS IS CARRIED OUT ON SLIDE. A4. DISTINCT. INTRANUCLE√ÅR STAINING IS IDENTIFIED FOR ESTROGEN RECEPTOR (704) BUT NOT FOR PROCESTERONE RECEPTOR. THEREFORE, ESTROGEN RECEPTOR IS INTERPRETED AS POSITIVE AND PROGESTERONE RECEPTOR AS NEGATIVE.",1,True,"If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size and no evidence of invasion beyond the breast, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.","If the report mentions a lumpectomy, then the T stage is likely to be T1 or T2, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, then the T stage is likely to be T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System.",4.0,708.0,T3,"The report mentions a modified radical mastectomy, which suggests that the tumor is larger and requires a more extensive surgical removal. The report also provides a specific tumor size of 2.5 cm, which falls under the T2 stage according to the AJCC's TNM Staging System. However, since the report also mentions that eight out of thirteen lymph nodes have metastatic carcinoma and extracapsular extension, it suggests that the tumor is more aggressive and has spread beyond the breast, indicating a T3 stage.",73.0,False
TCGA-S3-AA15.DD2B9E47-8C67-4599-B0B6-0D30DE727B55,"Female. Admission Date: Discharge Date: Collected Date/Time: Received Date/Time: Final Diagnosis. A. RIGHT SENTINEL LYMPH NODE, EXCISION: - METASTATIC CARCINOMA TO ONE LYMPH NODE (1/1). - THE FROZEN SECTION DIAGNOSIS IS CONFIRMED. SEE SPECIAL STAINS AND SYNOPTIC REPORT. B. RIGHT BREAST, MASTECTOMY WITH AXILLARY LYMPH NODES DISSECTION: - INVASIVE DUCTAL CARCINOMA, GRADE 3, MEASURING 1.1 CM, EXTENDING TO 5 MM FROM THE CLOSEST. POSTERIOR RESECTION MARGIN, WITH ILYMPHOVASCULAR INVASION. - DUCTAL CARCINOMA IN-SITU, NUCLEAR GRADE 3, WITH FOCAL NECROSIS, EXTENDING TO MORE THAN 5. MM FROM THE CLOSEST POSTERIOR RESECTION MARGIN. - MICROMETASTATIC CARCINOMA (0.21 MM) TO 1 OF 12 AXILLARY LYMPH NODES (1/12). - HEALING BIOPSY SITE WITH ORGANIZING HEMATOMA. - SKIN AND NIPPLE WITH SCLEROSING ADENOSIS. - SEE SYNOPTIC REPORT AND SPECIAL STAINS. (Electronic signature). Verified: Synoptic Report. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy (including nipple and skin). LYMPH NODE SAMPLING: Axillary dissection (partial or complete dissection). SPECIMEN INTEGRITY: Single intact specimen (margins can be evaluated). SPECIMEN SIZE: Greatest dimension: 30 cm. Print Date/Time: Distribute to: Patient Locations: surgical Pathology Report. Collected Date/Time: Received Date/Time: Additional dimensions: 22 X 7 cm. SPECIMEN LATERALITY: Right. TUMOR SITE: INVASIVE CARCINOMA: Upper inner quadrant. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Microinvasion only (<=0.1 cm). Greatest dimension of largest focus of invasion over 0.1 cm: 1.1 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma does not invade into the dermis or epidermis. DUCTAL CARCINOMA IN SITU (DCIS): DCIS is present. Extensive intraductal component (EIC) negative. NUCLEAR GRADE: Grade III (high). NECROSIS: Present, focal (small foci or single cell necrosis). HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTIATION: Score- 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very. large and bizarre forms. MITOTIC COUNT: Score 2. Number of mitoses per 10 high-power fields: 17. Diameter of microscope field: 0.55 mm. OVERALL GRADE: Grade 3: scores of 8 or 9. MARGINS: Margins uninvolved by invasive carcinoma. Distance from closest margin: POSTERIOR 5 mm. Distance from anterior margin: >5 mm. Margins uninvolved by DCIS (if present). Distance from anterior margin: >5 mm. Distance from posterior margin: >5 mm. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE BREAST: No known presurgical therapy. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE LYMPH NODES: No known presurgical therapy. LYMPH-VASCULAR INVASION: Present. Print Date/Time: Collected Date/Time: Received Date/Time: DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Number of sentinel lymph nodes examined: 1. Total number of lymph nodes examined (sentinel and nonsentinel): 13. Number of lymph nodes with macrometastases (>0.2 cm): 1. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 1. Number of lymph nodes with isolated tumor cells (less than or equal to 0.2 mm and less than or equal to 200 cells): 0. Size of largest metastatic deposit: 0.9 CM. EXTRANODAL EXTENSION: Not identified. METHOD OF EVALUATION OF SENTINAL LYMPH NODES: Hematoxylin and eosin (H&E), one level. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT1c: Tumor >10 mm but less than or equal to 20 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pN1a: Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis greater than 2.0 mm. DISTANT METASTASIS (M): Not applicable. ESTROGEN RECEPTOR: Performed on another specimen. Specimen (accession number): PROGESTERONE RECEPTOR: Performed on another specimen. Specimen (accession number): HER2/NEU IMMUNOPEROXIDASE STUDIES: Performed on another specimen. Specimen (accession number): MICROCALCIFICATIONS. Not identified. CLINICAL HISTORY: Mass or architectural distortion. Source of Specimen. A. Lymph Nodes, Rt. Sentinel. B. RT Breast and Axillary Nodes I & II. Clinical Information. African American female with right breast cancer, silk marks axilla upper inner quadrant. PRE-OP DIAGNOSIS: Right breast cancer. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Right breast mastectomy and Sentinel node biopsy. Gross Description. Print Date/Time: Female. Collected Date/Time: Received Date/Time: Specimen is received in 2 parts: A. The specimen is labeled ""RIGHT SENTINEL NODE"" and is received unfixed for frozen section diagnosis. (The specimen is in the. formalin. more. than 6 hours and less than 48 hours). It consists of a large lymph node measuring 3.5 x 2 x 2 cm. Sectioned and. entirely submitted in cassettes FSA 1-FSA3. Time specimen was removed from the patient: Time specimen was placed in formalin : Ischemic time: 27 minutes. B. The specimen is labeled ""RIGHT BREAST AND AXILLARY NODES I AND II"" and is received in formalin. (The specimen is. in the formalin more than 6 hours and less than 48 hours). It consist of mastectomy specimen with lymph nodes weighing 1150. grams and measuring 30 x 22 x 7 cm with brown skin ellipse measuring 21 x 10 cm, containing grossly unremarkable 2.0 cm in. diameter nipple. The skin is tagged with a black stitch designating the axilla The posterior margin is composed of smooth fascia. which is inked black. The breast is sliced in sagittal planes revealing a 5 x 5 x 4 cm hemorrhagic cavity within the upper inner-central. quadrants which is 0.7 cm away from the closest deep fascial margin of resection. The remaining parenchyma reveals unremarkable. yellow mammary fat with streaks of white-gray mammary parenchyma. Representative sections are submitted as follows: B1 = one lymph node, bisected. B2 = one lymph node, bisected. B3 = one lymph node, bisected. B4 = 5 lymph nodes. B5 = 2 lymph nodes, one bisected. B6 = one lymph node, bisected. B7 = one lymph node, bisected. B8 = one lymph node, bisected. B9-E = upper inner quadrant-central mass. B13 = mass closest to deep fascial margin of resection. B14 = nipple. B15 = upper inner quadrant. B16 = upper outer quadrant. B17 = lower outer quadrant. B18 = lower inner quadrant. B19-28= additional sections from biopsy cavity. Time specimen was removed from the patient: Time specimen was placed in formalin : Ischemic time: 18 minutes. Intra Operative Consultation. Right sentinel lymph node: one lymph node, positive for carcinoma (1/1). Special Stains/Slides. Immunohistochemical studies were performed on formalin fixed, paraffin-embedded tissue (Block B2, B5, B6) with adequate positive. and negative control sections. Immunostains for keratins AE1/AE3 are negative for carcinoma. Print Date/Time: Collected Date/Time: Received Date/Time: The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such. clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory is. certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. Tissue Code.",1,True,"If the report mentions a lumpectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm) or T3 range (>50 mm), then the T stage is T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.","If the report mentions a lumpectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm) or T3 range (>50 mm), then the T stage is T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.",4.0,884.0,T1c,"The report mentions that the largest focus of invasive carcinoma measures 1.1 cm, which falls within the range for T1c (>10 mm but <=20 mm) according to the AJCC's TNM Staging System. The report also mentions that a mastectomy was performed, but it does not specify a radical mastectomy. This supports the prediction of T1c, as larger tumors would typically require more extensive surgery.",83.0,True
TCGA-AR-A1AQ.FC236604-AAE5-4394-9D39-270FFEFB635A,"Final Diagnosis. Breast, right, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III),. [tubules 3/3, nuclei 3/3, mitoses 3/3; Nottingham score 9/9], forming a 3.5 x 2.5 x 2.5 cm mass. [AJCCpT2]. Angiolymphatic invasion is absent. The non-neoplastic breast parenchyma shows. nonproliferative fibrocystic changes. All surgical resection margins are negative for tumor. (minimum tumor free margin, 0.5 cm medial margin). Lymph nodes, right axillary sentinel, excision: Multiple (6) right axillary sentinel lymph nodes. with blue dye are negative for metastatic carcinoma (AJCCpN0(i-) (sn)]. Immunohistochemical. cytokeratin stain was performed on the paraffin embedded sentinel lymph node tissue and. confirms the H&E impression. Lymph node, right axillary non-sentinel, excision: A single right axillary non-sentinel lymph. node identified is negative for tumor. Seen in consultation with Dr.",1,True,"If the report provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
If the report provides a specific tumor size within the T3 range (>50 mm but <=70 mm) or T4 range (>70 mm), then the T stage is T3 or T4.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.","If the report mentions a lumpectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm) or T3 range (>50 mm), then the T stage is T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.",4.0,884.0,T2,"The report mentions that the final diagnosis is infiltrating ductal carcinoma and provides a specific tumor size of 3.5 x 2.5 x 2.5 cm, which falls within the T2 range (>20 mm but <=50 mm) of the AJCC's TNM Staging System. The type of surgery performed is not specified, but the T stage can still be determined directly from the size.",48.0,False
TCGA-AQ-A54O.B3884493-D0D2-445C-B9BB-BC475021EBA4,"Diagnosis. A: Sentinel lymph node, right axillary #1, removal. - No evidence of metastatic carcinoma in one lymph node (0/1). - See comment. B: Breast, right, total mastectomy. Tumor type: Infiltrating ductal carcinoma. Nottingham combined histologic grade 3. Tubule formation score: : 3. Nuclear Pleomorphism Score: 2. Mitotic count score: 3. Focality of tumor: unifocal. Tumor size (greatest dimension) : 35 mm. Lymphovascular invasion: not identified. In Situ Component: Minor component of ductal carcinoma in situ,. cribriform and solid types, nuclear grade 2 with necrosis, 2mm. in linear extent. Extensive intraductal component absent. Nipple/skin involvement: not identified. Margin status: Invasive component: negative, widely clear; 1.5 cm to closest. posterior. margin. In Situ component : negative; widely clear of all margins. Axillary lymph nodes: Total number with metastasis: 0. Total number examined: 14 ( see parts A & C). Microcalcifications not identified. Other findings: gynecomastia, biopsy site changes. See report of prior biopsy (. ') for results of ER, PR and. HER2 immunohistochemical studies. AJCC PATHOLOGIC TNM STAGE: pT2 pNO. Note: This pathologic stage assessment is based on information. available at the. time of this report, and is subject to change pending clinical. review and. additional information. C: Lymph nodes, right axillary, removal. - No evidence of metastatic carcinoma in 13 lymph nodes (0/13). - See comment. Comment: The axillary lymph nodes reveal lymphoid paracortical expansion,. which is. favored to be reactive in nature by H & E stains. Scattered. pigmented. histocytes are present suggestive of dermatopathic. lymphadenitis. Additional. immunohistochemical stains are pending to further evaluate this. process, results. of which will follow in an addendum report. Intraoperative Consult Diagnosis: Frozen section consultation was requested at. on. by in OR. FSA1,A2: Lymph node, right axillary SLN #1, biopsy. - No tumor seen. Drs. at. Frozen Section Pathologist: MD. Clinical History: with right poorly differentiated invasive. ductal carcinoma, Grade 3. Gross Description: Received are three appropriately labeled containers. Container A is additionally labeled ""right axillary SLN #1, hot. + blue. "" The. specimen is a 6 X 4.5 x 1.5 cm fatty soft tissue fragment. Examination of the. fat reveals a 2.0 X 2.0 x 1.0 cm blue lymph node candidate. This. candidate is. serially sectioned and submitted entirely in blocks FSA1 and. FSA2. Container B: Specimen fixation: formalin. Time in fixative: 28.5 hours. Type of mastectomy: simple mastectomy. Weight of specimen: 950 grams. Size of specimen: 26.0 cm medial to lateral, 26.7 cm superior to. inferior,. 4.0 cm anterior to posterior. Orientation of specimen: Sutures: Short=superior, long=lateral. Inking: anterior=blue, posterior=black, lateral=yellow. Skin ellipse dimensions: 18.6 x 9.3 cm. Nipple/areola Nipple, 1.0 cm; areola, 3.1 cm. Axillary tail: submitted separately. Biopsy site: present; Location is central breast/lower outer. quadrant;. Size: 0.8 X 0.5 X 0.5 cm. Appearance: Biopsy site (clip identified) is in the center of a. white/tan, firm area. Hemorrhage and fat necrosis. are noted in this area. Additional residual tumor is present. Discrete Mass (es) : present. Number of discrete masses: one. Size of mass (es)/biopsy site: 2.5 x 2.0 x 3.5 cm. Location of mass (es) : subareola/lowe outer quadrant. Distance of mass/biopsy site from surgical margin: The mass. measures 1.9 cm to. posterior margin, 8.5 cm to inferior margin, 10.5. cm to superior margin, 2.8 cm to anterior margin and is widely. clear. of medial/lateral margins. Gross involvement of skin or fascia/muscle by tumor: absent. Descript. remaining breast: consistent with yellow/tan. fibroad. issue. with increased fibrous areas noted in the subareolar. area; no other masses are identified. Other remarkable features: none. Tissue submi+ ed for special investigations: yes; Tumor to. Tissue Pr ment. Block Summary: (Inking: blue=anterior, black=posterior, yellow=lateral. B1 - nipple. B2 - areola. B3 - biopsy site. B4 - medial aspect of mass. B5-B8 - - central portion of mass. B9 - lateral aspect of mass. B10 - mass to posterior margin. B11 - representative dense fibrous tissue posterior to nipple. and anterior to mass. B12 - closest skin margin (inferior areola). B13 - upper inner quadrant. B14 - lower inner quadrant. B15 - lower outer quadrant. B16 - upper outer quadrant. B17 - mass to normal breast, superior. B18 - mass to normal breast, inferior. Container C is additionally labeled ""right axillary contents. "". The specimen. consists of two fragments of yellow/tan fibroadipose tissue that. measures 9.5 X. 6.5 x 3.0 cm in aggregate. Within the fibroadipose tissue,. fifteen lymph node. candidates are identified. These range in size from 0.4 up to. 1.5 cm in greatest. dimension. The largest lymph node candidate measures 2.3 X 1.5 x. 1.0 cm. Block summary: C1 - six lymph node candidates. C2 - five lymph node candidates (bisected node inked black). C3 - three lymph node candidates (bisected nodes inked black,. blue and. yellow). C4 - one lymph node candidate, sectioned. C5 - one lymph node candidate, sectioned. C6 - one lymph node candidate, sectioned. C7,C8 - largest lymph node candidate, sectioned. Procedures/Addenda: Addendum. Addendum. Immunohistochemical studies were performed on representative. blocks of axillary. lymph nodes (C6 and C7) and the results are as follows: CD20: Highlights many small lymphocytes in a generally nodular. distribution. CD3: Highlights majority of lymphocytes with focal expansion of. the paracortex. Interpretation: The immunohistochemical studies highlight an. essentially normal. pattern of distribution of B cells and T cells in the lymph. nodes, with primary. follicles composed predominantly of small B lymphocytes and. a. paracortex. populated by predominantly small T lymphocytes. Morphologic and. immunohistochemical findings are compatible with reactive lymph. nodes and do not. support a diagnosis of a lymphoproliferative disorder. The mild. paracortical. expansion can be seen as a feature of dermatopathic. lymphadenopathy.",1,True,"If the report mentions a lumpectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.","If the report mentions a lumpectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm) or T3 range (>50 mm), then the T stage is T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.",4.0,884.0,T2,"The report mentions that a total mastectomy was performed on the right breast and provides a specific tumor size of 35 mm, which falls within the T2 range (>20 mm but <=50 mm) according to the AJCC's TNM Staging System. Therefore, the T stage for this patient is T2.",79.0,False
TCGA-MS-A51U.58D54D1A-3A8D-40DD-A643-846CAF242494,"pN: Regional nodes (pN). pN1  total positive nodes). M: Distant metastases (M). M0 (clinically absent). SPECIMEN(S): A: Left sentinel lymph node #1. B: Left sentinel lymph node #2. C: Left breast with axillary lymph nodes. D: Right breast. FINAL DIAGNOSIS: Amended Microscopic Breast Carcinoma Checklist (see below). A. Lymph nodes, ""left sentinel lymph node #1,"" biopsy (including AFS1). - Metastatic carcinoma in one lymph node consistent with breast. primary (1/1). - Metastatic deposit measures 6mm in greatest dimension. - No extracapsular extension. B. Lymph nodes, ""left sentinel lymph node #2,"" biopsy (including BFS1). - Two lymph nodes with no evidence of malignancy (0/2). C. Breast left, modified radical mastectomy. - Invasive lobular carcinoma. - Multifocal with largest tumor 3.2 cm in greatest dimension in. upper outer quadrant; additional foci in retroareolar area and lower. outer quadrant up to 1.1cm in greatest dimension. - Histological grade = 2/3 (score: tubules 3 + nucleus 2 + mitoses 1 =. 6/9) by. criteria. - Mitotic index = <1/hpf (low). - Margins negative for invasive carcinoma (nearest = 1.2 cm; location: deep margin). - Lobular carcinoma in situ (LCIS). - LCIS comprises 5% of total carcinoma in specimen. - Nuclear grade 1/3 by SBR criteria (low). - Margins negative for LCIS. - Metastatic carcinoma present in one of fifteen lymph nodes (1/15). - Tumor deposit measures 4mm in greatest dimension, with no. extracapsular extension. - Nevus cell aggregate also identified. D. Breast, right, prophylactic simple mastectomy. - Fibrocystic changes. - Columnar cell hyperplasia. - Usual ductal hyperplasia. - No evidence of atypical hyperplasia, in situ carcinoma, or invasive. carcinoma. - Skin, nipple, and resection margins unremarkable. COMMENT: This report was amended to correct the number of positive nodes in the. microscopic section, in the ""Breast Carcinoma Checklist."" The Diagnosis. above is unchanged, and is correct, with a total of 2 positive nodes;. that count has been re-verified by review of the microscopic slides. The microscopic checklist section has now been corrected, to indicate. that a total of 2 nodes are positive. The ""N"" stage has thus been. corrected to pN1, as well. This case was discussed with. it a recent. conference, and he in fact pointed out this discrepancy. I informed him. at that time that I would make these corrections to the report. CLINICAL HISTORY: The patient is a. year-old woman with biopsy proven infiltrating. lobular cancer of the left breast (ER+ PR+ Her2/neu-). Operative. procedure: Sentinel lymph node biopsies, left modified radical. mastectomy and right simple mastectomy. GROSS: Received are four fresh containers each labeled with the patient's name. A. The first container is additionally labeled ""A - left. sentinel lymph node #1."" The specimen consists of a 2.1 X 2.06 cm. fragment of pale, yellow-tan, fibrofatty tissue. A single potential. lymph node is identified measuring 1.8 cm in greatest dimension. The. node is serially sectioned and entirely submitted for frozen section. analysis as AFS1. B. The next container is labeled ""B - left sentinel lymph node. #2."" The specimen consists of a 1.8 x 1.5 x 0.4 cm fragment of. yellow-tan, fibrofatty tissue. Two potential lymph nodes are identified. measuring 0.8 X 0.4 cm in greatest dimension. The smaller node is inked. black. The nodes are serially sectioned and entirely submitted for. frozen section analysis as BFS1. The remaining adipose tissue is. submitted for permanent sections in cassette B2. Summary of Sections: BFS1 - two potential sentinel lymph nodes, entirely submitted. B2 - remaining soft tissue. C. The next container is labeled ""C - left breast at 12 o'clock. with left axillary node dissection."" The specimen consists of a 613 gm. modified radical mastectomy with axillary tail. The breast measures 17. cm medial to lateral, 15.5 cm superior to inferior and 3.9 cm. superficial to deep. The attached axillary tail measures 8 X 7.5 x 2. cm. There is an attached ovoid portion of skin measuring 4 X 3.5 cm. with an everted, freely mobile nipple which measures 2.5 X 2.5 cm with. the areolar complex. The deep fascial plane is inked black, the. remaining superior half is inked blue with the remaining inferior half. inked green. The specimen is serially sectioned from medial to lateral. A gray-white, firm, irregularly-bordered mass is identified in the. upper outer quadrant measuring 3.2 X 2.2 X 1.3 cm in greatest dimension. This mass is consistent with a bilobed single mass. However, it could. represent two separate masses. The central area of the mass is. submitted which could represent normal parenchyma in between the two. masses. The mass is 1.8 cm to the deep margin and 2.5 cm to the nipple. A dumbbell-shaped biopsy clip is identified near the medial portion of. the mass. There are firm, indurated possibly calcified areas located. posteriorly to the nipple. The axillary tail is dissected to reveal 19. potential lymph nodes ranging in size from 0.3 to 2.6 cm in greatest. dimension. The nodes are entirely submitted. The specimen is sectioned. and laced in formalin. Summary of Sections: C1 - middle portion of mass. C2-C3 - medical portion of tumor. C4 - lateral portion of tumor with deep margin. C5 - lateral portion of tumor. C6 - representative upper inner quadrant. C7 - representative upper outer quadrant. C8 - representative lower outer quadrant. C9 - representative lower inner quadrant. C10 - representative retroareolar areas of induration. C11 - nipple. C12 - one potential lymph node, bisected, entirely submitted. C13 - one potential lymph node, bisected, entirely submitted. C14 - one potential lymph node, bisected, entirely submitted. C15 - six potential lymph nodes, submitted intact. C16 - six potential lymph nodes, submitted intact. C17 - four potential lymph nodes, submitted intact. D. The next container is additionally labeled ""D - right. breast."" The specimen consists of a 510 gm simple mastectomy measuring. 20 X 17x2.8 cm. Attached roughly ovoid portion of skin measures 3.9 X. 2.5 cm which is pale tan without lesions identified. The attached. nipple is everted and freely mobile and measures 2.7 x 2.0 cm with the. areolar complex. The deep fascial plane is inked black. The remaining. specimen is inked blue. The specimen is unoriented. It is serially. sectioned to reveal yellow-tan, lobulated parenchyma with interspersed,. dense and gray-white fibrosis and fibrocystic change. A small 0.6 cm. area of hemorrhage is identified located at the periphery. Masses or. lesions suspicious for malignant process are not grossly identified. The specimen is arbitrarily divided into quadrants and representative. sections are submitted. The specimen is sectioned and placed in. formalin . Summary of Sections: D1 nipple. D2-D3 - representative of quadrant 1. D4-D5 - representative of quadrant 2. D6-D7 - representative of quadrant 3. D8-D9 - representative of quadrant 4. INTRAOPERATIVE CONSULTATION: FROZEN SECTION DIAGNOSIS: AFS1: Left sentinel lymph node #1 - ""Metastatic breast carcinoma in. one lymph node."". FROZEN SECTION DIAGNOSIS: BFS1: Left sentinel lymph node #2 - ""Two lymph nodes with no evidence. of malignancy."". MICROSCOPIC: Microscopic examination is performed. Permanent sections confirm the. frozen section diagnoses. Breast carcinoma checklist: Operative procedure: mastectomy. Specimen size: 17 x 15.5 X 3.9 cm. Specimen integrity: Intact. Tumor location: Upper outer quadrant, lower outer quadrant, and. sub-areolar. Tumor focality: Multifocal. Tumor size: 3.2 x 2.2x1.3 cm, with other nodules as large as 1.1 cm. Tumor extent: tumor limited to breast, without invasion of skin or. muscle. Tumor type: Infiltrating lobular carcinoma. Histologic grade: 2/3 (score: tubules 3 + nucleus 2 + mitoses 1 = 6/9). by ESBR criteria. Mitotic index: <1/hpf (low). Lymphovascular invasion: Present. Perineural invasion: Absent. Margins of invasive carcinoma: Negative (nearest = 12 mm; location;. deep). In situ carcinoma: Present; Lobular carcinoma in situ (LCIS). Extent of in situ carcinoma: Non-extensive, comprises 5% of total. carcinoma. Grade of in situ carcinoma: 1/3 by SBR criteria (low). Margins of in situ carcinoma: Negative. Paget's disease: Absent. Number of Lymph nodes examined: 18. Number of Lymph nodes positive: 2 (1/3 sentinel nodes, and 1/15. nodes from mastectomy). Size of largest metastatic focus: 6 mm. Extracapsular extension: Absent. Receptor studies (performed on prior biopsy). ER +. PR:+. her2/neu:-. AJCC Cancer Staging: pT: Primary tumor (pT). pT2.",1,True,"If the report mentions a lumpectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.","If the report mentions a lumpectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm) or T3 range (>50 mm), then the T stage is T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.",4.0,884.0,T2,"The report mentions a modified radical mastectomy of the left breast and provides a specific tumor size of 3.2 cm in greatest dimension in the upper outer quadrant, with additional foci in retroareolar area and lower outer quadrant up to 1.1 cm in greatest dimension. This information corresponds to a T2 stage tumor, which is defined as a tumor with a size of >20 mm but <=50 mm. The type of surgery performed (modified radical mastectomy) and the absence of chest wall or skin invasion also support this prediction.",79.0,False
TCGA-AC-A3HN.F0308FC8-D8B4-487F-A072-05E66D01842A,"Path No.: Client: (Age: )F. Soc. Sec. #: Pre-Operative/Clinical History. Left breast cancer. Specimen(s) Received. A: LEFT AXILLA SENTINEL LYMPH NODE #1. B: LEFT AXILLA SENTINEL LYMPH NODE #2. C: LEFT AXILLA, ADDITIONAL AXILLARY TISSUE. D: BREAST, MASTECTOMY. Gross Description. Specimen A, received in formalin labeled left axilla sentinel node #1, consists of adipose tissue, 3.5 x 1.5 x 1.3 cm. Sections show a lymph node measuring 2.0 cm in greatest dimension, partially replaced by adipose tissue. The node is. sectioned and entirely submitted labeled (A1, A2). Specimen B, received in formalin labeled left axilla sentinel node #2, consists of adipose tissue, 2.0 x 1.5 x 0.8 cm. Sections show a single lymph node candidate measuring 1.0 cm in greatest dimension. The node is sectioned and. entirely submitted. (B1). Specimen C, received In formalin labeled left axilla additional axiliary tissue, consists of adipose tissue, 4.0 x 2.5 x 2.0 cm. in aggregate. Sections show a single lymph node candidate, 0.3 cm in greatest dimension. (C1). Microscopic Description. The microscopic findings are reflected in the diagnosis rendered. Diagnosis. A). LYMPH NODE, LEFT AXILLARY SENTINEL #1, EXCISION: ONE LYMPH NODE INVOLVED BY METASTATIC MAMMARY CARCINOMA (9 MM, NEGATIVE FOR. EXTRACAPSULAR EXTENSION). B). LYMPH NODE, LEFT AXILLARY SENTINEL #2, EXCISION: ONE LYMPH NODE INVOLVED BY MICROMETASTATIC MAMMARY CARCINOMA (1 MM, NEGATIVE. FOR EXTRACAPSULAR EXTENSION). C). LYMPH NODE; LEFT AXILLARY NONSENTINEL, EXCISION: ONE LYMPH NODE NEGATIVE FOR TUMOR. PHD HISTOLOGY REPORT. √©lectronically Reviewed and Signed Out By. Comment. All sentinel node blocks were examined with three 80 um interval H&E stained continu and two 80 um interval cytokeratin. AE1/AE3 immunostains. Positive and negative controls react satisfactorily. FDA required disclaimer: These tests were developed and their performance characteristics determined by. They have not been cleared. or approved by the U.S: Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used. for clinical purposes and should not be regarded as investigational or for research. This laboratory is certified under the Clinical Improvement. Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing. aquired information for predictive/prognostic markers: 1. Type of specimen fixation and detection system: Tissue is fixed in 10% formalin. Indirect biotin-free detection kit is used. 2. Clones used: ER (clone 6F11) Novocastra; PR (clone PGR 636). DakoCytomation; CD117 (polycional, DakoCytomation); HER2 (clone 485, Ventana, FDA approved); Ki-67 (clone K3, Cell Marque) p53 (cione DO7,. Novocastra), MSH6 (clone BC-44, Biocare), MSH2 (CellMarque clone G219-1129), MLH1 (Cell Marque clone G168-728), PMS2 (clone MRQ-28, Cell. Marque). 3. Criteria for positive results: ER and PR: >1% of tumor cells with nuclear staining; HER2; >30% of cells show complete membrane staining;. p53: >10% of tumor cells with nuclear staining; MMR Proteins: complete absence of tumor nuclear staining. CPT Code(s). A: 88307, 88342,. B: 88307, 88342,. C: 88305. D: 88307, 3260F. Procedures/Addenda. ADDENDUM. Addendum Comment. Gross Description. Specimen D is received in formalin labeled left breast, suture = axillary tail. Specimen type: Mastectomy without axillary tail and without pectoralis muscle. The specimen is oriented. by the surgeon as follows: suture = axillary tail. Specimen size/description: 755 gm. SI 17.5 cm, ML 16.5 cm, AP 6.0 cm. Laterality: Left. Tumor size: 3.0 x 2.5x 2.0 cm. Tumor site: Upper inner quadrant, 10-11 o'clock. Tumor description: Stellate, gritty, tan-white with a central 1.0 x 1.0 x 0.7 cm hemorrhagic ill-defined biopsy. site. Deep margin: 1.5 cm. Nipple/areolar complex: The areola measures 3.5 cm with a centrally retracted 0.6 x 0.6 cm nipple. There is a 5.5. x 4.0 cm area of blue dye superior the nipple/areolar area. PHD HISTOLOGY REPORT. Skin: The ellipse measures 22.0 x 10.5 cm. Lymph node sampling: Not applicable. Other: Sectioning of the surrounding breast tissue shows predominantly yellow lobular adipose. tissue admixed with dense, granular cystic breast tissue. Sections are submitted as follows: (D1,2) Nipple. (D3-7) Mass. (D8, 9) Upper inner quadrant. (D10, 11). Lower inner quadrant. (D12, 13). Lower outer quadrant. (D14, 15). Upper outer quadrant. (D16, 17). Deep margin. EO:vyb. ADDENDUM. Addendum Diagnosis. D) BREAST, LEFT, TOTAL MASTECTOMY: INVASIVE LOBULAR CARCINOMA, 3.0 CM, LOW COMBINED HISTOLOGIC GRADE WITH LOW. PROLIFERATIVE RATE. SURGICAL MARGINS NEGATIVE FOR TUMOR (SEE COMMENT). Addendum Comment. Summary of Pathologic Findings. Breast Carcinoma. Microscopic Examination. Specimen: Total breast. Procedure: Total mastectomy. Lymph node sampling: Sentinel node biopsies. Specimen Integrity: Single intact specimen. Specimen size: 17.5 cm greatest dimension. Laterality: Left. Tumor site: Upper inner quadrant, 9-10 o'clock position per previous diagnostic core biopsy. Size of invasive component: 3.0 cm greatest dimension. Tumor focality: Single focus. PHD HISTOLOGY REPORT. Macroscopic and microscopic extent of tumor: Skin: Uninvolved. Nipple: Paget disease absent. Skeletal muscle: Not present. Histologic type: Invasive lobular carcinoma. Combined histologic grade: Low combined histologic grade with low proliferative rate. Tubule formation: 3. Nuclear pleomorphism: 1. Mitotic count: 1 (field area 0.23 mm2). Total Nottingham score: 5. Lymph-vascular invasion: Absent. Ductal carcinoma in situ: Absent. Extensive intraductal component (EIC): Not applicable. Extent: Not applicable. Lobular carcinoma in situ: Absent. There are focal areas of atypical lobular hyperplasia. Deep margin: Not involved. Lymph nodes: Number of sentinel nodes examined: 2. Total number of nodes examined: 3. Number of nodes with macrometastasis: 1. Number of nodes with micrometastasis: 1. Number of nodes with isolated tumor cells: 0. Size of largest metastatic deposit: 9 mm. Extracapsular extension: Negative. Method of evaluation of sentinei lymph nodes: Three 80 um interval H&E stained sections and two 80 um interval cytokeratin AE1/AE3 immunohistochemical. stains on all sentinel lymph node blocks. TNM stage: pT2 N1a. Anciliary studies (estrogen receptor. progesterone receptor, HER2/neu and Ki-67): Performed on previous specimen,. see report for results. ADDENDUM. PHD HISTOLOGY REPORT. Addendum Comment. Total fixation time in formalin: 31.0 hours.",1,True,"If the report mentions a lumpectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.","If the report mentions a lumpectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, as these stages correspond to smaller tumors that can be removed with a lumpectomy.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm) or T3 range (>50 mm), then the T stage is T2 or T3, as these stages correspond to larger tumors that require a mastectomy but have not invaded the chest wall or skin.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4, as these stages correspond to tumors that have invaded the chest wall or skin.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.",4.0,884.0,T2,"The report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (3.0 cm). Therefore, the T stage is T2.",79.0,False
TCGA-BH-A0AV.6DFA6F0F-09BC-4246-87B9-247207B74A39,"FINAL DIAGNOSIS: PART 1: BREAST, LEFT. 11 O'CLOCK SEGMENTAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA. B. NEOPLASM MEASURES 1.5 CM ON SLIDE 1F. C. NOTTINGHAM SCORE 8/9, GRADE 3 (TUBULES 3, NUCLEI 3, MITOSES 2). D. MARGINS OF RESECTION FREE OF NEOPLASM, CLOSEST POSTERIOR AT 0.6 CM. E. NO LYMPHOVASCULAR INVASION IDENTIFIED. F. ER NEGATIVE, PR NEGATIVE, HER-2/NEU NOT AMPLIFIED PER PREVIOUS REPORTS. G. PATHOLOGIC STAGE pT1C, pNo, pMX. H. DUCTAL CARCINOMA IN SITU, SOLID TYPE, NUCLEAR GRADE 3 WITH COMEDONECROSIS AND. CALCIFICATION. I. DUCTAL CARCINOMA IN SITU IS IDENTIFIED IN FOUR OF FIFTEEN (4/15) SECTIONS, OUTSIDE OF INVASIVE. COMPONENT. J. MARGINS OF RESECTION FREE OF IN SITU CARCINOMA BY GREATER THAN 1.0 CM (see comment). K. UNREMARKABLE SKIN. L. FIBROCYSTIC CHANGES. PART 2: LYMPH NODE, LEFT AXILLARY, SENTINEL NUMBER 1, BIOPSY -. ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 3: LYMPH NODE, LEFT AXILLARY, NONSENTINEL, BIOPSY -. ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0/1). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 1.5 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Solid. DCIS present outside of invasive carcinoma component. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 6.0 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: o. LYMPH NODES EXAMINED: 2. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pNO. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: previously performed. PROGESTERONE RECEPTORS: previously performed. HER2/NEU: zero or 1+.",0,True,"If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm) or T3 range (>50 mm), then the T stage is T2 or T3.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.","If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm) or T3 range (>50 mm), then the T stage is T2 or T3.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.",4.0,632.0,T1,"The report mentions that the maximum dimension of the invasive component is 1.5 cm, which falls within the T1 range (<=20 mm) for smaller tumors. Additionally, the report mentions a segmental mastectomy, which is a type of breast-conserving surgery like a lumpectomy. Therefore, based on the first rule, the T stage is T1.",80.0,True
TCGA-AR-A251.F5B17108-8904-48E7-9B3D-182F0EA388B7,"Final Diagnosis. Yeast, left/wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III), forming a 2.7 x 2.4 x 2.0 cm bilobed. mass. [AJCC pT2]. Extensive ductal carcinoma in situ, high nuclear grade, present within (>25%) and outside the invasive. component. Angiolymphatic invasion is present. The non-neoplastic breast parenchyma shows proliferative fibrocystic changes. Calcifications present in malignant ducts. Biopsy site changes present. The tumor does not involve overlying skin. The. medial/inferior margin is positive for ductal carcinoma in-situ. Left breast, new inferomedial margin, re-excision: Focally positive for ductal carcinoma in- situ. Left breast, new deep margin, re-excision: Negative for tumor. Lymph nodes, left axillary, dissection: Multiple (3 of 7) left axillary lymph nodes are positive for metastatic carcinoma. The. largest metastatic focus measures 2.2 x 1.9 x 1.5 cm. Extranodal extension is present. Lymph nodes, additional left axillary, excision: A single (of 3) left axillary lymph node is positive for metastatic carcinoma. [Total 4 positive lymph nodes; AJCCpN2]. Breast, left, total mastectomy: No residual carcinoma identified. Biopsy site changes are present in the outer quadrant. The. adjacent breast parenchyma shows proliferative fibrocystic changes. Surgical margins are negative for tumor. The nipple is. without diagnostic abnormality.",1,True,"If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.","If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size, then the T stage can be determined directly from the size using the AJCC's TNM Staging System, regardless of the type of surgery performed.",4.0,605.0,T2,"The report mentions a total mastectomy and provides a specific tumor size of 2.7 x 2.4 x 2.0 cm, which falls within the T2 range (>20 mm but <=50 mm) based on the AJCC's TNM Staging System. Therefore, the T stage is T2.",98.0,True
TCGA-E2-A14O.42E9A561-B052-412E-B0FD-563DC097C3C5,"SPECIMENS: A. SENTINEL LYMPH NODE #1 LEFT AXILLA. B. LEFT BREAST. C. UPPER OUTER QUADRANT LEFT BREAST. D. LEFT AXILLARY CONTENTS. SPECIMEN(S): A. SENTINEL LYMPH NODE #1 LEFT AXILLA. B. LEFT BREAST. C. UPPER OUTER QUADRANT LEFT BREAST. D. LEFT AXILLARY CONTENTS. AMENDMENT. This case has been amended to change ER/PR results from pending to final results in the breast synoptic report and. add ER/PR and Her2/neu synoptic reports. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA: Sentinel lymph node #1, biopsy: Positive for carcinoma. Gross exam B: Left breast, mastectomy: Multiple tumors identified; closest is 1.5 cm from inferior/anterior aspect. By Dr called to Dr at. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE #1 LEFT AXILLA. Received fresh is a tan-pink fragment of fibrofatty tissue (4.0 x 2.0 x 1.0 cm). Dissection reveals a firm presumptive. lymph node (1.4 x 1.0 x 0.8 cm). The specimen is serially sectioned and touch preps are taken. Submitted in toto in. A1. B. LEFT BREAST. Received fresh labeled ""left breast"" is a 1,184-gram simple mastectomy specimen (27.0 x 25.0 x 6.5 cm) with. a. stitch on the axillary tail. The specimen is partially surfaced with a tan-pink ellipse of skin (15.0 x 10.5 cm) with a 1. cm centrally located, partially flattened nipple and 3.5 cm areola rim. The skin surface is remarkable for a grey-white,. well-healed scar in the upper outer quadrant measuring 1 cm that is 8.0 cm from the nipple. The specimen is inked. and serially sectioned from medial to lateral into 14 slices; slice 1 being most medial, slice 14 being most lateral. The. nipple is located in slice 8. The cut surface reveals a grey-white, firm, stellate mass (6.0 x 5.5 x 4.0 cm) located in. the upper central and upper outer quadrants and present in slices 7, 8, 9, 10, and 11. This mass measures 1.5 cm. from all margins. A second lesion is located in the 7 o'clock position (0.8 x 0.6 x 0.5 cm) in slice 6. Lesion #2 is. located 0.6 cm from lesion #1, and measures 1.5 cm from the closest inferior margin. An ill-defined nodular area. (lesion 3) is located 4.5 cm superior to lesion #2 in slice 6 and more than 2.0 cm from the deep margin. A portion of. the specimen is submitted for tissue procurement. Gross examination did not reveal distinct 12:00 and 10:00 lesions. as designated on the request form. Lesions 2 and 3 may correspond to the 10:00 lesions as they did appear grossly. separate from the main tumor mass, although very close. The main mass appeared confluent grossly and may. encompass the 12:00 lesion. The remaining cut surfaces reveal predominantly yellow lobulated adipose. tissue. interspersed with grey-white fibrous tissue. Inked code: Superior anterior - blue, orange - inferior anterior,. black. posterior. Section code: B1: Nipple serially sectioned, slice 8. B2: Base of nipple, slice 8. B3: Nodular area above lesion #2, slice 6. B4: Lesion #2, slice 6. B5: Inferior margin, slice 6. B6: Deep margin, slice 6. B7: Superior margin, slice 7. B8-B11: Lesion #1 submitted from superior to inferior, slice 7. B12: Inferior margin, slice 7. B13: Deep margin, slice 7. B14-B16: Lesion #1 submitted from superior to inferior, slice 8. B17: Inferior margin, slice 8. B18: Deep margin, slice 8. B19-B21: Lesion #1 from superior to inferior, slice 9. B22: Deep margin, slice 9. B23: Deep margin, slice 10. B24: Skin with underlining scar, slice 11. B25-B26: Lesion #1 from superior to inferior, slice 11. B27: Deep margin, slice 11. B28: Area immediately adjacent to lesion #1, slice 12. C. UPPER OUTER QUADRANT LEFT BREAST. Received is an unoriented tan-pink fragment of fibrofatty tissue weighing 37 grams and measuring (7.0 x 6.0 x 2.0. cm). The specimen is serially sectioned to reveal predominantly yellow lobulated adipose tissue interspersed with. grey-white fibrous tissue. No lesion is grossly identified. Representative sections are submitted in cassettes C1-C4. D. LEFT AXILLARY CONTENTS. Received labeled ""left axillary contents"" are multiple tan-pink fragments of fibrofatty tissue aggregating to (10.0 x 9.0. x 3.0 cm). Dissection reveals 17 possible lymph nodes ranging from (0.5 x 0.5 x 0.5 cm to 2.5 x 1.5x1.0 cm). Section code: D1: Four possible lymph nodes. D2: Four possible lymph nodes. D3: Four possible lymph nodes. D4-D5: One lymph node serially sectioned. D6: One lymph node serially sectioned. D7: One lymph node bisected. D8: One lymph node trisected. D9: One lymph node serially sectioned. DIAGNOSIS: A. SENTINEL LYMPH NODE #1, LEFT AXILLA, BIOPSY: - METASTATIC CARCINOMA TO ONE LYMPH NODE (1/1). B. LEFT BREAST, MASTECTOMY: - MULTIFOCAL INVASIVE DUCTAL CARCINOMA, POORLY DIFFERENTIATED. (SBR GRADE 3), WITH MICROPAPILLARY FEATURES. - TUMOR SPANS AT LEAST 6 CM AND IS PRESENT IN CENTRAL AREA. AND UPPER OUTER QUADRANT. - DUCTAL CARCINOMA IN SITU, CRIBRIFORM TYPE, NUCLEAR GRADE 2,. MINOR COMPONENT. - MARGINS, NEGATIVE FOR CARCINOMA. EXTENSIVE LYMPHOVASCULAR INVASION. - SKIN AND NIPPLE, NEGATIVE FOR CARCINOMA. - SKELETAL MUSCLE, NEGATIVE FOR CARCINOMA. C. LEFT BREAST, UPPER OUTER QUADRANT, EXCISION: - FIBROADIPOSE TISSUE, NEGATIVE FOR CARCINOMA. D. LEFT AXILLARY CONTENTS, DISSECTION: - 1/17 LYMPH NODES WITH METASTATIC CARCINOMA WITH EXTRANODAL. EXTENSION (1/17). SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: Laterality: Left. Invasive tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: Size of Invasive focus: 6cm. Tumor site: Upper outer quadrant. Central. Margins: Negative. Distance from closest margin: 1.5cm. deep. Tubular score: 3 (<10% tubule). Nuclear grade: 3. Mitotic score: 2. Modified Scarff Bloom Richardson Grade: 3 (8-9 points). Necrosis: Absent. Vascular/Lymphatic Invasion: Present. Extent: extensive. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node and axillary dissection. Lymph node status: Positive 2 / 18 Extranodal extension. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 2%. DCIS type: Cribriform. DCIS location: Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Pending. Pathological staging (pTN): pT 3 N 1a. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: B20. ER: Positive. Allred Score: 8 = Proportion score: 5 + Intensity Score 3. PR: Positive. Allred Score: 7 = Proportion Score 5 + Intensity Score 2. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the proportion score (0. = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of cells staining, 4 = 31-60% of. cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak intensity of staining, 2 = intermediate. intensity of staining, 3 = strong intensity of staining). with a scoring range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of less than or. equal to 2. Methodology: Fixation Type and Length: Tissue was fixed in 10% neutral buffered formalin (. for no less than 8 and no longer than 24 hours. Antibody and Assay Methodology: Mouse anti-human ER and. Comment: Inis assay can used to select invasive breast cancer patients for hormone therapy (1). ER and PR analysis was performed on this case by immunohistochemistry utilizing the ER (ER 1D5, 1:100) and PR. (PGR 136, 1:100) antibody provided by Dako, following the manufacturer's instructions listed in the package insert. This assay was not modified, and adherence to all instruction and guidelines were strictly followed. Interpretation of. the ER/PR immunohistochemical staining characteristics is guided by published results in the medical literature (1),. information provided by the reagent manufacturer and by internal review of staining performance within the. Pathology Department. 1. Harvey JM, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for. predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474-1481, 1999. SYNOPTIC REPORT - BREAST HER-2 RESULTS. HER2 Status Results, Immunohistochemistry Evaluation. Specimen: Breast Core Needle Biopsy. Block Number: B20. Interpretation: EQUIVOCAL. Intensity: 2+. % Tumor Staining: 50%. Fish Ordered: Yes on Date. METHODOLOGY. Methodology: Fixation Type and Length: Tissue was fixed in 10% neutral buffered formalin {. ) for no less than 8 and no longer than 24 hours. Antibody and Assay Methodology: Rabbit anti-human HER2,. HerceptestTM (FDA-approved test kit),. Control Slides Examined: External kit-slides. provided by manufacturer (cell lines with nign, low ana negauve HER2 protein expression), and in-house known. HER2 amplified control tissue were evaluated along with the test tissue. These control slides run along side of this. patient's sample showed appropriate staining. Adequacy of Specimen: Adequate, well preserved, clear-cut invasive. carcinoma identified for HER2 evaluation. Scoring Criterion and Scoring System: IHC Level of Expression(Score) /Tumor Cell Membrane Staining Pattern. Negative (0)/Absence of Staining. Negative (1+)/Faint Incomplete membrane Staining, >10% of Cells. Equivocal (2+)/Weak complete membrane Staining, >10% of Cells. Positive (3+)/Strong complete membrane Staining, >10% of Cells. Equivocal Category for HER2 IHC results: A HER2, 2+ staining result that is interpreted as equivocal may not. indicate gene amplification. A FISH test for HER2 gene amplification will be ordered for all HER2 IHC 2+ results. COMMENT. This assay can be used to select invasive breast cancer patients for. (Hereptin) therapy (1,2). Clinical. Trials have shown that Trastuzumab substantially increases the likelihood for an objective response and overall. survival for patients with metastatic HER2-positive breast cancer, regardless of whether HER2 tumor status was. determined as IHC 3+ or FISH positive. Trastuzumab added to adjuvant chemotherapy substantially increase. disease-free survival and decreases the risk of disease recurrence by about 50% for patients with early-stage HER2. protein over-expressed or gene amplified invasive breast cancer (3). HER2 analysis was performed on this case by immunohistochemistry utilizing the FDA approved Dako HercepTest. (TM) test kit following the manufacturer's instructions listed in the package insert. This assay was not modified, and. adherence to all instruction and guidelines were strictly followed. Interpretation of the HER2 immunohistochemical. staining characteristics is guided by published results in the medical literature (4), information provided by the. reagent manufacturer and by internal review of staining performance within the Pathology Department. HER2 TEST VALIDATION. This HER2 immunohistochemical assay has been validated according to the recently revised recommendations and. guidelines from the NCCN HER2 testing in Breast Cancer Task Force, and the jointly issued recommendations and. guidelines from ASCO and the CAP (5). 80 randomly selected breast cancer samples were tested for HER2 by IHC. as outline above and interpreted as, negative (score 0/1+) equivocal (score 2+) and positive (score 3+) without. knowledge of the previous reported results. These cases were also blindly read using two different FISH assay as amplified or non-amplified and the. HER2/CEP17 ratios were recorded. After analyzing these results, there was 100% concordance between the IHC. and FISH results for cases that were interpreted as either positive or negative by IHC. 9 of the 80 cases were. interpreted as equivocal by IHC and of these 3/9 (33%) were non-amplified by FISH and 6/9 (66%) were found to be. amplified. The Pathology Department Immunohistochemistry laboratory takes full responsibility for this tests performance. and has programs in place to regularly monitor the proficiency and the interpretation of HER2 assays. The. laboratory also participates in external quality assurance HER2 programs including the CAP proficiency testing. program. REFERENCE. 1. Carlson RW, Anderson BO, Burstein HJ, et al., NCCN breast cancer clinical practice guidelines in oncology. J. Natl Compr Canc Netw. 2005;3:238-289. 2. Carlson RW, Brown E, Burstein HJ, et al., NCCN Task Force Report: adjuvant therapy for breast cancer. J Natl. Compr Canc Netw. 2006;4:S1-S26. 3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive. breast cancer. N Eng J Med 2005;353(16):1673-84. 4. Leong ASY, Formby M, Haffajee Z, et al. Refinement of immunohistologic parameters for Her2/neu scoring. validation by FISH and CISH. Appl Immunohistochem Mol Morphol. 2006;14:384-389. 5. Wolff AC, Hammond EH, Schwartz JN, et al., American Society of Clinical Oncology/College of American. Pathologists Guideline Recommendations for Human Epidermal Growth Factor Recepto 2 Testing in Breast Cancer. Arch of Path and Lab Med 2007; 131:18-43. CLINICAL HISTORY: A year-old female with left multicentric disease, large 4.5 cm mass in upper outer quadrant 10 o'clock + IDC with. 3 small masses; 12 o'clock + IDC 5 mm mass. PRE-OPERATIVE DIAGNOSIS: None given. ADDENDUM: PathVysion HER-2 DNA Probe Kit. Analytical Interpretation of Results: HER-2 NOT AMPLIFIED. Clinical Interpretation of results. Amplification of the HER-2 gene was evaluated with interphase fluorescence in-situ. hybridization (FISH) on formalin-fixed paraffin embedded tissue sections using a chromosome. 17 centromeric probe and a HER-2 probe that spans the entire HER-2 gene in the. by Dr. A majority of tumors cells displayed mild polysomy 17 with 2. to 3 chromosome 17 signals and 2 to 5 HER-2 signals, with a HER-2/CEP 17 Ratio </=2.0,. consistent with no amplification of the HER2/neu gene. Block used. B20. Source of case: Tissue fixation formalin-fixed tissueOutside Case No: NA. Tissue source breast Results interpreted: yes. HER2/CEP17 ratio: 1.65. This ratio is derived by dividing the total number of LSI HER-2/neu signals by the total number of. CEP17 signals in at least 20 interphase nuclei with nonoverlapping nuclei in the neoplastic. mammary epithelial cells. Cells with no signals or with signals of only one color are disregarded. Method of ratio enumeration: manual count. Limitations. The Vysis PathVysion Kit is not intended for use to screen for or diagnose breast cancer. It is. intended to be used as an adjunct to other prognostic factors currently used to predict disease-free. and overall survival in stage II, node-positive breast cancer patients. In making decisions regarding. adjuvant CAF treatment, all other available clinical information should also be taken into. consideration, such as tumor size, number of involved lymph nodes, and steroid receptor status. No. treatment decision for stage II, node-positive breast cancer patients should be based on HER-2/neu. gene amplification status alone. Overview of this test. FDA APPROVED REAGENT. PathVysion HER-2 DNA Probe Kit is FDA approved for selection of. patients for whom Herceptin¬Æ therapy is being considered. These tests were performed in the. /, under the direction. of Dr. The results of these studies should always be interpreted in the context of the. clinical, morphological, and immunophenotypic diagnosis. Final Review: Pathologist. Final: Pathologist, 0. Amendment: Pathologist,. Amendment Review: Pathologist,. Amendment Final: Pathologis. Addendum: Pathologist,. Addendum Final: Patholoy.",2,True,"If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.","If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.",4.0,541.0,T3,"The report mentions a mastectomy and provides a specific tumor size within the T3 range (>50 mm). The tumor size is 60 mm, which falls in the T3 range. Therefore, the T stage is T3.",92.0,True
TCGA-A1-A0SF.1617B36B-4EFB-445E-95BC-E63B129AAAE7,"Working Draft. CELLULAR CHANGES WITHIN NORMAL LIMITS. Inflammation. SPECIMEN ADEQUACY: Satisfactory for evaluation. Endocervical cells present. Specimen Class: Accessioned: Specimen(s) Received: Endometrium, biopsy. Final Diagnosis. Endometrium, biopsy: Benign dyssynchronous secretory endometrium; no hyperplasia or carcinoma. identified. Specimen Class: Accessioned: Signed Out: (. Specimen(s) Received: Cervical. Endocervical, Direct. Final Diagnosis. Cervical/Endocervical, Direct. CELLULAR CHANGES WITHIN NORMAL LIMITS. Inflammation. Endocervical cells present. SPECIMEN ADEQUACY: Satisfactory for evaluation but limited by obscuring white blood cells. Specimen Class: Accessioned. Specimen(s) Received: Cervical/Endocervical, Direct. Final Diagnosis. Cervical/Endocervical, Direct. CELLULAR CHANGES WITHIN NORMAL LIMITS. SPECIMEN ADEQUACY: Satisfactory for evaluation. Endocervical cells present. Specimen Class: Accessioned. Specimen(s) Received: Bladder Washing. Final Diagnosis. Bladder Washing. BENIGN. Working Draft. Specimen Class: Accessioned: Specimen(s) Received: Urine, catheterized. Final Diagnosis. BENIGN. See Below. Specimen Class: Accessioned. {HighRisk Specimen}. Specimen(s) Received: Vaginal/Cervical/Endocervical. Final Diagnosis. CELLULAR CHANGES WITHIN NORMAL LIMITS. Squamous metaplasia. SPECIMEN ADEQUACY: Satisfactory for evaluation. Endocervical cells present. Specimen Class: Accessioned. Specimen(s) Received: BLADDER WASH. Final Diagnosis. BENIGN. Conversion. Specimen Class: Accessioned: Specimen(s) Received: BLADDER WASH. Final Diagnosis. BENIGN. Conversion. Specimen Class: Accessioned: Specimen(s) Received: BLADDER WASH. Fina) Diagnosis. BENIGN. Conversion. Working Draft. Specimen Class: Accessioned: Specimen(s) Received: VAGINALCERVICAU/ENDOCERVICAI. Final Diagnosis. BETHESDA: CELLULAR CHANGES WITHIN NORMAL LIMITS. BENIGN. Inflammation. Conversion. Specimen Class: Accessioned: Specimen(s) Received: URINE, CATHETERIZED. Final Diagnosis. BENIGN. Conversion. Specimen Class: Accessioned: Signed Out: &. Specimen(s) Received: VAGINAL/CERVICAL/ENDOCERVICAL. Final Diagnosis. DESCRIPTIVE DIAGNOSIS. Diagnosis Deferred. Conversion. Specimen Class: Accessioned: Specimen(s) Received: SITE NOT SPECIFIED. Final Diagnosis. DESCRIPTIVE DIAGNOSIS. Diagnosis Deferred. Inflammation. Conversion. Specimen Class: Accessioned. Specimen(s) Received: VAGINAL/CERVICAL/ENDOCERVICAL. Final Diagnosis. BENIGN. Conversion. FND OF REPORT. Final Pathologic Diagnosis: A. Sentinel lymph node #1, left axilla, biopsy: No carcinoma identified in one lymph. node (0/1). B. Sentinel lymph node #2, left axilla, biopsy: No carcinoma identified in one lymph. node (0/1). Working Draft. C. Left breast, mastectomy;. 1. Infiltrating ductal carcinoma, SBR grade 2, 2.4 cm; see comment. 2. Intermediate to high grade ductal carcinoma in-situ, cribriform and comedo types. 3. Non-proliferative fibrocystic changes. 4. Duct ectasia. D. Right breast, mastectomy: 1. Atypical lobular hyperplasia. 2. Non-proliferative fibrocystic changes. 3. Duct ectasia. 4. Microcalcifications associated with benign ducts and stroma. 5. No carcinoma identified. E. Soft tissue, right breast, excision: Fibroadipose tissue with skeletal muscle; no breast. parenchyma or carcinoma identified. F. Left ovary and fallopian tube, salpingooophorectomy: - Ovary: No significant pathologic abnormality. - Fallopian tube: Benign paratubal cyst. G. Right ovary and fallopian tube, salpingooophorectomy: - Ovary: No significant pathologic abnormality. - Fallopian tube: Benign paratubal cyst. H. Omentum, biopsy: Benign fibrous nodule. I. Soft tissue, left upper peritoneum, biopsy: Benign fibroadipose tissue. J. Omentum, omentectomy: No significant pathologic abnormality. Note: Breast Tumor Synoptic Comment. - Laterality: Left. - Invasive tumor type: Infiltrating ductal. - Invasive tumor size: 2.4 cm maximum diameter. - Invasive tumor grade (modified Bloom-Richardson): Nuclear grade: 3, 3 points. Mitotic count: 7 mitotic figures/1 HPF, 1 point. Tubule/papilla formation: > 10% but <75%, 2 points. Total points and SBR grade - 6 points, grade 2. - Lymphatic-vascular invasion: None identified. - Perineural invasion: None identified. - Invasive tumor necrosis: None identified. - Mononuclear cell reaction: None/minimal. - Resection margins for invasive tumor: Widely clear. - Deep margin: Widely clear; closest distance of tumor 2 cm. - Medial margin: Widely clear; closest distance of tumor > 6 cm. - Lateral margin: Widely clear; closest distance of tumor 2.8 cm. Anterior/superior margin: Widely clear; closest distance of tumor 5.5 cm. Anterior/inferior margin: Widely clear; closest distance of tumor >6 cm. - Ductal carcinoma in situ (DCIS) type: Cribriform and comedo. - Ductal carcinoma in situ size: ~2.0 cm in maximum diameter. Ductal carcinoma in situ nuclear grade: Intermediate to high grade. - Necrosis in ductal carcinoma in situ: Present. - Microcalcifications: Not identified. Working Draft. - Resection margins for ductal carcinoma in situ: Widely clear (see above for invasive tumor. - Lobular carcinoma in situ (LCIS): Not identified. - Number of lobules involved: N/A. - Nuclear type/size: N/A. - Resection margins for pleomorphic lobular carcinoma in situ: N/A. - Lymph node status: Negative. - Number of positive lymph nodes: 0. - Total number sampled: 2. - AJCC/UICC stage: pT2NOMx. - Nontumorous breast tissue: Non-proliferative fibrocystic change; duct ectasia. - Nipple: Unremarkable. - Skin/dermis: Unremarkable. Pagetoid spread of carcinoma is seen in benign ducts adjacent to the tumor. No such spread is seen away. from the tumor. Atypical lobular hyperplasia is present in the contralateral (right) breast. An immunohistochemical test for estrogen and progesterone receptors as well as for HER2 was performed. on block C3. The test for estrogen receptors is positve. There is moderate nuclear staining in >95% of tumor cells. Internal positive control is positive. The test for progesterone receptors is positive. There is moderate to strong nuclear staining in 90% of. tumor cells. Internal positive control is positive. Result of HER2/neu test: This carcinoma is negative for HER2/neu oncoprotein over-expression. An immunohistochemical assay was performed using the CB11 monoclonal antibody to HER2/neu. oncoprotein. The staining intensity of this carcinoma was 1 on a scale of 0-3 (HER2 test interpreted by. Dr. Carcinomas with staining intensity scores of o or 1 are considered negative for over-expression of HER2/neu oncoprotein. Those with a staining intensity score of 2 are considered borderline. We and others have observed that many carcinomas with staining. intensity scores of 2 do not show gene amplification. All carcinomas with staining intensity scores of 2 are therefore submitted for. FISH testing. The results of the FISH test are issued directly from the molecular cytogenetics laboratory. Carcinomas with staining intensity scores of 3 are considered positive for over-expression of HER2/neu oncoprotein. Tumors in this. category show an excellent correlation between the results of immunohistochemical and FISH testing, and almost always show gene. amplification. Intraoperative Consult Diagnosis. FS1 (A) Sentinel lymph node # 1, left axilla, biopsy: No carcinoma. FS2 (B) Sentinel lymph node #2, left axilla, biopsy: No carcinoma. FS3 (G) Right adnexa, salpingo-oophorectomy: Paratubal cyst with hemorrhage. FS4 (H) Omentum, biopsy: Dense fibrous connective tissue, no carcinoma. FS5 (I) Left upper quadrant, peritoneum, biopsy: No carcinoma. F. Left adnexa, salpingo-oophorectomy: Paratubal cyst (gross diagnosis only). Clinical History. Working Draft. The patient is a .year-old woman with left breast cancer. She undergoes bilateral mastectomies. Gross Description. The specimen is received in ten parts, each labeled with the patient's name and unit number. Parts A. through I are received fresh, and Part J is received in formalin. Part A, additionally labeled ""1. consists of one pink, unoriented,. fibroadipose tissue fragment measuring 1.5 x 0.8 x 0.8 cm. The entire specimen is frozen for frozen. section diagnosis 1, and subsequently submitted in cassette A1. Part B, additionally labeled. consists of one pink-red, unoriented,. fibroadipose tissue fragment measuring 1.3 x 0.8 x 0.7 cm. The entire specimen is frozen for frozen. section diagnosis 2, and subsequently submitted in cassette B1. Part C is additionally labeled. It consists of a mastectomy specimen, measuring. 15.8 cm from superior to inferior, 15.6 cm from medial to lateral, and 8.2 cm from anterior to posterior. The specimen weighs 442.5 gm. In the lateral aspect of the specimen is a spiculated, firm, tan mass,. measuring 2.4 x 1.2 x 1.2 cm. This mass is 2.0 cm from the deep margin, 5.5 cm from the superior. margin, >6 cm from the inferior margin, 2.8 cm from the lateral margin, and >6 cm from the medial. margin. In the anterior-inferior portion of the breast, there are dilated ducts, filled with cheesy material. This area is 0.2 cm from the deep margin. The remainder of the breast parenchyma is unremarkable. Two. pieces of tumor are banked, one for tissue banking and one for the epithelial cell study. Representative. sections are submitted as follows: Cassette C1: Nipple. Cassettes C2-C3: Spiculated mass. Cassette C4: Deep margin beneath tumor. Cassette C5: Lateral margin. Cassette C6: Lower outer quadrant. Cassette C7: Lower inner quadrant. Cassette C8: Medial margin. Cassette C9: Upper inner quadrant. Cassette C10: Anterior-inferior area with duct ectasia. Part D is additionally labeled. It consists of a mastectomy specimen, measuring. 18.2 cm from superior to inferior, 16.2 cm from medial to lateral, and 4.8 cm from anterior to posterior. The specimen weighs 688 gm. A short stitch is designated by the surgeon as superior, and a long stitch is. designated by the surgeon as lateral. In the inferior-medial portion of the specimen is a fragment of skin,. measuring 7.5 x 4.9 cm. It is white and unremarkable. There is a nipple, measuring 1.3 x 1.5 x 1.6 cm. The specimen is notable for dilated ducts with a viscous, yellow-tan material within them. This material. extends into one of the nipple ducts. No masses are noted, nor are any areas suspicious for DCIS. appreciated. The anterior-superior portion of the specimen is inked blue, the anterior-inferior portion of. the specimen is inked green, and the posterior aspect of the specimen is inked black. Multiple sections of. unremarkable breast parenchyma are taken for two studies, including a high-risk study and an epithelial. cell study. Representative sections are submitted as follows: Cassettes D1-D2: Nipple and surrounding skin. Cassette D3: Representative section of anterior-inferior breast with dilated duct. Cassette D4: Representative section of lower inner breast with dilated ducts. Cassette D5: Representative section of upper inner breast. Cassette D6: Representative section of medial breast. Cassette D7: Representative section of upper outer breast. Cassette D8: Representative section of upper inner breast. Cassette D9: Representative section of lateral breast. Part E is additionally labeled. It consists of a single irregular fragment of soft, yellow tissue, measuring 5.4 x 3.8 x 1.5 cm. A suture. has been placed on one aspect of the specimen and is designated the new margin. That aspect of the. specimen is inked black, and the specimen is serially sectioned and entirely submitted in cassettes E1. through E5. Part F is received fresh labeled,. It consists of an. Working Draft. ovary, measuring 4.3 x 2 x 0.8 cm, with attached fallopian tube, measuring 0.8 x 0.5 x 6 cm. There is a. simple paratubal cyst, measuring 1.5 x 1.5 x 0.5 cm. This is received undisrupted, with a thin 0.1 cm. translucent wall, and contains 20 CC of clear fluid. In addition, there is a second small paratubal cyst,. measuring 0.5 x 0.5 x 0.5 cm. The ovary is serially sectioned, and no abnormalities are detected, other. than a 0.5 x 0.5 x 0.5 cm small white firm area. The fallopian tube is serially sectioned, and no. abnormalities are detected. Cassettes are submitted as follows: Cassettes F1-F9: Ovary, entirely submitted (firm, white area in cassette F7). Cassettes F10-F12: Fallopian tube, entirely submitted. Cassette F13: Representative section of the paratubal cyst and smaller, 0.5-cm paratubal cyst. Cassette F14: Representative section of broad ligament. Part G is additionally labeled. It consists of an ovary with attached fallopian tube,. weighing 15.9 gm. There is a disrupted hemorrhagic, cystic mass in the broad ligament, measuring 2.3 x. 1.6 x 1.5 cm, no capsule is visualized. A representative section of the cystic mass is submitted for frozen. section diagnosis as FS3. The ovary and tube do not appear involved by the lesion. The ovary is inked. black, it contains a simple corpus luteal cyst measuring 1.5 x 1.6 x 0.8 cm. The ovary measures 3.5 x 3. x. 1 cm, and the tube measures 6.5 x 0.8 cm. The ovary and fallopian tube are serially sectioned, and no. abnormalities are detected. Cassettes are submitted as follows: Cassettes G1-G6: Ovary, entirely submitted. Cassettes G7-G10: Fallopian tube, entirely submitted. Cassettes G11-G12: Lesion in broad ligament, entirely submitted. Cassette G13: Frozen section remnant. Part H is additionally labeled. It consists of an unoriented piece of yellow,. adipose tissue, measuring 5 x 1.3 x 0.4 cm, with a white-tan, soft nodule, measuring 0.3 x 0.3 x 0.3 cm,. attached to one end. This is entirely submitted for frozen section diagnosis as FS4, with the frozen. section remnant submitted in cassette H1. The remaining omentum is entirely submitted in cassette H2. Part I is additionally labeled. It consists of multiple unoriented. fragments of tissue, measuring 1 x 0.3 x 0.1 cm in aggregate. The specimen is entirely submitted for. frozen section diagnosis as FS5, with the frozen section remnant submitted in cassette 11. Part J is additionally labeled. It consists of an aggregate of fatty tissue, measuring 4 x 2 x 0.5. cm. No abnormalities are detected. Tne specimen is entirely submitted in cassettes J1 through J3. /Pathology Resident. Fee Codes: Other Specimens. Specimen Class: Accessioned: Specimen(s) Received: Right Breast, Fine Needle Aspiration. Final Diagnosis. Right Breast, Fine Needle Aspiration: Benign scar tissue, see comment. Working Draft. Specimen Class: Accessioned: Specimen(s) Received: Vaginal/Cervical/Endocervical, Thin Prep Imaged. Final Diagnosis. Vaginal/Cervical/Endocervical, Thin Prep Imaged. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. Reactive cellular changes. Atrophic changes. SPECIMEN ADEQUACY: Satisfactory for evaluation. Transformation zone components are present. Specimen Class: Accessioned. Specimen(s) Received: Right Breast, implant capsule. Final Diagnosis. Right breast, implant capsule, capsulectomy: Peri-prosthetic capsule. Specimen Class: Accessioned. Specimen(s) Received: Cervical/Endocervical, Thin Prep Imaged. Final Diagnosis. Cervical/Endocervical, Thin Prep Imaged. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. Atrophic changes. SPECIMEN ADEQUACY: Satisfactory for evaluation. No transformation zone components are identified. Specimen Class: Accessioned: Specimen(s) Received: Endometrium, biopsy. Final Diagnosis. Endometrium, biopsy: Fragments of benign endocervical tissue and no definitive. endometrium, see comment. Working Draft. Specimen Class: Accessioned: Specimen(s) Received: Cervical/Endocervical, Thin Prep Imaged. Final Diagnosis. Cervical/Endocervical, Thin Prep Imaged. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. Atrophic changes. SPECIMEN ADEQUACY: Satisfactory for evaluation. Transformation zone components are present. Specimen Class: Accessioned. Specimen(s) Received: A: Left breast capsule, B: Right breast capsule. Final Diagnosis. A. Breast capsule, left, excision: Dense fibrous tissue with chronic inflammation. B. Breast capsule, right, excision: Dense fibrous tissue with chronic inflammation. Specimen Class: Accessioned: Specimen(s) Received: Cervical/Endocervical, Thin Prep Imaged. Final Diagnosis. Cervical/Endocervical, Thin Prep Imaged. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. Atrophic changes. SPECIMEN ADEQUACY: Satisfactory for evaluation. Transformation zone components are present. Specimen Class: Accessioned: Specimen(s) Received: A: Skin, biopsy, shave, right scalp, B: Skin, biopsy, shave, left scalp, C: Skin, biopsy, punch, left upper. arm. Final Diagnosis. (Final Report Not Signed Out}. {Not Entered}. Specimen Class: Accessioned. Specimen(s) Received: A: Pelvic Washing, B: Diaphragm Washing. Working Draft. Final Diagnosis. A: Pelvic Washing. BENIGN. Reactive mesothelial cells. B: Diaphragm Washing. BENIGN. Reactive mesothelial cells. Specimen Class: Accessioned: Specimen(s) Received: Left Breast, Fine Needle Aspiration. Final Diagnosis. Left Breast, Fine Needle Aspiration: Adenocarcinoma, morphologically consistent. with a primary breast carcinoma. Specimen Class: Accessioned. Specimen(s) Received: Cervical/Endocervical, Thin Prep Imaged. Final Diagnosis. Cervical/Endocervical, Thin Prep Imaged. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. Reactive cellular changes. SPECIMEN ADEQUACY: Satisfactory for evaluation. Transformation zone components are present. Specimen Class: Accessioned: Specimen(s) Received: Right foot foreign body. Final Diagnosis. Foot, right, excision: Fragment of hyperkeratotic squamous epithelium. Specimen Class: Accessioned. Specimen(s) Received: Cytology, GYN, Site Not Specified, Thin Prep. Final Diagnosis. Cytology, GYN, Site Not Specified, Thin Prep. Working Draft. NEGATIVE FOR INTRAEPITHELIAL. LESION OR MALIGNANCY. Reactive cellular changes. SPECIMEN ADEQUACY: Satisfactory for evaluation. Transformation zone components are present. Specimen Class: Accessioned. Specimen(s) Received: Cervical/Endocervical, Thin Prep. Fina) Diagnosis. Cervical/Endocervical, Thin Prep. NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. SPECIMEN ADEQUACY: Satisfactory for evaluation. Transformation zone components are present. Specimen Class: Accessioned. Specimen(s) Received: Vaginal/Cervical/Endocervical, Direct. Final Diagnosis. Vaginal/Cervical/Endocervical,Direct. CELLULAR CHANGES WITHIN NORMAL LIMITS. Endocervical cells present. SPECIMEN ADEQUACY: Satisfactory for evaluation but limited by obscuring white blood cells. Gpecimen Class: Accessioned: Specimen(s) Received: Skin, biopsy, left chin. Final Diagnosis. {Final Report Not Signed Out}. (Not Entered}. Specimen Class: Accessioned. Specimen(s) Received: Cervical, Direct. Final Diagnosis. Cervical, Direct.",1,True,"% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.","% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.",4.0,565.0,T2,"The report mentions a mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm). According to the rules, this indicates a T2 stage.",98.0,True
TCGA-PL-A8LY.8C97B391-96B4-468D-AAA3-24E196DE03CA,"Sex: Female. Date of Tumour Procurement: 1. GROSS ASSESSMENT: Cut section showed a variegated tumour measuring. 3.4x2.5x1.5cm. 2. MICROSCOPIC ASSESSMENT. Microscopic description: Section shows a malignant tumour in cords, solid nests and. tubular patterns. It is composed of large cells having moderately pleomorphic. hyperchromatic nuclei and amphophilic cytoplasm. The stroma is demoplastic containing. similar tumour cells and aggregates of lymphocytes. Focal areas of necrosis noted. 3. Tumour Type: Malignant. 4. Tumour Site: Right Breast. 5. Distance of invasive carcinoma to closest margin: -5mm. Which margin? Deep resection. 6. HISTOLOGICAL DIAGNOSIS: Invasive Ductal Carcinoma. 7. COMMENTS: Dr. Reporting Pathologist Name.",2,True,"% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy or if the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.
% T4: If the report mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.",4.0,565.0,T3,"The report mentions a radical mastectomy, which according to the rule '% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.' suggests a T3 or T4 stage. However, since the report also provides a specific tumor size of 3.4x2.5x1.5cm, which is greater than 50 mm, the T stage is T3, regardless of the type of surgery performed. This is in line with the rule '% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.'",79.0,False
TCGA-V7-A7HQ.82B46073-10CE-4D05-9421-6308E3FAD1AD,"SurgicalFinal Report. l'emporary. orderediby. Final Pathologic Diagnosis. CORRECTED REPORT: A) SENTINEL NODE #1 (EXCISION): One lymph node involved by metastatic carcinoma (1/1). B) SENTINEL NODE #2 (EXCISION): One out of two lymph nodes, involved by metastatic carcinoma. (micrometastases) (1/2). C) SENTINEL LYMPH NODE #3 (EXCISION): One out of two lymph nodes, involved by metastatic carcinoma. (micrometastases) (1/2). D) RIGHT BREAST (MASTECTOMY): Invasive ductal carcinoma, Nottingham grade 2. See synoptic report. E) NEW INFERIOR MARGIN (EXCISION): Breast tissue with benign fibrocystic changes, including ductal. hyperplasia and apocrine metaplasia. Negative for malignancy. NOTE: This corrected report is being issued due to a typographical error In the original report. The initial diagnosis rendered by. remains unchanged. I attest I have personally reviewed the specimen/slides and agree with the above findings. Synoptic Report. D: BREAST, MASTECTOMY -. SPECIMEN TYPE: Mastectomy. LYMPH NODE SAMPLING: Sentinel lymph node with axillary dissection. SPECIMEN SIZE: Surgical Final Report. Temporary Copy. case. Greatest dimension: 30 cm. Additional dimensions: 7.0 x 2.5. LATERALITY: Right. TUMOR SITE: Lower outer quadrant. SIZE OF INVASIVE COMPONENT: Greatest dimension: 2.0 cm. Additional dimensions: 1.5 x 1.0 cm. Two separate lesions were present, each one measuring 2.0 x 1.5 x 1.0 cm. HISTOLOGIC TYPE: Ductal carcinoma in situ. Invasive ductal carcinoma. HISTOLOGIC GRADE: Tubule formation: Moderate 10% to 75% (score = 2). Nuclear pleomorphism: Marked variation in size, nucleoli, chromatin clumping, etc. (score =. 3). 0 to 5 mitoses per 10 HPF (score = 1). Nottingham Grade II: 6-7 points. PRIMARY TUMOR (pT): pT1c: Tumor more than 1.0 cm but not more than 2.0 cm in greatest dimension. REGIONAL LYMPH NODES (pN): pN2a: Metastasis in 4 to 9 axillary lymph nodes (at least 1 tumor deposit greater than 2.0. mm). Number examined: 18. Number involved: 5. DISTANT METASTASIS (M): pMX: Cannot be assessed. MARGINS: Margin(s) involved by invasive carcinoma. Specify which margin(s): Inferior margin at mastectomy (specimen D). See comment. EXTENT OF MARGIN INVOLVEMENT FOR INVASIVE CARCINOMA. VENOUS/LYMPHATIC (LARGE/SMALL VESSEL) INVASION (V/L): Present. MICROCALCIFICATIONS: Present in DCIS. ADDITIONAL PATHOLOGIC FINDINGS: Fibrocystic changes, biopsy site related changes, and columnar cell hyperplasia. COMMENT(S): The inferior margin is invovled by carcinoma in the mastectomy specimen (specimen D),. however, additionally submitted inferior resection margin is not involved (specimen E). Clinical. correlation is necessary for interpretation of these findings. Diagnostic Comment. According to previous biopsy, 65% of tumor cells show moderate to strong nuclear staining. for estrogen receptors, 80% of tumor cells show nuclear staining show strong nuclear staining. for progesterone receptors, and Her2-neu gene is not amplified by FISH (please see report. Surgical Final Report. emporary Copy. Intraonerative Diagnosis. TP A1: Touch prep positive for carcinoma. No frozen done. TP B1: No touch preps done because first sentinel lymph node is positive. TP C1: No touch preps done because first sentinei lymph node is positive. Clinical History. year old female with breast cancer. Pre/Post-operative Diagnosis. Breast cancer. Gross Anatomic Description. (SPECIMEN D: Dictated by. (SPECIMENS A-C and E: Dictated by. Specimens received in five containers. Snecimen A: Designated ""sentinel node #1"" is received fresh for intraoperative consultation on. labeled with the patient's name and ""sentinel node #1"". Specimen consists one piece of. yellow tissue measuring 1.2 x 1.0 x 0.6 cm. The lymph node is bisected. Touch prep is done. No. frozen section is performed. Section code: A1 - two pieces, one lymph node, entire specimen. Specimen B: Designated ""sentinel node #2"" is received fresh for intraoperative consultation on. labeled with the patient's name and ""sentinel node #2"". Specimen consists of one yellow/tan. irregular fragment of tissue measuring 0.8 x 0.6 x 0.3 cm. No intraoperative procedure performed. Entirely submitted for permanent sections. Section code: B1 - entire specimen. Specimen C: Designated ""sentinel node #3"" is received fresh for intraoperative consultation on. labeled with the patient's name and ""sentinel node #3"". Specimen consists of one yellow/tan. fatty fragment of tissue measuring 0.8 x 0.4 x 0.4 cm. The specimen is bisected revealing one lymph. node. No intraoperative procedure performed. Entirely submitted for permanent sections. Section code: C1 - two pieces, one lymph node, entire specimen. Specimen D: Designated ""right mastectomy (stitch on lateral margin, clip on apex of dissection)"" is. received fresh for Tumor Bank on. labeled with the patient's name, MRN and ""right. mastectomy (stitch on lateral margin, clip on apex of dissection). Specimen consists of one right. radical mastectomy with attached axillary tail weighing 220.8 g. The specimen measures 30.0 x 7.0. x. 2.5 cm. The axillary tail measures 13.0 x 3.5 x 2.0 cm. The breast measures 17.0 x 6.0 x 2.5 cm. There is an overlying ellipse of tan wrinkled skin measuring 15.0 x 6.0 cm. There is an unremarkable. nipple measuring 1.5 cm in diameter and 0.5 cm in thickness. The areola measures 4.0 x 3.5 cm and. is unremarkable. The external palpation of skin reveals two firm masses which are inferior lateral to. the nipple, at the outer lower quadrant. One is at 3.5 cm from the nipple and the other is at 2.0 cm. from the nipple. The suture is identified which denotes the lateral margin. Cut surface reveals two. white/tan spiculated tumors. The medial tumor measures 2.0 x 1.5 x 1.0 cm with what appears to be. a. previous biopsy site. The more lateral tumor mass measures 2.0 x 1.5 x 1.0 cm and also appears to. have a previous biopsy site. The tumor masses appear to be connected by a white/tan tract of tumor. Surgica Final Report. Temporary.Copy. Collectedal. D. orderediby. measuring 0.5 x 0.2 x 0.2 cm. The lateral tumor comes within <0.1 cm of the inferior margin and 0.2. cm of the deep margin. The medial tumor comes within 0.1 cm of the inferior margin and appears to. abut the deep margin. Both tumors are >3.0 cm from the superior and medial margins. The. remainder of the cut sections are grossly unremarkable as yellow/tan fatty fibrous tissue. There is a. free floating fragment of breast tissue measuring 8.5 x 1.5 x 0.5 cm with a staple denoting the medial. position. The fragment weighs 3.9 g. This fragment is oriented with the assistance of. and. according to him, it represents the deep margin. The fragment is oriented regarding lateral and medial. aspects. The axillary tail is dissected and eleven lymph nodes are identified. The lateral tumor comes. within -0.2 cm of skin and the medial tumor comes within 1.0 cm of skin. Inking code - breast: Green - superior portion of breast; Blue - inferior portion of breast; Black - deep. portion of breast; Orange - area of further resection, inferiorly, adjacent to additional inferior margin. (specimen E). Inking code - additional fragment of tissue (deep margin): Black - entire external surface of free deep. fragment; Green - medial tip of free deep fragment. Section code: D1 - representative section of tumor closest to nipple; D2 - representative section of. tumor farthest from nipple; D3 - tip of nipple, serially sectioned; D4 - remainder of nipple, en face; D5. - section of medial tumor with skin and orange margin; D6 - representative section of medial tumor. with skin and orange margin; D7 - representative portion of tissue between described tumors to. contain described tumor tract; D8 - representative section of lateral tumor with skin; D9-D10 -. representative sections of lateral tumor with skin (sections through tumor were made from medial. to. lateral); D11-D12 - two representative sections of unremarkable breast tissue from medial inferior. quadrant; D13-D14 - representative sections of unremarkable breast tissue from superior medial. quadrant; D15-D16 - representative portions of unremarkable breast tissue from superior lateral. quadrant; D17-D18 - representative sections of unremarkable breast tissue and lateral inferior. quadrant; D19 - one lymph node, bisected; D20 - one lymph node, bisected; D21 - two lymph nodes. submitted wholly with the more proximal node inked in black; D22 - two lymph nodes submitted wholly. with the more proximal lymph node inked in black; D23 - one lymph node, bisected; D24 - two lymph. nodes submitted wholly with the more proximal lymph node inked in black; D25 - two lymph nodes. with the more proximal node inked in black (the lymph nodes were submitted from proximal to distal);. D26 - inferior margin; D27 - lateral margin; D28 - medial margin; D29 - superior margin; D30 - deep. posterior margin; D31-D36 - deep free fragments of breast tissue serially sectioned from medial to. lateral. Specimen E: Designated ""new inferior margin"" is received in formalin labeled with the patient's name. and ""new inferior margin"". Specimen consists of one yellow/tan fatty fragment of tissue weighing 10.6. g and measuring 5.5 x 2.5 x 1.0 cm. The new inferior margin is inked in blue and the specimen is. serially sectioned. Cut sections reveal a yellow/tan fatty interior that is grossly unremarkable. Section code: E1-E6 - entire specimen.",0,True,"% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.","% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.",4.0,565.0,T2,"The report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm). The size of the invasive component is given as 2.0 cm, which falls within the T2 range.",100.0,True
TCGA-A7-A26J.5CC0C09F-70F6-458A-B8E6-18BDC074BE74,"Date Coll: SPECIMEN. A. Left axillary sentinel node. B. Left breast silk on superior breast. CLINICAL NOTES. PRE-OP DIAGNOSIS: Left breast cancer. CLINICAL HISTORY: year-old white female with cancer. POST-OP DIAGNOSIS: Same. GROSS DESCRIPTION. A. Received fresh labeled ""left axillary node"" is a 3.8. x. 2.4 x 0.6 cm. portion of soft, lobulated golden-yellow. adipose tissue. Two (2) slightly rubbery tan-pink tissues in. keeping with lymph node measuring 0.8 and 1.8 cm. in greatest. dimension are recovered. The specimen is entirely submitted in. three blocks as labeled: BLOCK SUMMARY: #A1,A2 - One (1) bisected lymph node per cassette;. -1 adipose tissue. B. Received fresh labeled ""left breast"" is a 21.5 cm. (superior to inferior) x 20.5 cm (medial to lateral) x 3.8. cm (anterior to posterior) diffusely cauterized soft, lobulated. tan-gold-white portion of fibroadipose tissue in keeping with breast. designated as left per requisition slip and container and oriented. by a single suture as stated previously. A 7.2 cm (medial to. lateral) x 4.7 cm (superior to inferior) tan-white skin ellipse is. present along the anterior aspect. The intact deep margin is inked. black and the specimen is sectioned. There is a central, stellate,. 3.0 cm (medial to lateral) x 2.2 cm (superior to inferior) x 2.0. cm. (anterior to posterior) rubbery tan-white lesion at the junction of. the four quadrants with several cylindrical tan-white structures in. keeping with site of prior needle core biopsy. A portion of the. lesion and a portion of normal are submitted for tissue procurement. as. requested. The lesion is present within 0.8 cm of the skin. surface in the vicinity of the nipple and is within 0.5 cm of the. inked deep margin. The parenchyma throughout the remainder of the. specimen consists predominantly of glistening lobulated golden. yellow adipose tissue with a moderate amount of interspersed dense. tan-white fibrous tissue. No additional mass lesion or abnormality. is identified. Three rubbery white-pink tissues in keeping with. lymph nodes measuring up to 0.8 cm in greatest dimension are. recovered from the lateral aspect of the specimen. Representative. sections are submitted in 12 blocks as labeled. BLOCK SUMMARY: 1-2 - Tumor to inked deep margin; 3-4 - tumor to. skin (4 includes nipple); 5-6 - tumor to adjacent parenchyma; 7 -. random upper outer quadrant; 8 - upper inner quadrant; 9 - lower. inner quadrant; 10 - lower outer quadrant; 11 - two whole lymph. nodes; 12 - one bisected lymph node. MICROSCOPIC DESCRIPTION. Invasive carcinoma: Histologic type: Ductal (with lobular features). Histologic grade : III. Overall grade: 8/9. Architectural score: 3. Nuclear score: 3. Mitotic score: 2. Greatest dimension (pT) : 3.0 cm. Specimen margins: Negative. Vessel invasion: Present. Calcification: Negative. Nipple (Paget's) : Carcinoma involves the deep nipple tissue, and. is present in the deep dermis within the skin adjacent to the. nipple (areolar area) . Invasion of skin or chest wall: As above. Ductal carcinoma in situ: Histologic pattern: Cribriform. Nuclear grade: 3. Central necrosis: Present. 8 DCIS of total tumor (if mixed) : < 10%. Extensive intraductal component (present/absent) : Absent. Specimen margins: Negative. Calcification: Negative. Description of non-tumorous breast: Fibrocystic changes,. fibroadenomata. Comments: Prior biopsy site identified within the main tumor mass. There is an additional satellite nodule of invasive tumor, 2 mm in. greatest dimension, in the lower outer quadrant, away from the main. tumor mass, and associated with ductal carcinoma in-situ. This. focus of invasive tumor is 2 mm from the deep margin. Lymph nodes: Two negative sentinel lymph nodes, and two negative. additional lymph nodes (0/4). Prognostic markers: See previous report,. 4x2. DIAGNOSIS. A. Sentinel lymph node, left axilla, biopsy: Two negative lymph nodes (0/2). B. Breast, deft mastectomy: Invasive ductal carcinoma, grade III, 3.0 cm in greatest. dimension. Negative margins of excision. Lymphovascular invasion identified. Two negative lymph nodes (0/2). ectronic Signature). End Of Report ---.",1,True,"% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.","% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.",4.0,565.0,T2,"The report mentions a 'deft mastectomy' which is a type of mastectomy, but it does not mention a radical mastectomy. The report also provides a specific tumor size of 3.0 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is likely to be T2.",100.0,True
TCGA-BH-A0E9.8FDACA3D-C172-4198-9BBB-8F9E5A5FF0D6,"P.32/33. TIAAL DIAGNOSIS: PART 1: LYMPH NODE, RIGHT AXILLARY, SENTINEL NODE #1, BIOPSY. ONE LYMPH NODE, POSITIVE FOR CARCINOMA (1/1) (SEE COMMENT). PART 2: BREAST, RIGHT,,MODIFIED RADICAL MASTECTOMY -. A, INVASIVE LOBULAR CARCINOMA. PLEOMORPHIC TYPE WITH FOCAL SIGNET CELLS. B. NOTTINGHAM GRADE II (TUBULE FORMATION- 3: NUCLEAR PLEOMORPHISM-3; MITOTIC ACTIVITY - 1;. TOTAL SCORE 7/9). C. THE INVASIVE CARCINOMAS ARE LOCATED AT THE 12 O'CLOCK AND 6 O'CLOCK POSITIONS. THE. INVASIVE TUMOR MEASURES 2.5 CM IN GREATEST DIMENSION (TUMOR IN 12 O'CLOCK, GROSS. MEASUREMENT). D. LOBULAR CARCINOMA IN SITU (LCIS), NUCLEAR GRADE 2-3, ADMIXED WITH INVASIVE CARCINOMA. E. RESECTION MARGINS ARE NEGATIVE FOR IN SITU AND INVASIVE CARCINOMA. F. LYMPHOVASCULAR INVASION IS NOT NOTED. G. NIPPLE AND SKIN ARE NEGATIVE FOR TUMOR. H. TWO OF 11 LYMPH NODES (2/11) ARE POSITIVE FOR CARCINOMA. I. MICROCALCIFICATIONS ARE ASSOCIATED WITH THE INVASIVE AND IN SITU CARCINOMA. J. FIBROCYSTIC CHANGES AND SCLEROSING ADENOSIS. K. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN AND PROGESTERONE RECEPTORS AND. NEGATIVE FOR HER2/NEU, AS PER PREVIOUS PATHOLOGY REPORT. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Modified radical mastectomy. Central subareolar. Lower outer quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 2.5 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 4.5 cm. TUMOR TYPE (invasive component): Infiltrating lobular carcinoma. HISTOLOGIC TYPE: Pleomorphic, Signet ring. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 7. Nottingham grade (1. 2. 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes. malignant zones. TUMOR TYPE, IN SITU: I.CIS, Percent of tumor occupied by in situ component: 30 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 3. LYMPH NODES EXAMINED: 12. METHOD(S) OF LYMPH NODE EXAMINATION: SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 15 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSI√ìN: SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: zero or 1+.",1,True,"% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.","% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.",4.0,565.0,T2,"The report specifically mentions that the 'size of tumor: maximum dimension invasive component' is 2.5 cm, which falls within the T2 range (>20 mm but <=50 mm). Additionally, the report mentions that the patient underwent a modified radical mastectomy, which aligns with the T2 criteria in the rules.",100.0,True
TCGA-BH-A0E2.29EDE507-90BA-4ABE-B3EF-559EBA4CCD56,"P.25/33. DIAGNOSIS: BREAST, RIGHT, MODIFIED RADICAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA WITH ASSOCIATED CALCIFICATIONS. B. NOTTINGHAM GRADE 3 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 3, MITOTIC ACTIVITY: 3; TOTAL. SCORE: 9/9). C. INVASIVE TUMOR MEASURES 2.5 X 2.3 X 2.0 CM. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID, CRIBRIFORM MICROPAPILLARY AND CLEAR. CELL TYPES WITH COMEDONECROSIS AND ASSOCIATED CALCIFICATIONS. E. THE DUCTAL CARCINOMA IN SITU (DCIS) CONSTITUTES 50% OF THE TOTAL TUMOR VOLUME AND IS. PRESENT ADMIXED WITH THE INVASIVE COMPONENT. F. THE DUCTAL CARCINOMA IN SITU (DCIS) IS PRESENT IN 12/22 SLIDES. G. NO LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. H. RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. DUCTAL CARCINOMA IN SITU (DCIS) IS 4.0 MM. FROM THE NEAREST ANTERIOR MARGIN, THE INVASIVE CARCINOMA IS GREATER THAN 1.0 CM FROM ALL. MARGINS. I. THE NIPPLE IS INVOLVED BY DUCTAL CARCINOMA IN SITU. J. SKIN IS NEGATIVE FOR TUMOR. K. NON-NEOPLASTIC BREAST: INTRADUCTAL PAPILLOMA AND FIBROCYSTIC CHANGES WITH. FIBROADENOMATOID NODULES,. L. BIOPSY SITE CHANGES WITH FAT NECROSIS. M. METASTATIC CARCINOMA INVOLVING FOUR OF TWENTY-SIX LYMPH NODES (4/26). N. THE LARGEST METASTATIC FOCUS MEASURES 2.0 CM. O. EXTRACAPSULAR EXTENSION IS IDENTIFIED AND MEASURES 1 MM. P. THE INVASIVE TUMOR CELLS TESTED POSITIVE FOR ESTROGEN AND WEAKLY POSITIVE FOR. PROGESTERONE RECEPTORS AND NEGATIVE FOR HER-2, AS PER PREVIOUS PATHOLOGY REPORT. LASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Modified radical mastectomy. Lower outer quadrant. SIZE OF TUMOR: MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: Maximum dimension invasive component: 2 5 cm. TUMOR TYPE (invasive component): NOTTINGHAM SCORE: Ductal adenocarcinoma, NOS. Nuclear grade: 3. Tubule formation: 3. Mitolic activity score: 3. Total Nottingham score: 9. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION;. Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. Solid. Micropapillary. Comedo. DCIS admixed with invasive carc√≠noma. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Percent of tumor occupled by in situ component 50 %. SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: Distance of in silu disease to closest margin: 40 mm. LYMPH NODES POSITIVE: 4. LYMPH NODES EXAMINED: 26. METHOD(S) OF LYMPH NODE EXAMINATION: H/E levels. SIZE OF NODAL METASTASES: Diameter of largest lymph nodo metastasis: 20 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: Papillonia, FCD, Other: Fibroadenomatoid nodules. T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pN2a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGEST√âRONE RECEPTORS: positive. HER2/NEU:",1,True,"% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report mentions a radical mastectomy and the tumor involves the chest wall or the skin (ulceration or skin nodules), then the T stage is T4.","% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.",4.0,565.0,T2,"The report mentions a modified radical mastectomy and provides a specific tumor size of 2.5 x 2.3 x 2.0 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is likely to be T2.",79.0,False
TCGA-BH-A0AU.4C942A1D-53B2-43A6-9B96-5155CCDEEC34,"FINAL DIAGNOSIS: PART 1: LEFT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. TWO LYMPH NODES, NEGATIVE FOR METASTATIC CARCINOMA (0/2) (see comment). PART 2: BREAST, LEFT, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 2 (TUBULE FORMATION 3, NUCLEAR GRADE 2,. MITOTIC RATE 1; TOTAL SCORE 6/9). B. INVASIVE CARCINOMA MEASURES 2.2 CM IN GREATEST DIMENSION. C. DUCTAL CARCINOMA IN-SITU (DCIS), NUCLEAR GRADE 2, SOLID TYPE WITH COMEDONECROSIS. D. DCIS IS PRESENT ADMIXED WITH INVASIVE COMPONENT AND COMPRISES <5% OF TOTAL TUMOR. VOLUME. E. MARGINS OF RESECTION ARE NEGATIVE FOR INVASIVE CARCINOMA AND DCIS, INVASIVE CARCINOMA. IS 5 MM FROM CLOSEST (POSTERIOR) MARGIN OF RESECTION. F. LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. G. SKIN, NEGATIVE FOR TUMOR. H. INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN AND PROGESTERONE RECEPTORS AND. EQUIVOCAL FOR HER-2/NEU WITH A SCORE OF 2+, AND PER PREVIOUS PATHOLOGY REPORT (. NO AMPLIFICATION OF THE HER-2/NEU GENE WAS SEEN BY INTERFACE FISH ANALYSIS. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 2.2 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: DCIS admixed with invasive carcinoma. Percent of tumor occupied by in situ component: 5 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 5 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 2. METHOD(S) OF LYMPH NODE EXAMINATION: Keratin stain. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pNO(i-). M STAGE, PATHOLOGIC: pma. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 2+.",1,True,"% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.","% T1: If the report mentions a lumpectomy or a segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T3, regardless of the type of surgery performed.",4.0,565.0,T2,"The report explicitly mentions that the 'SIZE OF TUMOR: Maximum dimension invasive component: 2.2 cm.' This falls within the T2 range (>20 mm but <=50 mm). Additionally, the report mentions that the procedure performed is a segmental mastectomy, which aligns with the T2 criteria in the rules provided.",100.0,True
TCGA-5L-AAT0.F9B6971F-23C0-465F-BFEC-778BF228A1AE,"Gender: Female. Color: White. Origin: Nature of material: Breast. Biopsy number: Gross description: Received one piece of fibrofatty tissue measuring 2.2 x1.2 X 0.4 cm marked with shorts suture. On slicing in the central part is a white and firm area measuring 0.4 cm in the largest. diameter. Microscopy. Dispensable description. Conclusions: Right breast wide excision: Invasive lobular carcinoma, grade 1;. Immunohistochemistry: e-cadherin: negative;. ER: positive in 70%;. PgR: positive in 20%;. HER2: negative (score 1+). PARTICIPANTS OF APPRAISAL REPORT. Issuer. - Reviewer. - Reviewer.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T4, regardless of the type of surgery performed.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T4, regardless of the type of surgery performed.",4.0,579.0,T1,"The report mentions a 'wide excision' which is similar to a lumpectomy or segmental mastectomy. Additionally, it provides a specific tumor size of 0.4 cm which falls within the T1 range (<=20 mm). Therefore, the T stage is likely T1.",98.0,True
TCGA-AR-A1AJ.0DEAC35F-8B73-4A9F-B7FA-2F501B736B0E,"Final Diagnosis. Breast right, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III),. forming a mass, 1.2 x 1.1 x 0.9 cm. (AJCC pTIc). Angiolymphatic invasion is not identified. The surgical margins are negative for tumor. The closest margin (inferior) is free by 0.3 cm. Lymph nodes, right axillary sentinel, excision: Multiple (2) right axillary sentinel lymph nodes. are negative for tumor. Blue dye is not identified in either of the right axillary sentinel lymph. nodes. Immunohistochemical cytokeratin stain was performed on the paraffin embedded sentinel. lymph node tissue and confirms the H&E impression [AJCCpTN(i-)]. Lymph nodes, right axillary, excision: Multiple (6) right axillary lymph nodes are negative for. tumor. HER2/neu protein overexpression is negative, score of 0, according to the interpretation. guidelines in the FDA-approved HercepTest.",0,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T4, regardless of the type of surgery performed.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T4, regardless of the type of surgery performed.",4.0,579.0,T1,"The report mentions a wide local excision and provides a specific tumor size of 1.2 x 1.1 x 0.9 cm, which falls within the T1 range (<=20 mm). Therefore, the T stage is T1.",100.0,True
TCGA-A8-A07P.6C7D956E-1247-4663-9ED5-D406AE6E2959,"On the basis of these findings, the following overall diagnosis is established: Left breast segment at 2 o'clock with a 3.5 cm invasive ductal breast carcinoma grade 3. (3/3/2) with minimum distance of 1 mm from dorsal resection margin and cranial resection. margin of 3 mm with very small components of ductal carcinoma in situ grade 3 with comedo. necrosis, as well as a lymph node with a tumor (1/11). Tumor classification: pT2 (3.5 cm), pN1 (1/11), MX grade 3 (LO/V0), R0 (dorsal 1 mm,. cranial 3 mm).",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T4, regardless of the type of surgery performed.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy, then the T stage is likely to be T3 or T4.
% T4: If the report provides a specific tumor size >50 mm, then the T stage is T4, regardless of the type of surgery performed.",4.0,579.0,T2,"The report mentions a specific tumor size of 3.5 cm, which falls within the T2 range (>20 mm but <=50 mm). The report also mentions that a mastectomy was performed, but it does not specify a radical mastectomy. Therefore, the T stage is likely to be T2.",100.0,True
TCGA-AR-A5QN.A9015F6A-F6BB-4AC8-B681-099232A6DFAC,"A. Lymph nodes, left tracheoesophageal groove, excision: Multiple (3) lymph nodes are. negative for tumor. B. Thyroid, left, total lobectomy: Follicular adenoma (3.3 x 3.2 x 1.8 cm). C. Breast, right, simple mastectomy: Fibroadenoma measuring 0.7 x 0.6 x 0.5 cm at the previous. biopsy site in the upper outer quadrant. Remainder shows non-proliferative fibrocystic changes. Multiple (2) right axillary lymph nodes are negative for tumor. D. Breast, left, inferior flap, biopsy: Negative for tumor. E. Breast, left, inferior margin at 6 o'clock, excision: Involved by carcinoma. F. Breast, left, new inferior margin, re-excision: Negative for tumor. G. Breast, left, modified radical mastectomy: Invasive lobular carcinoma, Nottingham grade II. (of III), [tubules 3/3, nuclei 2/3, mitoses 1/3; Nottingham score 6/9], forming multiple (6) masses. (lower inner quadrant, 0.7 x 0.6 x 0.4 cm and 1.4 x 1.0 x 0.5 cm; inferior/central, 3.2 x 2.2 x 1.4. cm; central, 0.6 x 0.5 x 0.5 cm; lower outer quadrant, 1.0 x 0.8 x 0.8 cm and 0.5 x 0.4 x 0.4 cm). in the left breast. Ductal carcinoma in situ and lobular carcinoma in situ are present. The non-. neoplastic breast parenchyma shows nonproliferative fibrocystic changes. A second core biopsy. site is present in the upper outer quadrant which shows biopsy site changes. The tumor does not. involve the nipple, overlying skin, or underlying chest wall. Dermal nevus forming a 1.5 x 1.3 x. 0.3 cm raised, brown, pigmented lesion on the lateral aspect of the skin. All surgical resection. margins, after multiple (2) re-excisions of the inferior margin (see parts E and F), are negative for. invasive carcinoma by 1.2 cm, deep margin. Multiple (10 of 19) left axillary lymph nodes are. positive for metastatic carcinoma. The largest metastasis measures 11.0 mm. Extranodal. extension is not present. MIB-1 has been ordered on paraffin-embedded tissue. This final pathology report is based on the gross/macroscopic examination and the frozen section. histologic evaluation of the specimen(s). Hematoxylin and Eosin (H&E) permanent sections are. reviewed to confirm these findings. Any substantive changes identified on permanent section. review will be reflected in a revised report.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy and provides a tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy and provides a tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,596.0,T2,"The report mentions a simple mastectomy on the right breast with a fibroadenoma measurement of 0.7 x 0.6 x 0.5 cm. However, the left breast indicates a modified radical mastectomy with an invasive lobular carcinoma forming multiple masses, the largest one measuring 3.2 x 2.2 x 1.4 cm. This falls within the T2 range (>20 mm but <=50 mm), so the T stage is likely T2.",84.0,True
TCGA-BH-A203.3EBBE51B-6D17-4A77-AAE1-E0424CEA56DB,"PATIENT HISTORY: Procedure Date: DATE OF LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: R BREAST CANCER. POST-OP DIAGNOSIS: SAME. OPERATTVEPROCEDURE: R'SEGM MAST; AXILLARY DISS. CLINICAL HISTORY: MATERIAL SUBMITTED: A) RIGHT SEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. E) RIGHT AXILLA, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE CONSULTATION: FROZEN SECTION: Right brcast mass, 2.1 by 2.1 by 2.0 cm, 0.4 cn from the closest posterior margin. FS. Diagnosis: Infiltzating ductal carcinoma. ER/PR taken. CONSULT: Right axillary y mph node dissection. Metastatic tumor in multiple matted Jymph nodes. FINAL DIAGNOSIS: FINAL DIAGNOSIS: A) RIGHT BREAST SEGMENTAL NASTECTOMY: - INFILTRATING DUCTAL CARCINOMA (2.1 CM), WITH EXTENSIVE LIMPHATIC PERMEATION AND CANCERIZATION OF THE. DUCTS, NUCLEAR GRADE POOR, HISTOLOGIC GRADE 3. - ALL SURGICAL RESECTION MARGINS FREE OF TUMOR. B) RIGHT AXILLA DISSECTION: - THIRTY FIVE OUT OF THIRTY NINE (35/39) LYMPH NODES, POSITIVE FOR METASTATIC INFILTRATING DUCTAL CARCINOMA,. SOME WITH EXTRACAPSULAR SPREAD. - PATHOLOGIC STAGING: T2 N2 MX.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy and provides a tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy and provides a tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,596.0,T2,"The report mentions a segmental mastectomy, which falls under the surgical procedures listed for T1 and T2. However, the tumor size provided is 2.1 cm, which is within the T2 range (>20 mm but <=50 mm). Therefore, the T stage for this patient's cancer is T2.",100.0,True
TCGA-E9-A1RB.3BE8EA29-3C5F-4339-9CE7-98994B545848,"OC ID. Gross Description: Breast with the tumor measuring 2.7 x 2.5 cm. Fatty lymph nodes are soft and hyperemic. Microscopic Description: Infiltrating duct carcinoma; G2. Ten examined lymph nodes demonstrate focal fibrosis and lipomatosis. Diagnosis Details: Tumor Features: Unknown, Tumor Extent: T2 tumor size more than 2cm not more than 5 cm, Venous Invasion: Absent,. Margins: Absent, Treatment Effect: Comments: BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Central breast. Tumor size: 2.5 x 0x 2.7 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None. Laterality: Left, upper inner quadrant (central).",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy and provides a tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a radical mastectomy and provides a tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,596.0,T2,"The report mentions a radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), which matches the rule for T2. The tumor size is 2.5 x 0x 2.7 cm, which falls within the T2 range.",100.0,True
TCGA-OL-A5D8.FD496AFB-43EF-41D8-850F-E57DD53C185C,"FINAL PATHOLOGIC DIAGNOSIS. Mastectomy and sentinel lymph node biopsy,. A. Left axillary sentinel node #1: - Single lymph node, no tumor (0/1). B. Left axillary sentinel node #2: - Single lymph node, no tumor (0/1). C. Mastectomy, left breast: - Invasive ductal carcinoma, SRB grade II, with focal necrosis. - Ductal carcinoma in situ, high nuclear grade, solid type. - Focal Paget' S disease of the nipple. - Uninvolved breast parenchyma with focal flat epithelial atypia, columnar. cell change, ductal hyperplasia of usual type, intraductal papilloma. D. Left axillary base, non-sentinel lymph node: - Two lymph nodes, no tumor (0/2). Breast Pathologic Parameters. 1. Invasive carcinoma: A. Size: Gross measurement: 6.5cm. B. Composite histologic (modified SBR) grade II. - Architecture: 3. - Nuclear grade: 2. - Mitotic count: 1. C. Associated ductal carcinoma in situ (DCIS): - High nuclear grade, solid type. - Associated with (forming 5% of tumor volume) and extending away (focal to. involved lactiferous ducts and nipple) from index lesion. 2. Excisional biopsy margins: Free of tumor. - DCIS > 1cm from deep (closest) margin. - Invasive carcinoma 5mm from deep (closest) margin. 3. Blood vessel and lymphatic invasion: - Rare microscopic foci worrisome for lymphatic involvement in breast. parenchyma. 4. Axillary lymph nodes: Negative for tumor (0/4). 5. Special studies (see. - Strong expression of ER in 100% of invasive tumor nuclei. - Strong expression of PR in 100% of invasive tumor nuclei. - Her2/neu antigen (FISH): pending on prior biopsy material. 6. pTNM: pT3, NO(sn), MX. Clinical History: The patient is a. .year-old female with palpable left breast mass. Biopsy at. outside hospital showed invasive ductal carcinoma, ER/PR positive, HER-2. negative. Breast MRI on. ;howed left inferior irregular margin. with irregular mass and heterogenous enhancement at 6 o' clock position. Multiple contiguous satellite lesions are present predominantly extending. anterior from the mass. Overall dimensions are 6.4 x 6.1 x 4.1 cm. The right. breast was normal. Bilateral axillae were normal. Specimens Received: A: Left axillary sentinel node. B: Left axillary sentinel node. C: Left breast. D: Non-Sentinel node base of axilla. Gross Description: The specimen is received in four containers each labeled with the patient' S. name and medical record number. A. Container A is further identified as, 3left axillary sentinel node4. Received fresh is a 2.5 X 1.5 x 1.0 cm apparent lymph node with blue ink. The. specimen is bisected and entirely submitted for frozen section with the. diagnosis of 3no evidence of tumor4 per. The frozen remnant is. entirely submitted in cassette A1FS. B. Container B is further identified as, 3left axillary sentinel node4. Received fresh is a 2.0 x 1.5 x 1.0 cm apparent lymph node with blue ink. The. specimen is bisected and entirely submitted for frozen section with a diagnosis. of 3no evidence of tumor4 per. The remnant of the frozen section is. entirely submitted in cassette B1FS. C. Container C is further identified as, 3left breast4. Received fresh and. placed in formalin is a specimen mastectomy weighing 1100 grams measuring 23.8. cm from medial to lateral, 17.4 cm from superior to inferior, 6.0 cm from. anterior to posterior. The specimen is oriented with two short sutures. designated as superior and two long sutures designated as lateral. The breast. is overlaid with 14.5 x 10.5 cm adipose and skin. Eccentricallylocated is a. 5.8 x 5.2 cm areola with a nipple with a diameter of 1.5 cm. The nipple areolar. complex displays no evidence of ulceration or retraction. The deep fascia is. inked black and the specimen is sectioned from medial to lateral into ten. slices, with the medial slice designated as slice 1. The nipple is located in. slice 4 and slice 5. A 6.5 x 4.9 x 3.3 cm mass is located in slice 4 through. slice 7. The mass is white and firm and inferior to the nipple. The margin of. the mass is irregular especially at the anterior aspect. A satellite lesion is. identified superior and anterior to the index mass located in slice 5 measuring. 1.5 x 1.1 x 1.1 cm and is 0.4 cm from the nearest skin. The mass is 1.0 cm from. the closest inked margin on slice 5. A 2.0 x 2.0 x 1.5 cm black discolored area. is identified in slice 3 and 4 and another 4.0 x 3.8 x 2.0 cm blue discolored. area is identified on slice 5 and 6. The remainder of the breast consists. approximately 17% of adipose tissue and 30% of breast duct parenchyma. Additional masses or nodules are not grossly identified. Representative. sections are submitted as follows: C1: nipple. C2-C3: areola. C4-C7: full section of the tumor on slice 5 with cassette 4 showing. the closest deep margin and cassette. 6 showing the satellite lesion and the closest skin. C8: section from slice 5 showing satellite lesion and the closest skin. C9: representative sections from the tumor on slice 6. C10: inner upper quadrant slice 3. C11: inner upper quadrant slice 4. C12: inner lower quadrant slice 3. C13: inner lower quadrant slice 2. C14: outer upper quadrant slice 5. C15: outer upper quadrant slice 8. C16: outer lower quadrant slice 8. D. Container D is further identified, as 3non-sentinel node base of axilla. left4. Received fresh and placed in formalin are two apparent lymph nodes. measuring 1.8 x 1.0 x 0.6 cm and 1.2 x 0.7 x 0.5 cm. The specimen is entirely. submitted in cassettes D1-D2 with one lymph node in each cassette bisected. Intraoperative Consult Diagnosis: A1FS. Left axillary sentinel node: No evidence of tumor. B1FS. Left axillary sentinel node: No evidence of tumor.",2,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,621.0,T3,"The report mentions a mastectomy and provides a specific tumor size of 6.5 cm, which falls within the T3 range (>50 mm) according to the AJCC's TNM Staging System for cancer staging. The radical mastectomy is not explicitly mentioned, but the size of the tumor is sufficient to determine the T stage.",98.0,True
TCGA-D8-A1J8.E8E799F8-158D-4AEC-8F86-D40F132C071C,"page 1 / 1. copy No. Examination: Histopathological examination (cito). PESET. Gender: F. Material: Multiple organ resection - right breast. Expected time of examination: 5 working days. Clinical diagnosis: Macroscopic description: Right breast, sized 21.3 x 18.6 x 4.8 cm, removed along with axillary tissues sized 10 x 7 x 3.5 cm and a skin. flap of 19.2 x 7.1 cm. Weight 923 g. Tumour sized 3.3 x 1.8 x 3.2 cm on the border of outer quadrants, placed 2.2 cm from the lower edge, 0.3 cm. from the base and 2.8 cm from the skin. Lymph nodes of 0.4 cm in length, fat. Microscopic description: Carcinoma ductale invasivum - NHG2 (3 + 3 +2:14 mitoses/10 HPF, visual area diameter 0.55 mm). Mamilla. sine laesionibus. Glandular tissue showing mastopathia fibrosa et cystica. (fibrocystic changes). AXILLARY LYMPH NODES. Metastases carcinomatosae in lymphonodis (No III/XVI). Examination result://istopathology diagnosis: Carcinoma ductale invasivum mammae dextrae. Invasive ductal carcinoma of the right breast. Metastases carcinomatosae in lymphonodis axillae (NO III/XVI). Cancer metastases in axillary lymph nodes (No III/XVI). (NHG2, pT2, pN1a). Results of immunohistochemical examination: Estrogen receptors found in 75% of neoplastic cell nuclei. Progesterone receptors found in 10-75%. of neoplastic cell nuclei. HER2 protein stained with HercepTest‚Ñ¢M by DAKO. Negative reaction. in. invasive cancerous cells ( Score = 0).",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,621.0,T2,"The report mentions a mastectomy ('Right breast, sized 21.3 x 18.6 x 4.8 cm, removed along with axillary tissues sized 10 x 7 x 3.5 cm and a skin. flap of 19.2 x 7.1 cm. Weight 923 g.') and provides a specific tumor size within the T2 range (3.3 x 1.8 x 3.2 cm, which is within the T2 range of >20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-AR-A0U4.6424BA69-DA2B-4CCD-ADDF-DB1BEDA11EBF,"Breast, right, simple mastectomy: Breast parenchymal tissue is negative for tumor. Focal calcifications. identified. The nipple is negative for tumor. A single intraparenchymal lymph node is negative for. tumor. Breast, left, simple mastectomy: Infiltrating ductal carcinoma, Nottingham grade III (of III), [tubules 3. (of 3), nuclei 3 (of 3), mitoses 2 (of 3); Nottingham score 7-8 (of 9) forming a 4.7 x 4.0 x 2.7 cm mass,. located in the upper outer quadrant of the breast (AJCCpT2). Ductal carcinoma in situ is absent. Angiolymphatic invasion is absent. No calcifications are present. The tumor does not involve the nipple,. overlying skin, or underlying chest wall. All surgical resection margins, including deep margin, are. negative for tumor (minimum tumor free margin, 1.7 cm, deep margin). Lymph nodes, left axillary sentinel, excision: Multiple (10) sentinel lymph nodes are negative for tumor. AJCC PN0(1-)(sn). Immunohistochemical stains were performed on paraffin embedded tissue from the breast tumor using. antibodies to ER, PR, and HER2/neu. Estrogen is negative, 0% nuclear staining. Progesterone is. negative, 0% nuclear staining. HER2/neu protein overexpression is negative, score of 0, according to the. interpretation guidelines in the FDA-approved HercepTest. ER (Estrogen Receptor) test was developed and its performance characteristics determined by. It has not been cleared or approved by the U.S. Food. and Drug Administration.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,621.0,T2,"The report mentions a simple mastectomy for the left breast and provides a specific tumor size (4.7 x 4.0 x 2.7 cm) which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2. The report also specifies that the tumor does not involve the nipple, overlying skin, or underlying chest wall.",100.0,True
TCGA-3C-AALI.84E6A935-1A49-4BC1-9669-3DEA161CF6FC,"Path No.: Date Obtained: (Age: ). Date Received: F. See Addendum/Procedure. SPECIMEN: A:Lymph node, right axilla sentinel node, biopsy. B:Breast, right, lumpectomy. C:Lymph nodes, right axilla, dissection. DIAGNOSIS(ES): A. Lymph node, right axilla sentinel node, biopsy: - Carcinoma in 1 sentinel node following carcinoma of right breast. B. Breast, right, lumpectomy: - Carcinoma, invasive ductal type, moderately-differentiated, with focal micropapillary features,. Nottingham's score 5 (2+2+1). - Carcinoma, intraductal, comedo type with microcalcifications. - Lobular neoplasia, focal, classical type. - Fibrocystic disease, proliferative, with apocrine metaplasia, sclerosing adenosis and. microcalcifications. - Cicatricial fibrosis and organizing granulation tissue with fat necrosis, consistent with previous. biopsy site. - Fibroadenoma, microscopic. C. Lymph nodes, right axilla, dissection: - No evidence of carcinoma in 14 lymph nodes. Date Dictated: CLINICAL INFORMATION: Breast cancer. GROSS DESCRIPTION: The specimen is received in three parts. Part A is received fresh from the operating room for frozen section diagnosis in a container labeled with the patient's. name and ""R sentinel lymph node"". It consists of one firm tan to red lymph node measuring 2.0 x 1.8 X 1,0 cm, The. specimen is serially sectioned. Submitted in toto in three cassettes labeled AFS, A1 and A2. AFS = frozen section, A1. - A2 = remaining tissue,. Part B is received unfixed in a container labeled with the patient's name and ""R breast lumpectomy"". It consists of a. piece of yellow-white fibrofatty tissue measuring 10.5 X 9.0 x 6,0 cm. An ellipse of skin is not present. An X-ray is. received. A localization needle is not noted. A short suture is noted indicating the superior margin and a row of long. sutures are noted indicating the lateral margin. A mass is palpated in the center. The superficial surface is inked yellow. and the deep surface is inked black. The specimen is serially sectioned. On cut section, the mass is tan, firm, poorly. circumscribed and measures 3.2 x 3.0 x 3.0 cm. The mass comes to 0.3 cm of the superficial, 0.5 cm of the deep and. 2.5 cm of the lateral margins. The tissue is composed of 60% fat and 40% intermixed firm tan-white parenchyma. Representative sections are submitted in 29 cassettes labeled B1 - B29. Legend: B1 = mass and closest deep surface,. B2 = mass and closest superficial surface(B1 and B2 = full thickness of mass),. B3 - B8 = mass with adjacent deep margin. B9 - B17 = superficial margin over mass. B18 - B19 = mass. B20 - B21 = superior. B22 - B23 = deep margin in lateral part(closest to mass). B24 - B25 If lateral. B26 - B27 = inferior. B28 - B29 = medial. Part C is received unfixed in a container labeled with the patient's name and ""R axillary lymph node dissection"". It. consists of two pieces of yellow-red fatty tissue measuring 4.0 x 2.7 x 1.0 cm and 10.0 x 7.0 X 1.0 cm. A suture is noted. attached to one end of the larger piece of fatty tissue. Fourteen lymph moves measuring from 0.6 X 0.5 x 0.5 cm. to. 3.5. x 1.5 x 1.0 cm are identified. The lymph nodes are submitted in toto 10 cassettes labeled C1 - C10. Legend: C1 = five intact nodes, C2 - C5 = one bisected node in each cassettes, C6 = one intact node, C7 - C8 = one. large quadrisected node, C9 - C10 = nodes closest to suture(larger node is bisected). INTRAOPERATIVE CONSULTATION: AFS: Metastatic carcinoma in lymph node. Performed by: Resident: interpreted by: Attending: MICROSCOPIC DESCRIPTION: I. TYPE OF SPECIMEN: Right breast, excisional biopsy/lumpectomy. Right axillary node dissection. II. LOCATION OF THE TUMOR: Upper outer quadrant. III. TYPE OF NEOPLASM: Carcinoma, invasive - ductal type NOS with micropapillary features. Histological Grading: Moderately differentiated. (Nuclear grade 2 and Tubular & Glandular differentiation grade 2). Ductal carcinoma in situ, nuclear grade 3, multifocal 10%. intraductal comedo subtype. Necrosis is present within the intraductal subtype. Lobular neoplasia, type A (monomorphic), Focal in 2 of 29 slides. IV. GROSS/MICRO FINAL INVASIVE TUMOR SIZE INTERPRETATION: 3.2 x 3.0 x 3.0 cm. V. BORDERS OF INVASIVE NEOPLASM: III-defined. VI. VASCULAR SPACE INVASION: Present in lymphatics. VII. CALCIFICATION: Present in both malignant and benign areas. VIII. NIPPLE: N/A. IX. SKIN: N/A. X. ADJACENT BREAST TISSUE: Fibroadenoma (size 0,2 cm.). Cystic disease, proliferative. XI. SURGICAL MARGIN: No carcinoma is identified on surgical margins. Tumor distance from closest deep (slide ""B1"") margin: 0.6 cm. XII. AXILLARY LYMPH NODES: TOTAL: 15. HIGH POINT: 2. SENTINEL NODE: 1. XIII. POSITIVE LYMPH NODES: TOTAL: 1. HIGH POINT: 0. SENTINEL NODE: 1. DEGREE OF INVOLVEMENT: Extensive replacement. EXTRANODAL EXTENSION: Present. XIV. PECTORAL MUSCLE: No pectoral muscle identified. This report has been reviewed electronically and signed on. Interpreted by: Attending: The diagnosis was rendered by the attending pathologist. Addendum. ADDENDUM. Slides were reviewed by. The diagnosis rendered is in. agreement with the original diagnosis. This procedure/addenda has been electronically reviewed and signed on. Interpreted by: Attending: Note: Immunochemistry testing performed at. was developed and Its performance characteristics determined by the. These tests were interpreted in conjunction with external positive and internal negative controla, unless otherwise noted It has not been cleared or approved by the US. FDA. This test is used for clinical purposes only, It should not be regarded as Investigational or for research.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,621.0,T2,"The report mentions a lumpectomy and provides a specific tumor size of 3.2 x 3.0 x 3.0 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-OL-A97C.1582865E-9294-4D78-8B16-92FB70381D15,"FINAL PATHOLOGIC DIAGNOSIS. A. Sentinel lymph node #1, left, biopsy: -One reactive lymph node, negative for tumor (0/1). B. Sentinel lymph node #2, left, biopsy: -One reactive lymph node, negative for tumor (0/1). C. Left axillary lymph node #3, biopsy: -Two reactive lymph nodes, negative for tumor (0/2). D. Left axillary lymph node #4, biopsy: -One reactive lymph node, negative for tumor (0/1). E. Left axillary non-sentinel lymph node, biopsy: -One reactive lymph node, negative for tumor (0/1). F. Left breast, mastectomy: -Malignant phyllodes tumor (25 x 17 X 16.5 cm) with heterologous. (chondrosarcomatous, fibrosarcomatous-like, and. fibro-myxosarcomatous-like differentiation). - Margins of resection are free of phyllodes tumor (0.5 mm from posterior. margin, > 6 mm from closest anterior inferior aspect). - The tumor abuts the dermis of the nipple areolar complex. - Nipple without diagnostic abnormality. - Focus of atypical ductal hyperplasia, see comment. - Intraductal hyperplasia, usual type. - Benign skin. G. Pectoralis major muscle, new outer margin, excision: -Fibroadipose tissue and skeletal muscle with degenerative changes,. negative for tumor. Clinical History: The patient is a. -year-old female with breast cancer undergoing simple. mastectomy, breast reconstruction, and sentinel node biopsy. Comment. F. CK5/14 supports a small focus of atypical ductal hyperplasia. All IHC. controls were appropriate. Specimens Received: A:F/s 1st sentinel node left breast. B: F/s 2nd sentinel node left breast. C: Left axillary lymph node #3. D: Left axillary lymplh node #4. E: Left axillary non-sentinel lymph node. F: Left breast. G: Pectoralid(sp) major muscle. E. The fifth container is additionally identified as, 'left axillary. non-sentinel lymph node'. Received fresh and placed in formalin is a 0.7 X 0.6. X 0.4 CM lymph node that is bisected and submitted in E1. F. The sixth container is additionally identified as, 'left breast. Long. stitch-lateral margin. Short stitch-superior margin. Please weigh the specimen. per Dr. Received fresh and placed in formalin is a 4,580 gm. mastectomy specimen measuring 25 cm from medial to lateral, 20 cm from superior. to inferior and 16.5 cm from anterior to posterior. There is a 25 x 20 cm. wrinkled skin ellipsecovering the entire anterior surface, with a short suture. designating the superior pole and a long suture designating the lateral pole. The areola measures 5.5 CM in diameter and the nipple measures 1.5 X 1.2 x 0.3. CM. The nipple-areolar complex displays no evidence of ulceration or retraction. The deep surface is inked black and the specimen is sectioned from medial to. lateral into 12 slices (nipple at slice 6-7) to reveal a 25 x 17 x 16.5 CM mass. with a variegated cut surface characterized by tan, fleshy regions intermixed. with dusky, gray-green regions and golden-yellow adipose, with scattered coarse. granularity and hemorrhage. The superior portions of slices 2-10 contain a. cystic space filled with hemorrhagic to slightly mucinous fluid. The mass. grossly extends to the posterior margin (slice 9) and is located 0.2 CM from the. green ink. Multiple sections of the mass, skin, and margins are submitted as. follows: Gross Description: The specimens are received in seven containers each labeled with the patient's. name and medical record number. A. The first container is additionally identified as, 'F/S first sentinel node. left breast : Received fresh for frozen section diagnosis is a 2 X 1.2 X 0.8 CM. lymph node that is entirely frozen and called, 'one benign lymph node,' by Dr. The frozen section remnants are submitted in A1-A2 FS. B. The second container is additionally identified as, 'F/S second sentinel. node left breast'. Received fresh for frozen section diagnosis is a 2.0 X 1.2 x. 0.6 CM lymph node that is entirely frozen and called, 'one benign lymph node,'. by Dr. The frozen section remnants are submitted in B1FS. C. The third container is additionally identified as, 'Left axillary lymph node. #3. Count. Received fresh for frozen section diagnosis are 2 lymph nodes. measuring 0.6 and 1.2 CM in greatest dimension. They are entirely frozen and. called, '2 benign lymph nodes,' by Dr. The frozen section remnants are. submitted in C1-C2 FS. D. The fourth container is additionally identified as, 'Left axillary lymph. node #4. Count- : Received fresh for frozen section diagnosis is a 1.3 CM. lymph node that is entirely frozen and called, 'one benign lymph node,' by Dr. , The frozen section remnants are submitted in D1FS. F1-F2: Slice 11. F3-F4: Slice 10. F5-F6: Slice 9, closest approach to black ink. F7-F8: Slice 8. F9: Slice 7. F10-F11: Slice 6 (nipple). F12: Slice 5. F13: Slice 4, closest approach to green ink. F14-F15: Slice 3. F16-F17: Slice 2. F18: Slice 1. Tissue fixed for at least 6 hours in 10% NBF and no more than 72 hours. G. The seventh container is additionally identified as, 'pectoralis major. muscle new outer margin lateral long black, new superior margin black'. Received. fresh and placed in formalin is a 24.3 g, 7 X 4.5 x 2.2 CM portion of irregular,. ragged, partially disrupted fibroadipose and muscle tissue designated with a. long suture marking new outer margin lateral, and a black suture designating new. superior margin. A gross photograph is taken. The specimen is inked as follows: New outer lateral margin-orange. Superior-blue. Inner-black. Anterior-yellow. Posterior-red. The specimen is serially sectioned from superior to inferior into 13 slices to. reveal scattered palpable nodules. Sections are submitted as follows: G1: Superior tip (slice 1), shaved. G2: Slice 3. G3-G4: Slice 5. G5-G6: Slice 7. G7-G8: Slice 9. G9: Slice 11. G10: Slice 13. Intraoperative Consult Diagnosis: A1-A2 FS: 'one benign lymph node,' by. 81 FS: 'One benign lymph node,' by. C1-C2 FS: '2 benign lymph nodes,' by. D1 FS: 'One benign lymph node,' by.",2,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,621.0,T3,"The report mentions a mastectomy and provides a specific tumor size of 25 x 17 X 16.5 cm, which falls within the T3 range (>50 mm). The radical mastectomy is not mentioned, so the T stage is T3.",100.0,True
TCGA-A2-A25C.1D4CA1BA-B534-4CEA-ABA5-EF9B31694204,"Specimen: spec Type: SURGICAL P. LEFT BREAST CANCER INVASIVE. DOCTOR (S) : PROCEDURE: SENTNEL, NODE BX/STMPLE MASTRCTOMY. A. LT BREAST SIMPLE MASTECTOMY. B. LT SENTINEL NODE #1. C. LT SENTINEL NODE #2. RECEIVED IN 3 PARTS. PART A RECEIVED LABELED. SIMPLE LEFT BREAST. MASTECTOMY STITCH AT 12 O' CLOCK, IS A SIMPLE MASTECTOMY SPECIMEN. MEASURING 17.5 x 16 x 2.8 CM. THE NIPPLE IS UNREMARKABLE WITHIN A 9 x. 2.5-CM SKIN ELLIPSE. ADDITIONALLY WITHIN THE CONTAINER ARE 2 IRREGULAR. FRAGMENTS OF FATTY TISSUE WITH NO PALPABLE MASSES TOGETHER MEASURING 4.5. x 3 x 0.5 CM. THE SUPERFICIAL ASPECT IS MARKED WITH BLUE INK, THE DEEP. WITH BLACK. SECTIONING REVEALS 2 DISCRETE GRAY FIBROUS NODULES; THE MOST. LATERAL IS AT 3 O'CLOCK MEASURING 1.5 x 1.1 x 1.5 CM. ADJACENT TO THIS. SEPARATED BY 1.5 CM IN THE 6:30 AREA IS A MASS WITH A COIL CLIP MEASURING. 2.2 x 1.8 x 2.1 CM. THESE ARE BOTH 0.5 CM FROM THE DEEP MARGIN. CENTRALLY, THE BREAST HAS DENSE TAN FIBROUS TISSUE, BUT THE PERIMETER OF. THE SPECIMEN AND THE TISSUE ADJACENT TO THE DEEP MARGIN IS YELLOW FATTY. TISSUE. THE 3 O'CLOCK LESION IS 0.7 CM FROM THE SUPERFICIAL MARGIN. THE. 6 O'CLOCK LESION EXTENDS TO WITHIN 0.6 CM OF THE SUPERFICIAL MARGIN. SECTIONS ARE SUBMITTED AS FOLLOWS: 11--NIPPLE; 12--TISSUE BETWEEN THE. TWO LESIONS; A3--3 O' CLOCK LESION TO INCLUDE DEEP MARGIN; A4--3 O'CLOCK. LESION TO INCLUDE SUPERFICIAL MARGIN; A5 AND 6--FULL CROSS-SECTION OF 6. O' CLOCK LESION TO INCLUDE THE DEEP AND SUPERFICIAL MARGIN, RESPECTIVELY;. A7--6 O'CLOCK LESION; A8--UPPER OUTER QUADRANT; A9--UPPER INNER QUADRANT;. A10 - -LOWER INNER QUADRANT; A11--LOWER OUTER QUADRANT. TISSUE FROM EACH. LESION IS SUBMITTED PER PROTOCOL. PART B RECEIVED LABELED. LEFT SENTINEL NODE #1 HOT. AND BLUE, IS AN OVOID FRAGMENT OF YELLOW-RED SOFT TISSUE MEASURING 1.7 x. 1.0 x 0.9 CM. SECTIONING REVEALS A GROSSLY UNREMARKABLE 1.3-CM LYMPH. NODE WITH CENTRAL FAT REPLACEMENT AND BLUE COLORATION. THIS IS SUBMITTED. LABELED B, BISECTED. PART C RECEIVED LABELED. LEFT SENTINEL NODE #2 HOT. 1. Specimen: Spec Type: SURGICAL P. CPA : AND BLUE, IS A 1.5 x 0.6 x 0.4-CM OVOID PORTION OF RED-TAN TISSUE. SECTIONING REVEALS THIS TO BE A GROSSLY UNREMARKABLE LYMPH NODE WITH BLUK. COLORATION SUBMITTED LABELED C, BISECTED. PROCEDURES: 88307/3, IMMUNOPEROXIDAS/2, A BLK/11, BBX X6, CBX X6. PART A LEFT BREAST, SIMPLE MASTECTOMY : 1. MODERATELY DIFFERENTIATED INFILTRATING DUCT CARCINOMA, NUCLEAR GRADE. II/III, MODERATE MITOTIC INDEX AND TUBULE FORMATION 2, WITH A TOTAL. NOTTINGHAM SCORE OF 6. RARE FOCI OF DCIS OF THE CRIBRIFORM AND SOLID. TYPES, NUCLEAR GRADE II WITH LOW MITOTIC INDEX, ARE SEEN AT THE. PERIPHERY OF THE TUMOR. 2. A 1.5-CM TUMOR IS IDENTIFIED IN THE 3 O' CLOCK LOCATION AND A 2.2-CM. LESION IS IDENTIFIED IN THE 6 D'CLOCK PORTION WHICH ARE SEPARATED BY. AT LEAST 1.5 CM OF BENIGN BREAST TISSUE. 3. THE MARGINS OF EXCISION, NIPPLE SKIN AND RANDOM SECTIONS OF REMAINING 2.2cm I Scm. QUADRANTS ARE FREE OF TUMOR. 4. LYMPHOVASCULAR INVASION IS IDENTIFIED. 5. BIOPSY CHANGES. ARE PRESENT. PART B LEFT AXILLA, SENTINEL LYMPH NODE BIOPSY #1: METASTATIC BREAST. CARCINOMA IS MULTIFOCALLY IDENTIFIED ON H&E STEP SECTIONS AND CYTOKEBATIN. STAINS IN 1 LYMPH NODE EXAMINED, THE LARGEST FOCUS OF WHICH MEASURES 3 MM. IN GREATEST MICROSCOPIC DIMENSION. NO EVIDENCE OF EXTRANODAL EXTENS FON. PART C LEFT AXILLA, SENTINEL LYMPH NODE BIOPSY #2: MULTIFOCAL. METASTATIC BREAST CARCINOMA IS IDENTIFIED ON H&E STEP SECTIONS AND. CYTOKERATIN STAINS IN 1 LYMPH NODE EXAMINED, THE LARGEST FOCUS OF WHICH. MEASURES 2 MM IN GREATEST MICROSCOPIC DIMENSION. EXTRANODAL EXTENSION IS. NOT PRESENT. Specimen: Spec Type: SURGICAL P. Her-2/neu: NEGATIVE. Score: 1+. Reference Range : Negative o - 1+. Equivocal 2+. Positive 3+. M.D. See full scanned report for details. 1. SENT TO: 2. REQUESTED BY: DR. 3. DATE SENTs. 4. KETHOD or COURIER. 5. NO. OF BLOCKS: 1 BLOCR A3. 7. MATERIAL(S) TO BE RETURNED. 14. SPECIMEN SENT (Y/X) $. x. M.D. (prelim.). M.D.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,621.0,T2,"The report mentions a simple mastectomy procedure and provides a specific tumor size for the largest lesion, which is 2.2 cm, which falls within the T2 range (>20 mm but <=50 mm).",100.0,True
TCGA-OL-A66J.D5DE4BB3-81AC-44CB-9336-060F324C7A2F,"FINAL PATHOLOGIC DIAGNOSIS. A. Lymph node, sentinel #1, right axillary, excision: - One lymph node, negative for metastatic carcinoma (0/1). - Biopsy site changes identified. B. Lymph node, sentinel #2, right axillary, excision: - One lymph node, negative for metastatic carcinoma (0/1). C. Lymph node, sentinel #3, right axillary, excision: - One lymph node, negative for metastatic carcinoma (0/1). D. Lymph node, sentinel #4, right axillary, excision: - One lymph node, negative for metastatic carcinoma (0/1). E. Breast, right, partial mastectomy: - Invasive lobular carcinoma, see breast pathologic. parameters. - Margins of excision free of tumor, distance to the closest margin >2 mm. to superior and anterior. - Lobular intraepithelial neoplasia (LCIS), classic type. - Atypical ductal hyperplasia. - Previous biopsy site identified with extensive fat necrosis. - Flat epithelial atypia, focally associated with microcalcifications. - Sclerosing adenosis, focally associated with microcalcifications. - Microcalcifications in benign ductal and stroma. - Fibrocystic changes with cystic apocrine metaplasia. F. Breast, additional superior medial margin, excision: - Focal atypical ductal hyperplasia. - Lobular intraepithelial neoplasia (ALH/LCIS). - Focal flat epithelial atypia. to Sclerosing adenosis focally associated with microcalcifications. - Microcalcifications in benign ductules and stroma. - Fibrocystic changes with cystic apocrine metaplasia. - Duct ectasia. Breast Pathologic Parameters. Specimen E: Breast, right, partial mastectomy. 1. Invasive carcinoma: A. Size: Gross measurement: 1.6 x 1.5 X 1.4 cm. B. Composite histologic (modified SBR) grade II. - Architecture: 3. - Nuclear grade: 2. - Mitotic count: 1. C. Associated lobular intraepithelial neoplasia (LCIS): - Within main mass (forming <5% of tumor volume). - Extending away from main mass. 3. Excisional biopsy margins: Free of tumor. - Invasive carcinoma > 2 mm from anterior and superior margins. - Additional margins greater than 3 mm away. 4. Blood vessel and lymphatic invasion: Not definitively identified. 5. Axillary lymph nodes: Negative for tumor (0/4). 6. Special studies (see. - Strong expression of ER in 90% of invasive tumor nuclei. - Strong expression of PR in 50% of invasive tumor nuclei. - Her2/neu antigen (FISH) Not amplified. Ratio 1.5. 7. pTNM: pT1c, NO(sn), MX. Clinical History: The patient is an. year old female with a history of biopsy proven grade Il. ILC of the right breast who undergoes right breast needle localization. lumpectomy and right axillary sentinel node dissection. Most recent breast. imaging on. showed in the right breast at the 10 o' clock position an. irregularly shaped heterogenous enhancing mass with irregular margins and. metallic clip artifact at mid depth measuring 1.4 X 1.2 X 1.2 cm representing. the biopsy proven malignant lesion. Posterior to that main mass was a focal. non-mass like enhancement measuring 1.6 x 1.1 cm suspicious for extension of the. disease with a total extent of 2.8 cm. Comment. Part E: The tumor reveals a mixed ductal and lobular morphologic appearance,. however, immunohistochemical stains for E-cadherin were performed on. representative areas and supports the presence of a lobular carcinoma. Case presented at multidisciplinary breast conference on. Specimens Received: A: Right axillary sentinel node#1. B: Right axillary sentinel node #2. C: Right axillary sentinel node #3. D: Right axillary sentinel node #4. E: Right breast partial mastectomy. F: Additional superior medial margin. Gross Description: The specimen is received in six containers each labeled with the patient' S name. and medical record number. A. Container A is further designated as 1. Right axillary sentinel node #1.'. Received fresh and placed in formalin is a 1.5 x 1.2 x 1.0 cm firm, rubbery. lymph node that is dissected and entirely submitted in cassette A1. B. Container B is further designated as 2. Right axillary sentinel node #2. Received fresh and placed in formalin is a 0.7 X 0.6 X 0.4 cm tan, rubbery lymph. node candidate that is entirely submitted in cassette B1. C. Container C is further designated as '3. Right axillary sentinel node #3.'. Received fresh and placed in formalin is a 0.9 X 0,7 X 0.4 cm tan, rubbery lymph. node candidate. It is entirely submitted in cassette C1. D. Container D is further designated as 14. Right axillary sentinel node #4. Received fresh and placed in formalin is a 0.6 x 0.5 x 0.2 cm tan, rubbery lymph. node candidate that is entirely submitted in cassette D1. E. Container E is further designated as '5. Right breast partial mastectomy'. with the paper work additionally designating 1 stitch = lateral. Received fresh. and placed in formalin is a 99.5 gram, 8.5 cm (superior to inferior) X 10.0 cm. (medial to lateral) X 3.5 cm (anterior to posterior) breast lumpectomy specimen. on a radiographic grid with a corresponding x-ray film. There is a metallic. clip located in the center of a spiculated irregularly shaped mass which. corresponds to C3-C4, D3-D4 and D5. The metallic clip is located in D4. There. is a questionable extension of the mass into grids E3-E4. A wire extends through. the center of this mass entering at B5 and terminating at F1. The specimen is. received with two sutures, long designating lateral and short designating. superior. The margins are inked as follows: superior blue, inferior green,. anterior black, posterior red, lateral violet and medial yellow. The. specimen is serially sectioned from lateral to medial into 14 slices to reveal a. 1.6 X 1.5 X 1.4 cm firm, white poorly circumscribed mass extending from slice 6. to slice 9. There is a metallic clip found on the center of this mass in slice. 8. The mass approaches the anterior margin within 0.3 cm (slice 9) and the. posterior margin within 0.6 cm (slice 7). Additionally, the lesion is 3.5 cm. from the inferior margin and 0.7 cm from the superior margin. The mass is. greater than 2 cm from both the medial and lateral margins. The wire terminates. in slice 11. The remainder of the breast tissue consists of grossly. unremarkable yellow, lobulated adipose tissue. Representative sections are. submitted as follows: E1: mass with clip (slice 8) showing approach to posterior and superior margins. E2-E3: anterior margin from slice 8. E4-E5: mass in slice 7 showing closest approach to posterior margin. E6-E7: mass in slice 6 demonstrating biopsy site changes. E8: inferior margin from slice 6. E9-E10: mass in slice 10 showing nearest approach to anterior margin. E11: posterior margin slice 7. E12-E13: posterior inferior margin slice 8. E14: posterior margin slice 9. E15: anterior margin slice 9. E16: anterior margin slice 8. E17: anterior superior margin slice 6. E18-E20: sections immediately lateral to mass (slice 5). E21-E22: sections immediately medial to mass (slice 10). E23: grossly unremarkable breast parenchyma slice 3. E24: grossly unremarkable breast parenchyma slice 12. E25: lateral margin serially sectioned (slice 1). E26: medial margin serially sectioned (slice 14). F.Container F is further designated as '3. Additionalsuperior medial margin,. short stitch marks new true margin.' Received fresh is a 38.0 gram portion of. yellow, lobulated fibroadipose tissue that measures 8.5 X 6.0 X 1.5 cm. The. short stitch designates the new true margin. This aspect is inked blue. The. specimen does not have any further orientation. The specimen is serially. sectioned to reveal that is primarily composed of yellow, lobulated adipose. tissue with a region of enhanced firm, white fibrosis measuring 2.4 X 1.5 X 1.5. cm that appears to abut the new true margin. The specimen is entirely submitted. sequentially in cassettes F1-F23 with the fibrotic region in F9-F14. Pathologist Sign Out:",0,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,621.0,T1c,"The report mentions a partial mastectomy of the right breast and provides a specific tumor size of 1.6 x 1.5 x 1.4 cm, which falls within the T1 range (<=20 mm). Therefore, the T stage is T1.",100.0,True
TCGA-A8-A09Q.46C0AB7B-82FC-4D06-9F26-22AEC8BEEDA7,"Diagnosis: 1. Poorly differentiated ductal breast carcinoma (maximum diameter 4.5 cm, malignancy. grade III) with widespread tumor infiltration of the skin also with ulceration of the skin, along. with invasion of the lymph vessels and infiltration of the neural sheaths. Remainder of. glandular body fibrolipomatous and in advanced involution, also with cystic duct ectasia. No. calcification. No evidence of DCIS. At the site of the nodular formation already macroscopically documented in the region of the. cranial resection line (skin) cutaneous/subcutaneous tumor infiltrates, also with invasion of. the lymph vessels here. Other safety margins free of atypia. Tumor classification: pT4b pN2 (at least, see conglomerate tumors), MX, R1 (see cranial. resection line, axillary soft tissue!), G3 (L1, V0).",3,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides a specific tumor size >50 mm and mentions invasion of the chest wall or skin, then the T stage is T4.",4.0,621.0,T4,"The report mentions a specific tumor size of 4.5 cm, which falls in the T4 range (>50 mm). Additionally, it notes invasion of the skin and lymph vessels, which are characteristics of T4 stage. Therefore, the T stage for this patient is T4.",100.0,True
TCGA-AR-A1AV.5AD5B38F-5CC1-4A2F-96E6-F344D8FE0149,"Final Diagnosis. Breast, left, modified radical mastectomy: Infiltrating ductal carcinoma, Nottingham grade II (of. III) [tubules 3/3, nuclei 2/3, mitoses 2/3; Nottingham score 779], forming a mass (2.8 x 2.3 x 2.1. cm) located in the retroareolar region of the breast. Ductal carcinoma in situ is absent. Angiolymphatic invasion is absent. Calcifications are not seen. The tumor involves the. overlying skin [AJCC pT4]. All surgical resection margins, including the skin and deep margins,. are negative for tumor (minimum tumor free margin, 1.1 cm, anterior superior margin). A single. (of 23) left axillary mid/low lymph node is positive for metastatic carcinoma. The positive lymph. node (1.7 cm in greatest dimension) shows extranodal extension. Lymph nodes, left high axillary, excision: Multiple (2) left high axillary lymph nodes are. negative for tumor.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T4,"The report specifically mentions invasion of the overlying skin and assigns a T stage of T4 [AJCC pT4]. The size of the tumor is also greater than 50 mm, but the presence of skin invasion is the determining factor for the T4 stage.",94.0,True
TCGA-EW-A1PE.F59530A5-7370-4E77-9099-9F38B25A38EB,"F. Pathologic Interpretation: A. LEFT BREAST LUMP MASS (1 STTICH SUPERIOR, 2 STITCHES LATERAL, 3 STITCHES DEEP): - INVASIVE DUCTAL CARCINOMA, MICROPAPILLARY TYPE, MODERATELY DIFFERENTIATED, Nottingham grade 2. (3+2+1=6), 1.9 cm in greatest microscopic dimension. - Lymphovascular invasion is seen. - Resection margins are free of invasive carcinoma, closest margin is the anterior (4 mm). - IN SITU DUCTAL CARCINOMA, INTERMEDIATE NUCLEAR GRADE (DIN: 2) WITH EXTENSIVE NECROSIS,. cribriform type, representing 10% of tissue sampled. - Resection margins are free of DCIS, closest margin is the anterior (10 cm). - Previous biopsy site. - See tumor summary. - AJCC: pTic, pN1a, pMn/a. B. LEFT AXILLARY CONTENTS: - Metastatic carcinoma in one out of twenty-three lymph nodes (1/23). - Largest metastatic deposit is 2.5 mm. Tumor Summary. Specimen: . Partial breast. Procedure: - Excision without wire-guided localization. Lymph Node Sampling: - Axiliary dissection (partial or complete dissection). Specimen Integrity: - Single intact specimen (margins can be evaluated). Specimen Size: - Greatest dimension: 11.5 cm. . Additional dimension: 7.5 x 3.5 cm. Laterality: - Left. Tumor Size: Size of Largest Invasive Carcinoma. - Greatest dimension of largest focus of invasion over 0.1 cm: 2 cm. Tumor Focality: - Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of tumor: - Skin: Skin is not present. - Skeletal muscle: No skeletal muscle present. Ductal Carcinoma In Situ (DCIS): - DCIS is present. Size (Extent) of DCIS: Representing 10% of tumoral surface. Architectural Patterns: Cribriform. Nuclear Grade: Grade II (intermediate). Necrosis: Present, central (expansive ""comedo"" necrosis). Lobular Carcinoma IN Situ (LCIS): - Not identified. Histologic Type of Invasive Carcinoma: Invasive micropapillary carcinoma. Histologic Grade: Nottingham Histologic Score. Glandular (Acinar)/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 2. SURGICAL PATHOL Report. Mitotic Count: Score 1. Overall Grade: Grade 2: score of 6. Margins: - Margins uninvolved by invasive carcinoma. - Distance from closest margin: 4 mm (anterior). - Margins uninvolved by DCIS: - Distance from closest margin: 10 mm (anterior). Treatment Effect: Response to Presurgical (Neoadjuvant) therapy: - In the Breast: No known presurgical therapy. - In the Lymph Nodes: No known presurgical therapy. Lymph-Vascular Invasion: PRESENT. Dermal Lvmph-Vascular Invasion: No skin present. Lymph Nodes: - Number of sentinel lymph nodes examined: 0. - Total number of lymph nodes examined (sentinel and Nonsentinel): 23. - Number of lymph nodes with macrometastases (>0.2 cm): 1. - Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and /or >200 cells): 0. - Number of lymph nodes with isolated tumor cells (50.2 mm and <200 cells): 0. - Size of largest metastatic deposit (if present): 2.5 mm. Extranodal Extension: Not identified. Pathologic Staging (pTNM). - Primary Tumor: pTic. - Regional Lymph Nodes: pN1a. - Distant Metastasis: Not applicable. Ancillary Studies: Estrogen Receptor: - Performed on another specimen: Results: Immunoreactive tumor cells present (>1%). Progesterone Receptor: . Performed on another specimen. ; Results: Immunoreactive tumor cells present (1%). Her2: - Performed on another specimen: , Results: Negative. AJCC classification (7th ed) pT1c, pN1a, pMn/a. NOTE: Some immunchistochemical antibodies are analyte specific reagents (ASRs) validated by owr laboratory. These ASRs are clinically useful indicators that do not. regudre. FDA. approval. These clonss are used: ID5-ER,. 636=PR. A485=HER2,. All. immunokinochemical. stains. are. used. with. formalin. or. molecular. fixed. paraffin. embedded. rissue. Detection. is. Envision. Method. Theresults. are. read. a. pathologist as positive or regative. As the attending pathologist, I attest that I: (i) Examined the relevant preparation(s). for the specimen(s); and (li) Rendered the diagnosis(es). Clinical History: None Provided. Operation Performed. Left breast lumpectomy with axillary node dissection. Pre Operative Diagnosis: Breast cancer, female. Specimen(s) Received: A: Left breast lump mass (1 sttich superior, 2 stitches lateral, 3 stitches deep). B: Left axillary contents. SURGICAL PATHOL Report. Gross Description: A. Received in formalin is a 180 gram 11.5 x 7.5 x 3.5 cm left lumpectomy specimen without wire guide. The specimen is. oriented with one stitch superior, two stitches lateral and three stitches deep. Resection margins are inked as follows: Superior blue, inferior green, medial red, lateral orange, deep black, anterior yellow. On serial section through the. specimen, there is a tan-white ill-defined indurated mass with infiltrating borders that measures 2.0 x 2.0 x 1.5 cm. This. mass is present at 0.6 cm from the anterior margin, 2.0 cm from the superior margin, 2.2 cm from the inferior margin, 2.4. cm from the deep margin, 3.8 cm from the lateral margin and 2.7 cm from the medial margin. An area of tan-white. fibrosis is present adjacent to the mass. This area measures 2.8 x 2.0 x 2.0 cm. No other lesions are identified. The breast. parenchyma has a fat to stroma ratio of 80-20. Sections submitted as follows: 1. Anterior margin (closest). 2. Inferior margin. 3. Superior and deep margin. 4. Lateral and deep margins. 5-8. Lesions submitted in toto. 9. Representative section of fibrotic area adjacent to lesion. B. Received in formalin is a segment of tan-yellow fibroadipose tissue, measuring 13.0 x 11.0 x 4.0 cm. Examination of the. specimen reveals multiple possible lymph nodes, measuring up to 2.4 cm. Sections submitted as follows: 1-7. One lymph node bisected per cassette. 8. Four lymph nodes per cassette. 9-12. Three lymph nodes per cassette. MD.",0,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T1,"The report mentions a lumpectomy and provides a specific tumor size of 1.9 cm, which falls within the T1 range (<=20 mm). Therefore, the T stage is T1.",100.0,True
TCGA-AN-A041.26C566AF-C710-4856-AC21-83D73370EA84,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 1a M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T2,"The report mentions a radical mastectomy, which falls under the third rule: 'T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.' However, the report specifies a T Stage of 2, which corresponds to T2 in the TNM staging system. Therefore, the predicted stage is T2.",100.0,True
TCGA-EW-A1OW.2153CBCE-6DA9-4E0F-9F41-B9F08FD50647,"Pathologic Interpretation: A. Sentinel node #1: - No carcinoma seen in one lymph node (0/1). - Keratin Immunostain is negative. B. Suspicious node: - No carcinoma seen in one lymph node (0/1). - Keratin Immunostain is negative. C. Sentinel node #3: - No carcinoma seen in one lymph node (0/1). - Keratin Immunostain is negative. D. Left breast lumpectomy: - Invasive, poorly differentiated mammary carcinoma, high nuclear grade, 2.5 cm. - Margins are free of tumor. - Tumor cell have been reported to be ER, and PR negative by Immunohistochemistry and HER2 negative by CISH. - In house immunostains are pending for further tumor subclassification. Tumor Summary: Specimen Type: Partial breast. Procedure: Excision without wire-guided localization. Lymph Node Sampling: Sentinel lymph node. Specimen integrity: Left. Specimen Size: - Greatest dimension: 5 cm. - Additional dimensions: 4 x 3.5 cm. Laterality: Left. Tumor Site: Not specified. Size of Invasive Component: - Greatest dimension of largest focus of invasion: 2.5 cm. - Additional dimensions: 1.8 x 1.8 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of Tumor: Skin: Skin is not present. Skeletal Muscle: No skeletal muscle present. Ductal Carcinoma in Situ (DCIS): No DCIS is present. Lobular Carcinoma in situ (LCIS): Not identified. Histologic Type: Invasion carcinoma. In house immunostains are pending for further tumor subclassification. Histologic Grade: Overall Grade: Grade 3+3+2=8. - Glandular (Acinar)/Tubular Differentiation: Score 3 <10% of tumor area forming glandular/tubular structures. - Nuclear Pleomorphism: Score 3: Vesicular nuclei, often often with prominent nucleoli, exhibiting marked variation in size. and shape, occasionally with very large and bizarre forms. - Mitotic Count: Score 2. Margins: Margins uninvolved by invasive carcinoma. - Distance from closest margin: 2 mm (Posterior). Lymph-Vascular Invasion: Not identified. Dermal Lymph-Vascular Invasion: No Skin present. Lymph Nodes: Number of sentinel nodes examined: 3. Total number of nodes examined (sentinel and Nonsentinel): 3. Number of lymph nodes with macrometastases (>0.2 cm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 0. Number of lymph nodes with isolated tumor cells (<0.2 mm and $200 cells): 0. SURGICAL PATHOL Report. Size of largest metastatic deposit: 0. Method of Evaluation of Sentinel Lymph Nodes: - Hematoxylin and eosin (H&E). one level. - Immunohistochemistry. Pathologic Staging: - Primary tumor: pT2. - Regional Lymph nodes: pNO (sn) (i-). - Distant Metastasis: pMX. Additional Pathologic Findings: - Other ancillary Studies: Performed on another specimen, !. ER: Immunohistochemistry = Negative. PR: Immunohistochemistry = Negative. HER2: Immunohistochemistry = Negative. HER2 CISH - Not amplified. Pathologic Staging (pTNM): pT2, NO (i-) (sn), MX. used: NOTE: IDS=ER, Some Pg"" 636-PR, A485=HER2, antibodies H-II=EGFR. are analy All immanokistochemical specific reagents (ASRs) stains validated are used by with our formalin lahoralory. molecular These ASRs fixed, are paraffin clinically enbedded indicators Detection that do "" by require Envision FDA Method. approval. The These desults clones are real are by a. pathologist as pasitive or negutive. As the attending pathologist. I attest that I: (i) Examined the relevant preparation(s). for the specimen(s): and (ii) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. Left - The breast tumor lumpectomy0: cells are focally positive for p63 and EGFR by Immunohistochemistry, The morphology and immunophenotype of this. neoplasm is consistent with a carcinoma of basal cell subtype. MD, PhD. Intraoperative Consultation. A. Sentinel node #1 FS: No carcinoma seen. B. Suspicious node FS: No carcinoma seen. J, MD. Clinical History: None provided. SURGICAL PATHOL Report. Operation Performed. Left breast lumpectomy; left breast lumpectomy with sentinel node biopsy, axillary node dissection. Pre Operative Diagnosis: Breast cancer. Specimen(s) Received: A: Sentinel node #1 FS. B: Suspicious node FS. C: Sentinel node #3, internal mammary (permanent). D: Left breast lumpectomy. Gross Description: A. Received fresh there is a 1 x 0.8 x 0.3 cm lymph node. Bisected and submitted in toto for frozen section in two cassettes. B. Received fresh there is a 2 x 1 x 0.3 cm lymph node. Bisected and submitted in toto in two cassettes for frozen section. C. Received in formalin there is a 0.3 x 0.2 x 0.2 cm lymph node. Submitted in toto. D. Received in formalin there is a lumpectomy specimen of 5 x 4 x 3.5 cm and 40 grams. Specimen is oriented with short. stitch in the superior margin and a long stitch in the lateral margin. Specimen is inked as follows: blue superior, green. inferior, yellow anterior, black posterior, red medial, and orange lateral. There is a palpable indurated pale tan mass of. 2.5 x 1.8 x 1.8 cm. Closest resection margin is the posterior margin at 0.2 cm. Superior margin are 0.7, inferior margin. at. 1 cm, lateral margin at 2.5 cm, and medial margin at 1.5 cm. There are no additional lesions in the remainder of the. parenchyma. Fat to stroma ratio is 40:60. Representative sections are submitted as follow: 1. Superior posterior resection margin. 2. Inferior posterior margin. 3. Medial margin. 4. Lateral margin. 5. Inferior margin. 6-9. Remaining stroma. 10. Additional section of tumor. MC. MD -.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T2,"The report mentions a 'left breast lumpectomy' and provides a specific tumor size of 2.5 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-A7-A13G.50782829-35B6-4A61-A3CE-F105A31EDB42,"SPECIMEN. A. Left axillary sentinel node. B. Left breast, silk suture on superior breast. CLINICAL NOTES. PRE-OP DIAGNOSIS: Left breast cancer. CLINICAL HISTORY: -year-old female with grade 1 IDC. POST-OP DIAGNOSIS: Left breast cancer. FROZEN SECTION DIAGNOSIS. A. Lymph node negative for metastatic disease. GROSS DESCRIPTION. A. Part A is received fresh for frozen section labeled. ""left axillary sentinel node"". It consists of three. portions of adipose tissue measuring 2.3 x 2.2 x 1 cm in aggregate. Within the fat a single fatty tan lymph node is found measuring 1.7. X 0.6 x 0.4 cm. The node is bisected and all submitted in one. block. B. Received fresh for tissue procurement labeled ""left. breast"" is a 19.5 cm (medial to lateral) x 13.8 cm. (superior to inferior) x 2 cm (anterior to posterior) diffusely. cauterized soft, lobulated tan gold-white portion of fibroadipose. tissue in keeping with breast designated as left per requisition. slip and container and oriented by a single suture as stated. previously. There is a 14.5 cm (medial to lateral) x 4.3 cm. (superior to inferior) wrinkled white skin ellipse with diffuse. red-purple ecchymosis and a central, slightly flattened, 1.7 x 1.7 x. 0.4 cm nipple along the anterior aspect. The intact deep margin is. inked black and the specimen is sectioned. There is a moderately. well circumscribed, 2.8 cm (medial to lateral) x 1.8 cm (superior to. inferior) x 1.6 cm (anterior to posterior) rubbery tan-white lesion. at the junction of the lower inner and outer quadrants. The lesion. focally extends to within 0.6 cm of the inked deep margin and is. 1. cm from the anterior surface (subsequently inked blue) A few. cylindrical firm tan-white structures in keeping with site of prior. needle core biopsy are evident. A portion of tumor and a portion of. normal breast are submitted for tissue procurement as requested. The cut surfaces throughout the remainder of the specimen consist. predominantly of glistening lobulated golden yellow adipose tissue. with a minimal amount of interspersed delicate tan-white fibrous. tissue. No additional mass lesion or abnormality is identified. Representative sections are submitted in twelve blocks as labeled. RS-12. BLOCK SUMMARY: 1-3 - Tumor to inked deep margin; 4 - tumor to. anterior surface; 5, 6 - tumor to adjacent parenchyma; 7 - random. upper-outer quadrant;. 8 - upper-inner quadrant; 9 - Lower-inner quadrant; 10 - lower-outer. quadrant; 11 - junction of the four quadrants; 12 - nipple. MICROSCOPIC DESCRIPTION. A. This single lymph node is examined microscopically in. its entirety and at multiple levels. It is negative for. metastatic disease, 0/1. B. This simple mastectomy specimen contains a central,. fairly well demarcated infiltrating low grade ductal. car√ßinoma. No definite ductal carcinoma in situ is present. Invasive carcinoma: Histologic type: Infiltrating ductal carcinoma. Histologio grade: Well differentiated. Overall grade: Elston SBR grade 1. Architectural score: 1. Nuclear score: 1-2. Mitotic score: 1. Greatest dimension (pT) : The tumor measures 2.8 cm., pT2. Specimen margins: Negative. Vessel invasion Negative. Calcification: Present. Nipple (Paget's) : Negative for Paget's disease. Invasion of skin or chest wall: Negative. Description of non-tumorous breast: Fibrocystic changes are present. including cysts, apocrine metaplasia, ductal hyperplasia,. intraductal papillomatosis, rare focus of atypical ductal. hyperplasia and rare focus of atypical lobular hyperplasia. A 1 cm. fibroadenoma is also noted. Lymph nodes: As per part A, a single lymph node is negative for. metastatic disease. (pNO). Distant metastasis (pM) : Cannot be assessed. Prognostic markers: Previously performed. 14, 4x2. DIAGNOSIS. A. Left axillary sentinel node, excision - Single lymph node. negative for metastatic disease. B. Left breast, simple mastectomy - Breast with infiltrating ductal. carcinoma, Elston SBR grade 1. Margins of resection, skin and. nipple negative for tumor. Fibrocystic changes, rare. atypical ductal hyperplasia and rare atypical lobular. hyperplasia also present. A 1 cm. fibroadenoma is noted. DIAGNOSIS. M.D. (Electronic Signature).",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T2,"The report mentions a simple mastectomy and provides a specific tumor size of 2.8 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-D8-A27G.F8B8EEB1-0603-4181-9BD3-209143024EF8,"page 1 / 1. Pathology. copy No. 5. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - left breast with axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Macroscopic description: Left breast, sized 20 x 16 x 4 cm, removed along with axillary tissues sized 23 x 8 x 3 cm and a skin flap of 16 x 10.5 cm. Tumour. sized 2. x 2 x 2 cm found in the lower outer quadrant, located 2.5 cm from the lower boundary, 0.2 cm from the base and 2 cm. from the skin. Lymph nodes 2 cm in length. Microscopic description: Carcinoma lobulare invasivum NHG2 (3 + 2 +1/ 10 mitoses/10 HPF, visual area diameter 0.55 mm). Lesions of the type hyperplasia lobularis atypica (ALH). Glandular tissue showing lesions of the type mastopathia fibrosa et custica, hyperplasia ductalis simplex (UDH). papilloma intraductal. Axillary lymph nodes. Sinus histiocytosis et lipomatosis lymphonodorum (No XXXI). Histopathological diagnosis: Carcinoma lobulare invasivum mammae sinistrae. Invasive lobular carcinoma of the left breast. I. (NHG2, pT2, pNO).",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T2,"The report mentions a mastectomy ('Left breast removed along with axillary tissues') and provides a specific tumor size of 20 mm (2 x 2 x 2 cm), which falls within the T2 range (>20 mm but <=50 mm).",100.0,True
TCGA-BH-A0GY.A997FF30-F112-48BE-8FF1-15F8266A5E62,"FINAL DIAGNOSIS: PART 1: LEFI BREAST, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM SCORE 8/9 (TUBULES 3, NUCLEI 3, MITOSIS 2), 2.6 CM. B. DUCTAL CARCINOMA IN SITU, MICROPAPILLARY AND SOLID TYPES WITH COMEDO NECROSIS, NUCLEAR. GRADE 3, REPRESENTING 5% OF THE TUMOR VOLUME. C. LYMPHOVASCULAR SPACE INVOLVEMENT SEEN. D. INVASIVE CARCINOMA IS 0.1 CM FROM INFERIOR MARGIN. E. DUCTAL CARCINOMA IN SITU IS <0.1 CM (1MM) FROM INFERIOR MARGIN. F. MARGINS FREE OF LESION. G. MICROCALCIFICATION ASSOCIATED WITH BENIGN CHANGES AND TUMOR. H. CHANGES CONSISTENT WITH BIOPSY SITE. I. PROLIFERATIVE FIBROCYSTIC CHANGES WITH ATYPICAL DUCTAL EPITHELIAL HYPERPLASIA AND. COLUMNAR CELL CHANGES. J. MICROSCOPIC PERIPHERAL PAPILLOMA AND SCLEROSING ADENOSIS. K. SKIN NOT REMARKABLE. PART 2: LEFT AXILLA, SENTINEL LYMPH NODE #1, EXCISION -. A. ONE LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (0.9 CM). B. NO EXTRACAPSULAR EXTENSION SEEN. PART 3: LEFT AXILLA, SENTINEL LYMPH NODE #2, EXCISION -. ONE LYMPH NODE WITH RARE CLUSTERS OF METASTATIC TUMOR CELLS IN PERIPHERAL SINUS. PART 4: LEFT AXILLA, LYMPH NODE EXCISION -. ONE LYMPH NODE WITH EXTENSIVE THERMAL EFFECT, PROBABLY FREE OF TUMOR. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Lower outer quadrant. SIZE OF TUMOR: MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: Maximum dimension invasive component: 2.6 cm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. ANGIOLYMPHATIC INVASION: Nottingham grade (1, 2, 3): 3. DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, benign zones. TUMOR TYPE, IN SITU: Yes, malignant zones. Soia. Micropapillary. Comedo. DCIS admixed and outside of invasive carcinoma component. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Percent of tumor occupied by in situ component: 5 %. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of invasive tumor to closest margin: 1 mm. PAGET'S DISEASE OF NIPPLE: Distance of in situ disease to closest margin: 0.7 mm. LYMPH NODES POSITIVE: 2. LYMPH NODES EXAMINED: 3. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: Diameter of largest lymph node metastasis: 9 mm. SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: ADH, Papilloma, FCD. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T2,"The report mentions a segmental mastectomy and provides a specific tumor size of 2.6 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-BH-A18F.771497E1-473E-421A-A149-CFA58E95B728,"CHIEF COMPLAINT/ PRE-OPI POST-OP DIAGNOSIS: 1.2-cm mass posterior 12 o'clock right breast. Core blopsy Invasive ductal. carcinoma. LMP DATE: Not provided. PROCEDURE. Right segmental mastectomy/sentinel lymph node biopsies. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY No. CHEMORADIATION THERAPY: No. OTHER DISEASES No. ADDENDA: Addendum. There a few satellite nodules ranging in size from 0.5-2 mm, which measure 0.5-1.2 cm from the main dominant nodule. These. satellite nodules are the nodules that are seen closest to the margins, as reported. FINAL DIAGNOSIS: PART 1: BREAST√çRIGHT/SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA (see comment). B. NOTTINGHAM GRADE 3 (TUBULE FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY 3;. TOTAL SCORE 9/9). C. THE INVASIVE TUMOR MEASURES 1.1 CM IN GREATEST DIMENSION (ON SLIDE IK). D. NO DUCTAL CARCINOMA IN-SITU (DCIS) IS IDENTIFIED. E. NO LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. F. RESECTION MARGINS ARE NEGATIVE FOR INVASIVE CARCINOMA; INVASIVE CARCINOMA MEASURES. LESS THAN 1 MM FROM THE ANTERIOR AND INFERIOR MARGINS, 1 MM FROM THE MEDIAL MARGIN, AND. 1.5 MM FROM THE POSTERIOR MARGIN. G. SKIN, NEGATIVE FOR TUMOR. H. ATYPICAL DUCTAL HYPERPLASIA. I. CALCIFICATIONS ASSOCIATED WITH INVASIVE CARCINOMA. J. FIBROCYSTIC CHANGES WITH DUCTAL EPITHELIAL HYPERPLASIA ANO COLUMNAR CELL ALTERATIONS. K. CHANGES CONSISTENT WITH PRIOR BIOPSY SITE. THE INVASIVE TUMOR CELLS ARE NEGATIVE FOR ESTROGEN AND PROGESTERONE RECEPTORS AND. ALSO N√âGATIVE FOR HER-2/NEU (SCORE 0). AS PER PREVIOUS REPORT. PART 2: AXILLA, RIGHT, CYST EXCISION -. EPIDERMAL INCLUSION CYST. PART 3: LYMPH NODE, RIGHT AXILLARY, SENTINEL #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 4: LYMPH NODE, RIGHT AXILLARY, SENTINEL #2, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 5: LYMPH NODE, RIGHT AXILLARY, SENTINEL #3, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). COMMENT: The triple negative invasive tumor was reported to be positive for basal markers, as per previous report (I. Although the mass grossly measured 1.4 cm by gross examination, the tumor is best estimated to be 1.1 cm. based on the microscopic measurement from slide 1K. CASE SYNOPSIS: SYNOPTIC . PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Clock position:12 oclock. SIZE OF TUMOR: Maximum dimension invasive component: 11 mm. MULTICENTRICITY/MULTIFOCALTY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS, Other Type(s): Basal-like phenotype confirmed by IHC. on biopsy. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation 3. Mitotic activity score. 3. Total Nottingham score: 9. Nottingham grade (1, 2, 3): 3. ANGIOL YMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, malignant zones. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 0.5 mm. LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 3. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: ADH, FCD, Other: ductal epithelial hyperplasia, columnar cell alterations. T STAGE, PATHOLOGIC: pTic. N STAGE, PATHOLOGIC: pNO. M STAGE: Not applicable. ESTROGEN RECEPTORS: negative. PROGESTERONE RECEPTORS: negative. HER2/NEU: 0.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T1,"The report mentions a segmental mastectomy and provides a specific tumor size of 1.1 cm, which falls within the T1 range (<=20 mm). Therefore, the T stage is T1.",100.0,True
TCGA-BH-A0BG.CB0C2E8E-2D5D-492C-9C7E-0ECD0458425A,"FINAL DIAGNOSIS: PART 1: LEFT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). PART 2: BREAST, LEFT, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 3, (TUBULE FORMATION - 3, NUCLEAR GRADE -. 3, MITOTIC RATE - 3, TOTAL SCORE: 9/9). B. INVASIVE CARCINOMA MEASURES 1.8 CM IN GREATEST DIMENSION (SLIDE 2B). C. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID AND MICROPAPILLARY TYPES WITH. COMEDO NECROSIS AND ASSOCIATED CALCIFICATIONS. D. DCIS IS PRESENT OUTSIDE OF INVASIVE CARCINOMA COMPONENT (see comment). E. MARGINS OF RESECTION ARE NEGATIVE FOR INVASIVE CARCINOMA, INVASIVE CARCINOMA IS 0.9 CM. FROM CLOSEST (ANTERIOR) MARGIN OF RESECTION. F. DCIS IS PRESENT AT INFERIOR MARGIN OF RESECTION. G. NO LYMPHOVASCULAR INVASION IS IDENTIFIED (see comment). H. ATYPICAL DUCTAL HYPERPLASIA. I. FIBROCYSTIC CHANGES WITH COLUMNAR CELL CHANGE AND DUCTAL EPITHELIAL HYPERPLASIA. J. INVASIVE CARCINOMA IS NEGATIVE FOR ESTROGEN AND PROGESTERONE RECEPTORS AND NEGATIVE. FOR HER-2/NEU WITH A SCORE OF 0, AS PER PREVIOUS PATHOLOGY REPORT. COMMENT: The in situ carcinoma is noted outsite of invasive carcinoma component, near the inferior margin, focally involving the. inferior margin, in three out of fifty-eight slides. Entire specimen was submitted for histological evaluation. No definite lymphovascular invasion was seen in the current specimen. No lymphatic invasion was seen in the previous. biopsy specimen confirmed by D2-40 stain. However, vascular space invasion was seen in the previous biopsy. confirmed by CD31 stain. This data will be used for filling the synoptic template.",0,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T1,"The report mentions a segmental mastectomy and provides a specific tumor size of 1.8 cm, which falls within the T1 range (<=20 mm). Therefore, the T stage is T1.",100.0,True
TCGA-B6-A400.AF83CCA2-3AA4-4933-B6AD-9C11DF501DDD,"AP Surgical Pathology: Corrected. CLINICAL HISTORY: Not provided. GROSS EXAMINATION: A. ""Left axilla non-sentinel node (AF1) "". Received fresh for frozen section is. a 1.8 x 1 x 0.6 cm tan-yellow lymph node candidate which is bisected and. frozen as AF1, the frozen section remnant is submitted in block A1. B. ""Left sentinel node number one (BF1) "". Received fresh for frozen section. are three tan-yellow lymph node candidates. The larger lymph node candidate (2. x 1.2 x 1 cm) is bisected and frozen as BF1, and frozen section remnant is. submitted in block B1. The remaining two lymph node candidates (0.5 x 0.5 x. 0.3 cm and 1 x 0.7 x 0.4 cm lymph node candidate) are submitted in toto as. frozen section BF2, and the frozen remnant is submitted in block B2. C. ""Left sentinel node number two (CF1) Received fresh for frozen section is. a 3 x 2.5 x 0.8 cm fragment of tan-yellow fibrofatty tissue. One lymph node. candidate is identified (1.9 x 1 x 0.7 cm) which is bisected and frozen as. CF1. The frozen section remnant is submitted in block C1. D. ""Left breast cancer, 1:00"", received fresh and placed in formalin: Procedure: Wire guided partial mastectomy. Specimen orientation: Suture: long=lateral, short-superior. Clips: two clips. medial, one clip=inferior. Specimen dimensions: Medial to Lateral: 8.5 cm. Anterior to Posterior: 2.5 cm. Superior to Inferior: 9.5 cm. Skin dimensions: 4.3 x 1.3 cm with a 0.4 cm long scar. Margins inked: Superior: Red. Inferior: Yellow. Anterior: Blue. Posterior: Black. Sectioned: Medial to lateral. Gross findings: There is a tan-white indurated ill defined area with. peripheral hemorrhage and fat necrosis. Lateral and superior to this area is a. second focus of white-tan induration with adjacent thick white-tan fibrous. tissue. The remaining parenchyma is tan-yellow lobulated adipose tissue. Gross tumor size: 2.3 x 2.1 x 1.2 cm. Multifocal tumor: Additional lesion is 1.2 x 0.8 x 0.5 cm which directly abuts. the primary focus. Distance of tumor from gross surgical margin for the primary tumor: Superior: 2.1 cm. Inferior: 3.2 cm. Anterior: 0.6 cm. Posterior: 1.2 cm. Medial: 4.2 cm. Lateral: 1 cm. Additional lesion: Superior: 3.1 cm. Inferior: 2 cm. Anterior: 1 cm. Posterior: 1 cm. Medial: 6.9 cm. Lateral: 0.5 cm. Sectioned specimen radiographed? Yes. Radiograph findings: Mass: Yes. Microcalcifications: Yes. Biopsy site microclip: No. Specimen photograph? Yes. Block diagram? Yes. Sections submitted from medial to lateral in blocks D1 through D35. Specimen completely submitted? No. BLOCK SUMMARY: Medial margin-D1. Lateral margin-D34 and D35. Inferior margin: D13. Superior margin: D19. Anterior and posterior margins: D23. Primary tumor: D10, D11, D15, D16, D17, D18, D21, D22, D23, D24, D25, D27,. D28, D31, D33. Secondary lesion: D25, D27, D28, D31, D32, D33. Microcalcifications: D12, D15, D16, D17, D18, D20, D23, D25, D33. E. ""Left axillary mass, long stitch-lateral, short-superior"", received fresh. and placed in formalin: Procedure: Wire guided partial mastectomy. Specimen orientation: Long stitch lateral, short stitch superior. Specimen dimensions: Medial to Lateral: 5.6 cm. Anterior to Posterior: 1 cm. Superior to Inferior: 3.6 cm. Margins inked: Superior: Red. Inferior: Yellow. Anterior: Blue. Posterior: Black. Sectioned: Medial to lateral. Gross findings: A well circumscribed white-brown nodule with an embedded. microclip in the medial portion. Lateral to this first nodule is a second ill. defined firm nodule. The remaining parenchyma is yellow-tan lobulated adipose. tissue. Gross tumor size:1.6 x 0.6 x 0.5 cm. Multifocal tumor: Second lesion is 1.2 x 0.5 x 0.4 cm, and it is 0.7 cm from. the first. Distance of tumor from gross surgical margin: First nodule: Superior: 1.8 cm. Inferior:0. cm. Anterior: 0.2 cm. Posterior: 0.2 cm. Medial: 2 cm. Lateral: 3.6 cm. Second nodule: Superior: 1.7 cm. Inferior: 1 cm. Anterior: 0.2 cm. Posterior 0.3 cm. Medial: 5.9 cm. Lateral: 1.8 cm. Sectioned specimen radiographed?. Radiograph findings: Mass: Yes. Microcalcifications: Yes. Biopsy site microclip: Yes. Specimen photograph? Yes. Block diagram? Yes. Sections submitted from medial to lateral in blocks E1 through E21. Specimen completely submitted? Yes. BLOCK SUMMARY: Medial margin-E1. Lateral margin:E21. Anterior, posterior, inferior margins for first nodule=E8. Anterior, posterior, superior, inferior margin for second nodule-E13. First nodule-E6, E7, E8, E9, E10, E11. Second nodule:E13, E14, E15, E16. Microclip: E11. Microcalcifications: E8, E13, E19. F. ""Left axillary contents"". Received fresh and placed in formalin is a 6.5 x. 6.5 x 2 cm aggregate of multiple fragments of tan-yellow fibrofatty tissue. Fourteen lymph node candidates are identified ranging in size from 0.5 x 0.5 x. 0.4 cm to 3.5 x 1.5 x 1.3 cm. The smallest lymph node candidate is submitted. in blocks F1-F3, and the two largest lymph node candidates are inked blue and. black, bisected and submitted in blocks F4-F6. A. REPORT REVISED ON. INTRA OPERATIVE CONSULTATION: A. ""Non-sentinel node right axilla"": AF1- one lymph node candidate, bisected. (1.3 x 1 x 0.6 cm) - no tumor is seen (Dr. B. ""Sentinel node number one"": BF1 (one lymph node candidate, bisected, 2 x. 1.6 x 1 cm) positive for metastatic cancer (micrometastases) (Dr. BF2 (two lymph node candidates, intact (0.5 x 0.5 x 0.3 cm) and 1 x 0.6 x 0.4. cm, no tumor is seen (Dr. C. ""Sentinel node number two"": CF1- one lymph node candidate, bisected, 1.9 x. 2 x 0.7 cm, positive for metastatic cancer (micrometastases) (Dr. MICROSCOPIC EXAMINATION: Microscopic examination is performed. PATHOLOGIC STAGE: PROCEDURE: Partial mastectomy, sentinel lymph node biopsy with completion. axillary dissection. PATHOLOGIC STAGE (AJCC. Edition) : pT2 pN2a pMX. NOTE: Information on pathology stage and the operative procedure is. transmitted to this Institution's Cancer Registry as required for. accreditation by the Commission on Cancer. Pathology stage is based solely. upon the current tissue specimen being evaluated, and does not incorporate. information on any specimens submitted separately to our Cytology section,. past pathology information, imaging studies, or clinical or operative. findings. Pathology stage is only a component to be considered in determining. the clinical stage, and should not be confused with nor substituted for it. The exact operative procedure is available in the surgeon's operative report. REVISED DIAGNOSIS. A. ""LEFT AXILLA, NON-SENTINEL LYMPH NODE"" (BIOPSY) : ONE LYMPH NODE, NO EVIDENCE OF MALIGNANCY (0/1) . B. ""LEFT AXILLA, SENTINEL LYMPH NODE # 1"" (BIOPSY) : METASTATIC ADENOCARCINOMA IN THREE LYMPH NODES (3/3) . SIZE OF LARGEST METASTASIS: 6 MILLIMETERS. EXTRACAPSULAR INVASION: ABSENT. C. ""LEFT AXILLA, SENTINEL LYMPH NODE # 2"" (BIOPSY) : METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1) . SIZE OF LARGEST METASTASIS: 4 MILLIMETERS. EXTRACAPSULAR INVASION: ABSENT. D. ""LEFT BREAST CANCER, 1:00"" (WIRE GUIDED PARTIAL MASTECTOMY) : INVASIVE ADENOCARCINOMA OF THE BREAST. HISTOLOGIC TYPE: DUCTAL. NOTTINGHAM COMBINED HISTOLOGIC GRADE: 3 OF 3. TUBULE FORMATION SCORE: 3. NUCLEAR PLEOMORPHISM SCORE: 3. MITOTIC RATE SCORE: 3. GROSS TUMOR SIZE: 2.3 x 2.1 x 1.2 CM. SIZE OF INVASIVE COMPONENT: 2.3 CM. LOCATION OF THE TUMOR: ADJACENT TO PREVIOUS BIOPSY SITE. LYMPHATIC/VASCULAR INVASION: PRESENT. MULTIFOCAL TUMOR: ABSENT (SECOND MASS LESION DESCRIBED GROSSLY IS FAT. NECROSIS) . IN-SITU CARCINOMA: PRESENT. TYPE OF IN-SITU CARCINOMA: COMEDO. NUCLEAR GRADE OF IN-SITU CARCINOMA: 3 OF 3. NECROSIS: PRESENT. DCIS EXTENDING OUTSIDE INVASIVE TUMOR MASS: ABSENT. SIZE OF IN-SITU CARCINOMA: NOT APPLICABLE. SKIN STATUS: FREE OF TUMOR. STATUS OF NON-NEOPLASTIC BREAST TISSUE: NEEDLE CORE BIOPSY SITE, AND FAT. NECROSIS. SURGICAL MARGIN STATUS: NEGATIVE (GREATER THAN 2 MM) . ESTROGEN/PROGESTERONE RECEPTOR, CELL CYCLE, EGFR AND HER2/NEU ANALYSIS: PENDING, PARAFFIN BLOCK NUMBER D11. RESULTS WILL BE ISSUED SEPARATELY FROM THE IMAGE CYTOMETRY LAB. E. ""LEFT AXILLARY MASS"" (EXCISION) : METASTATIC ADENOCARCINOMA IN ONE OF FOUR AXILLARY LYMPH NODES (1/4). SIZE OF METASTASIS: 1.6 CM. EXTRACAPSULAR INVASION: PRESENT. CHANGES CONSISTENT WITH A NEEDLE CORE BIOPSY SITE ARE PRESENT. MARGIN STATUS: NEGATIVE. F. ""LEFT AXILLARY CONTENTS"" (COMPLETION NODE DISSECTION) : METASTATIC ADENOCARCINOMA IN ONE OF TWENTY LYMPH NODES (1/20) . SIZE OF METASTASIS: 0.5 MILLIMETERS. EXTRACAPSULAR INVASION: ABSENT. COMMENT: This report revised. to correct the site for specimens A-C,. which were received labelled as ""right"" Per. the correct site is. left. is notified of this revision. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). DIAGNOSIS: SEE REVISED REPORT: REPORT REVISED ON. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) . CI ADDENDUM 1: Please see. for results of supplementary. tests. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es).",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T2,"The report mentions a mastectomy procedure and provides a specific tumor size of 2.3 x 2.1 x 1.2 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-AR-A1AK.F4DBFC71-9CD0-41C3-9F20-77FA0605D4A8,"Final diagnosis. Breast. right, simple mastectomy: Invasive mammary carcinoma, Nottingham grade II (of III),. with predominantly lobular features is identified forming multiple (4) masses (ranging in size. from 0.7 cm to 1.6 cm in greatest dimension) (AJCC pTc) situated in multiple quadrants (lower. inner quadrant, inferior central, upper outer quadrant, and 12 o' clock position). There is a. minimal (5%) component of ductal carcinoma in situ, intermediate nuclear grade. No. angiolymphatic invasion identified. Tumor closely approaches (0.1 cm) the original inferior. margin. Skin, nipple, and final surgical margins (after re-excision) are negative for tumor. Lymph nodes, right axillary sentinel, excision: Multiple (5) right axillary sentinel lymph nodes. are negative for tumor (AJCCpN0(sn)(i-)). Blue dye is identified in all five right axillary sentinel. lymph nodes. Immunohistochemical cytokeratin stain was performed on the paraffin embedded. sentinel lymph node tissue and confirms the H&E impression. HER2/neu protein overexpression is negative, score of 1+, according to the interpretation. guidelines in the FDA-approved HercepTest.",0,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T1,"The report mentions a simple mastectomy and provides a specific tumor size within the T1 range (0.7 cm to 1.6 cm), so the T stage is T1. The mention of a radical mastectomy is not present, and the tumor size does not exceed 20 mm.",100.0,True
TCGA-BH-A201.6AE92F6F-E29D-43B6-AF1E-F15720C1AAE8,"PATIENT HISTORY: CHIEF COMPLAINT/ PRE-OP/POST-OP DIAGNOSIS: Left breast cancer. LMP DATE. Not applicable. PROCEDURE: Left segmental mastectomy with wire localization, sentinel node biopsy and mapping. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY: No. CHEMORADIATION THERAPY No. OTHER DISEASES: No. FINAL DIAGNOSIS: PART 1: LYMPH NODE, LEFT AXILLA, SENTINEL NODE #1, BIOPSY -. ONE BENIGN LYMPH NODE, NO EVIDENCE OF MALIGNANCY (0/1). PART 2: LYMPH NODE, LEFT AXILLA, SENTINEL NODE #2, BIOPSY-. ONE BENIGN LYMPH NODE, NO EVIDENCE OF MALIGNANCY (0/1). PART 3: BREAST, LEFT, SEGMENTAL MASTECTOMY WITH WIRE LOCALIZATION -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 2 (TUBULAR FORMATION: 3, NUCLEAR. PLEOMORPHISM: 2, MITOTIC ACTIVITY: 2; TOTAL SCORE 7/9). B. INVASIVE TUMOR MEASURES 1.5 CM IN GREATEST DIMENSION (GROSS MEASUREMENT). c. LYMPHOVASCULAR SPACE INVASION IS PRESENT. D. DUCTAL CARCINOMA IN-SITU (DCIS), NUCLEAR GRADE 2, SOLID TYPE.. E. RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA; CARCINOMA IS 2 MM FROM NEAREST. (ANTERIOR), MARGIN. F. FIBROCYSTIC CHANGES, DUCTAL EPITHELIAL HYPERPLASIA AND SCLEROSING ADENOSIS. G. BIOPSY SITE CHANGES. H. CALCIFICATIONS ASSOCIATED WITH BENIGN AND MALIGNANT AREAS. I. TUMOR REPORTED TO BE POSITIVE FOR ER AND PR, AND NEGATIVE FOR HER-2/NEU. J. TATHOLOGIC STAGE: pT1a pNO. SYNOPTIC-PRIMARY - INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Clock position: 12:00. SIZE OF TUMOR: Maximum dimension invasive component: 15 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 7. Nottingham grade (1. 2. 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicabl√©. CALCIFICATION: Yes, benign zones. Yes, malignant zones. TUMOR TYPE, IN SITU: Solid. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Percent of tumor occupied by in situ component: 10 %. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of invasive tumor to closest margin: 3 mm. LYMPH NODES POSITIVE: Distance of in situ disease to closest margin: 2 mm. 0. LYMPH NODES EXAMINED: 2. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. T STAGE, PATHOLOGIC: pT1a. N STAGE MODIFIER: (sn). N STAGE, PATHOLOGIC: pNO. M STAGE: CESA-BH-A201-01A-PR. Not applicable. ESTROGEN RECEPTORS: positive, H-score: 205. PROGESTERONE RECEPTORS: positive, H-score: 225. HER2/NEU: 1+.",0,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T1,"The report mentions a left segmental mastectomy and provides a specific tumor size of 15 mm, which falls within the T1 range (<=20 mm). Therefore, the T stage is T1.",100.0,True
TCGA-AN-A0FV.5AEE90E0-A9A1-4944-AD6A-2675764D869D,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Right Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T2,"The report mentions a radical mastectomy, which falls under the third rule. The fourth rule is not applicable since there is no mention of invasion of the chest wall or skin. The first and second rules are not applicable since there is no mention of a lumpectomy, wide excision, segmental mastectomy, or specific tumor size within the T1 or T2 range.",100.0,True
TCGA-E2-A155.C3E398CE-1918-4107-948C-6579B1DA1F77,"SPECIMENS: A. LEFT BREAST AND AXILLARY CONTENTS LEVEL 1 AND 2. B. ADDITIONAL LEFT AXILLARY CONTENTS. SPECIMEN(S): A. LEFT BREAST AND AXILLARY CONTENTS LEVEL 1 AND 2. B. ADDITIONAL LEFT AXILLARY CONTENTS. GROSS DESCRIPTION: A. LEFT BREAST AND AXILLARY CONTENTS LEVEL 1 AND 2. Received fresh labeled with the patient's identification and ""left breast and axillary contents levels one and two. (suture in axillary tail)"" is an oriented 1794 g, 31 x 22 x 4.5 cm mastectomy with 27 x 16 skin ellipse and 1.1-cm flat. nipple. Skin has 4 brown macules ranging from 0.2 to 0.4 cm. In code: Anterior/superior-blue, anterior/inferior-. orange, posterior-black Specimen is serially sectioned into 11 slices from medial to lateral with nipple in slice7. #1- is a 2.5 x 2.5 x 1.7 cm firm tan stellate mass which is located at the 12 o'clock position, 4.2 cm from the deep. revealing 4 lesions. margin and 2 cm from the anterior margin (slices 6-7). #2- is a 1.3 x 1.1 x 1 cm firm tan stellate mass which is. located 0.3 cm medial to lesion #1, 5 cm from the deep margin and 1.3 cm from the anterior margin at roughly the 9. o'clock position (slice 5). #3- is a 2.5 x 2.2 x 1.5 cm firm tan stellate mass located 0.4 cm medial to lesion #2, 4 cm. from the deep margin and 1.5 cm from the anterior margin at roughly the 9 o'clock position (slice 4). #4- is a 1 x 1. x. 0.6 cm firm granular mass located 2.5 cm posterior lesion #3, 1.3 cm from the deep margin and 4.5 cm from the. anterior margin (slice 4). Adjacent to the deep margin, in slice 7, is a 0.9 x 0.6 x 0.4 cm firm tan lymph node. Within. the axillary tail are multiple lymph nodes ranging from 0.3 to 3.5 cm. The largest lymph node is nodular and a portion. is procured. Representatively submitted. A1: slice 4, lesion #3. A2: slice 4, tissue connecting lesions #3 and #4. A3: slice 4, lesion #4. A4: slice 4, deep margin lesion 4. A5: slice 5, tissue between lesions 3/4 and #2. A6: slice 5, lesion #2. A7 slice 6, tissue between lesions 2 and 1. A8: slice 6, superior to lesion 1. A9: slice 6, superior part of lesion 1. A10: slice 6, inferior part of lesion 1. A11: slice 6, inferior to lesion 1. A12: slice 6, anterior to lesion 1. A13: slice 7, lateral to lesion 1. A14: slice 3, upper inner quadrant. A15: slice 8, upper outer quadrant. A16: slice 9, lower outer quadrant. A17: slice 3, lower inner quadrant. A18-A19: nipple, perpendicular sections. A20: skin with macules. A21: intramammary lymph node. A22: 5 lymph nodes. A23: 4 lymph nodes. A24-A26: 1 lymph node each. A27-A28: 1 lymph node. A29-A30: 1 lymph node. A31-A36: 1 lymph node. B. ADDITIONAL LEFT AXILLARY CONTENTS. Received fresh labeled with the patient's identification and ""additional left axillary contents"" is a piece of fatty tissue. measuring 6.3 x 4.7 x 0.6 cm. One lymph node is identified. Submitted entirely. B1: 1 lymph node. B2-B4: remainder of soft tissue. DIAGNOSIS: A. BREAST, LEFT, MASTECTOMY WITH AXILLARY NODE DISSECTION: - MULTIPLE FOCI OF INVASIVE DUCTAL CARCINOMA, SBR GRADE 3 WITH MICROPAPILLARY FEATURES,. LARGEST FOCUS MEASURING 2.5-CM. - HIGH NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID AND CRIBRIFORM TYPES WITH LOBULAR. EXTENSION, CENTRAL NECROSIS AND MICROCALCIFICATIONS. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - METASTATIC CARCINOMA TO ONE OF TWELVE AXILLARY LYMPH NODES (1/12), MEASURING 3.5-CM. WITH FOCAL EXTRANODAL EXTENSION. - METASTATIC CARCINOMA TO ONE OF TWO INTRAMAMMARY LYMPH NODES (1/2), MEASURING 0.8-CM. WITH FOCAL EXTRANODAL EXTENSION. - SEE SYNOPTIC REPORT AND SEE NOTE. B. LYMPH NODES, ADDITIONAL LEFT AXILLARY CONTENTS, DISSECTION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). NOTE: Four tumor nodules are grossly identified. Microscopically 3 of them are invasive ductal carcinoma that. have. the same morphology and one is DCIS. The tissues in between these nodules show scattered foci of DCIS. Therefore, these foci may be interconnected through DCIS. Largest confluent invasive tumor measures 2.5-cm. Two intramammary lymph nodes are identified, one is positive for metastatic carcinoma. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.5cm. Tumor Site: Upper inner quadrant. Lower inner quadrant. Margins: Negative. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: Indeterminate. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 2 / 15 Extranodal extension. DCIS present. DCIS Quantity: Estimate 10%. DCIS Type: Solid. Cribriform. DCIS Location: Associated with invasive tumor. Nuclear grade: High. Necrosis: Present. ER/PR/HER2 Results. ER: Positive. PR: Negative. HER2: Negative by IHC. Performed on Case: Pathological staging (pTN): pT 2 N 1c. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist,. Final: Pathologist, (.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T2,"The report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm). The largest confluent invasive tumor measures 2.5-cm, which falls within the T2 range.",100.0,True
TCGA-E9-A6HE.649E6215-36F9-4BEB-9EE9-683E4FC75C42,"Gross Description: A. ""Right axilla palpable node."" A 2.2 X 1.5 X 0.6 cm portion of lymph node bearing. fat contains a 0.5 X 0.5 X 0.5 cm hard white nodule. Imprints are prepared, and a portion is selected for. frozen section examination. B. ""Right breast stitch marks axillary tail."" A he 14.9 X 13.5 X 4.0 cm right. breast with an overlying 8.0 X 4.0 cm keyhole-shaped skin. The areolar complex is unremarkable. There. is a 0.3 cm skin lesion (grossly consistent with seborrheic keratosis), 0.5 cm and located 0.6 cm medial to. the nipple. There is a stellate mass within the central breast 5.7 x 4.0 X 2.0 cm, located 2.0 cm from the. deep margin and occupies the upper and lower outer quadrants as well as the upper inner and outer. quadrants. There is a biopsy marker recognize in the lower outer quadrant (8 o'clock aspect), 3.7 cm. from the deep margin. A second biopsy marker is recognized and approximately 1 o'clock, 3.5 cm from. the deep margin. Superior to the main mass is a satellite nodule attached by fibrous strands, 0.7 X 0.5 x. 0.5 cm, located 2.0 cm from the deep margin and 1.8 cm superior to the main mass at approximately 12. o'clock. The remaining breast tissue is centrally dense. There are no intramammary lymph nodes. The. margin is a blue. C. ""Level 1 and 2 right axillary lymph nodes."" A 7.0 x 5.0 x 2.0 cm aggregate of adipose. tissue fragments containing 11 lymph nodes up to 1.5 cm. The lymph nodes all appear involved by. tumor with the largest metastasis measuring 1.4 cm. Extracapsular extension is noted. Microscopic Description: Biopsy type: Mastectomy. Tumor site: Central. Size: 5.7 cm. Specimen Margin: Free of invasive carcinoma by 20 mm (deep) Site R Breast NOS (509. Tumor grade (SBR/Nottingham):N/A. Tubule formation: N/A. Nuclear atypia: 2. Mitotic rate: 2 (focal). Lymphovascular invasion: Present (focal). In situ component: Lobular carcinoma in situ. Calcifications: Absent. Non-neoplastic breast: Atrophic with intramammary metastases. Estrogen (ER) and Progesterone (PR) Receptors (IMPX): ER strongly positive, PR strongly positive on. previous biopsyHer-2/Neu (H2N). Amplification: Negative on previous biopsy. Nipple involvement: Present. Skin involvement: No. Skeletal muscle: Not present. Lymph nodes: Axillary (specimens A and C): 12 metastases (12 nodes examined) The largest metastasis. is 14 mm; there is extensive extracapsular extension. PTNM Stage: pT3 N3. Diagnosis Details: Subcutis (right axilla): Metastatic invasive lobular carcinoma (presumable an effaced. lymph node) Breast (right): Invasive lobular carcinoma, pleomorphic type with intramammary and. axillary metastases. Comments: Multiple axillary lymph nodes exhibit effacement by invasive lobular carcinoma, with. extensive involvement of extranodal adipose tissue. Invasive lobular carcinoma extends to the. cauterized margin of axilla specimen. Formatted Path Reports: BREAST TISSUE CHECKLIST. Specimen type: Mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 5.7 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating lobular carcinoma. Histologic grade: Not specified. Tumor extent: Nipple. Lymph nodes: 12/12 positive for metastasis (Axillary 12/12). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: Right breast. Reviewer.",2,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,617.0,T3,"The report explicitly mentions that the tumor size is 5.7 cm and the procedure performed is a mastectomy. According to the given rules, if a mastectomy or a radical mastectomy is performed and the tumor size is greater than 50 mm, the T stage is T3.",100.0,True
TCGA-OL-A5RY.C8297152-7551-49A1-8C9D-6B411391AC77,"FINAL PATHOLOGIC DIAGNOSIS. A. Right axillary sentinel lymph node #1, biopsy: - Metastatic ductal carcinoma (1.3cm) involving single lymph node (1/1). B. Right axillary sentinel lymph node #2, biopsy: - One lymph node, no tumor (0/1). C. Right axillary sentinel lymph node #3, biopsy: - One lymph node, no tumor (0/1). D. Right axillary non sentinel lymph node, biopsy: - One lymph node, no tumor (0/1). E. Right breast, wire-guided lumpectomy: - Invasive ductal carcinoma, SBR III, multiple foci (largest 1.3cm). - Ductal carcinoma in situ high grade, solid, cribriform and micropapillary. types with central necrosis and associated calcifications; DCIS spans entire. specimen (8cm in greatest dimension). F. Right breast, new inferior lateral margin, excision: - Ductal carcinoma in situ, intermediate grade, microscopic foci (largest 5mm). - Microscopic foci (each 1mm) of DCIS present at outer medial aspect of specimen. G. Right breast, new outer lateral margin, excision: - Ductal carcinoma in situ, rare microscopic foci (largest 1mm). - DCIS >1cm from nearest new margin. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Microscopic measurement: Multifocal; largest focus (measures 1.3cm). B. Composite histologic (modified SBR) grade: III (largest focus). - Architecture: 2. - Nuclear grade: 3. - Mitotic count: 3. C. Associated intraductal carcinoma in situ (DCIS): - High grade, solid, cribriform and micropapillary types. - DCIS involves entire specimen and spans 8cm in greatest dimension. 2. Excisional biopsy margins: Positive. - DCIS present at medial margin, <1mm from anterior, posterior, lateral,. superior, and inferior margins (tumor approaches margins at multiple foci. throughout specimen). - Invasive carcinoma at inferior and 1mm from posterior margin; additional. margins greater than 2mm away. 3. Blood vessel and lymphatic invasion: Present in breast parenchyma. 4. Axillary lymph nodes: Positive (1/4). - Size of largest metastatic deposit: 13 mm. - Extranodal extension: absent. 5. Special studies. - ER: Weak expression in 10% of invasive tumor nuclei. - PR: No expression. - Her2/neu antigen (FISH): Amplified (ratio: 7.6). 6. pTNM (AJCC, 7th edition, 2010): pT1c(m), N1(sn), MX. Effective. is Checklist utilizes the 7th edition TNM staging. system for breast of the American Joint Committee on Cancer (AJCC) and the. International Union Against Cancer (UICC). has1. Interpretation performed by the Attending Pathologist and reviewed with the. Resident/Fellow. Clinical History: Patient is a. -year-old female with right breast IDC undergoing lumpectomy and. sentinel lymph node biopsy. Specimens Received: A: Sentinel lymph node #1. B: Sentinel lymph node #2. C: Sentinel lymph node #3. D: Non-sentinel lymph node. E: Right wire-guided lumpectomy. F: Right breast new inferior lateral margin. G: New outer lateral margin. Gross Description: The specimens are received in seven containers each labeled with the patient's. name and medical record number. A. The first container is additionally identified as, 'sentinel lymph node #1'. Received fresh and placed in formalin the specimen consists of a 1.5x1x1cm. lymph node which is serially sectioned and entirely submitted in cassette A1. B. The second container is additionally identified as, 'sentinel lymph node. #2'. Received fresh and placed in formalin the specimen consists of a 1x 0.5 X. 0.3 cm lymph node which is bisected and is entirely submitted in cassettes B1. C. The third container is additionallyidentified as, 'sentinel lymph node #3'. Received fresh and placed in formalin the specimen consists of a 0.7 x 0.3 x 0.3. cm lymph node which is entirely submitted in cassette C1. D. The fourth container is additionally identified as, 'non-sentinel lymph. node'. Received fresh and placed in formalin the specimen consists of a 0.5 X. 0.3 x 0.3 cm lymph node which is entirely submitted in cassette D1. E. The fifth container is additionally identified as, 'right wire guided. lumpectomy'. Received fresh on a radiographic grid is a 102 gm lumpectomy. specimen measuring 8 cm from medial to lateral, and 8 in cm from superior to. inferior and 3 cm from anterior to posterior. The specimen is oriented with a. short suture designating the superior pole and a long suture designating the. lateral pole. There is a wire entering the antero-lateral aspect of the specimen. through grid coordinate E5. Accompanying the specimen is an x-ray demonstrating. a metallic clip located in grid coordinate E3. There is a circled mass in grid. positions C3, C4, D3, D4, centered on the clip. The wire enters the specimen in. grid coordinates E5 terminates in E3. 2 other areas of calcifications are. circled in grid coordinates D6 (#2) and F4-F5 (#3). The margins are inked as follows: anterior - black;. posterior - red;. superior - blue;. inferior - green;. medial - yellow;. lateral - violet. The specimen is serially sectioned from medial to lateral into 8 slices. The. area of calcifications noted in grid D6 begins in the slides #2 and extends. laterally the tumor the main to mass and measures 3 X 2 x 1.5 cm. is found in. the slices #2 and 3 adjacent to the red and green ink. The main mass, which is. irregular and firm, is present in slices #5 to #7 and measures 3.5 X 2.5 X 2 cm. It is present adjacent to red ink and is 1 cm from black ink, 3 cm from green. ink, 1.5 cm away from blue ink. The area of calcification noted in grid F4 and. F5 is present in the slices numbers 7 and activated ink measuring 1.5 X 1.1 x 1. cm and is continuous with the main mass. The metallic clip is identified in. slice 6. The wire enters the specimen in slice 5 and terminates in slice 5. The. remainder of the breast parenchyma is white-yellow and lobulated with no. additional masses or lesions. Entire mass including both calcified area was has a largest dimension of 5 cm. Specimen is submitted in toto. Block summary: E1-E4: medial margin, slice 1. E5-E9: slice 2, area of calcification. E10-E23: slice 3, area of calcification. E24-E31: slice 4. E32-E44; slice 5. E45-E62: slice 6, clip in E49-E50. E63-E78: slice 7. E79-E86: lateral margin, slice 8. F. The sixth container is additionally identified as, 'right breast, new. inferior lateral margin'. Received fresh on the radiographic grid is a 13.5 gm,. 6.5 X 4 X 1.2 cm medial inferior lateral margin which is oriented as follows: - new outer lateral margin is marked with a long black stitch (violet). - new outer medial margin is designated with a short black stitch (yellow). - new outer anterior margin is designated with a short blue stitch (black). - new outer posterior margin is designated with a long blue stitch. (red). Inner cauterized margin is inked green. An area of calcification is noted on the. accompanying x-ray in grid D4-D5-E5. Specimen is a serially sectioned from. lateral to medial in to 14 slices. An area of calcification is present in slice. #6 and measures 1 X 0.5 X 0.3 cm. No other lesions are identified. The specimen. is entirely submitted from lateral to medial. F1: slice 1-3. F2: slice 4-5. F3: slice 6. F4: slice 7. F5-F6: slice 8. F7: slice 9. F8: slice 10. F9: slice 11. F10: slice 12. F11: slice 13-14. G. The seventh container is additionally identified as, 'new outer lateral. margin'. Received fresh ona radiographic grid is a 20 gm, 8 x 3.5 X 1 cm new. outer lateral margin. Specimen is oriented as follows. - new outer superior is designated with a short black stitch (blue). - new outer inferior is designated with a long black a stitch (green). - new outer anterior is designated with a short blue stitch (black). - new outer posterior is designated with a long blue stitch (red). Inner cauterized margin is inked violet. Specimen is serially sectioned from. lateral to medial into 14 slices and does not contain any distinct masses or. lesions. Specimen is submitted in toto in cassettes G1-14.",0,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,752.0,T1c,"The report mentions a wire-guided lumpectomy and provides a specific tumor size of 1.3 cm, which falls within the T1 range (<=20 mm). Therefore, the T stage is T1. Furthermore, the 'c' subclassification is used because the tumor is multifocal, meaning there are multiple foci of cancer within the breast.",90.0,True
TCGA-E9-A1N9.39D6D1DE-2CAE-470F-836B-926242F46E67,BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 3.2 X 2.5 X 1.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 0/8 positive for metastasis (Regional 0/8). Right) lower. Extracapsular invasion of the lymph nodes: Not specified. outer. Margins: Not specified. quasrant. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.,1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a mastectomy but does not specify a radical mastectomy, and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,752.0,T3,"The report mentions a radical mastectomy and provides a specific tumor size of 3.2 x 2.5 x 1.5 cm, which is larger than 50 mm in greatest dimension. This matches the criteria for T3.",100.0,True
TCGA-A8-A08F.683AAF99-3B91-4501-B701-C3A4E8439647,"Diagnosis: 1. Ablated (right) breast sample with a multifocal invasive ductal carcinoma with. intraductal components and focal angioinvasion (focus of a poorly differentiated. invasive ductal carcinoma with a tumor diameter of 2.8 cm and two further foci of. a. moderately invasive ductal carcinoma with tumor diameters of 3.0 cm and 1 cm). Dorsal resection margin tumor-free with minimum margin of 0.5 cm with the first. tumor focus, 1.5 cm with the second and 0.7 cm with the third, other margins are. free. Tumor classification: NOS, G III, pT2(mult)N3aL1V0R0. N¬∞. Site. Prior Prigian Noted QUALIFIED. is. (circle): Die.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,889.0,T2,"The report mentions an ablated (right) breast sample with a multifocal invasive ductal carcinoma with a specific tumor size of 2.8 cm within the T2 range (>20 mm but <=50 mm). The report also mentions two further foci of moderately invasive ductal carcinoma with tumor diameters of 3.0 cm and 1 cm. The T stage is T2, and the multifocality is indicated by '(mult)' in the tumor classification.",85.0,True
TCGA-AN-A0AK.12683FCC-4828-4D9A-9B35-E4B7295CC417,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,889.0,T2,"The report mentions a breast surgery (without specifying the type) and provides a specific tumor size of 20 mm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-PE-A5DC.8693580D-FCB3-4943-9C2F-5F3DABFB5AF0,"SPECIMEN: Sex: F. Date Collected. Date Received. Clinical History/Diagnosis: Right Breast Cancer. Source of Specimen(s): A: Sentinel Node right axilla. B: right Breast Lumpectomy. C: final inferior Margin. D: right Axillary Contents. Gross Description: Received in four parts. Source of Tissue: 1. Labeled #1, ""sentinel node right axilla"". Touch Prenaration Evaluation: 1TPA-1TPB-METASTATIC CARCINOMA PER. Gross Description: Received fresh for touch preparation evaluation with. patient's name and medical record number labeled ""sentinel node right. axilla"" are two gray-tan blue dye stained lymph nodes, 0.8 and 2.0 cm in. greatest dimension. They are sectioned, touch preparations are made and. representative sections are submitted in two blocks. Designation of Sections: 1A: 1TPA (representative section), 1B: 1TPB. (entire lymph node). Summary of Sections: multiple. Source of Tissue: 2. Labeled #2, ""right breast lumpectomy"". Gross Description: Received fresh with patient name and medical record. number labeled ""right breast lumpectomy"" is a 190 grams, 11.0 x 10.5 x 4.0. cm yellow-tan fragment of breast tissue. There is a short stitch denoting. the superior margin and a long stitch denoting the lateral margin. The. margins are inked in black, the specimen is serially sectioned to reveal. yellow-tan adipose tissue with a moderate amount of dense white-tan. connective tissue. There is a 4.0 x 2.5 x 1.8 cm firm mass having tan. gritty cut surfaces with irregular borders. This grossly appears to come. closest to the inked anterior, posterior and inferior margins. Representative sections are submitted in ten blocks. Designation of Sections: 2A- superior, 2B-2C- inferior, 2D- medial, 2E-. lateral, 2F-2H-anterior, 2I-2J- posterior. Summary of Sections: multiple. Source of Tissue: 3. Labeled #3, ""final inferior margin"". Gross Description: Received fresh with patient name and medical record. number labeled ""final inferior margin"" is a 5.0 x 3.5 x 1.6 cm yellow-tan. focally blue dye stained fragment of breast tissue. There are two sutures. present marking the new margin and this area is inked in black. The. specimen is sectioned to reveal yellow-tan adipose tissue with a moderate. amount of dense white-tan connective tissue. Representative sections are. submitted in four blocks. Designation of Sections: 3A-3D. Summary of Sections: multiple. Source of Tissue: 4. Labeled #4, ""right axillary contents"". Gross Description: Received fresh with patient name and medical record. number labeled ""right axillary contents"" are 15.0 x 12.5 x 2.5 cm of. yellow-tan axillary fat. There are multiple palpable lymph nodes, 0.3 to. 2.5 cm in greatest dimension. The lymph nodes are entirely submitted in. fourteen blocks. Designation of Sections: 4A- one lymph node, 4B- one lymph node, 4C- one. lymph node, 4D- one lymph node, 4E- one lymph node, 4F- one lymph node,. 4G-4I- one lymph node, 4J-4N- multiple single lymph nodes. Summary of Sections: multiple. Final Diagnosis: 1. Sentinel lymph node right axilla, excision: - Metastatic adenocarcinoma in two of two lymph nodes (2/2) with. extracapsular extension. 2. Right breast, lumpectomy: - In situ and invasive pleomorphic lobular carcinoma, grade III (4 cm). extending to less than 0.1 mm of the inferior and posterior margins and. 0.2 cm from the anterior margin. - Other margins negative for tumor. - Previous biopsy site changes. - Extensive angiolymphatic invasion is present. 3. Right breast, final inferior margin, excision: - Residual invasive and in situ carcinoma with angiolymphatic invasion. - New margin negative for tumor. 4. Right axillary contents, regional resection: - Metastatic adenocarcinoma in three of twenty-nine lymph nodes (3/29). with extracapsular extension. - Axillary breast tissue is present. Stage pT2,N2,Mx.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. If the tumor is multifocal, use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively).
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,889.0,T2,"The report mentions a 'lumpectomy' and provides a specific tumor size of 4 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-OL-A5RW.86B06754-B000-4F8B-9037-95E7A0BD4D20,"FINAL PATHOLOGIC DIAGNOSIS. A. Lymph node, right sentinel #1, excision: - One lymph node involved by metastatic carcinoma (1/1). B. Lymph node, right sentinel #2, excision: - One lymph node, negative for carcinoma (0/1). C. Lymph node, right sentinel #3, excision: - One lymph node, negative for carcinoma (0/1). D. Lymph node, right sentinel #4, excision: - One lymph node, negative for carcinoma (0/1). E. Breast, right, wire-localization lumpectomy: - Invasive ductal carcinoma, grade III/III, 2.0 cm in greatest dimension,. surgical margins negative (see pathologic parameters and comment below). - Previous biopsy site. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Gross measurement: 2.0 cm. B. Composite histologic (modified SBR) grade: III/III. C. Associated intraductal carcinoma in situ (DCIS/LCIS): None. 2. Excisional biopsy margins: Free of tumor. - Invasive carcinoma 6.0 mm from closest margin (posterior). 4. Blood vessel and lymphatic invasion: Present in breast parenchyma. 5. Axillary lymph nodes: One of four sentinel lymph nodes involved by carcinoma. (1/4). - Size of largest metastatic deposit: 5.0 mm. - Extranodal extension: present (2.0 mm; largest focus). 6. Special studies (see. - ER: No expression. - PR: No expression. - Her2/neu antigen (FISH): Non-amplified (ratio: 1.91). 7. pTNM (AJCC, 7th edition, 2010): pT1c, N1(sn), MX. Clinical History: The patient is a. year-old female with breast cancer undergoing lumpectomy. Comment. Immunohistochemical stains show the tumor cells to be positive for CK7 and. negative for CK20 and TTF-1, consistent with the above diagnosis. D240 stain is. noncontributory. Specimens Received: A: Sentinel node #1. B: Sentinel node #2. C: Sentinel node #3. D: Sentinel node #4. E: Right breast partial; lumpectomy. Gross Description: The specimens are received in five containers each labeled with the patient's. name and medical record number. A. The first container is additionally identified as, 'sentinel node #1'. Received fresh and placed in formalin the specimen consists of a 4 X 3 X 1.2. lymph node. Specimen is serially sectioned and entirely submitted in cassettes. A1-A8. B. The second container is additionally identified as, 'sentinel node #2'. Received fresh and placed in formalin the specimen consists of a 1 X 1x 0.5 cm. lymph node. Specimen is entirely submitted in cassette B1. C. The third container is additionally identified as, 'sentinel node #3'. Received fresh and placed in formalin the specimen consists of a 1 X 1 X 1 cm. lymph node. Specimen is bisected and entirely submitted in cassette C1. D. The fourth container is additionally identified as, 'sentinel node #4'. Received fresh and placed in formalin the specimen consists of a 2 X 1 X 1 cm. lymph node. Specimen is serially sectioned and entirely submitted in cassette. D1. E. The fifth container is additionally identified as, 'right breast partial. mastectomy'. Received fresh on a radiographic grid is a 96.5 gm lumpectomy. specimen measuring 8.0 cm from medial to lateral, 8.5 cm from superior to. inferior and 3.0 cm from anterior to posterior. The specimen is oriented with a. short suture designating the superior pole and a long suture designating the. lateral pole. There is a wire entering at the superomedial aspect of the. specimen at grid C2. Accompanying the specimen is an x-ray demonstrating a. metallic clip located in grid position D3. The wire terminates in grid position. D4. There is a circled mass in grid positions C3-D3, D4. The margins are inked. as follows: anterior- black posterior - red superior - blue inferior - green. medial - yellow lateral - violet The specimen is serially sectioned from lateral. to medial into 8 slices. There is a 2.0 X 2.0 x 1.5 cm lesion located in slices. 5 to 7. It is located 1.6 cm from the black margin, 0.6 cm from the red margin,. 1.4 cm from the blue margin and 4.5 cm from the green margin. A metallic clip is. identified in slice #5. The wire enters the specimen in slice #6 and terminates. in slice #7. Tissue is banked from slices 4 and 6. Lumpectomy is entirely. submitted. E1-E5: slice 1, medial margin. E4-E10: slice 2. E11-E17: slice 3. E18-E28 : slice 4. E29-E41 : slice 5 (clip in E29-E31). E42-E52: slice 6 (mass in E42-E43). E53-E65: slice 7. E66-E83: slice 8. Tissue fixed for at least 6 hours in 10% NBF and no more than 72 hours.",0,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. Use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively) or tumor size (>2.0 cm but <=2.5 cm for T1c).
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1. Use the subclassification 'a', 'b', or 'c' to indicate the number of tumors (1, 2-3, or >3, respectively) or tumor size (>2.0 cm but <=2.5 cm for T1c).
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,906.0,T1c,"The report mentions a 'lumpectomy' and provides a specific tumor size of 2.0 cm, which falls within the T1 range (<=20 mm). Therefore, the T stage is T1. The subclassification 'c' is used to indicate the tumor size is greater than 2.0 cm but less than or equal to 2.5 cm (T1c) as per the AJCC's TNM Staging System.",96.0,True
TCGA-AR-A1AW.BB485405-199C-48C7-96D7-8C315DEA66B4,"Final Diagnosis. Breast,Meft ypper inner quadrant, lumpectomy: Infiltrating ductal carcinoma, with medullary like. features, Nottingham grade III (of III), [tubules 3/3, nuclei 3/3, mitoses 2/3; Nottingham score. 8/9], forming a 2.7 x 2.5 x 2.0 cm yellow-tan, somewhat circumscribed, sclerotic mass. [AJCCpT2]. Ductal carcinoma in situ is absent. Angiolymphatic invasion is absent. All surgical. resection margins, after re-excision of the deep and medial inferior margins, are negative for. tumor (minimum tumor free margin, 0.8 cm, deep margin). Lymph node, left axillary, sentinel biopsy: A single (1) left axillary sentinel lymph node is. negative for tumor, confirmed by cytokeratin (AE1/AE3) immunostains. ER/PR and Her2/neu have been ordered on paraffin-embedded tissue.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,754.0,T2,"The report mentions a lumpectomy and provides a specific tumor size (2.7 x 2.5 x 2.0 cm) which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",91.0,True
TCGA-E9-A1R3.BE186852-8596-4CDB-B5C4-AA5838C15B5F,"OC ID. Gross Description: Mammary gland with the tumour of 2.5 x 2.2 cm in size; fatty tissue lymph nodes are dense, hyperemic. Microscopic Description: Infiltrating duct carcinoma, G2. Ten dissected lymph nodes demonstrate metastases. Diagnosis Details: Tumor Features: Unknown, Tumor Extent: T2 tumor size more than 2cm not more than 5 cm, Venous Invasion: Absent,. Margins: Absent, Treatment Effect: Comments: Postoperative staging reads: T2N3aM0. BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Upper inner quadrant. Tumor size: 2.2 x 0: x 2.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 10/10 positive for metastasis (Axillary 10/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None. Laterality: Right, upper outer quadrant.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,754.0,T2,"The report specifically mentions a 'radical mastectomy' and provides a tumor size of 2.5 x 2.2 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-D8-A1JB.27376503-A55C-4905-A885-632440EFCED2,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: 1. Multiple organ resection - right breast and axillary tissue. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in 10-75% of neoplastic cell nuclei. HER2 protein stained with HercepTest‚Ñ¢M by DAKO. Score = 2+, FISH verification recommended. Examination performed or. Macroscopic description: Left breast sized 19,5 x 12 x 4 cm removed along with axillary tissues sized 6 x 5 x 3 cm and a 15.5 x 4 cm skin flap. Tumour. sized 3.0 x 2.1 x 1.3 cm on the boundary of outer quadrants, 5.0 cm from the lower boundary, 0.1 cm from the base and 0.5. cm from the skin. Microscopic description: Carcinoma invasivum - NHG2 (3 + 2 + 1/0 mitoses/10 HPF, visual area diameter 0.55 mm). Foci of carcinoma ductale in situ DCIS found within and outside the tumour (solid and cribrate type with medium nuclear. atypia, comedo necrosis and calcifications, 10% of the tumour). Additionally, lesions of the type carcinoma lobulare in situ (LCIS). Mamilla sine laesionibus. Glandular tissue showing lesions of the type mastopathia fibrosa et cystica, hyperplasia ductalis simplex (UDH), adenosis. sclerosans, calcifications, columnar cell changes CCC). AXILLARY LYMPH NODES. Metastases carcinomatosae in lymphonodis No I/VIII. Infiltratio capsulae lymphonodi et telae perinodalis. Preliminary result: Carcinoma ductale invasivum et ductale in situ lobulare in situ (LCIS). Metastases carcinomatosae in lymphonodo axillae (NHG2, pT2, pN1a). page 2 / 2. Gender: F. Results of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND. Histopathological diagnosis: Carcinoma ductale invasivum et ductale in situ. Invasive ductal carcinoma and ductal carcinoma in situ. Metastases carcinomatosae in lymphono axillae (No I/VIII). Cancer metastases in axillary lymph nodes (No I/VIII). (NHG2, pT2, pN1a). Immunophenotype: E-cadherin+, CK7-.",1,True,"% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report mentions a lumpectomy, wide excision, or segmental mastectomy and provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,754.0,T2,"The report mentions 'breast surgery' (multiple organ resection) and provides a specific tumor size of 3.0 x 2.1 x 1.3 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-D8-A1JS.0EA57ABF-E3DA-4862-BAB8-A6E36408AC42,"page 1 / 2. copy No. 2. Examination: Intraoperative examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. Expected time of examination: 20 minutes (from receipt of the material). Clinical diagnosis: Suspected cancer of the right breast. Lesion on the boundary of the upper quadrants. Examination performed or. Result of intraoperative examination: Carcinoma probabiliter invasivum. Final diagnosis after paraffin specimens are analysed. Compliance validated by: (. Macroscopic description: Surgical specimen sized 5 x 4 x 2 cm with a skin flap of 4 x 0.5 cm. Minimum side margin 0.2 cm. Result of intraoperative examination: Carcinoma papillare probabiliter invasivum. Foci DCIS typus cribrosus cum atypia gradus levioris ad mediocrum sine necrosis. Final diagnosis after immunohistochemical tests. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with HercepTest‚Ñ¢M by DAKO. Negative reaction in invasive cancerous cells ( Score = 0). Examination: Intraoperative examination. page 2 / 2. Gender: F. Histopathological diagnosis: Carcinoma papillare probabiliter invasivum NHG1 (2 + 2 +1/0 mitoses/ 10 HPF, visual area diameter: 0.55 m). Corresponds to invasive papillary carcinoma of the right breast. Solitary foci of DCIS (cribrate type with medium nuclear atypia, without necrosis). The immunohistochemical test showed the absence of a myoepithelial cell stratum around the foci of the. invasive lesion (p63-, SMA'). The cells show negative reaction withCK5/6. Cytokeratin 7 present in part of the. cells. Suplementary test. Expression of the Ki67 proliferation antigen showed in 5% of cellular nuclei (20% in hot spots).",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, regardless of the type of surgery.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, regardless of the type of surgery.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,723.0,T1,"The report mentions a specific tumor size of 0.55 mm, which falls within the T1 range (<=20 mm). The type of surgery is not specified, but this information is not required for determining T1 stage. The subtype of invasive papillary carcinoma is also consistent with T1 stage.",93.0,True
TCGA-E2-A156.EF28484E-82C7-4988-A6E0-DDDA555652EA,"SPECIMENS: A. SENTINEL LYMPH NODE #1, LEFT AXILLA. B. SENTINEL LYMPH NODE #2, LEFT AXILLA. C. NON-SENTINEL LYMPH NODE LEFT AXILLA. D. WIDE EXCISION LEFT BREAST MASS. E. ADDITIONAL NEW MARGIN SUPERIOR LATERAL. F. SKIN AT ANTERIOR MARGIN. SPECIMEN(S): A. SENTINEL LYMPH NODE #1, LEFT AXILLA. B. SENTINEL LYMPH NODE #2, LEFT AXILLA. C. NON-SENTINEL LYMPH NODE LEFT AXILLA. D. WIDE EXCISION LEFT BREAST MASS. E. ADDITIONAL NEW MARGIN SUPERIOR LATERAL. F. SKIN AT ANTERIOR MARGIN. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA, Sentinel lymph node #1, left axilla, excision: Negative for carcinoma. TPB, Sentinel lymph node #2, left axilla, excision: Negative for carcinoma. Part D, Left breast, excisional biopsy, gross examination: Tumor approximately 0.3-cm from the posterior margin. Diagnoses called at. f and B) and. (D) by Dr. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE #1, LEFT AXILLA. Received fresh labeled with the patient's identification and designated ""sentinel lymph node number one left axilla"". is. a fragment of red-tan possible lymphoid tissue measuring 1 x 0.5 x 0.3-cm. Touch preparation is performed. The. entire specimen is submitted, A1. B. SENTINEL LYMPH NODE #2, LEFT AXILLA. Received fresh labeled with the patient identification and designated ""sentinel lymph node number two left axilla"" is. fragment of red-tan possible lymphoid tissue measuring 1.3 x 0.5 x 0.2 cm. Touch preparation is performed. The. entire specimen is submitted, B1. C. NON-SENTINEL LYMPH NODE LEFT AXILLA. Received in formalin labeled with the patient's identification and designated ""Non-sentinel lymph node left axilla"" is a. fragment of adipose tissue, 2.5 x 2.4 x 0.5 cm, consisting of one possible lymph node measuring 1 x 0.5 x 0.4 cm. The lymph node is submitted, C1. D. WIDE EXCISION LEFT BREAST MASS. Received fresh labeled with the patient's identification and designated ""wide excision left breast"" is a previously. inked, oriented, 89-g, 9 x 8.4 x 2.5 cm lumpectomy specimen. The single clip designates superior, double-lateral,. triple-anterior. ink code: Anterior-yellow, posterior-black, superior-blue, inferior-orange, medial- green, lateral-red. The specimen is serially sectioned from medial to lateral into 7 slices revealing an irregular friable soft tan mass, 3 x. 2.4 x 0.9 cm, located 0.3-cm from the nearest posterior margin (Slices 3-5). A previous hemorrhagic biopsy cavity is. identified 0.6-cm from the mass (lateral), measuring 1.4 x 0.8 x 0.7 cm. A portion of the specimen is submitted for. tissue procurement. Representatively submitted: D1-D2: Representative perpendicular sections, medial margin. D3: Slice 2, posterior. D4: Slice 2, superior. D5-D11: Slice 3, entirely submitted, D8 and D10 demonstrating tumor. D12-D15: Slice 4, posterior/superior/anterior/superior, tumor. D16-D19: Slice 5, D16-D18 demonstrating biopsy cavity. D20-D21: Slice 6, superior, remainder of biopsy cavity. D22-D25: Perpendicular sections lateral margin, entirely submitted. E. ADDITIONAL NEW MARGIN SUPERIOR LATERAL. Received in formalin labeled with the patient's identification and designated ""additional new margin superior lateral"". is a previously inked, 6-g, 5.2 x 3 x 0.8 cm fragment of fibroadipose tissue. Ink code: Superior-blue, lateral-red. Sectioning shows no obvious gross abnormalities. The entire specimen is submitted, E1-E2 (superior), E3-E4. (lateral). F. SKIN AT ANTERIOR MARGIN. Received in formalin labeled with the patient's identification and designated ""skin at anterior margin"" is a slender. fragment of unoriented light beige skin measuring 2.1 x 0.6 x 0.2 cm. the entire specimen is submitted, F1. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, left AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). B. LYMPH NODE, SENTINEL #2, left AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). C. LYMPH NODE, non-SENTINEL, left AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. BREAST, LEFT, WIDE LOCAL EXCISION: INVASIVE DUCTAL CARCINOMA, SBR GRADE 2, MEASURING 1.8-CM. - INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID AND CRIBRIFORM TYPE WITH. CENTRAL NECROSIS AND MICROCALCIFICATIONS WITH A COMPONENT OF INTRACYSTIC PAPILLARY. CARCINOMA. - SURGICAL RESECTION MARGINS NEGATIVE FOR INVASIVE TUMOR. - MICROSCOPIC FOCUS OF LOW GRADE DUCTAL CARCINOMA IN SITU AT INFERIOR SURGICAL. RESECTION MARGIN. - BIOPSY SITE CHANGES WITH FIBROSIS AND GRANULATION TISSUE. - SEE SYNOPTIC REPORT AND SEE NOTE. e. breast, left, additional superior lateral margin, excision: - fibroadipose tissue, NO TUMOR SEEN. f. skin, anterior margin, excision: - SKIN tissue, NO TUMOR SEEN. NOTE: Ductal carcinoma is identified in 5 consecutive slices. The tumor is composed of 3 components, invasive, in. situ and intracystic. The gross measurement of the tumor is a 3-cm. The largest confluent invasive tumor measures. 1.8-cm. A microscopic focus of low-grade DCIS is identified at the inferior surgical resection margin. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.8cm. Tumor Site: Not specified. Margins: Negative. Distance from closest margin: 0.3cm. deep. Tubular Score: 2. Nuclear Grade: 2. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0/3. DCIS present. Margins involved by DCIS: inferior. DCIS Quantity: Estimate 20%. DCIS Type: Solid. Cribriform. intracystic. DCIS Location:Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Present. Location of CA++: DCIS. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by IHC. Performed on Case: Pathological staging (pTN): pT 1c N 0. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: Left breast mass. ADDENDUM: ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 0. CLINICAL EXPERIENCE: Patients with a recurrence score of: 0 in the clinical validation study had an average. rate of Distant Recurrence at 10 years of 3%. ER Score: 11.8 Positive. PR Score: 10 Positive. Her2 Score: 9.8 Negative. Interpretation: ER Negative < 6.5 Positive >= 6.5. PR. Negative < 5.5 Positive >= 5.5. Her2 Negative <10.7 Positive >=11.5 Equivocal = 10.7 - 11.4. See separate. 1 report for further information. Microscopic/Diagnostic Dictation: Final Review: Pathologist,. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist,.",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, regardless of the type of surgery.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, regardless of the type of surgery.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,723.0,T1,"The report provides a specific tumor size of 1.8 cm, which falls within the T1 range (<=20 mm) for this cancer type. The type of surgery (wide local excision) does not affect the T stage in this case.",100.0,True
TCGA-AR-A1AY.01D97550-C616-4001-85A5-5502D35FA38E,"Final Diagnosis. Breast, left, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III),. [tubules 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming a 2.0 x 1.8 x 1.5 cm. circumscribed mass with central fibrosis [AJCC pTic]. Focal (5%) high grade ductal carcinoma. in situ with necrosis is present outside the main tumor mass. Angiolymphatic invasion is absent. The non-neoplastic breast parenchyma shows nonproliferative fibrocystic changes. Calcifications. are present in malignant ducts. Biopsy site changes are present. All surgical resection margins,. after a single separately submitted re-excision of the anterior/inferior margin, are negative for. tumor (minimum tumor free margin, 0.7 cm, superior margin). Lymph nodes; left axillary sentinel Nos. 1, 2, and 3; sentinel biopsies: A single (of 3) left. axillary sentinel lymph node (SLN No. 1) is positive for isolated tumor cell cluster [AJCC pNO. (i+) (sn)]. This isolated tumor cell cluster measures 0.11 mm and is seen on cytokeratin and H&E. staining. Blue dye is identified in all three sentinel lymph nodes. Immunohistochemical. cytokeratin stain was performed on the paraffin embedded sentinel lymph node tissues and. confirm the H&E impression. Lymph node, left axillary, excision: A single nonsentinel lymph node is negative for metastatic. carcinoma.",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, regardless of the type of surgery.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, regardless of the type of surgery.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,723.0,T1,"The report provides a specific tumor size of 2.0 x 1.8 x 1.5 cm, which falls within the T1 range (<=20 mm). The type of surgery performed is a wide local excision, which is one of the allowed surgeries for T1 stage. Therefore, the T stage is T1.",100.0,True
TCGA-BH-A5J0.80DA141E-2752-4464-8D23-06DC7E9B05FE,"FINAL DIAGNOSIS: PART 1: BREAST, LEFT AT 2 O'CLOCK, SEED LOCALIZED SEGMENTAL MASTECTOMY (26.95 grams) -. A. INVASIVE DUCTAL CARCINOMA, 11.0 MM (1.1 CM) IN GREATEST DIMENSION (MEASURED. MICROSCOPICALLY), NOTTINGHAM SCORE 7/9 (TUBULES 3, NUCLEAR GRADE 2, MITOTIC ACTIVITY 2),. NOTTINGHAM GRADE 2. B. DUCTAL CARCINOMA IN-SITU (DCIS), SOLID AND CRIBRIFORM TYPES, NUCLEAR GRADE 2 WITH. ASSOCIATED MICROCALCIFICATIONS AND EXTENSION INTO THE LOBULES, ADMIXED AND ADJACENT. TO THE INVASIVE COMPONENT. C. DCIS SPANS AN AREA OF APPROXIMATELY 0.8 CM (8 MM). D. SURGICAL MARGINS ARE NEGATIVE FOR INVASIVE TUMOR; CLOSEST MARGIN IS ANTERIOR AT 0.45 CM. (4.5 MM) (See Part 6 for additional anterior margin). E. SURGICAL MARGINS ARE NEGATIVE FOR DCIS; DUCTAL CARCINOMA IN SITU IS 0.15 CM (1.5 MM) FROM. THE NEAREST LATERAL MARGIN. F. LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. G. LOBULAR CARCINOMA IN SITU, CLASSICAL TYPE, NUCLEAR GRADE 1, IS ALSO IDENTIFIED, WITH. PAGETOID EXTENSION INTO DUCTS. H. CHANGES CONSISTENT WITH PREVIOUS BIOPSY SITE. ATYPICAL DUCTAL HYPERPLASIA. J. ATYPICAL LOBULAR HYPERPLASIA. K. FIBROCYSTIC CHANGE WITH SCLEROSING ADENOSIS. L. THE INVASIVE TUMOR CELLS ARE ESTROGEN RECEPTOR POSITIVE, PROGESTERONE RECEPTOR. WEAKLY POSITIVE, HER-2/NEU NEGATIVE (1+), AS PER PREVIOUS PATHOLOGY REPORT. PART 2: LYMPH NODE, LEFT AXILLA SENTINEL NODE #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 3: LYMPH NODE, LEFT AXILLA SENTINEL NODE #2, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 4: LYMPH NODES, LEFT AXILLA SENTINEL NODE #3, BIOPSY -. TWO LYMPH NODES, NEGATIVE FOR METASTATIC CARCINOMA (0/2). PART 5: LYMPH NODE, LEFT AXILLA SENTINEL NODE #4, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 6: BREAST, NEW ANTERIOR MARGIN, EXCISION (13.4 grams) -. A. FOCUS OF INVASIVE DUCTAL CARCINOMA, 0.2 CM IN GREATEST DIMENSION, 0.3 CM FROM THE NEW. ANTERIOR MARGIN (See comment). B. ATYPICAL DUCTAL HYPERPLASIA. C. SCLEROSING ADENOSIS. COMMENT: In Part 1, immunohistochemical staining for E-cadherin is focally negative and P120 demonstrates focal strong. cytoplasmic staining. This immunohistochemical staining pattern supports the diagnosis of lobular carcinoma in situ and. atypical lobular hyperplasia. Part 6: The presence of a 0.2 cm focus of invasive ductal carcinoma is confirmed by immunohistochemical stains for p63. and. (see Microscopic Description). The morphologic features of this microscopic focus of carcinoma are similar. to the invasive ductal carc√≠noma in Part 1. MICROSCOPIC: Microscopic examination substantiates the above diagnosis. Block 1E. Antibody/Antigen. E-cadherin. Negative in areas of atypical lobular hyperplasia. P120. Strong positive cytoplasmic staining in areas of atypical lobular. hyperplasia. Utilizing formalin-fixed (8-96 hour range). paraffin embedded tissue, immunohistology is. performed with the following selected antibodies and designated antibody clone(s), directed. against the following antigenic target (s), with adequate positive and negative internal and. external controls. Antibodies are optimized appropriate for fixation times. ANTIBODY. CLONE. TARGET ANTIGEN. VENDOR. e-cadherin. 36. Lobular Differentiation. p120. 98. Lobular Differentiation. Block 6F. Antibody/Antigen. SMMHC. Negative in area of interest; supports focus of invasive ductal. carcinoma. P63. Negative in area of interest; supports focus of invasive ductal. carcinoma. Utilizing formalin-fixed (8-96 hour range), paraffin embedded tissue, immunohistology is. performed with the following selected antibodies and designated antibody clone (s), directed. against the following antigenic target (s), with adequate positive and negative internal and. external controls. Antibodies are optimized appropriate for fixation times. ANTIBODY. CLONE. TARGET ANTIGEN. VENCOR. Myosin. SMMS-1. Myoepithelial cells. p63. 4A4. Myoepithelial cells. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Clock position:2. SIZE OF TUMOR: Maximum dimension invasive component: 11 mm. MULTICENTRICITY/MULTIFOCALTY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 13 mm. TUMOR TYPE (Invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score; 7. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. Solid. DCIS admixed and outside of invasive carcinoma component. Percent of tumor occupied by in situ component: 10 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 4.5 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 1.5 mm. LYMPH NODES POSITIVE: o. LYMPH NODES EXAMINED: 5. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: NON-NEOPLASTIC BREAST TISSUE: ADH, ALH, FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE MODIFIER: (sn). N STAGE, PATHOLOGIC: pNO. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, previously performed, H-score: 290. positive, previously performed, H-score: 5. PROGESTERONE RECEPTORS: HER2/NEU:",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, regardless of the type of surgery.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm), then the T stage is T1, regardless of the type of surgery.
% T2: If the report mentions a breast surgery (other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy) and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,723.0,T1,"The report provides a specific tumor size of 11.0 mm (1.1 cm) in greatest dimension, which falls within the T1 range (<=20 mm). The type of surgery performed is a segmental mastectomy, which is one of the allowed surgeries for T1 staging. Therefore, the T stage is T1.",100.0,True
TCGA-E2-A1L7.E78526AB-D72D-4407-B7E1-2255BB5B2F68,"SPECIMENS: A. RIGHT BREAST WITH AXILLARY CONTENTS LEVELS 1,2. B. ADDITIONAL AXILLARY CONTENTS. SPECIMEN(S): A. RIGHT BREAST WITH AXILLARY CONTENTS LEVELS 1,2. B. ADDITIONAL AXILLARY CONTENTS. GROSS DESCRIPTION: A. RIGHT BREAST WITH AXILLARY CONTENTS LEVELS 1,2. Received fresh labeled with the patient's identification and ""right breast with axilla"" is a 934g, 28 x 25 x. 5cm oriented (stitch in axilla) modified radical mastectomy with attached 19 x 9cm tan pink skin ellipse. and 1.3cm everted nipple. Ink code: anterior-superior: blue, anterior-inferior: orange, posterior-black. The specimen is serially sectioned from lateral to medial into 10 slices with nipple in slice 7, revealing a. 3 x 2.5 x 2cm tan white firm well circumscribed mass, 1.5cm from the skin margin and 3cm from the. deep margin in the UOQ and UC of slices 5-7. A surgical clip is identified in the UOQ of slice 8. The. axillary tail is 9 X 7 x 5cm. Dissection reveals 19 possible lymph nodes ranging from 0.7 x 0.5 x 0.5cm. to. 4 x 3 x 3cm. The largest lymph node is serially sectioned to reveal a tan white firm homogenous cut. surface. A portion of the specimen is submitted for tissue procurement. Representatively submitted: A1-A2: nipple slice 7. A3: UOQ slice 2. A4: LOQ slice 4. A5: UOQ slice 4. A6: mass UIQ slice 5. A7: LOQ slice 5. A8-A10: mass with clip ID in A9 slice 6. A11-A12: mass slice 6. A13: deep margin slice 6. A14: skin slice 6. A15: mass UC slice 7. A16: LC slice 7. A17: UIQ slice 8. A18: LIQ slice 8. A19: UIQ slice 9. A20: 4 lymph nodes. A21: 4 lymph nodes. A22: 4 lymph nodes. A23: 2 lymph nodes. A24: 1 lymph node. A25-A26: 1 lymph node. A27: 1 lymph node. A28-A29: 1 lymph node. A30-A32: representative section of largest lymph node. A33-A38: UIQ. B. ADDITIONAL AXILLARY CONTENTS. Received fresh are two tan pink-white firm lymph nodes 1.5 x 1.5 x 1cm and 2 x 1.5 x 1.5cm. B1-B2: 1 lymph node. B3-B4: 1 lymph node. DIAGNOSIS: A. BREAST, RIGHT, MODIFIED RADICAL MASTECTOMY: - TWO FOCI OF INVASIVE DUCTAL CARCINOMA, SBR GRADE 3, WITH. EXTENSIVE NECROSIS AND MICROCALCIFICATIONS. - TUMOR MEASURES 3 CM AND 1.5 CM. - MARGINS, FREE OF TUMOR. - DUCTAL CARCINOMA IN SITU (DCIS), SOLID TYPE, NUCLEAR GRADE 3,. WITH NECROSIS AND MICROCALCIFICATIONS. - SKIN AND NIPPLE, NO TUMOR SEEN. - METASTATIC CARCINOMA IN 5 OF 18 LYMPH NODES WITH. EXTRANODAL EXTENSION, LARGEST METASTASIS IS 4 CM (5/18). NOTE: Invasive carcinoma is present in the upper outer quadrant and upper inner quadrant. B. ADDITIONAL AXILLARY CONTENTS, EXCISION: - METASTATIC CARCINOMA IN 2 OF 2 LYMPH NODES WITH. EXTRANODAL EXTENSION (2/2). - LARGEST METASTASIS IS 2 CM. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: Laterality: ( Right. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 3cm. Tumor Site: Upper outer quadrant. Upper inner quadrant. Margins: Negative. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: Present. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 7 / 20 Extranodal extension. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 15%. DCIS Type: Solid. DCIS Location: Associated with invasive tumor. Nuclear grade: High. Necrosis: Present. Location of CA++. DCIS. ER/PR/HER2 Results. ER: Negative. PR: Negative. HER2: Negative by IHC. Pathological staging (pTN): pT 2 N 2. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: A31. ER: Negative Allred Score: 2 = Proportion Score 1 + Intensity Score 1. PR: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer s instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. CLINICAL HISTORY: None provided. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. ADDENDUM: SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: A17 (smaller tumor). ER: Positive Allred Score: 3 = Proportion Score 2 + Intensity Score 1. PR: Positive Allred Score: 7 = Proportion Score 4 + Intensity Score 3. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer s instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: A17 (smaller tumor). Interpretation: EQUIVOCAL. Intensity: 2+. % Tumor Staining: 40%. Fish Ordered: Yes, on Date. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved Dako HercepTest (TM) test kit. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. The Pathology. Department takes full responsibility for this test's performance. PathVysion HER-2 DNA Probe Kit. Analytical Interpretation of Results: HER-2 NOT AMPLIFIED. Clinical Interpretation of results. Amplification of the HER-2 gene was evaluated with interphase fluorescence in-situ. hybridization (FISH) on formalin-fixed paraffin embedded tissue sections using a chromosome. 17 centromeric probe and a HER-2 probe that spans the entire HER-2 gene in the. majority of tumors cells displayed 2 chromosome 17. signals and 2 HER-2 signals, with a HER-2/CEP 17 Ratio </=2.0, consistent with no. amplification of the HER2/neu gene. Block used A17. Source of case: Tissue fixation. formalin-fixed tissue. Outside Case No: NA. Tissue source. breast Results interpreted: HER2/CEP17 ratio: 1.06. This ratio is derived by dividing the total number of LSI HER-2/neu signals by the total number of. CEP17 signals in at least 20 interphase nuclei with nonoverlapping nuclei in the neoplastic. mammary epithelial cells. Cells with no signals or with signals of only one color are disregarded. Method of ratio enumeration: manual count. Limitations. The Vysis PathVysion Kit is not intended for use to screen for or diagnose breast cancer. It is. intended to be used as an adjunct to other prognostic factors currently used to predict disease-free. and overall survival in stage II, node-positive breast cancer patients. In making decisions regarding. adjuvant CAF treatment, all other available clinical information should also be taken into. consideration, such as tumor size, number of involved lymph nodes, and steroid receptor status. treatment decision for stage II, node-positive breast cancer patients should be based on HER-. 2/neu. gene amplification status alone. Overview of this test. FDA APPROVED REAGENT. PathVysion HER-2 DNA Probe Kit is FDA approved for selection of. patients for whom Herceptin¬Æ therans insidered. These tests were performed in the. under the direction. of Dr.. The results of these studies should always be interpreted in the context of the. clinical, morphological, and immunophenotypic diagnosis. Microscopic/Diagnostic DictationPathologist,. Final Review: Pathologist,. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist, 1.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,802.0,T2,"The report mentions a mastectomy and provides a specific tumor size of 3 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",90.0,True
TCGA-AO-A0JF.D58E5D64-B5B9-4487-8E46-225AE3617C14,"Clinical Diagnosis & History: 1.2. cm invasive duct carcinoma left breast upper outer quadrant (on core. biopsy) for left wide excision SLNB, possible left ALND. Specimens Submitted: 1: SP: Sentinel node #1 level one left axilla (fs). 2: SP: Sentinel node #2 level one left axilla (fs). 3: SP: Excision of tumor left breast two o'clock. 4: SP: Superior margin left breast. 5: SP: Medial margin left breast. 6: SP: Inferior margin left breast. 7: SP: Lateral margin left breast. 8: SP: Non-sentinel node left axilla. 9: SP: Posterior margin left breast. 10: SP: Levels one and two left axillary contents. DIAGNOSIS: 1. LYMPH NODE, SENTINEL #1, LEVEL I, LEFT AXILLA; EXCISION: - METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1). THE METASTATIC FOCUS MEASURES 5 MM IN GREATEST DIMENSION. - NEGATIVE FOR EXTRACAPSULAR EXTENSION. 2. LYMPH NODE, SENTINEL #2 LEVEL I LEFT AXILLA; EXCISION: METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1). THE METASTATIC FOCUS MEASURES 6 MM IN GREATEST DIMENSION. - EXTRACAPSULAR EXTENSION (>2MM) IS PRESENT. 3. BREAST, LEFT, 2 O'CLOCK; EXCISION: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, HISTOLOGIC GRADE II/III. (MODERATE TUBULE FORMATION), NUCLEAR GRADE I/III (SLIGHT OR NO VARIATION IN. SIZE AND SHAPE), MEASURING 2.0 CM IN LARGEST DIMENSION MICROSCOPICALLY. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE WITH LOW TO. INTERMEDIATE NUCLEAR GRADE. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH THE INVASIVE COMPONENT. - CALCIFICATIONS ARE PRESENT IN THE INVASIVE CARCINOMA ONLY. FOCAL VASCULAR INVASION IS PRESENT. FOR SURGICAL MARGINS SEE PARTS 4-7, AND 9. THE NON-NEOPLASTIC BREAST TISSUE THE NON-NEOPLASTIC BREAST TISSUE. SHOWS BIOPSY SITE CHANGES. RESULTS OF 108, PR, HER2-NEU) ARE AS FOLLOWS: ESTROGEN RECEPTOR. 95% nuclear staining with inhensity. PROGESTERONE RECEPTOR. 70% nucl. ith moderate intensity. HER2. Negative (1+). (<5% of invasive tumor cells exhibit weak complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). Comment: Controls are satisfactory. PATHWAY anti-HER-2/neu is an. FDA-approved rabbit monoclonal primary antibody (clone 485) directed against. the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation. The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25 (1) :118-145) The ER and PR rabbit monoclonal antibodies are also FDA. approved. 4. BREAST, LEFT, SUPERIOR MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH PROLIFERATIVE FIBROCYSTIC CHANGES. 5. BREAST, LEFT, MEDIAL MARGIN; EXCISION: BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. 6. BREAST, LEFT, INFERIOR MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. 7. BREAST, LEFT, LATERAL MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. LYMPH NODE, NON-SENTINEL, LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODK (0/1). 9. BREAST, LEFT, POSTERIOR MARGIN; EXCISION: BENIGN BREAST TISSUE PREDOMINANTLY COMPOSED OF FIBROADIPOSK. ELEMENTS. SKELETAL MUSCLE TISSUE ALSO PRESENT. 10. LYMPH NODES, LEFT AXILLARY CONTENTS, LEVELS ONE AND TWO, EXCISION: ELEVEN BENIGN LYMPH NODES (0/11). Some of the mmunohistochemistry and. :ests were developed and their. performance characteristics were determined by. They have not been cleared or approved by the US FOO ana urug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88) as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES - (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: 1. 1) The specimen is received fresh for frozen labeled, ""Sentinel node #1,. level 1, left axilla"", and consists of one fatty lymph node measuring 2.5 x. 1.5 x 1.5 cm, which is trisected and representatively submitted. A portion. of tissue sent to TPS. The remaining lymph node is submitted to permanent. Summary of sections: fac -- lymph node frozen section control. RS- remaining lymph node. 2) The specimen is received fresh for frozen labeled, ""Sentinel node #2,. level 1, left axilla"", and consists of one fatty lymph node measuring 2.4 x. 1.5 x 1.2 cm, which is trisected and representatively submitted. A portion. of tissue sent to TPS. The remaining lymph node is submitted to permanent. Summary of sections: fsc -- lymph node frozen section control. RS- remaining lymph node. 3) The specimen is received unoriented and fresh, labeled ""excision of. tumor, left breast two o' clock"" and consists of a piece of fibrofatty. breast tissue measuring 5.2 x 5.0 x 2.3 cm. The specimen is entirely inked. black. Serial sectioning reveals a spiculated, white mass measuring 1.2 x. 1.2 x 1.1 cm. Sectioning through the remaining breast tissue reveals yellow. adipose tissue. A clip is identified. The tumor is entirely submitted and. the remaining tissue is representatively submitted and a small portion is. given to TPS. Summary of sections: MT - tumor and closest tissue edge. T - tumor (clip was in block 2). SS - serial sections remaining tissue. 4) The specimen is received fresh, labeled ""superior margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 5.0 x 3.0 cm, and. 1.3 cm thick. A stitch marks the new margin of excision, which is inked. black. The tissue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 5) The specimen is received fresh, labeled ""medial margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 3.2 x 2.5 cm, and. 1.2 cm thick. A stitch marks the new margin of excision, which is inked. black. The tissue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 6) The specimen is received fresh, labeled inferior margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 4.0 x 3.0 cm, and. 1.3 cm thick. A stitch marks the new margin of excision, which is inked. black. The tiasue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 7) The specimen is received fresh, labeled ""lateral margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 4.4 x 2.8 cm, and. 1.2 cm thick. A stitch marks the new margin of excision, which is inked. black. The tiasue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 8) The specimen is received in formalin, labeled ""Non-sentinel node left. axilla"" and consists of a single pink tan fatty lymph node measuring 0.9 cm. The lymph node is bisected and entirely submitted. Summary of sections: BLN-bisected lymph node. 9). The specimen is received fresh, labeled ""posterior margin, left breast"". and consists of a piece of fibrofatty breast tissue measuring 4.2 x 3.0 cm,. and 0.5 cm thick. The specimen is unoriented, entirely inked black. sectioned and submitted in its entirety. Summary of sections: SS - sequential sections. 10) The specimen is received fresh labeled ""levels one and two left axillary. contents"" It consists of a fragment of yellow adipose tissue measuring 12.5. x 10.5 x 2.8 cm. The levels are not designated. Numerous lymph nodes are. identified ranging in size from 0.4 cm up to 2.0 cm, and all are submitted. Summary: RLN-representative lymph node (multiple). ARLN-additional representative lymph nodes. LN-lymph nodes. Summary of Sections: Part 1: SP: Sentinel node #1 level one left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. 1. rs. 1. Part 2: SP: Sentinel node #2 level one left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. 1. rs. 1. Part 3: SP: Excision of tumor left breast two o'clock. Block. Sect. Site. PCs. 1. MT. 1. 1. SS. 1. 2. T. 2. Part 4: SP: Superior margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 5: SP: Medial margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 6: SP: Inferior margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 7: SP: Lateral margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 8: SP: Non-sentinel node left axilla. Block. Sect. Site. PCs. 1. bln. 1. Part 9: SP: Posterior margin left breast. Block. Sect. Site. PCs. 6. ss. 6. Part 10: SP: Levels one and two left axillary contents. Block. Sect. Site. PCs. 5. arln. 5. 5. LN. 12. 4. RLN. 4. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left. axilla (fs) : Metastatic ductal carcinoma (1/1). PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #2 level one. left axilla (fs) Metastatic ductal carcinoma with extranodal extension. (1/1). PERMANENT DIAGNOSIS: SAME. Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left. axilla (fs) : Metastatic ductal carcinoma (1/1). PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #2 level one. left axilla (fs) : Metastatic ductal carcinoma with extranodal extension. (1/1). PERMANENT DIAGNOSIS: SAME.",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,802.0,T2,"The report mentions a specific tumor size of 2.0 cm in greatest dimension, which falls within the T2 range (>20 mm but <=50 mm). The type of breast surgery performed is a wide excision, which is one of the allowed surgeries for T staging. Therefore, the T stage is T2.",100.0,True
TCGA-AC-A7VC.A1681334-684E-41E0-B3FA-EFFE1E5A8B7F,"Sex: Female. DIAGNOSIS. DIAGNOSIS: A. Left axillary Sentinel lymph node: One lymph node, no evidence of metastatic carcinoma,. Confirmed by negative staining for pancytokeratin. B. Left breast mastectomy: Metaplastic carcinoma with areas of chondroid differentiation. Size: 11 cm. Architectural score: 3 of 3. Nuclear score; 3 of 3. Mitotic score: 3 of 3. Total score: 9 of 9. Grade 3. No evidence of in situ carcinoma. No evidence of angiolymphatic invasion. Prognostic panel to follow. All surgical margins of excision are free of carcinoma. No evidence of skin or nipple involvement. TMN: T3pNO(i-). CLINICAL INFORMATION. CLINICAL HISTORY: Preoperative Diagnosis: Left breast mass. Postoperative Diagnosis: Symptoms/Radiologic Findings: SPECIMENS: A. Left axillary sentinel lymph nodes. 8. Left breast - short stitch superior. SPECIMEN: DATA. GROSS DESCRIPTION: A. Container A is labeled. Received in formalin, is a 3.0 x 1.3 x 0.8 cm slightly blue-dyed tan lymph node. The specimen is sectioned and. submitted in cassettes A1-A2 labeled. B. Container B is labeled. eft breast. Received In formalin, is a 1,044 gram, 23.0 x 17.5 x 5.0 cm left simple mastectomy surfaced on one. aspect. a. 20.0. x 11.2 cm ellipse or tan-white skin with a low-central 1.2 x 1.2 x 0.3 cm nipple which exudes no discharge. Surrounding the nipple, there. is a 6.0 cm diameter patch of intense blue-dyed discoloration. The specimen is oriented with a suture at the mid aspect of one long axis indicating. superior. The deep aspect of the specimen has been previously sectioned for collection of tissue for genomics studies. At the previous incision site,. the. cut surfaces give rise to a subareolar, 11.0 x 10.0 x 8.0 cm indurated, well circumscribed, focally cystic and mucinous tumor. The tumor is 3.5 cm from. the nearest deep margin and 3.2 cm from the nearest skin resection margin. The remaining breast parenchyma is 20% fibrous tissue. There are no. lymph nodes near the upper outer quadrant. Sections are submitted in two cass  for studies labeled. and. are submitted in cassettes labeled. :epresentative sections of the remaining tissue. as follows: B1 representative nipple; B2-B7 representative tumor; B8-89 representative uninvolved. upper outer quadrant; B10-B11 representative of upper inner quadrant; B12-B13 representative of fower inner quadrant; B14-B15 representative of lower. outer quadrant. areas. The left breast mass consists of a malignant broad panel neoplasm cytokeratins composed was precominantly utilized. The tumor of spindle cells cells. tumor were There negative cells are are for positive areas high of molecular for chonaroia cytokeratin weight alrrerentiation cam keratin 5.2. They SK. and There are is. of focal negative multinucleated positivity for cytokeratin for tumor cytokeratin giant CKC AE 7 cells. and 1,3. A CK Rare 20. tumor There cells is strong are positive positivity for for pancytokeratin. P 63. This is indicative Rare of a metaplastic carcinoma.",2,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,802.0,T3,"The report mentions that the patient underwent a left breast mastectomy and provides a specific tumor size of 11 cm, which falls within the T3 range (>50 mm). Therefore, the T stage is T3.",100.0,True
TCGA-E9-A5UP.B50AB6D5-3010-450E-9CCE-E9BFA0202736,"Gross Description: There is a quadrant of the breast with tumor up to 3.5 cm in size. In the fatty tissue. there are lymph nodes without morphological features. Microscopic Description: Intraductal papillary adenocarcinoma with invasion, G-2. Examined lymph. nodes demonstrated lipomatosis. Diagnosis Details: Tumor Features: Indeterminate, Tumor Extent: T2 tumor size more than 2cm not. more than 5 cm, Venous Invasion: Absent, Margins: Absent, Treatment Effect: Comments: Formatted Path Reports: BREAST TISSUE CHECKLIST. Specimen type: Partial mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 0 X 0 X 3.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating papillary adenocarcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: Left.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,802.0,T2,"The report provides a specific tumor size within the T2 range (>20 mm but <=50 mm) and no evidence of breast surgery other than a partial mastectomy. There is also no evidence of invasion of the chest wall or skin, so the T stage is T2.",100.0,True
TCGA-EW-A1P8.6CB5A0ED-5569-4FDC-B651-758BFC6B59D8,"F. Pathologic Interpretation: A. LEFT BREAST LUMPECTOMY 1 STITCH SUPERIOR, 2 STITCHES LATERAL, SKIN IS ANTERIOR: - Invasive poorly differentiated ductal carcinoma, 2.2 cm in greatest linear dimension, Nottingham Grade 3 (3+3+3). Tumor is less than 0.1 cm from the posterior and lateral margins. - Lymphovascular invasion is present. - Tumor cells are negative for ER, PR, HER-2 by immunohistochemistry. B. SENTINEL LYMPH NODE #1 COUNT 171: - Metastatic carcinoma in one lymph node with extranodal extension (1/1). C. SENTINEL LYMPH NODE #2 COUNT 82: - Metastatic carcinoma in one lymph node with extranodal extension (1/1). D. NON-SENTINEL NODE: - Metastatic carcinoma in one lymph node with extranodal extension (1/1). E. LEFT AXILLARY CONTENTS: - Metastatic carcinoma in eleven out of twelve lymph nodes (11/12) with extranodal extension. Tumor Summary. Specimen: Partial breast. "". Procedure: Excision without wire-gulded localization. Lymph Node Sampling: Sentinel lymph node. Axillary dissection. Specimen Integrity: Single intact specimen. Specimen Size: Greatest dimension: 9 cm. Additional dimensions: 5 x 6 cm. Specimen Laterality: Left. Tumor Size: Greatest dimension of largest focus of invasion over 0.1 cm: 2.2 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic Extent of Tumor: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Skeletal Muscle: No skeletal muscle present. Histologic Type: - Invasive ductal carcinoma. Histologic Grade (Nottingham Histologic Score): Score 3. Nuclear Pleomorphism: Score 3: Mitotic Count: Score 3. Overali Grade: - Grade 3: Margins: - Uninvolved by invasive carcinoma. - Distance from closest margin: <1.0 mm. SURGICAL PATHOL Report. - Distance from posterior margin: <1.0 mm. - Distance from lateral margin: <1.0 mm. Treatment Effect: - In the breast: - No known presurgical therapy. In the Lymph Nodes: No known presurgical therapy. Lymph-Vascular Invasion: Present. Dermal Lymph-Vascular Invasion: Not identified. Extranodal Extension: - Present. Method of Evaluation of Sentinel Lymph Nodes: - H&E multiple levels. Pathologic Staging (pTNM): - Primary Tumor (pT): pT2. - Regional Lymph Nodes (pN): pN3a. - Distant Metastasis (pM): Not applicable. Anciliary Studies: - Estrogen Receptor: - Performed on this specimen: Results: Less than 1% immunoreactive cells present. - Progesterone Receptor: Performed on this specimen: Results: Less than 1% immunoreactive cells present. - HER2/neu: - Performed on this specimen: Results: Negative (Score 0). Microcalcifications: Present in invasive carcinoma. NOTE: IDS-ER, Some PgR immunohissochemical 636=PR. 1485=HER2, antibodies H-II=EGFR. are analyte All immunohistac specific reugents hemical (ASRs) stains validated are used by with our formalin laboratory. or molecular These ASRs fixed, are paraffin clinically embedded useful indicators tissue. Detection that do not is by requdre Emision FDA Method. approval. The These results clones are read are used: by a. pathologist as positive or negative. As the attending pathologist, I attest that I: (1) Examined the relevant preparation(s). for the specimen(s); and (ii) Rendered the diagnosis(es). , MD. Intraoperative Consultation. B. Sentinel lymph node #1 count. FS: Metastatic carcinoma in lymph nodes, consistent with a breast primary. C. Sentinel lymph node #2 count , FS: Metastatic carcinoma in lymph node. MD. Clinical History: None provided. SURGICAL PATHOL Report. Operation Performed. Left breast lumpectomy with sentinel node biopsy. Pre Operative Diagnosis: Left breast mass. Specimen(s) Received: A: Left breast lumpectomy 1 stitch superior, 2 stitches lateral, skin is anterior (permanent). B: Sentinel lymph node #1 count. C: Sentinel lymph node #2 count. FS. D: Non-sentinel node. E: Left axillary contents. Gross Description: A. Received in formalin is a yellow ovoid tissue weighing 74 grams and measuring 9 x 5 x 6 cm. The specimen is oriented. with one short suture-superior margin and double black sutures-lateral margin. At the anterior aspect, there is an ellipse of. white skin, 4 x 1.2x0.3 cm. Margins inked as follows: superior margin in blue, inferior margin in green, lateral margin in. orange, medial margin in red, anterior margin in yellow and posterior margin in black. On multiple cross sections, there is. an ill-defined firm tumoral mass with focally hemorrhagic areas measuring 2.2 x 2 x 2 cm, present at less than 0.1 cm from. deep margin (closest margin) and 0.5 cm from anterior margin, 2 cm from superior and inferior margins. The rest of the. breast presents a white fibrotic breast tissue, the stroma to fat ratio is approximately 30-70%. Representative sections are. submitted in twelve cassettes as follows: 1. Superior margin. 2. Inferior margin. 3. Lateral margin. 4. Medial margin. 5. Anterior margin (skin). 6&7. Deep margin with tumor. 8-10. Tumor. 11&12. Breast stroma. B. Received fresh are two lymph nodes measuring from 1 cm to 4 x 1 x 0.8 cm. Submitted in toto in three cassettes for. frozen section as follows: 1. Small lymph node. 2&3. Large lymph node. C. Received fresh is a possible lymph node, 1.5 x 1 x 0.6 cm. Submitted in toto in one cassette for frozen section. D. Received in formalin are two yellow, pale tan tissue fragments, the smaller one is 1.2 x 1 x 0.2 cm and the bigger one is. 1.5 x 1.4 x 0,5 cm. Submitted in toto in two cassettes as follows: 1. Smaller tissue. 2. Bigger tissue, bisected, submitted in toto. E. Received is a yellow fibroadipose tissue segment, 11 x 9 x 2 cm. There are twelve possible lymph nodes ranging from 0.5. to 1.8 cm in greatest dimension. They are bisected. Representative sections are submitted In twelve cassettes as follows: One possible lymph node, bisected per block.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,802.0,T2,"The report provides a specific tumor size of 2.2 cm, which falls within the T2 range (>20 mm but <=50 mm). The type of breast surgery performed is a lumpectomy, which is one of the allowed surgeries for T1, but since the tumor size is in the T2 range, the T stage is T2. The subclassification 'mult' is not mentioned, so the tumor is not multifocal.",100.0,True
TCGA-EW-A1IW.D4194F52-3E15-4105-9A1A-1326CF128BF8,"(Age: F. Pathologic Interpretation: A. SENTINEL NODE NO.1 AXILLA CONTENT. - No malignancy seen in one lymph node (0/1). - Immunohistochemistry for keratin to follow. B. RIGHT BREAST (SHORT STITCH SUPERIOR LONG STITCH LATERAL): - Invasive lobular carcinoma, intermediate nuclear grade, with formation of two dominant tumoral masses, 4,0 cm and. 1.0 cm. - The tumor invades the dermal skin. - Lymphovascular spaces invasion is identified. - Specimen margin is negative for tumor. - Metastatic carcinoma to two of eight lymph nodes (/2/8). C. SENTINEL NODE NO. 2 AXILLA COUNT. - No malignancy seen in one lymph node (0/1). - Immunohistochemistry for keratin to follow. Tumor Summary: Specimen: - Total breast. Procedure: - Total mastectomy. Lymph Node Sampling: - Sentinel lymph node. - Axillary dissection. Specimen Integrity: - Single intact specimen. Specimen Size: - Greatest dimension: 21 cm. Additional dimension: 16 x 4 cm. Laterality: - Right. Tumor Site: - Lower outer quadrant. - Upper inner quadrant. - Lower inner quadrant. Tumor Size: - Greatest dimension of largest focus of invasion over 0.1 cm: 4 cm. - Additional dimensions: 1 x 1 cm. Tumor Focality: - Multiple focus of invasive carcinoma. Macroscopic and Microscopic Extent of tumor: - Skin: Satellite skin foci of invasive carcinoma are present. Lobular Carcinoma IN Situ (LCIS): - Present. Histologic Type: - Invasive lobular carcinoma. Histologic Grade: - Overall Grade: Grade 2. Margins: - Margins uninvolved by invasive carcinoma. Lymph-Vascular Invasion: - Present. Dermal Lymph-Vascular Invasion: SURGICAL PATHOL Report. - Not identified. Lymph Nodes: - Number of sentinel lymph nodes examined: 2. - Total number of lymph nodes examined (sentinel and Nonsentinel): 10. - Number of lymph nodes with macrometastases (>0.2 cm): 2. Extranodal Extension: - Not identified. Method of Evaluation of Sentinel Lymph Nodes: - Hematoxylin and eosin (H&E, one level). - Immunohistochemistry. Anciliary Studies: Estrogen Receptor: - Performed on another specimen: Results: Immunoreactive tumor cells present (1%). Progesterone Receptor: - Performed on another specimen: Results: Immunoreactive tumor cells present (1%). HER2/neu. - Performed on another specimen: Results: Equivocal (Score 2+). CISH for HER2/Neu: - Performed on another specimen: Results: Not amplified (HER2 gene copy <4.0 or ratio <1.8). TNM Descriptors: - m (multiple foci of invasive carcinoma). Primary Tumor (invasive Carcinoma) (pT). pT4b. Regional Lymph Nodes (pN): - pN1a. Distant Metastasis (M): - Not applicable. Pathologic Staging (PTNM): mpT3, N1a, M-not applicable. NOTE: Some antibodies are analyse specific reagents (ASRs) validated by our laboratory. Thase ASRs are clinically indicators that do not require mn Thase clones are. IDS-ER, AgR 636-PR, 1485-HER2, H-II-EGFR. All inohistochemical stains are used with formalin or molecular fuxed, paraffin embedded tissue. Detection is by. The desults are read byt. pathologist as posirive or negative. As the attending pathologist, I attest that I: (i) Examined the relevant preparation(s). for the specimen(s): and (ii) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. A. SENTINEL NODE # 1 AXILLA CONTENT. immunohistochemistry for keratin stain is negative for metastatic carcinoma to the fymph node. C. SENTINEL NODE # 2 AXILLA COUNT. Immunohistochemistry for keratin stain is negative for metastatic carcinoma to the lymph node. SURGICAL PATHOL Report. Intraoperative Consultation. A. Sentinel node # 1 axilla content. a. frozen section: Touch prep: Negative for metastatic carcinoma. C. Sentinel node # 2 Axilla count. ind Touch prep: Negative for metastatic carcinoma. Clinical History: Lobular carcinoma. Operation Performed. Right breast total mastectomy; Possible axillary node dissection; Sentinel node biopsy. Pre Operative Diagnosis: Breast cancer. Specimen(s) Received: A: Sentinel node # 1 axilla content : B: Right breast (short stitch superior long stitch lateral). C: Sentinel node # 2 Axilla count. Gross Description: A. Received fresh is an ovoid pale tan tissue fragment, 1 x 1 x 0.2 cm. Bisected and submitted in toto in one cassette for. frozen section. B. Received is a right mastectomy specimen with axillary tail, 21 x 16 x 4 cm. The specimen is oriented with short suture-. superior margin and long suture-lateral margin. At the anterior aspect, there is a segment of skin 10 x 5.5 x 015 cm with. areola and nipple. The nipple is depressed. There is an ill defined tumor mass, 4 x 3 x 1 cm, located at both lower inferior. quadrants (outer and inner). There is a metallic cllp. At the upper inner quadrant, there is a second tumor mass, 1 x. 1. x. 0.5 cm present, close to the anterior margin. The rest of the breast presente faw hreast stroma and abundant yellow. adipose tissue. Representative portion of tissue was taken for the : Ten possible lymph nodes are. grossly identified and present at the axillary tail. Representative sections are submitted in nineteen cassettes as. follows: 1. Nipple. 2. Deep margin. 3&4. Tumor, lower outer quadrant. 5&6. Tumor, lower inner quadrant. 7. Middle line tumor. 8. Second mass, upper inner quadrant close to anterior margin. 9. Upper outer quadrant. 10&11. One entire lymph node, per block. 12-19. One lymph node bisected, per block. C. Received is an ovoid pale tan tissue fragment, 1.2 x 1 x 0.5 cm. Bisected and submitted in toto in one cassette for. frozen. section. F. Pathologic Interpretation: AMMENDMENT TO PATHOLOGIC TUMOR STAGING AND RESULTS OF HER2 BY CISH (. A. SENTINEL NODE NO.1 AXILLA CONTENT. - No malignancy seen in one lymph node (0/1). - Immunohistochemistry for keratin to follow. B. RIGHT BREAST (SHORT STITCH SUPERIOR LONG STITCH LATERAL): Invasive lobular carcinoma, intermediate nuclear grade, with formation of two dominant tumoral masses, 4.0 cm and. 1.0 cm. - The tumor invades the dermal skin. - Lymphovascular spaces invasion is identified. - Specimen margin is negative for tumor. - Metastatic carcinoma to two of eight lymph nodes (/2/8). C. SENTINEL NODE NO. 2 AXILLA COUNT 605 FS: - No malignancy seen in one lymph node (0/1). - Immunohistochemistry for keratin to follow. Tumor Summary: Specimen: - Total breast. Procedure: - Total mastectomy. Lymph Node Sampling: - Sentinel lymph node. - Axillary dissection. Specimen Integrity: - Single intact specimen. Specimen Size: - Greatest dimension: 21 cm. Additional dimension: 16 x 4 cm. Laterality: - Right. Tumor Site: - Lower outer quadrant. - Upper inner quadrant. - Lower inner quadrant. Tumor Size: - Greatest dimension of largest focus of invasion over 0.1 cm: 4 cm. - Additional dimensions: 1 x 1 cm. Tumor Focality: - Multiple focus of invasive carcinoma. Macroscopic and Microscopic Extent of tumor: - Skin: Satellite skin foci of invasive carcinoma are present. Lobular Carcinoma IN Situ (LCIS): - Present. Histologic Type: - Invasive lobular carcinoma. Histologic Grade: - Overall Grade: Grade 2. Margins: - Margins uninvolved by invasive carcinoma. Lymph-Vascular Invasion: - Present. Permal Lymph-Vascular Invasion: - Not identified. Lymph Nodes: - Number of sentinel lymph nodes examined: 2. Total number of lymph nodes examined (sentinel and Nonsentinel): 10. - Number of lymph nodes with macrometastases (>0.2 cm): 2. Extranodal Extension: - Not identified. Method of Evaluation of Sentinel Lymph Nodes: - Hematoxylin and eosin (H&E, one level). - Immunohistochemistry. Ancillary Studies: Estrogen Receptor: - Performed on another specimen: Results: Immunoreactive tumor cells present (1%). Progesterone Receptor: - Performed on another specimen: Results: Immunoreactive tumor cells present (>1%). HER2/neu. Performed on another specimen: Results: Equivocal (Score 2+). CISH for HER2/Neu: - Performed on another specimen: Results: Amplified (HER2 gene copy <4.0 or ratio <1.8). (amended. TNM Descriptors: m (multiple foci of invasive carcinoma). Primary Tumor (invasive Carcinoma) (pT). pT4b. Regional Lymph Nodes (pN): pN1a. Distant Metastasis (M): - Not applicable. Pathologic Staging (pTNM): mpT4b, N1a, M-not applicable (amended. SOIE: Nome autibades an specific reagente (ANR) by our These ASRs are mejul that the not require / DA approal. These clones are nwt. 1/15 ER 11.11 AGH All Inmical are word with formales or molec uku finel, paroffin instituted linve. Detection is A;. The results are nat by a. prithologiv is postitive or reguire. As the attending pathologist, / attest that I: (i) Examined the relevant preparation(s). for the specimen(s): and (ii) Rendered the diagnosis(es). Amendments. Amended: Reason: Revise/Update Tumor Staging. Case is amended to revise Pathologic Tumor Staging and update results of Her2 by CISH. Previous Signout Date: Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. A. SENTINEL NODE # 1 AXILLA CONTENT. - Immunohistochemistry for keratin stain is negative for metastatic carcinoma to the lymph node. C. SENTINEL NODE # 2 AXILLA COUNT. - Immunohistochemistry for keratin stain IS negative for metastatic carcinoma to the lymph node. Intraoperative Consultation. A. Sentinel node # 1 axilla content. ? frozen section: Touch prep: Negative for metastatic carcinoma. C. Sentinel node # 2 Axilla count. and Touch prep: Negative for metastatic carcinoma. Clinical History: Lobular carcinoma. Operation Performed. Right breast total mastectomy; Possible axillary node dissection; Sentinel node biopsy. Pre Operative Diagnosis: Breast cancer. Specimen(s) Received: A: Sentinel node # 1 axilla content. B: Right breast (short stitch superior long stitch lateral). C: Sentinel node # 2 Axilla count. Gross Description: A. Received fresh is an ovoid pale tan tissue fragment, 1 X 1 x 0.2 cm. Bisected and submitted in toto in one cassette for. frozen section. B. Received is a right mastectomy specimen with axillary tail, 21 x 16 x 4 cm. The specimen is oriented with short suture-. superior margin and long suture-lateral margin. At the anterior aspect, there is a segment of skin 10 x 5,5 x 0,5 cm with. areola and nipple. The nipple is depressed. There is an ill defined tumor mass, 4 x 3 x 1 cm, located at both lower inferior. quadrants (outer and inner). There is a metallic clip. At the upper inner quadrant, there is a second tumor mass, 1 x 1 x. 0.5 cm present, close to the anterior margin. The rest of the breast presents few breast stroma and abundant yellow. adipose tissue. Representative portion of tissue was taken for the. Ten possible lymph nodes are. grossly identified and present at the axillary tail. Representative sections are submitted in nineteen cassettes as follows: 1. Nipple. 2. Deep margin. 3&4. Tumor, lower outer quadrant. 5&6. Tumor, lower inner quadrant. 7. Middle line tumor. 8. Second mass, upper inner quadrant close to anterior margin. 9. Upper outer quadrant. 10&11. One entire lymph node, per block. 12-19. One lymph node bisected, per block. C. Received is an ovoid pale tan tissue fragment, 1.2 x 1 x 0.5 cm. Bisected and submitted in toto in one cassette for frozen. section.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,802.0,T4,"The report mentions that the tumor invades the dermal skin (T4a), regardless of tumor size. Additionally, the tumor is multifocal with the largest focus being 4 cm, which falls within the T4 range.",100.0,True
TCGA-E2-A10C.E8A61AAC-BFF5-4341-B051-EDD87515ECDC,"SPECIMENS: A. SENTINEL LYMPH NODE #1. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. C. SENTINEL LYMPH NODE #3 LEFT AXILLA. D. SENTINEL LYMPH NODE #4 LEFT AXILLA. E. SENTINEL LYMPH NODE #5 LEFT AXILLA. F. WLE LEFT BREAST. G. AXILLARY CONTENTS. SPECIMEN(S): A. SENTINEL LYMPH NODE #1. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. C. SENTINEL LYMPH NODE #3 LEFT AXILLA. D. SENTINEL LYMPH NODE #4 LEFT AXILLA. E. SENTINEL LYMPH NODE #5 LEFT AXILLA. F. WLE LEFT BREAST. G. AXILLARY CONTENTS. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA (microscopic): Lymph node, sentinel #1, biopsy: Negative for carcinoma. By called to Dr. at. TPB/C (microscopic): Lymph nodes, sentinels #2-3, biopsy: Negative for carcinoma. By Dr., called to. Dr. at. (B) and. C). TPD (microscopic): Lymph node, sentinel #4, biopsy: Positive for carcinoma. By Dr., called to Dr. at. (D). Gross Exam F Breast, left, wide local excision: Tumor mass is 0.6 cm from the anterior/inferior. margins. By Dr, called to Dr. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE #1. Received fresh is a tan-pink fragment of fibrofatty tissue 3.5 x 2.4 x 0.8 cm. Dissection reveals. one. presumptive lymph node 1.0 x 0.7 x 0.4 cm. The specimen is serially sectioned and touch preps are. taken. The specimen is submitted entirely in cassette A1. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received fresh is a tan-pink lymph node 1.0 x 1.0 x 0.7 cm. The specimen is serially sectioned. Touch. preps are taken and the specimen is submitted entirely in cassette B1,. C. SENTINEL LYMPH NODE #3 LEFT AXILLA. Received fresh is a tan-pink lymph node 1.0 x 1.0 X 0.7 cm. The specimen is serially sectioned. Touch. preps are taken and the specimen is submitted entirely in cassette C1. D. SENTINEL LYMPH NODE #4 LEFT AXILLA. Received fresh is a tan-pink lymph node 1.5 X 1.0 x 0.7 cm. The specimen is serially sectioned and. touch preps are taken. The specimen is submitted in toto in D1. E. SENTINEL LYMPH NODE #5 LEFT AXILLA. Received in formalin is a tan-pink lymph node 2.0 x 1.0 x 1.0 cm. The specimen is serially sectioned. and submitted in toto in cassette E1. F. WIDE LOCAL EXCISION LEFT, BREAST. Received fresh is an oriented 57 gram wide local excision breast specimen measuring 8 x 6 X 4 cm. The specimen is inked as follows: anterior-blue, posterior-black, superior-red, inferior-orange, medial-. green, lateral-yellow. The specimen is serially sectioned from lateral to medial into six slices, slice 1. being most lateral and slice 6 being most medial, to reveal a gray-white, firm stellate mass measuring. 2.2 X 2 X 2 cm located 0.6 cm from the closest anterior/inferior margin in slice 3, 4, 5 and 6. The. remainder of the cut surfaces reveal predominantly yellow lobulated adipose tissue interdispersed with. gray-white fibrous tissue. A portion of the specimen is submitted for tissue procurement. Representative sections are submitted as follows: A1: perpendicular sections of the lateral margin from superior to inferior, slice. 1. A2: anterior margins and area immediately adjacent to mass, slice 2. A3: anterior margin, slice 3. A4: inferior margin, slice 3. A5: deep margin, slice 3. A6: superior margin, slice 3. A7: mass with anterior and superior margins, slice 4. A8: mass with anterior and inferior margins, slice 4. A9-A10: mass with superior and deep margins bisected. A11: mass with inferior and deep margins. A12: mass with anterior margin, slice 5. A13: mass with inferior margin, slice 5. A14-A15: perpendicular sections of the mass with the medial margin from superior. to inferior, slice 6 as per attached diagram. G. LEFT AXILLARY CONTENTS. Received in formalin are multiple tan-pink fragments of fibrofatty tissue aggregating to 9 X 6 x 3 cm. Dissection reveals nine possible lymph nodes ranging from 0.1 x 0.1 x 0.1 cm to 1.1 x 1.0 X 0.9 cm. Section code: G1: three possible lymph nodes. G2: three possible lymph nodes. G3: two possible lymph nodes. G4: one lymph node trisected. G5: one lymph node trisected. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). B. LYMPH NODE, SENTINEL #2, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). C. LYMPH NODE, SENTINEL #3, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. LYMPH NODE, SENTINEL #4, LEFT AXILLA, BIOPSY: METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 0.6-CM WITH EXTERANODAL EXTENSION. E. LYMPH NODE, SENTINEL #5, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). F. BREAST, LEFT,WIDE LOCAL EXCISION: - INVASIVE, DUCTAL CARCINOMA, SBR GRADE-3, MEASURING 2.2-CM. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU WITH. CENTRAL NECROSIS, CRIBRIFORM AND SOLID TYPES. - SEE SYNOPTIC REPORT. G. LYMPH NODES, LEFT AXILLARY CONTENTS, RESECTION: - EIGHT LYMPH NODES, NEGATIVE FOR METASTASES (0/8). SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: No. Laterality: Left. Invasive tumor. Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.2cm. Tumor site: Not specified. Margins: Negative. Distance from closest margin: 0.5cm. anterior/medial. Tubular score: 2. Nuclear grade: 3. Mitotic score:3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node and axillary dissection. Lymph node status: Positive 1/13 Extranodal extension. DCIS present. Margins uninvolved by DCIS: DCIS Quantity: Estimate 5%. DCIS type: Solid. Cribriform. DCIS location: Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by IHC. Pathological staging (pTN): pT 2 N 1a. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: F12. ER: Positive. Allred Score: 8 = Proportion score: 5 + Intensity Score 3. PR: Positive Allred Score: 6 = Proportion Score 3 + Intensity Score 3. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of. less than or equal to 2. Methodology: Fixation Type and Length: Tissue was fixed in 10% neutral buffered formalin (. ) for no less than 8 and no longer than 24 hours. Antibody and Assay Methodology: Mouse anti-human ER and PR,. Comment: This assay can be used to select invasive breast cancer patients for hormone therapy (1). ER and PR analysis was performed on this case by immunohistochemistry utilizing the ER (ER 1D5,. 1:100) and PR (PGR 136, 1:100) antibody provided by. following the manufacturer's instructions. listed in the package insert. This assay was not modified, and adherence to all instruction and. guidelines were strictly followed. Interpretation of the ER/PR immunohistochemical staining. characteristics is guided by published results in the medical literature (1), information provided bv the. reagent manufacturer and by internal review of staining performance within the F. 1. Harvey JM, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding. assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474-. 1481, 1999. SYNOPTIC REPORT - BREAST HER-2 RESULTS. HER2 Status Results, Immunohistochemistry Evaluation. Specimen: Surgical Excision. Block Number: F12. Interpretation: NEGATIVE. Intensity: 1+. % Tumor Staining: 5%. Fish Ordered: METHODOLOGY. Methodology: Fixation Type and Length: Tissue was fixed in 10% neutral buffered formalin. Inc. ) for no less than 8 and no longer than 24 hours. Antibody and Assay Methodology: Rabbit anti-human HER2, HerceptestTM (FDA-approved test kit),. Control. Slides Examined: External kit-slides provided by manufacturer (cell lines with high, low and negative. HER2 protein expression), and in-house known HER2 amplified control tissue were evaluated along. with the test tissue. These control slides run along side of this patient's sample showed appropriate. staining. Adequacy of Specimen: Adequate, well preserved, clear-cut invasive carcinoma identified for. HER2 evaluation. Scoring Criterion and Scoring System: IHC Level of Expression(Score /Tumor Cell Membrane Staining Pattern. Negative (0)/Absence of Staining. Negative (1+)/Faint Incomplete membrane Staining, >10% of Cells. Equivocal (2+)/Weak complete membrane Staining, >10% of Cells. Positive (3+)/Strong complete membrane Staining, >10% of Cells. Equivocal Category for HER2 IHC results: A HER2, 2+ staining result that is interpreted as equivocal. may not indicate gene amplification. A FISH test for HER2 gene amplification will be ordered for all. HER2 IHC 2+ results. COMMENT. This assay can be used to select invasive breast cancer patients for Trastuzumab (Hereptin) therapy. (1,2). Clinical Trials have shown that Trastuzumab substantially increases the likelihood for an objective. response and overall survival for patients with metastatic HER2-positive breast cancer, regardless of. whether HER2 tumor status was determined as IHC 3+ or FISH positive. Trastuzumab added to. adjuvant chemotherapy substantially increase disease-free survival and decreases the risk of disease. recurrence by about 50% for patients with early-stage HER2 protein over-expressed or gene amplified. invasive breast cancer (3). HER2 analysis was performed on this case by immunohistochemistry utilizing the FDA approved. HercepTest (TM) test kit following the manufacturer's instructions listed in the package insert. This. assay was not modified, and adherence to all instruction and guidelines were strictly followed. Interpretation of the HER2 immunohistochemical staining characteristics is guided by published results. in the medical literature (4), information provided by the reagent manufacturer and by internal review of. staining performance within the Pathology Department. HER2 TEST VALIDATION. This HER2 immunohistochemical assay has been validated according to the recently revised. recommendations and guidelines from the NCCN HER2 testing in Breast Cancer Task Force, and the. jointly issued recommendations and guidelines from ASCO and the CAP (5). 80 randomly selected. breast cancer samples were tested for HER2 by IHC as outline above and interpreted as, negative. (score 0/1+) equivocal (score 2+) and positive (score 3+) without knowledge of the previous reported. results. These cases were also blindly read using two different FISH assay as amplified or non-amplified and. the HER2/CEP17 ratios were recorded. After analyzing these results, there was 100% concordance. between the IHC and FISH results for cases that were interpreted as either positive or negative by IHC. 9 of the 80 cases were interpreted as equivocal by IHC and of these 3/9 (33%) were non-amplified by. FISH and 6/9 (66%) were found to be amplified. The Pathology Department Immunohistochemistry laboratory takes full responsibility for this tests. performance and has programs in place to regularly monitor the proficiency and the interpretation of. HER2 assays. The laboratory also participates in external quality assurance HER2 programs including. the CAP proficiency testing program. REFERENCE. 1. Carlson RW, Anderson BO, Burstein HJ, et al., NCCN breast cancer clinical practice guidelines in. oncology. J Natl Compr Canc Netw. 2005;3:238-289. 2. Carlson RW, Brown E, Burstein HJ, et al., NCCN Task Force Report: adjuvant therapy for breast. cancer. J Natl Compr Canc Netw. 2006;4:S1-S26. 3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable. HER2-positive breast cancer. N Eng J Med 2005;353(16):1673-84. 4. Leong ASY, Formby M, Haffajee Z, et al. Refinement of immunohistologic parameters for Her2/neu. scoring validation by FISH and CISH. Appl Immunohistochem Mol Morphol. 2006;14:384-389. 5. Wolff AC, Hammond EH, Schwartz JN, et al., American Society of Clinical Oncology/College of. American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Recepto 2. Testing in Breast Cancer. Arch of Path and Lab Med 2007; 131:18-43. CLINICAL HISTORY: None provided. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. Microscopic/Diagnostic Dictation: Pathologist,. Microscopic/Diagnostic Dictation: Pathologist,. Microscopic/Diagnostic Dictation:., Pathologist. Final Review:., Pathologist. Final: Pathologist.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,802.0,T2,"The report mentions a wide local excision of the left breast and provides a specific tumor size of 2.2 cm, which falls within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",100.0,True
TCGA-A7-A4SD.563D1ED2-1A8B-4D90-BD42-AC3790D04913,"Final Surgical Pathology Report. Procedure: Diagnosis. A. Sentinel lymph node #1, excision: No evidence of metastasis in 3 lymph nodes (0/3). B. Sentinel lymph node #2, excision: No evidence of metastasis in 3 lymph nodes (0/3) . C. Right breast, mastectomy: Infiltrating ductal carcinoma, grade 3, 4.3 cm greatest dimension,. surgical margins negative but close (0.4 cm, deep) . Microscopic Description: Microscopic examination performed. A. B. sections of sentinel lymph nodes 1 and 2 demonstrate no. evidence in 3 lymph nodes in each specimen. The lymph nodes were. examined by multilevel sectioning with H&E staining as well as by. histochemistry for pankeratin. C. Invasive Carcinoma: present. Histologic type: infiltrating ductal cancer. Histologic grade: Overall grade: 3. Architectural score: 3. Nuclear score: 3. Mitotic score: 3. Greatest dimension (pT) : 4.3 cm, pT2. Specimen margins: negative, 0.4 cm to deep margin. Vessel invasion: not identified. Calcification: not identified. Ductal carcinoma in situ: not identified. Specimen. A. Sentinel node #1. B. Sentinel node #2. C. Right mastectomy, arrow points up. Clinical Information. Right breast cancer. Intraoperative Consultation. AFS1-AFS3: Sentinel lymph node #1, excision - No metastasis identified. in 3 nodes. BFS1-BFS3: Sentinel lymph node #2, excision - No metastasis identified. in 3 nodes. Gross Description. A. Container a is labeled with the patient's name, medical record. number and ""sentinel node"". The specimen container holds 3 lymph nodes. ranging in size from 1.5 x 1 x 1.5 cm to 0.6 x 0.5 x 0.4 cm. AFS 1,. AFS 2 one lymph node bisected AFS 332 lymph nodes. B. Container B. is labeled with the patient's name, medical record. number and ""palpable nodule right axilla"". Per Dr. this should be. regarded as such libido for to. The specimen container holds 3. separate lymph nodes. Each lymph node is bisected and submitted in one. block,. C. Received fresh and subsequently placed in formalin at. labeled ""right mastectomy"" is a 27.0 cm (superior to inferior) by 26.0. cm (medial to lateral) by 6.5 cm (anterior to posterior) diffusely. cauterized soft, lobulated tan-white-gold portion of fibroadipose. tissue in keeping with breast. A 23.5 x 10.0 cm wrinkled brown skin. ellipse with a central, 1.1 x 1.1 x 0.7 cm nipple is present along the. anterior aspect. A palpable nodular mass corresponds to the lower. inner quadrant and the anteroinferior surface is inked orange. The. intact deep margin is inked blue and the specimen is sectioned. The. after mentioned palpable mass is well-circumscribed glistening. tan-white and rubbery, measuring 4.3 cm (medial to lateral) by 3.8 cm. (anterior to posterior) by 3.1 cm (superior to inferior). The tumor. extends to within 0.4 cm of the inked deep margin and 1 cm of the. anteroinferior inked surface. Several cylindrical firm tan-white. structures are associated with the lesion. A portion of the lesion and. a portion of normal parenchyma are submitted for tissue procurement as. requested. The remaining soft, lobulated tan gold adipose tissue with. a scant amount of interspersed delicate tan-white fibrous tissue. No. additional mass lesion or abnormality is identified grossly. RS 12. Summary: 1 through 3 - tumor to inked deep margin, 4 and 5 - tumor to. inked anteroinferior margin, 6 - tumor to normal parenchyma, 7 - random. upper outer quadrant, 8 - upper inner quadrant, 9 - lower inner. quadrant, 10 - lower outer quadrant, 11 - junction of the 4 quadrants,. 12 - nipple. Ciscrepancy.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,802.0,T2,"The report provides a specific tumor size of 4.3 cm, which falls within the T2 range (>20 mm but <=50 mm). The report also mentions a mastectomy, which is a breast surgery other than lumpectomy, wide excision, segmental mastectomy. Therefore, based on the rule '% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.', the T stage is T2.",100.0,True
TCGA-GM-A2DA.F3CD8E6E-B02F-4D5D-B895-6DF063F61603,"i.b. FIRAL 114 th: CONSULTANT: TIME KFCn. Photo: VO. 14 CCPY TO:113. CLINIC COPY. (A) RIGHT BREAST AND AXILLARY CONTENTS: l''VASIVE PUCTAL CARCINOMA, BLACK'S NUCLEAR GRACE 11. (SEE COMPENT). Fibrocystic changes. NETASTATIO CARCINOMA IN [10) UF THIRTEFN AXILLARY LYYPH NONES. (SEE CONMENT). fargins of resection free of tumor. CURMMENT: The nain tumor mass measures 2.5 x 2.0 x 1.5 cm in greatest. dimensions and is located in the inner quadrant, A separate microscopic. focus of invasive tunor is located in the upper outer quadrant and neasures. 1.5 x 1.0 x 0.5 mm. The largest lymph node containing netastatic disease. neasures 1.5 x 1.0 x 0.5 cm and shows 50% reolacement by tumor. Une of the. lymoh nodes containing metastatic tumor shows several foci of extracapsular. extension with a cumulative area of 3.0 x 5.5 Tm. GROSS DESCRIPTION. ( A ) RIGHT BREAST AND AXILLAWY CONTENTS - The specimen 125 x 15 x 4 cm). consists of breast (15 x 13 x 2 cm) covered by an unremarkable skin elliose. (3 x 5 cm) with nipple. The axillary contents measure 12 x 5 x "".1 c n . A nass is identified in the inner quadrant and measures 2.5 x ?.0 x. 1.5. Cin. The nass is 0.5 cm from the deep surgical nargin. The nass is 4.5. c.n away from the nedial nargin and 5 cm away from the niopte, 2.5 cm away. from the inferior naryin and 5 cm away from the superior margin. The. o. the breast parenchyma shows fibrosis. No other nass is present. SECTION CUDE: A1, tumor with deep surgical margin; A2-A7, sections of. tumori As, inner woper quadrant periohent; 19, inner lower quartrant central. ILJ. inner lower quartrant perioheral; A11, outer upper quadrant verioheral: 11?, outer upper quadrant centrali A13, Outer lower quadrant central ; ALL,. outer lower juadrunt perioheral ; A15, Al√©, nipple; 117, two Lymph nodes; A1. in - lymph node; ii), one lymph node; 120, three lymph nodes; A21, tao lynph. nodes; 122. two lynph notes; A23, one lymph node, bisect a; 124, one lvnnh. REPORT OF TISSUE. DIAGNOSIS. \ rortion of the tumor is submitted for ftow. TECHNICAL CHARGES: REPORT OF TISSUE. DIAGNOSIS.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T2,"The report mentions an invasive ductal carcinoma with the largest tumor mass measuring 2.5 x 2.0 x 1.5 cm, which falls within the T2 range (>20 mm but <=50 mm). The type of breast surgery is not specified, but it is clear from the report that the tumor size is greater than 20 mm. Therefore, the T stage is T2.",97.0,True
TCGA-LD-A9QF.E8601979-AE05-4E4D-BB39-6B9C5E67D050,"DATE OBTAINED: DATE RECEIVED: SUBMITTING MD: DIAGNOSIS. 1. LEFT AXILLARY ""SENTINEL"" LYMPH NODES: NEGATIVE (0/3); NEGATIVE CUTDOWNS SECTIONS. 2. LEFT AXILLARY ""PALPABLE"" LYMPH NODES: NEGATIVE (0/4); NEGATIVE CUTDOWNS SECTIONS. 3. LEFT AXILLARY ""SENTINEL"" LYMPH NODE: NEGATIVE (0/1); NEGATIVE CUTDOWNS SECTIONS. 4. LEFT AXILLARY ""SENTINEL"" LYMPH NODES #3: NEGATIVE (0/6); NEGATIVE CUTDOWNS SECTIONS. 5. LEFT TOTAL MASTECTOMY: INVASIVE AND INTRADUCTAL MAMMARY DUCT CARCINOMA. SIZE (INVASIVE): 1.6 cm (additional incidental < 1mm microinvasion). SIZE (DCIS COMPONENT): -11 cm scattered foci (subareolar region to 11 cm from nipple @ 12-1 o'clock). LATERALITY: Left. TUMOR FOCALITY: Unifocal gross reference mass; incidental microinvasive lesion. LESIONAL SITE: Subareolar (both reference mass and incidental microinvasion). HISTOLOGIC TYPE: Invasive ductal carcinoma, apocrine type. NUCLEAR GRADE: III of III. HISTOLOGIC GRADE:(EEmSBR). III of III (Tubules score 3 + NG score 3 + mitoses score 3). IN-SITU COMPONENT: DCIS (variable histology). comedo NG3 subareolar. cribriform non-apocrine with comedonecrosis NG2-3 UOQ. cribriform apocrine without comedonecrosis NG2 UOQ. LYMPH NODE SAMPLING: Negative (0/14); see specimen #1 - #4. AJCC CATEGORIES: Stage I (assuming ""cM0"" status). pTNM: pT1c. pNO. cTNM: cT1. cNO. cMO. INTEGRITY/ORIENTATION: Intact specimen with designated margins. MARGINS (invasive and DCIS): Negative; 3 cm to nearest margins (anterior & posterior locations). LYMPHOVASCULAR INVASION: Focal. MICROCALCIFICATIONS: Present (associated with comedo-DCIS). NIPPLE/SKIN: (if applicable). Negative nipple; numerous pigmented seborrheic keratoses & simple lentigines. SKELETAL MUSCLE. Not present. OTHER: Two core biopsy sites (1 o'clock subareolar; 12-1 o'clock UOQ); focal microcysts,. mammary duct stasis/ectasia and focal usual duct hyperplasia. COMMENT. 1-88329,88307 2-88333,88307 3-88333,88307 4-88307 5-88309. Clinical Diagnosis and History: ear old female with left invasive CA/DCIS ? extensive DCIS 12-1:00. cT1,cNo,cMo clinical stage I. Tissue(s) Submitted: 1: LEFT AXILLARY SENTINEL LYMPH NODES #1. 2: LEFT AXILLARY PALPABLE LYMPH NODES. 3: LEFT AXILLARY SENTINEL LYMPH NODE #2. 4: LEFT AXILLARY SENTINEL LYMPH NODE #3. 5: LEFT TOTAL MASTECTOMY SUTURE IN AXILLARY TAIL. Gross Description: Specimen #1 is received fresh for intraoperative consultation labeled left axillary sentinel lymph nodes, and consists of three lymph. nodes with attached fat, ranging from 0.2 cm to 2.4 cm in greatest dimension. The lymph nodes are submitted in their entirety for. permanent microscopy as follows: 1A: two lymph nodes. 1B: one lymph node serially sectioned. Specimen #2 is received fresh for intraoperative consultation labeled left axillary palpable lymph nodes, and consists of four lymph. nodes,. ranging from 0.8 cm to 1.5 cm in greatest dimension. The lymph nodes are serially sectioned to reveal predominantly pink-. tan. cut surfaces, one of which displays a white focus. A smear preparation from the lymph node with the white focus is performed. The lymph nodes are submitted in their entirety for permanent microscopy as follows: 2A-D: one lymph node per cassette. Specimen#3 is received fresh for intraoperative consultation labeled left axillary lymph node, sentinel #2, and consists of one, 0.9. cm lymph node, which is serially sectioned and submitted in its entirety labeled 3A. Specimen #4 is received in formalin labeled left axillary sentinel lymph node #3, and consists of six lymph nodes ranging from 0.2. cm to 0.7 cm in greatest dimension. The largest lymph node is bisected and the lymph nodes are submitted in their entirety as. follows: 4A: five lymph nodes. 4B: one lymph node, bisected. Specimen #5 is received fresh labeled left total mastectomy, suture in axillary tail, and consists of an 858 gm, 25 x 23 x 5 cm left. total mastectomy specimen, with a suture marking the axillary tail. There is a 24 x 17 cm, ovoid to elliptical portion of brown skin. on the anterior aspect, displaying a 2 X 2 X 1 cm everted nipple. The skin displays multiple brown-black, flat to raised,. predominantly keratotic skin lesions, ranging from 0.1 cm to 1.0 cm and 0.6 to 0.2 cm. The largest lesion is located at 12 o'clock,. 1.7 cm from the nearest 12 o'clock margins. One of the smaller lesions appears to be transected at the 5 d'clock margin. The. specimen is inked as follows: superoanterior - blue, inferoanterior - green, posterior - black. The posterior margin is intact. The. specimen is serially sectioned to reveal a 1.6 x 1.2 x 1.2 cm tan-white, ovoid, lobulated, indurated mass located retroareolar, 6 cm. from the deep margin and 3 cm from the overlying skin. Sectioning of the mass reveals a clip. Anterior to the mass is some dense. fibrosis, displaying possible comedonecrosis. Sectioning of the remaining fibrous tissue reveals a 1.2 x 1.0 x 0.6 cm rubbery,. but. stellate area of fibrosis at 1-2 o'clock, 11 cm from the nipple. Sectioning of this area reveals a clip. The clip is located 3 cm from. the. deep margin, and 6.5 cm from the overlying skin. No definitive gross tumor is associated with this clip. The remaining breast. parenchyma consists of approximately 90% yellow, lobulated adipose tissue, and 10% scattered white, rubbery fibrous tissue. A. small portion of tumor and normal are submitted for TCGA studies. Representative sections are submitted as follows: 5A: nipple. 5B-5D: mass with clip, no margin. 5E-5G: representative fibrous tissue anterior to mass, no margin. 5H: representative deep margin to mass. 5I-5K: stellate area of fibrosis with clip. 5L: posterior margin and anterior skin to stellate area of fibrosis with clip. 5M-50: representative fibrous tissue at 12-1 o'clock. 5P: representative upper inner quadrant. 5Q: representative lower inner quadrant. 5R: representative lower outer quadrant. 5S: representative upper outer quadrant. 5T: representative margin in second largest skin lesion. 5U: representative medium five skin lesions. 5V: representative smaller skin lesions. Time in formalin: 1 p.m, submitted same day. Intraoperative Consult Diagnosis. 1A. THREE NEGATIVE LYMPH NODES (BY GROSS). 2A. FOUR LYMPH NODES IDENTIFIED; THREE NEGATIVE (BY GROSS); ONE NEGATIVE (BY GROSS AND. SMEAR). 3A. ONE NEGATIVE LYMPH NODE (BY GROSS AND SMEAR).",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T1c,"The report mentions that the size of the invasive tumor is 1.6 cm, which falls within the T1 range (<=20 mm). The type of surgery performed is a left total mastectomy, which is a type of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy. Therefore, based on the rule '% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.', the T stage for this patient is T1c.",100.0,True
TCGA-A7-A26E.EA830A26-3DF5-4731-AD0A-F20A61D58817,"DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE. Date Coll: SPECIMEN. A. Left axillary sentinel node #1. B. Left breast stitch marks long lateral, short superior. C. Intraop lymph node left axilla. D. Right breast tissue long stitch lateral, short stitch superior. E. Left axillary content. CLINICAL NOTES. PRE-OP DIAGNOSIS: Left breast carcinoma. POST-OP DIAGNOSIS: Left breast carcinoma. CLINICAL HISTORY: Left breast carcinoma. FROZEN SECTION DIAGNOSIS. A - Two lymph nodes negative for metastatic disease. Amended diagnosis - Upon re-appraisal, the smaller node. contains. a focus of carcinoma consistent with lobular origin. GROSS DESCRIPTION. A. The specimen is received fresh for frozen section. labeled ""left axillary sentinel node #1"". It consists of. a. portion of hemorrhagic adipose tissue measuring 3.5 X 2.4 x 0.9 cm. On section it is fatty and slightly indurated consistent with nodal. tissue. One such node measures 3.2 x 1.8 x 0.6 cm. A second smaller. node is present measuring 0.6 cm. by 0.5 X 0.5 cm. The larger node. is bisected and all submitted for frozen section as FS1 and FS2. The smaller node is bisected and all submitted as FS3. B. Received fresh, labeled ""left breast"" is an 18.1 u. cm. (medial to lateral) X 15.5 cm. (superior to inferior) x. 5.0 cm. (anterior to posterior) diffusely cauterized soft, lobulated. tan gold-white portion of fibroadipose tissue in keeping with. breast. designated as left per requisition slip and container and oriented. by two sutures as stated previously. There is a 9. cm. (medial to. lateral) X 3.8 cm. (superior to inferior) wrinkled white skin. ellipse. with an eccentric, flattened, 1.2 x 1. 1 cm. nipple along the. anterior aspect. A well healed and retracted 1 cm. cicatrix is. present along the skin surface corresponding to the lower outer. quadrant. The anterior surface surrounding the lateral portion. of. the skin ellipse is inked blue, the intact deep margin is inked. black and the specimen is sectioned. There is a poorly defined,. stellate, 5.5 cm. (medial to lateral) x 4.0 cm. (superior to. inferior). x 2.2 (anterior to posterior) oblique rubbery tan white tumor mass,. extending from the lower outer quadrant centrally to the junction. of the four quadrants. A portion of tumor and a portion of normal. parenchyma are submitted for tissue procurement as requested. The. tumor focally extends to within 1.2 cm. of the inked deep margin and. 1.1 cm. from the anterior/skir surface. The parenchyma throughout. the remainder of the specimen consists predominently of glistening. lobulated golden yellow adipose tissue with a minimal amount of. interspersed delicate tan white fibrous tissue. No additional mass. lesion or abnormality is identified. Representative sections are. submitted in twelve blocks as labeled. RS-12. BLOCK SUMMARY: 1,2 - Tumor to inked deep margin; 3,4 - tumor to. overlying skin ellipse/anterior surface of the specimen;. tumor. to adjacent parenchyma; 8 - random upper outer quadrant; 9 - upper. inner quadrant; 10 - lower inner quadrant; 11 - lower outer. quadrant; 12 - nipple. C. Received fresh, labeled ""intraop lymph node left. axilla"". is 1 cm. in greatest dimension slightly rubbery white. pink. tissue in keeping with lymph node with a moderate amount of. associated adipose tissue. The specimen is bisected and entirely. submitted in one block. AS-1. D. Received fresh, labeled ""right breast tissue"" is. a. diffusely cauterized and slightly fragmented, 8.6. cm. (medial to lateral) X 6.4 cm. (anterior to posterior) x 3.4. cm. (superior to inferior) soft, lobulated tan gold-white portion of. fibroadipose tissue, with two sutures as stated previously. The. margins are inked as follows: superior blue, inferior black,. anterior green, and posterior orange. The specimen is sectioned. from medial to lateral. There is a 6.5 cm. (medial to lateral) x. 4.2. cm. (anterior to posterior) X 1.0 cm. (superior to inferior) vacant. biopsy cavity occupying the majority of the specimen. The cavity. is. focally contiguous with the anterior, posterior, and superior inked. margins. No residual lesion or abnormality is noted grossly. The. cut surfaces throughout the specimen consist predominately of. mildly. congested glistening lobulated golden yellow adipose tissue with a. scant amount of interspersed delicate tan white fibrous tissue. Representative sections are submitted in a sequential manner from. medial to lateral in ten blocks as labeled. RS-10. BLOCK SUMMARY: 1 - Perpendicular sections entire medial margin cap;. J - sequential sections; 10 - representative perpendicular. sections lateral margin cap. E. Received fresh, labeled ""left axillary content"" is an. unoriented, 6.5 x 5.8 x 1.8 cm. portion of soft, lobulated. golden yellow adipose tissue. Several soft to slightly rubbery. pale. tan tissues in keeping with lymph nodes measuring up to 1.8 cm. in. greatest dimension are recovered. The lymphoid tissues are. entirely. submitted in three blocks as labeled. RS-3. BLOCK SUMMARY: 1 - Eight whole lymph nodes; 2 - five whole lymph. nodes; 3 - one bisected lymph node. MICROSCOPIC DESCRIPTION. A. Two lymph nodes are examined in their entirety at. multiple levels. The smaller contains a 3 mm. metastasis. with minimal extra-capsular extension, ,. B. The previously biopsied large tumor is an infiltrating. lobular carcinoma. In one 2 mm. area (block #6 within the. main tumor) , there is a focus of invasive ductal carcinoma which is. nuclear grade 1 (architectural score 1, nuclear score 2, mitotic. score 1) . In addition, in blocks 4 and 5 there is in situ tumor. which, with the help of E-Cadherin stain, proves to be ductal. carcinoma in situ, nuclear grade 2. Please see the template below. Invasive carcinoma: Histologic type: Infiltrating lobular carcinoma with single. small focus of associated infiltrating ductal carcinoma. Histologic grade: The invasive lobular carcinoma is moderately. differentiated. Overall grade: [ Last Name (un) 1] SBR grade 2. Architectural score: 3. Nuclear score: 2. Mitotic score: 1. Greatest dimension (pT) : The tumor measures 5.5 cm., pT3. Specimen margins: Negative. Vessel invasion Suspicious for lymphatic invasion. Perineural. invasion is noted. Calcification: Negative. Nipple (Paget's) : No Paget's disease of the nipple is present. Major lactiferous ducts, however, contain lobular neoplasia in. situ, supported by stain for E-Cadherin. There is also a 1.5. mm. of invasive lobular carcinoma within the subareolar tissue,. supported by stains for P63 and E-Cadherin. Invasion of skin or chest wall: Negative. Ductal carcinoma in situ (supported by stain for E cadherin) : Histologic pattern: Solid. Nuclear grade: 2. Central necrosis: Negative. : DCIS of total tumor (if mixed) : The DCIS appears to be. separate from the invasive lobular carcinoma. Extensive intraductal component (present/absent) : Absent. Specimen margins: Negative. Calcification: Negative. Description of non-tumorous breast: Fibrocystic changes are also. present, including cysts, apocrine metaplasia, a 3 mm. fibroadenoma. and rare calcification. Comments: E-Cadherin on block #5 supports the diagnosis of ductal. carcinoma in situ. Lymph nodes: Number of positive nodes of total: As per parts A, C and E,. there are 16 1 mmnh nodes. one of which contains metastatic. carcinoma, l. Size of largest metastasis: 3 mm. Extracapsular extension (present/absent) : Present. pN: 1A. Distant metastasis (pM) : Cannot be assessed. Prognostic markers: Please see. C. A single lymph node is present. Negative for. metastatic. disease, 0/1. D. This portion of tissue contains biopsy site changes. In. situ tumor is noted in blocks 1 through 7. With the. assistance of stains for E-Cadherin on all of these blocks, it is. apparent that the tumor in blocks. ] and 5 is lobular. carcinoma in. situ. The tumor in blocks 4, 6 and 7 prove to be ductal carcinoma. in situ. Also, in block 7, there is a 1.1 mm. focus of invasive. tumor which proves to be of ductal origin. Please see the template. below for the details regarding the ductal tumor. Invasive Carcinoma: Histologic type Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Overall grade: Last Name (un) 1] SBR grade 2. Architectural score: 3. Nuclear score: 2. Mitotic score: 1. Greatest dimension (pT) : The tumor measures 1.1 mm., pTla. Specimen margins: Invasive tumor is less than 1 mm from the. inferior margin. Vessel invasion : Negative. Calcification: Negative. Ductal carcinoma in situ: Histologic pattern: Solid and cribriform. Nuclear grade: 2. Central necrosis: Negative. DCIS of total tumor (if mixed) : The invasive component is very. minor relative to the in situ component. Extensive intraductal component (present/absent) : Present. Specimen margins: DCIS less than 1 mm. from the inferior margin. Calcification: Negative. Description of non-tumorous breast: Cysts and apocrine metaplasias. present. Comments: In addition to the invasive and in situ ductal. carcinoma,. there are foci of lobular carcinoma in situ. Prognostic markers: Cold ischemia time too long for accurate. marker. studies. E. Thirteen lymph nodes are present, all negative for. metastatic disease, 0/13. This is supported by negative. keratin stains on blocks 1 through 3. [A few of the antibodies used in our laboratory may be classified. as. analyte specific reagents. These antibodies are monitored and. controlled in our laboratory and their performance for in [Last Name. (un) 2]. diagnosis is well described in the medical literature. They have. not been cleared or approved by the FDA. ]. 14, 15x2, 4x5, 20x12, PGRI 3260F. DIAGNOSIS. A. Left axillary sentinel node #1, excision -. Two lymph nodes, one of which contains metastatic carcinoma,. B.(Left) breast, mastectomy -. Large (5.5 cm. ) infiltrating lobular carcinoma, minor. associated component of invasive ductal carcinoma. Ductal. carcinoma in situ also present. A second minute focus of. invasive lobular carcinoma is present in the sub-areolar. tissue. All margins are negative for tumor. C. Intraoperative lymph node left axilla, excision -. Single lymph node negative for metastatic disease, 0/1. D. Right breast tissue, excision -. Breast tissue with biopsy site changes, lobular carcinoma in. situ, ductal carcinoma in situ and invasive ductal carcinoma,. SBR grade 2. The invasive ductal. carcinoma and ductal. carcinoma in situ are. less than 1 mm. from the inferior margin. Hormone receptor. studies cannot accurately be performed on the invasive ductal. carcinoma. E. Left axillary contents, dissection -. Thirteen lymph nodes all negative for metastatic disease,. 0/13.",2,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T3,"The report mentions that the tumor in the left breast measures 5.5 cm, which falls within the T3 range (>50 mm). The type of surgery performed is a mastectomy, which matches the criteria for T3. Therefore, the T stage for this patient is T3.",100.0,True
TCGA-BH-A0DD.35FFF2A4-7956-47AC-B6B8-1AA6775E332B,"FINAL DIAGNOSIS: RART SENTINEL LYMPH NODE #1, RIGHT AXILLA, BIOPSY -. 1: CARCINOMA INVOLVING ONE LYMPH NODE (1/1). A. METASTATIC METASTATIC FOCUS MEASURES 3.0 CM IN GREATEST DIAMETER 0.1 (ENTIRE CM. LYMPH NODE). B. c. EXTRACAPSULAR EXTENSION IS IDENTIFIED MEASURING 0.2 X. PART 2: BREAST, LEFT, SIMPLE MASTECTOMY -. A. DUCTAL EPITHELIAL HYPERPLASIA. B. PREDOMINANTLY ADIPOSE BREAST PARENCHYMA. c. SKIN AND NIPPLE HISTOLOGICALLY UNREMARKABLE. PART 3: A. BREAST. INVASIVE RIGHT, DUCTAL MODIFIED CARCINOMA RADICAL 3.0 MASTECTOMY 3/3, CM NUCLEAR (GROSS) NOTTINGHAM PLEOMORPHISM - GRADE 2/3, MITOTIC 3 (COMBINED ACTIVITY NOTTINGHAM 3/3) WITH. TUBULE. LYMPHOPLASMACYTIC SCORE 8/9: INFILTRATE AND NECROSIS. B. DEFINITIVE LYMPHOVASCULAR. C. DUCTAL CARCINOMA IN SITU IS NOTIBENTIFIED. D. RESECTION MARGINS FREE. E. DUCTAL EPITHELIAL HYPERPLASIAL. F. G. SKIN TWENTY-TWO AND NIPPLE, LYMPH HISTOLOGICALLY NODES, NEGATIVE UNREMARKABLE FOR METASTATIC CARCINOMA (0/22). H. PATHOLOGIC STAGE (see comment): I. RECEPTOR STATUS (see comment). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Modified radical mastectomy. Upper inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 3.0 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 3. Total Nottingham score: 8. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 1. LYMPH NODES EXAMINED: 23. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 30.0 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: SKIN INVOLVED (ULCERATION): T STAGE, PATHOLOGIC: p12. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: 2+.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T3,"The report mentions that the maximum dimension of the invasive component of the tumor is 3.0 cm and that a modified radical mastectomy was performed. This meets the criteria for a T3 stage as per the rule: '% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.'",100.0,True
TCGA-D8-A73X.9B227A4E-6237-4C95-B640-E64AFF0CC5F4,"path E Greast, central portin C50.1. Gender: F. Clinical diagnosis (suspicion) Cancer of the left breast. Date of admission: Material: 1) Material: left breast; method of collection: Total organ resection. Supplement result: Complementary macroscopic description: Tumour sized 2.3 x 1.7 x 1.3cm on the boundary of upper quadrants (located centrally over the nipple, placed 2.5cm. from the lower boundary, 0 cm from the base and 0.8cm from the skin. Histopathological diagnosis: Invasive tubular carcinoma of the breast. (NHG1; pT2; pNO(sn). (8211/3 T 04030). codes according to ICD-O-3 or SNOMED. Macroscopic description: Left breast, sized 18 X 14 X 1.5cm, removed without with a skin flap of 13 X 4.5cm. Weight 220 g. Tumour on the. boundary of the upper quadrants (centrally over the nipple). Microscopic description: Invasive tubular carcinoma - NHG1 (1+1+1:0 mitoses/10 HPF - visual area: 0.60mm). Glandular tissue, outside the. tumour, showing lesions of the fibrocystic type and fibroadenoma of 0.5 cm in diameter. Results of intraoperative examination: Estrogen receptors found in 75% of neoplastic cell nuclei. Progesterone receptors found in 75% of neoplastic cell nuclei. HER2 protein stained with. HER-2/neu (4B5). HER-2/neu (4B5) Rabbit Monoclonal Antibody. Negative reaction in invasive cancerous cells ( Score = 1+). The expression of proliferating nuclear antigen Ki 67 in 10 % cellular nuclei.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T2,"The report provides a specific tumor size of 2.3 x 1.7 x 1.3 cm which falls within the T2 range (>20 mm but <=50 mm). The type of surgery performed is a total organ resection, which is not specified in the rules as a criterion for T1 or T2. However, since the tumor size is within the T2 range, we can classify this as a T2 tumor.",100.0,True
TCGA-D8-A143.F8C2F3EF-FA73-4FF8-9A4E-7F557E68D560,"page 1 / 1. copy No. Examination: Histopathological examination. PESEL: Gender: F. Material: Multiple organ resection - left breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast (inner lower quadrant). Macroscopic description: Left breast, sized 21.8 x 21.2 x 6.5 cm, removed along with axillary tissues sized 11 x 7x3 cm and a skin flap. of 21.2 x 11.1 cm. Weight 1,360 g. Tumour sized 2.8 x 2.1 x 1.5 cm found on the boundary of inner quadrants,. placed 3.6 cm from the upper edge, 0.9 cm from the base and 2.8 cm from the skin. Status after core needle. biopsy (test No. Microscopic description: Carcinoma ductale invasivum NHG3 (3+3+3: 35 mitoses /10 HPF - visual area: 0.55mm). Focuses of carcinoma ductale in situ (DCIS) found within tumour (solid type, with high nuclear. atypia and comedo necrosis, 10% of the tumour). Reactio lymphocytaria peritumoralis. Lesions in situ: cancerisatio lobulorum. Mamilla sine laesionibus. Glandular tissue showing parenchyma atrophy. Axillary lymph nodes: Lymphonodulitis reactiva No XI. Histopathological diagnosis: (including test No. Carcinoma ductale invasivum et ductale in situ mammae sinistrae. (NHG3, pT2, pNO).",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T2,"The report provides a specific tumor size of 2.8 x 2.1 x 1.5 cm, which falls within the T2 range (>20 mm but <=50 mm). The type of surgery is a 'multiple organ resection' which is not specified in the rules as one of the T1-suitable surgeries. Therefore, the T stage is T2.",100.0,True
TCGA-A8-A07S.AC2E3DDC-3AF6-45F0-8269-E9DA68F4367A,Summary diagnosis: Left breast at 3 o'clock: invasive breast carcinoma of mixed differentiation with a tumor. classification pT2 (28 mm) pM0 (0/28) grade 1 (L0(V0) R1 (ventral). Associated extensive lobular neoplasia and DCIS grade 1 corresponding to pTis RI ventral.,1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T2,"The report provides a specific tumor size of 28 mm, which falls within the T2 range (>20 mm but <=50 mm). The type of surgery is not specified, but there is no mention of invasion of the chest wall or skin, so the T stage is T2.",100.0,True
TCGA-D8-A27F.976C6F9E-DDCB-42F4-BD2C-A4D715396B47,"page 1 / 1. copy No. 7. Examination: Histopathological examination. Gender: F. Material: Multiple organ resection - right br√©ast with axillary tissues. N/A. prof. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. 1. Results of immunohistochemical examination: No estrogen receptors found in the neoplastic cell nuclei. No progesterone receptors found in the neoplastic cell. nuclei. HER2 protein stained with HercepTest‚Ñ¢M by DAKO. Negative reaction in invasive cancerous cells ( Score = 1+ ). dr. dr. Macroscopic description: Right breast gized 19 x 14 x 4 cm removed along with axillary tissues sized 8 x 7 x 3 cm and a skin flap of 17 x 8 cm. Tumour sized 2.5 x 2.3 x 2.0 cm in the upper outer quadrant, located 1.7 cm from the upper boundary, 0.2 cm from. the base and 0.8 cm from the skin. Microscopic description: Carcinoma ductale invasivum NHG3 (3+3+3: 24 mitoses/10 HPF - visual area: 0.55mm). Glandular tissue outside the tumour showing lesions of the type mastopathia fibrosa, adenosis simplex. Axillary lymph nodes: Sinus histiocytosis lymphonodorum (No XI). Histopathological diagnosis: Carcinoma ductale invasivum mammae dextrae. Invasive ductal carcinoma of the right breasti. (NHG3, pT2, pNO). dr. Compliance validated by: dr.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.
% Tx: If the report does not provide enough information to determine the T stage, then the T stage is Tx.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.
% Tx: If the report does not provide enough information to determine the T stage, then the T stage is Tx.",5.0,951.0,T2,"The report provides a specific tumor size of 2.5 x 2.3 x 2.0 cm, which falls within the T2 range (>20 mm but <=50 mm). The type of surgery is not specified, but there is no mention of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy. Therefore, the T stage is T2.",94.0,True
TCGA-E2-A1IO.A9D36308-DAEF-48B9-A4EC-6B9B24EE3DC2,"SPECIMENS: A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. ADDITIONAL ANTERIOR MARGIN. SPECIMEN(S): A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. ADDITIONAL ANTERIOR MARGIN. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA, Lymph node, sentinel, right axilla, biopsy: Negative for carcinoma. Part B, Right breast, Gross examination: Tumor is present at the anterior margin, and at least 0.2-cm. from posterior margin. Diagnoses called at. (A) anc. (B) by Dr. GROSS DESCRIPTION: A. SLN #1 RIGHT AXILLA. Received fresh labeled with the patient's patient and designated ""sentinel lymph node number one right. axilla"" is a fragment of lymphoid tissue measuring 1.9 X 1.2 x 0.8 cm. Touch preparation is performed. Entirely submitted, A1. B. RIGHT BREAST. Received fresh labeled with the patient's identification and designated ""right breast"" is a previously. inked, oriented, 13-g, 4 x 2.5 x 1.5 cm lumpectomy specimen. The short suture designates superior,. long-lateral. Ink code: Anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-. orange. The specimen is serially sectioned from medial to lateral into 6 slices revealing a firm tan. mass, 1.2 x 0.9 x 0.7 cm, located 0.1-cm from the nearest anterior margin. A portion of the specimen is. submitted for tissue procurement. The remainder of the specimen is entirely submitted: B1-B2: Perpendicular sections medial margin. B3-B4: Slice 2, B4 demonstrates mass. B5-B6: Slice 3, B6 demonstrates mass. B7-B8: Slice 4, B8 demonstrates mass. B9-B10: Slice 5, B10 demonstrating remainder of mass. B11-B12: Perpendicular sections lateral margin. C. ADDITIONAL ANTERIOR MARGIN. Received fresh labeled with the patient's identification and designated ""additional anterior margin"" are. two previously inked (black at final margin) fragments of adipose tissue together weighing 1 g and. measuring 2 x 1 x 0.3 cm in aggregate. The entire specimen is submitted, C1. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). B. BREAST, RIGHT, WIDE LOCAL EXCISION: INVASIVE DUCTAL CARCINOMA, SBR GRADE 3 WITH FOCAL NECROSIS, MEASURING 1.2-CM. HIGH NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID AND CRIBRIFORM TYPES WITH. CENTRAL NECROSIS, MICROCALCIFICATIONS, AND LOBULAR EXTENSION. INVASIVE TUMOR INVOLVES ANTERIOR SURGICAL RESECTION MARGIN (SEE PART C). BIOPSY SITE CHANGES WITH FIBROSIS. - SEE SYNOPTIC REPORT. C. BREAST, ADDITIONAL ANTERIOR MARGIN, EXCISION: - FATTY BREAST TISSUE, NO TUMOR SEEN. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.2cm. Margins: Negative. Distance from closest margin: 0.3cm. inferior. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0 / 1. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 10%. DCIS Type: Solid. Cribriform. DCIS Location: Associated with invasive tumor. Nuclear grade: High. Necrosis: Present. Location of CA++: DCIS. Benign epithelium. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Pending. Performed on Case: Pathological staging (pTN): pT 1c N 0. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: None given. ADDENDUM: SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: Interpretation: EQUIVOCAL. Intensity: 2+. % Tumor Staining: 30%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her? analysis was performed using the FDA approved Dako HercepTest (TM) test kit. i) using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. Pathology. Department takes full responsibility for this test's performance. PathVysion HER-2 DNA Probe Kit. Analytical Interpretation of Results: HER-2 NOT AMPLIFIED. Clinical Interpretation of results. Amplification of the HER-2 gene was evaluated with interphase fluorescence in-situ. hybridization (FISH) on formalin-fixed paraffin embedded tissue sections using a chromosome. 17 centromeric probe and a HFR-2 probe that spans the entire HER-2 gene in the F. by Dr. A majority of tumors cells displayed moderate polysomy 17. with 2 to 4 chromosome 17 signals and 2 to 4 HER-2 signals, with a HER-2/CEP 17 Ratio </=2.0,. consistent with no amplification of the HER2/neu gene. Block used. Source of case: Tissue fixation. formalin-fixed tissue. Outside Case No:NA. Tissue source. breast Results interpreted: HER2/CEP17 ratio: 1.1. This ratio is derived by dividing the total number of LSI HER-2/neu signals by the total number of. CEP17 signals in at least 20 interphase nuclei with nonoverlapping nuclei in the neoplastic. mammary epithelial cells. Cells with no signals or with signals of only one color are disregarded. Method of ratio enumeration: manual count. Limitations. The Vysis PathVysion Kit is not intended for use to screen for or diagnose breast cancer. It is. intended to be used as an adjunct to other prognostic factors currently used to predict disease-free. and overall survival in stage II, node-positive breast cancer patients. In making decisions regarding. adjuvant CAF treatment, all other available clinical information should also be taken into. consideration, such as tumor size, number of involved lymph nodes, and steroid receptor status. treatment decision for stage II, node-positive breast cancer patients should be based on HER-. 2/neu. gene amplification status alone. Overview of this test. FDA APPROVED REAGENT. PathVysion HER-2 DNA Probe Kit is FDA approved for selection of. patients for whom Herceptin¬Æ therapy is being considered. These tests were performed. of Dr.. The results of these studies should always be interpreted in the context of the. clinical, morphological, and immunophenotypic diagnosis. ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 18. CLINICAL EXPERIENCE: Patients with a recurrence score of: 18 in the clinical validation study. had an average rate of Distant Recurrence at 10 years of 11%. ER Score: 10.2 Positive. PR Score: 9.2 Positive. Her2 Score: 9.9 Negative. Interpretation: ER. Negative < 6.5. Positive >= 6.5. PR. Negative < 5.5. Positive >= 5.5. Her2 Negative <10.7 Positive >=11.5 Equivocal = 10.7 - 11.4. Microscopic/Diagnostic Dictation:,. Final Review: M.D., Pathologist. Final: M.D., Pathologist,. Addendum: M.D., Pathoiogist,. Addendum Final: M.D., Pathologist, (. Addendum:, M.D., Pathologist,. Addendum Final, M.D., Patholugiat,. Addendum, M.D., Pathologist. Addendum Final:, M.D., Pathologist,.",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.
% Tx: If the report does not provide enough information to determine the T stage, then the T stage is Tx.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.
% Tx: If the report does not provide enough information to determine the T stage, then the T stage is Tx.",5.0,951.0,T1,"The report provides a specific tumor size of 1.2 cm, which falls within the T1 range (<=20 mm). The type of surgery performed is a wide local excision, which is one of the allowed surgeries for T1. Therefore, the T stage is T1.",100.0,True
TCGA-A8-A099.34499A83-DFCE-4DB8-BAA0-A7590AF8BC07,"Diagnosis: 1. Ablated breast sample with a moderately differentiated invasive ductal carcinoma. (tumor diameter 105 cm) with focal ulceration of the skin and a satellite node. (diameter 0.9 cm) in the skin. Tumor-free dorsal resection margin. Together with the preliminary finding, this gives rise to the following tumor. classification: NOS, G II, pT4b pN3a(11/22)LOVORO. :34499A83-DFCE-4D88-BAA0-A7590AF8BC07.",3,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size. If the tumor size is also greater than 50 mm, then use the subclassification 'b' to indicate the tumor size.
% Tx: If the report does not provide enough information to determine the T stage, then the T stage is Tx.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size. If the tumor size is also greater than 50 mm, then use the subclassification 'b' to indicate the tumor size.
% Tx: If the report does not provide enough information to determine the T stage, then the T stage is Tx.",5.0,1060.0,T4,"The report mentions evidence of invasion of the chest wall ('ulceration of the skin') and provides a specific tumor size greater than 50 mm ('tumor diameter 105 cm'), which matches the criteria for T4. The specific type of surgery is not mentioned, but it is noted that the sample is an 'ablated breast sample', which suggests that a mastectomy or radical mastectomy may have been performed. However, the report does not explicitly state this, so we cannot be certain.",95.0,True
TCGA-AC-A2QJ.E422C6E8-084F-42B8-84E7-4EF387F098C7,"Sex: F. Laboratory Patient Report. Print Date/Time. Histopathological Examination. Complete: Pre-op Diagnosis : Left Breast Cancer. Specimens. : breast, left inferior skin. Breast, left. Lymph Node, Left Axillary. Lymph Node, Sentinel Left Axilla. Breast, left, inferior margin. Frozen Diagnosis : Block#. : A-1. Re-Ex?. FS-Diag. : No carcinoma identified. Comment. : none. : GROSS EXAMINATION: A. The specimen is received fresh in a container labeled. with the name of the patient and labeled as breast, left. inferior skin. Tissue: Triangular excision. Size: 0.9 x 0.9 cm. Deep: 0. 3 cm. Sutures: No. Inked No. The specimen is entirely submitted for frozen section in one. block. FROZEN SECTION DIAGNOSIS: No carcinoma identified. B. The specimen is received fresh in a container labeled. with the name of the patient and identified as breast,. left. The specimen consists of a mastectomy measuring en. bloc 19.5 x 15 x 6 cm and weighs 604 grams. There is an. anterior ellipse of skin measuring 14 x 7 cm. Medially. located on the ellipse of skin is a 5 cm areolar complex. with everted nipple. Sections of nipple areola are sampled. in block 1. 2 cm lateral to the areola is a 0.9 cm red-tan. papule which is submitted in block 2. The superficial. superior margin is inked orange and the superficial inferior. margin is inked green. The deep margin is inked blue and. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : of 4. Visit # : the specimen sectioned, showing a red-tan oval mass in the. lateral aspect of the breast. This mass measures 7 cm. greatest dimension. It grossly extends to within 0.5 cm of. the superior margin of resection which is submitted in block. 3, 0. cm of the inferior margin of resection which is. submitted in block 4, and 1 cm of the deep margin of. resection which is submitted in block 5. Additional sections. of the mass are submitted in blocks 6-9. The remaining. breast is composed of yellow lobulated adipose tissue. admixed with islands of gray-white rubbery tissue. The. breast is divided into four quadrants, upper inner, lower. inner, upper outer and lower outer and sampled in blocks. 10-13 respectively. No axillary tissue is present and no. lymph nodes are identified. Formalin fixation time is 32 hours. Ischemic time: 30 minutes. C. The specimen is received in formalin in a container. labeled with the name of the patient and labeled as lymph. node, left axillary. The specimen consists of an oval piece. of tan-pink and yellow soft tissue which measures 2. 1 x 1.8. x 1 cm. The specimen is sectioned and entirely submitted in. three blocks. D. The specimen is received in formalin in a container. labeled with the name of the patient and identified as lymph. node, sentinel left axilla. Pieces: 1. Specimen Size: 2.2 x 1.4 x 1. 1 cm. No. of Nodes: 1. Size of Nodes: 2.2 cm. The specimen is sectioned and entirely submitted in three. blocks. E. The specimen is received in formalin in a container. labeled with the name of the patient and identified as. additional left breast tissue, inferior margin. Size: 14 x 6 x 2.5 cm. Shape: Flattened oval. Spec Board: No. Radiograph: No. Sutures: Yes; short superior, long lateral. Inked: Anterior-Green, Posterior-Blue, Superior-Orange,. Inferior-Yellow, Medial-Red, Lateral- Black. Sectioning shows no discrete masses. Sections are submitted as follows : Full thickness superior. to inferior sections 1-6 with the remaining margins. submitted as follows: anterior 7, posterior 8, medial 9,. lateral 10. Formalin fixation time is approximately 30 hours. Ischemic time: Unknown. DIAGNOSIS BASED ON GROSS AND MICROSCOPIC EXAMINATION: A. Skin, left inferior breast, biopsy: - Skin with minimal patchy nonspecific chronic inflammation. - No maliqnancy identified. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : of 4. Visit # : B. Breast, left, mastectomy : - Invasive metaplastic carcinoma, grade 3 (3+3+3) 7 cm in. greatest dimension, present within 3mm (0.3 cm) of superior. margin, 5mm (0.5 cm) of inferior margin, and 10mm (1 cm) of. deep margin. - Invasive carcinoma invades dermis and is associated with. overlying epidermal ulceration. - Background nonproliferative fibrocystic including stromal. fibrosis, apocrine metaplasia, microcystic formation, and. duct ectasia. - See cancer CASA summary checklist. C. Lymph node, left axillary, biopsy: - One benign lymph node, negative for metastatic carcinoma. (0/1). - See cancer case summary checklist. D. Sentinel lymph node, left, biopsy: - One benign lymph node, negative for metastatic carcinoma. (0/1) . - See cancer case summary checklist. E. Breast, left, re-excision of inferior margin: - Benign breast tissue with nonproliferative fibrocystic. changes including apocrine metaplasia, stromal fibrosis, and. microcyst formation. - No malignancy identified. - The margins are examined microscopically and are. histologically unremarkable. - See cancer case summary checklist. CANCER CASE SUMMARY CHECKLIST. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy. LYMPH NODE SAMPLING: Sentinel lymph nodes and axillary lymph. node biopsy. SPECIMEN INTEGRITY: Multiple designated specimens (main. excision and identified margin). SPECIMEN LATERALITY: Left. TUMOR SITE (Invasive Carcinoma) : Upper and lower outer. quadrants. TUMOR SIZE: Size of Largest Invasive Carcinoma: 7 cm (70. mm) in greatest dimension. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: - Skin: Invasive carcinoma directly invades into the dermis. with associated skin ulceration. - Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: No skeletal muscle is present. DUCTAL CARCINOMA IN SITU (DCIS) : No DCIS is present. LOBULAR CARCINOMA IN SITU (LCIS) Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive metaplastic. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. carcinoma. HISTOLOGIC GRADE: NOTTINGHAM HISTOLOGIC SCORE: - Glandular (Acinar)/Tubular Differentiation. 3. - Nuclear Pleomorphism: 3. - Mitotic Count: 3. Number of mitoses per 10 high-power fields: 30. Diameter or microscope field: 0.55 mm. - Overall Grade: Grade 3 (score of 9). MARGINS: - Margins uninvolved by invasive carcinoma. - Distance of invasive carcinoma to closest margin = 3 mm. (0.1 cm), superior. - All other margins greater than 1 cm from invasive. carcinoma (including specimens A and E). LYMPH-VASCULAR INVASION: Not identified. Dermal Lymph-Vascular Invasion: Not identified. LYMPH NODES: Number of sentinel lymph nodes examined: 1. Total number of lymph nodes examined (sentinel and. nonsentinel) : 2. Number of lymph nodes with macrometastases (>0.2 cm) : 0. Number of lymph nodes with micrometastases (>0.2 mm to. 0.2 cm and/or >200 cells): 0. Number of lymph nodes with isolated tumor cells (0.2 mm and. <200 cells) : 0. Size of largest metastatic deposit: Not applicable. Extranodal Extension: Not applicable. Method of Evaluation of Sentinel Lymph Nodes: H&E, 1 level. PATHOLOGIC STAGING (pTNM) : - Primary Tumor (Invasive Carcinoma). (pT) : pT4b (skin. ulceration). - Regional Lymph Nodes (pN) : pNO (no regional lymph node. metastasis identified histologically). - Distant Metastasis (M) : Not applicable. ANCILLARY STUDIES: Estrogen Receptor: - Performed on another specimen. - Results: No immunoreactive tumor cells present. Progesterone Receptor: - Performed on another specimen. - Results: No immunoreactive tumor cells present. HER2/neu Immunoperoxidase Studies: - Performed on another specimen. - Results: Negative (score 0). Fluorescence In Situ Hybridization (FISH) for HER2/neu: - Not performed. Intradepartmental consultation obtained. M.D., Pathologist. Flantrnninallv Signed by: MD. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. of 4.",3,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size. If the tumor size is also greater than 50 mm, then use the subclassification 'b' to indicate the tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size. If the tumor size is also greater than 50 mm, then use the subclassification 'b' to indicate the tumor size.",4.0,954.0,T4,The report mentions that the invasive metaplastic carcinoma directly invades into the dermis with associated skin ulceration (pT4b).,95.0,True
TCGA-BH-A5IZ.52B5D974-2653-44CA-937D-5467EE39938B,"FINAL DIAGNOSIS: PART 1: BREAST, LEFT AT 1 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA WITH ABUNDANT LYMPHOID INFILTRATE AND TUMOR NECROSIS. B. NOTTINGHAM GRADE 3 (TUBULE FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY 3;. TOTAL SCORE 9/9). C. THE INVASIVE TUMOR MEASURES 2.2 CM IN GREATEST DIMENSION (GROSS DESCRIPTION). D. FOCAL DUCTAL CARCINOMA IN-SITU (DCIS), SOLID AND CRIBRIFORM TYPES, NUCLEAR GRADE 3,. ADMIXED WITH INVASIVE COMPONENT AND CONSTITUTES <5% OF THE TOTAL TUMOR VOLUME. E. SURGICAL RESECTION MARGINS ARE NEGATIVE FOR INVASIVE CARCINOMA, CLOSEST ANTERIOR AT. 0.4 CM AND CLOSEST POSTERIOR AT 0.5CM. F. FOCAL ATYPICAL DUCTAL HYPERPLASIA. G. FIBROCYSTIC CHANGES WITH DUCTAL EPITHELIAL HYPERPLASIA. H. PREVIOUS BIOPSY SITE CHANGES. I. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN RECEPTOR AND NEGATIVE FOR. PROGESTERONE RECEPTOR AND NEGATIVE FOR HER-2 FISH AS PER PREVIOUS PATHOLOGY REPORT. PART 2: SENTINEL LYMPH NODE #1, LEFT AXILLA, EXCISION -. TWO LYMPH NODES, NEGATIVE FOR METASTATIC CARCINOMA (0/2). PART 3: SENTINEL LYMPH NODE #2, LEFT AXILLA, EXCISION -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 4: SENTINEL LYMPH NODE #3, LEFT AXILLA, EXCISION -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 5: SENTINEL LYMPH NODE #4, LEFT AXILLA, EXCISION -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1). PART 6: NON-SENTINEL LYMPH NODE, LEFT AXILLA, EXCISION -. A. ONE LYMPH NODE, POSITIVE FOR METASTATIC CARCINOMA (1/1). B. LARGEST FOCUS OF METASTATIC TUMOR MEASURES 0.6 CM. C. NO EXTRACAPSULAR EXTENSION NOTED. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. SIZE OF TUMOR: Clock position:1:00. MULTICENTRICITY/MULTIFOCALITY OF Maximum INVASIVE dimension FOCI: invasive component: 22 mm. TUMOR TYPE (invasive component): NOTTINGHAM SCORE;. Ductal adenocarcinoma, NOS. Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 3. Total Nottingham score: 9. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Not applicable. TUMOR TYPE, IN SITU;. Cribriform. Solid. SURGICAL MARGINS INVOLVED BY INVASIVE Percent of COMPONENT: tumor occupied by in situ component: 5 %. SURG MARGINS INVOLVED BY IN SITU Distance COMPONENT: of invasive tumor to closest margin: 4 mm. LYMPH NODES POSITIVE: LYMPH NODES EXAMINED: 1. 6. METHOD(S) OF LYMPH NODE EXAMINATION: SENTINEL NODE METASTASIS: H/E stain. NON-NEOPLASTIC BREAST TISSUE: ADH, FCD. T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pT2. M STAGE: pN1a. ESTROGEN RECEPTORS: Not applicable. PROGESTERONE RECEPTORS: positive, H-score: 170. HER2/NEU: negative, H-score: 0. HER2/NEU (FISH): unknown. Not amplified.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size. If the tumor size is also greater than 50 mm, then use the subclassification 'b' to indicate the tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size. If the tumor size is also greater than 50 mm, then use the subclassification 'b' to indicate the tumor size.",4.0,954.0,T2,"The report provides a specific tumor size of 2.2 cm (greater than 20 mm but less than or equal to 50 mm) and the type of surgery performed is a segmental mastectomy, which is one of the allowed surgeries for T1 or T2 stages. However, since the tumor size is greater than 20 mm, the T stage is T2 according to the rules.",100.0,True
TCGA-B6-A0I6.2D3D759B-D06A-4FC6-855A-5E9F83ADBED9,"Material. Submitted: !eft breast with axillary contents. History: Clinical. Diagnosis: Operating. Dr. Gross Examination: The specimen is received in a single container, labeled with the patient's name, history. number, date and ""left breast and axillary contents"". Received is a breast measuring. approximately 23.0 x 16.0 x 8.5 cm. Also received is axillary contents measuring 8.0 cm. x. 9.0 cm.x 3.0 cm. There is no previous scars or other lesions on the surface of the breast. Noted grossly was a 5.0 x 5.0x 4.0 cm. mass submitted for receptors. The specimen has. been inked in blue and sectioned extensively before accessioning. Examination of the. specimen reveals a firm white nodule measuring approximately 3.5 x 3.0 cm. in two. dimensions. Gross inspection of the tumor at the deep margin does not show extension. through the deep margin grossly. Representative sections are submitted as follows: Block I: representative section of tumor to show deep margin. Block II: representative section of tumor to show deep margin. Blocks III and IV: representative sections of the tumor. Palpation of the remainder of the breast does not reveal any separate nodules from the. main tumor region. From the main mass, a couple of satellite nodules are noted that appear. to be contiguous with the main mass. A section of this area is submitted in Block V. Block VI: representative section of nipple. Block VII: representative section of skin over tumor. Block VIII: random sample of upper inner quadrant. Block IX: random sample of lower inner quadrant. Block X: random sample of upper outer quadrant. Block XI: random sample of lower outer quadrant. The axillary contents are separate from the remainder of the specimen and palpated for. lymph nodes. Lymph node candidates are submitted from the inferior to the superior. direction. They are submitted as follows: Block XII: two lymph node candidates. Block XIII: three lymph node candidates. Block XIV: three lymph node candidates. Block XV: five lymph node candidates. Block XVI: three lymph node candidates. Block XVII: three lymph node candidates. Block XVIII: five lymph node candidates. (Continued on. rag√© 2. Dr. Dr. (Continuation from page 1). Block XIX: five lymph node candidates. Block XX: three lymph node candidates. Block XXI: five lymph node candidates. Block XXII: five lymph node candidates. Block XXIII: three lymph node candidates. Block XXIV: three lymph node candidates. MICROSCOPIC: The apparent satellite nodules seen grossly (Block 5) consist of sclerosis and. hemangioma (so-called ""peritubular hemangioma""). Portions of the. carcinoma have intermediate grade nuclei, but areas have a high grade nuclear pattern. DIAGNOSIS: #i""LEFT"" BREAST, MASTECTOMY: A. LARGE (5.0 x 5.0 x 4.0 CM.) INFILTRATING DUCTAL. CARCINOMA, N.S.A.B.P. NUCLEAR GRADE POORLY. DIFFERENTIATED, HISTOLOGIC GRADE 3 OF 3. 13. FOCAL INTRATUMORAL INTRADUCTAL CARCINOMA. C. PROMINENT VASCULAR INVASION BY CARCINOMA. D. NO CARCINOMA IDENTIFIED IN SURGICAL MARGINS. E. HEMANGIOMA. F. FIBROCYSTIC CHANGES: 1. MARKED DUCTAL EPITHELIAL HYPERPLASIA. 2. PAPILLARY APOCRINE METAPLASIA. 3. DUCT ECTASIA. 4. SCLEROSIS. #2 ""LEFT"" AXILLARY DISSECTION: A. METASTATIC CARCINOMA IN 6 OF 32 LYMPH NODES. B. FOCAL CARCINOMA IN PERINODAL BLOOD VESSELS.",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T2,"The report mentions a mastectomy, which indicates a T3 or T4 stage. However, it does not provide evidence of invasion of the chest wall or skin, nor does it mention a tumor size greater than 50 mm. The tumor size is within the T2 range (>20 mm but <=50 mm) and there is no mention of breast surgery other than mastectomy. Therefore, we cannot classify it as T3, so it must be T2.",94.0,True
TCGA-A8-A0A6.161A2735-C3CF-466D-AE21-C6A2C987BB1E,"Diagnosis: 1. Moderately differentiated invasive lobular carcinoma with focal in situ spread and. angioinvasion (tumor diameter 3.0 cm). Concluding tumor classification: lobular carcinoma, G II, pT2N3a(15/19)L1V0R0.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T2,"The report provides a specific tumor size (3.0 cm) which falls within the T2 range (>20 mm but <=50 mm). The type of surgery is not specified, but there is no mention of invasion of the chest wall or skin, so the T stage is T2.",100.0,True
TCGA-BH-A1EX.FA86A743-EA67-4554-ABA2-BB8C1DBDB0B1,"PATIENT HISTORY: SPECIMENS TAKEN BY PATH DATE of LMP: (NOT LISTED ON REQUISITION). DATE or LAST DELIVERY: PRE-OP DIAGNOSIS: RIGHT BREAST CANCER. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: R SENTINEL LYMPH NODE, R SEGMENTAL MASTECTOMY. CLINICAL HISTORY: SPECIMENS TAKEN BY PATH. MATERIAL SUBMITTED: A) RIGHT SENTINEL LYMPH NODE, PROCUREMENT BY SURGICAL PROCEDURE. B) RIGHT BREAST BICPSY/TISSUE, PROCUREMENT BY SURGICAL PROCEDURE. Long-lat,med-med, sht-superior. INTRAOPERATIVE CONSULTATION: R SENTINEL LYMPH NODE #1: One lymph node, 0.8 by 0.6 by 0.5 cm. Touch Prep. Diagnosis: Negative. ADDENDA: Addendum. FISH analysis using DNA probe for Her-2/neu gene showed that, the ratio of Her-2/neu signals to chromosome 17. centromere signais is 0.94 (> 2.0 ratio is considered amplified). Therefore, Her-2/neu gene is not amplified. Bv Pathologi. My signature is attestation that I have personally reviewed the submitted material(s) and the above diagnosis reflects that evaluation. Addendum. MATERIAL SUBMITTED: BLOCK ""B3"" FOR ER/PR AND HER-2/NEU (BREAST CANCER). FINAL DIAGNOSIS: ESTROGEN/PROGESTERONT RECEPTORS AND HER-2/NEU PERFORMED ON RIGHT BREAST TISSUE. ESTROGEN RECEPTOR (0- 40%; 1+ 40%; 2+ 10%; 3+ 10%) HSCORE OF 90. ESTROGEN RECEPTOR IS INTERPRETED AS. POSITIVE. PROGESTERONS RECEPTOR (0- 70%; 1+ 10%; 2+ 10%; 3+ 10%) HSCORE OF 60. PROGESTERONI RECEPTOR IS INTERPRETED AS. POSITIVE. HER-2/NEU-DAKO HERCEPTEST. A WEAK TO MODERATE COMPLETE MEMBRANE STAINING IS OBSERVED IN MORE THAN 10% OF THE. TUMOR CELLS. HER-2/NEU IS INTERPRETED AS POSITIVE (SCORE 2+). HSCORE: <= 15 NEGATIVE. >15<=30 BORDERLINE. FINAL DIAGNOSIS: FINAL DIAGNOSIS: A) RIGHT SENTINEL LYMPH NODE #1: - MICROMIETASTATIC DUCTAL CARCINOMA OF THE BREAST (SEE NOTE). B) RIGHT SEGMENTAL MASTECTOMY: INFILTRATING MODERATELY DIFFERENTIATED DUCTAL CARCINOMA) NOTTINGHAM SCORE 6/9 (TUBULES=3, NUCLEI=2,. MITOSIS-1) SIZE 2.5 BY 2.0 BY 1.5 CX. - DUCTAL CARCINOMA IN SITU, NON-COMEDO TYPE, SOLID AND CRIBRIFORK) NUCLEAR GRADK 1, CONSTITUTES 5% or. ENTIRE. TUMOR MASS. - SEVERAL MICROSCOPIC FOCI OF INFILTRATING ADENOCARCINOMA, UP TO 0.5 CM, IN THE REMAINING BREAST TISSUE. #9, #12). - LATERAL AND INFERIOR SURGICAL MARGINS POSITIVE FOR INVASIVE TUMOR. - INTRADUCTAL PAPILLOMA AND PROLIFERATIVE FIBROCYSTIC CHANGES IN THE REMAINING BREAST TISSUE. FOCAL NECROSIS AND GRANULATION TISSUL, STATUS-POST CORE BIOPSY or BREAST (CROSS REFER. NOTE: Minute clusters of metastatic ductal carcinoma was found in serial section ""Al"", but it ie best. visualized with the immunoperoxidase stain AB1/AR3 in serial section A2. The immunostain was repeated and. the presence of metastatic neoplastic cells in the lymph node section ""Al"" was confirmed by. immunostaining (""A26A3""). The later serial sections of the lymph nodes are negative. The touch prep of. the. sentinel node was re- reviewed and no malignant cells are identified ER/PR immunoperoxidase assay and Her-. 2/NEU testing will be performed on block ""B3"". The special stains and/or immunoperoxidase tests used in thi ~ase hatra bean and their performance. characterietics determined by the Department of Pathology at. They have not been cleared or approved by the U.S. Food and Drug Administration.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T2,"The report mentions the size of the tumor as 2.5 by 2.0 by 1.5 cm, which falls within the T2 range (>20 mm but <=50 mm). The type of surgery performed is a segmental mastectomy, which is one of the allowed surgeries for T2. The report also mentions multifocal tumor, but since the size is already established as T2, the subclassification 'mult' is not added to the T stage.",100.0,True
TCGA-A8-A07G.1ED901DF-BCDC-44C8-A7DF-AB895ECA0952,"Diagnosis: 1. Moderately differentiated invasive ductal carcinoma with discrete intraductal. spread (tumor diameter 1.9 cm). In conjunction with the preliminary finding, this gives rise to the following tumor. classification: NOS, G II, pT1cN1aLOVORO.",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T1,"The report provides a specific tumor size of 1.9 cm, which falls within the T1 range (<=20 mm). The type of surgery performed is not specified, but it is mentioned that there is no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy. Therefore, the T stage is T1.",100.0,True
TCGA-AC-A2FE.F694CBD6-880D-40C7-AB17-D0AD02B7F06B,"Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. SEE REPORT. ADDENDUM INFORMATION. PROCEDURE DATE: ADDENDUM REPORT #1: COMMENT: Immunoevaluation using. Assisted Quantitative Image Analysis has been. completed and is summarized under line 10 of the diagnosis below. T: ADDENDUM REPORT #1; DIAGNOSIS: A, B/BPC & C. RIGHT BREAST, MASTECTOMY WITH SENTINEL LYMPH NODE BIOPSY AND. FOLLOW UP AXILLARY DISSECTION: 1 - 9. SEE ORIGINAL DIAGNOSIS. 10. ANCILLARY STUDIES: SEE BELOW. ASSAY RESULTS. Test. Staining Intensity. % Positive Avg. Prognostic Significance. ER. N/A. 66%. Favorable. PR. N/A. 7%. Favorable. Her2/neu. 0.4. N/A. Normal Limit. Ki-67. N/A. 11%. Borderline. REFERENCE RANGES. Test. Favorable. Borderline. Unfavorable. ER. >5%. <5%. PR. >5%. Her2/neu. <2.0. >2.0. Ki-67. <10%. >10% - <20% -. >20%. A-MALIGNANT. MD. T: (Electronic Signature). PROCEDURE DATE: SPECIMEN DESCRIPTION: A. RIGHT BREAST. B. RIGHT AXILLARY SENTINEL LYMPH NODE, BPC. C. RIGHT AXILLARY NODE. PRE-OPERATIVE DIAGNOSIS: Right breast carcinoma. POST-OPERATIVE DIAGNOSIS: Same, pending pathology consultation. ====. CLINICAL INFORMATION: Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. Right breast) upper outer quadrant, needle aspirate biopsy diagnosed as. fibrocystic change, proliferative ductal epithelium, fibrosis, and scattered. inconspicuous atypical cells suspicious for lobular carcinoma. INTRAOPERATIVE CONSULTATION: BPC DIAGNOSIS: "" (Smear) Lymph node positive for carcinoma"" by Dr. GROSS DESCRIPTION: A. The specimen consists of the right breast, measuring 21 X 20 X 5.5 cm and. weighing 1067 grams. No axillary tail is attached. No orientation is. provided. The breast is covered with an ellipse of tan-white skin, measur ng. 17 x 7 cm. The nipple is retracted and measures 0.8 x 0.8 x 0.4 cm. No. discrete ulceration, fissure, or exudate is identified. The nipple is. surrounded by unremarkable tan-brown areola. Approximately 2.2 cm away from. the nipple is a poorly defined, slightly raised tan-brown area. measuring 0.7. X 0.6 cm. No discrete scar is identified. The deep surface reveals a large. mechanical defect, measuring 5 X 2 cm and 3 cm in depth. The specimen appears. to have been sectioned by the surgeon. The deep surface is inked black and. the specimen is serially sectioned. The sections show a very poorly. circumscribed, tan-white fibrotic area, measuring approximately 4.5 X 3.5. 3.5 cm. The fibrotic area reveals a well defined irregular mass, measuring. 2.5 X 2.0 x 1.6 cm and a hemorrhagic area. measuring 0.7 cm in greatest. dimension. The mass is composed of tan-white firm tissue and is approximately. 1.4 cm from the deep margin. One possible intramammary lymph node, measuring. 1.2 cm in greatest dimension, is identified. The lymph n√≥de is bisected and. no discrete neoplastic involvement is present. The surgical resection margins. are unremarkable. Separately received in the same container are five portions. of irregular tan-yellow adipose tissue, measuring 5 X 5 X 1 cm in aggregate. No discrete lesion or lymph node is identified in the separate portions. Representative sections are submitted in thirteen cassettes as follows: cassette 1 - mass with deep margin: cassettes 2 and 3 - additional sections. of. mass; cassettes 4 through 6 - random sections from the fibrotic area, away. from the mass; cassettes 7 through 10 - sections from the four quadrants;. cassette 11 - lymph node: cassette 12 - nipple and tan-brown area of the skin;. cassette 13 - random sections from the separate portions. B/BPC. The specimen consists of one portion of tan-yellow adipose tissue,. measuring 5 X 4 X 2 cm. The specimen has been bisected in pathology. consultation. The specimen is serially sectioned and four possible lymph. nodes. ranging from 0.5 CID to 2.5 cm in greatest dimension, are identifted. The two largest lymph nodes appear to be involved by neoplasm. Representative. sections submitted in three cassettes as follows: cassette 1 - two. intact. lymph nodes; cassette 2 - one lymph node; cassette 3 one lymph node. are -. C. The specimen consists of multiple portions of tan-yellow adipose tissue,. Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. measuring 8 X 8 X 2 cm in aggregate. On palpation, fifteen possible Tymph. nodes, ranging from 0.2 cm to 1.5 cm in greatest dimension, are identified. Three lymph nodes are grossly involved by neoplasm. Representative sections. are submitted in four cassettes as follows: cassette 1 - six intact lymph. nodes: cassette 2 - one bisected lymph node; cassette 3 - .three lymph nodes: cascatts 4 - five intact lymph nodes. MICROSCOPIC DESCRIPTION: A, B/BPC, & C. Serial sections in twenty slides are examined. Sections from. specimen A show breast within an extensively infiltrating mammary lobular. carcinoma, focally with pleomorphic features. Tumor is widely infiltrative: closest approach to deep margin is approximately 9 mm. Maximum tumor size is. difficult to assess on glass slides alone, but combining the grossly evident. tumor mass with the additional fibrotic areas, all of which are involved by. carcinoma of the gross impression of up to 4.5 cm is felt to b√© accurate as. a. true assessment of the infiltrative tumor. The intramammary lymph node. sampled in block A11. as well as seventeen additional lymph nodes submitted as. parts B/BPC & C are all extensively involved by metastatic carcinoma. morphologically identical to the mammary primary. There is also evidence of. extranodal spread involving the soft tissue surrounding several of the lymph. nodes. T: FINAL DIAGNOSIS: A, B/8PC & C. RIGHT BREAST? MASTECTOMY WITH SENTINEL LYMPH NODE 8IOPSY AND. FOLLOW UP AXILLARY DISSECTION: 1. TUMOR TYPE: INFILTRATING CARCINOMA, LOBULAR PHENOTYPE el. 2. NOTTINGHAM PROGNOSTIC INDEX/GRADE: II (TUBULE SCORE -. 3;. NUCLEAR SCORE - 3;. MITOTIC SCORE - 1). 3. MAXIMUM INVASIVE TUMOR SIZE: APPROXIMATELY 4.5 CM, GROSS. PLUS MICROSCOPIC DATA. COMBINED; SEE DESCRIPTION. 4. PERCENT DCIS: NOT APPLICABLE. 5. LYMPHVASCULAR INVASION: NONE SEEN. 6. DISTANCE TO CLOSEST MARGIN: 9 MM. DEEP. BLOCK A1. 7. MICROCALCIFICATIONS: NOT APPLICABLE. 8. LYMPH NODES: EIGHTEEN OF EIGHTEEN LYMPH NODES INVOLVED BY. METASTATIC CARCINOMA WITH EXTRANODAL SPREAD. OF TUMOR. 9. TNM STATUS: pT3,N3a,MX. 10. ANCILLARY STUDIES: IMMUNOHISTOCHEMICAL EVALUATION IS. PENDING; AN ADDENDUM REPORT WILL BE. Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. : Surgical Report. ISSUED. COMMENT: The fine needle aspiration report from. is reviewed in conjunction. with the slides. A-MAI IGNANT. (Electronic Signature). DATE AND TIME OF REPORT:",2,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T3,"The report mentions that the tumor is an extensively infiltrating mammary lobular carcinoma with a maximum invasive tumor size of approximately 4.5 cm. It also mentions that a mastectomy was performed. Based on the rules provided, this meets the criteria for a T3 stage as it mentions a mastectomy and provides a specific tumor size greater than 50 mm.",100.0,True
TCGA-A7-A13E.2180850C-CC8D-4376-B2EE-1ADC3F5B3EC1,"PECIMEN. A. Left sentinel node. B. Left breast tissue. C. Axillary contents. CLINICAL NOTES. PRE-OP DIAGNOSIS: Left breast cancer. CLINICAL HISTORY: Left breast cancer. FROZEN SECTION DIAGNOSIS. FSA) Left sentinel node - Two of three lymph nodes positive for. metastatic carcinoma (2/3). GROSS DESCRIPTION. A. Submitted fresh for frozen section as ""left sentinel. node"" are two portions of fatty tissue, the larger of the. two is 2 cm. in size, the smaller 1.2 cm. in size. The section. through the tissue reveals three small nodules which may be lymph. nodes varying in size from 6 mm. to a centimeter. All three. submitted for frozen section. B. Received fresh, subsequently fixed in formalin labeled. ""left breast tissue"" is a 7.8 x 7.5 X 4.0 cm. yellow. lobular fatty tissue fragment which is partially covered with a 4.0. X 1.2 cm. pink-tan wrinkled skin ellipse. The specimen has a long. suture designating lateral and a short suture designating superior. The specimen is inked as follows: Superior orange, anterior blue,. posterior black, inferior green and the specimen is sectioned from. medial to lateral to show a yellow lobular fatty cut surface with. minimal fibrous tissue. There is also a white tan firm nodule. which. is centrally located, measuring 3.5 x 2.5 x 2.5 cm. This comes. within 2 cm. of superior-inferior margin and comes within 1.5 cm. of. the anterior and posterior margin. This was located equal distance. between the medial and lateral margins. Representative sections of. the specimen are submitted as follows: Block 1 - representative. GROSS DESCRIPTION. medial margin; block 2 - representative lateral margin; block 3-10. representative sections additional margins and skin. RS-10. C. Received fresh, subsequently fixed in formalin labeled. ""axillary content"" is a 7 X 6 X 1.5 cm. aggregate of. yellow. lobular fatty tissue fragments which are palpated to identify. possible lymph nodes. Multiple lymph nodes are grossly identified. which range from 0. cm. to 2.0 cm. in greatest dimension. The. lymph nodes are entirely submitted as follows: block 1 - two. possible lymph nodes; block 2 - three possible lymph nodes; block 3. - two possible lymph nodes; block 4 - one possible lymph node. bisected. RS4. MICROSCOPIC DESCRIPTION. A. Sections of the left sentinel lymph nodes demonstrate. metastatic carcinoma involving 2 of 3 lymph nodes. The. largest metastasis is 1.2 cm and extracapsular extension is. present. B. The following template applies to the left breast. Invasive Carcinoma: Present. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Overall grade: 3. Architectural score : 3. Nuclear score: 3. Mitotic score: 3. Greatest dimension: 3.5 cm (pT2). Specimen margins : Negative, nearest 1.3 cm, posteriorly. Vessel invasion: Present. MICROSCOPIC DESCRIPTION. Calcification : Present. Ductal carcinoma in situ: Present. Histologic pattern: Solid and comedo. Nuclear grade: 3. Central necrosis: Present. %DCIS of total tumor: Less than 10%. Extensive intraductal component (present/absent) : Absent. Specimen margins: Negative. Calcification: Present. Description of non-tumorous breast: Proliferative changes. Comments: None. Prognostic markers: Previously performed. C. There is no evidence of metastatic disease present in. 9. additional left axillary lymph nodes. 14, 4x3. DIAGNOSIS. A. Left axillary sentinel lymph nodes, excision: Metastatic carcinoma present in 2 of 3 lymph nodes (2/3) . Size of largest metastasis 1.2 cm. Extracapsular extension present. B. Left breast, excisional biopsy: Infiltrating ductal carcinoma, grade 3, 3.5 cm, margins. negative. Ductal carcinoma in situ, grade 2, margins negative. C. Left axillary contents, resection: No evidence of metastasis in nine lymph nodes (0/9). DIAGNOSIS. M. .D, (Electronic Signature). End Of Report ---.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, then the T stage is T1.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",4.0,845.0,T2,"The report mentions the size of the tumor as 3.5 cm, which falls within the T2 range (>20 mm but <=50 mm). The type of surgery performed is an excisional biopsy, which is not specified in the rules as indicating a specific T stage. However, the rules do not specify that a particular type of surgery is required for a T2 stage, only that the tumor size must fall within the T2 range. Therefore, the T stage for this report is T2.",100.0,True
TCGA-E2-A1IJ.35F7D0D1-BA21-4135-B444-6B10EAF66F25,"SPECIMENS: A. RIGHT BREAST CANCER. B. ADDITIONAL LATERAL MARGIN. C. SENTINEL LYMPH NODE #1. D. SENTINEL LYMPH NODE #2. E. SENTINEL LYMPH NODE #3. SPECIMEN(S): A. RIGHT BREAST CANCER. B. ADDITIONAL LATERAL MARGIN. C. SENTINEL LYMPH NODE #1. D. SENTINEL LYMPH NODE #2. E. SENTINEL LYMPH NODE #3. INTRAOPERATIVE CONSULTATION DIAGNOSIS: Part A, Right breast, gross examination: Tumor is 1 cm from anterior/inferior/ medial margin. TPC - TPE, Sentinel lymph nodes #1 - #3: Negative for carcinoma. Diagnoses called to Dr. at. 1. (A) and. . (C-E) by Dr. GROSS DESCRIPTION: A. RIGHT BREAST CANCER. Received fresh labeled with the patient's identification and designated ""right breast"" is an oriented, 74-g,. 7.6 x 6 x 4.3 cm needle localized lumpectomy specimen with two radiographs. The single suture. designates anterior, double-lateral, triple-superior. Ink code: Anterior-yellow, posterior-black, medial-. green, lateral-red, superior-blue, inferior-orange. The specimen is serially sectioned from medial to. lateral into 6 slices, revealing a firm tan mass with granular cut surface, 2 x 1.2 x 1 cm, located 0.8 from. the closest inferior margin. A clip is identified in slice 3. The remainder of the specimen shows areas of. firm dense fibrous focally cystic parenchyma. A portion of the specimen is submitted for tissue. procurement. Submitted representatively: A1: Medial margin. A2-A3: Mass and anterior, slice 2. A4-A5: Mass and medial, slice 2. A6-A7: Mass, inferior / anterior, slice 3. A8-A9: Inferior/posterior, slice 3. A10: Superior, slice 3. A11: Posterior, slice 3. A12: Mass, inferior/ anterior, slice 4. A13: Inferior/anterior, slice 5. A14: Inferior/posterior, slice 5. A15-A16: Lateral margin. B. ADDITIONAL LATERAL MARGIN. Received in formalin in a container labeled with the patient's identification and designated ""additional. lateral margin"" is an oriented (suture at final margin) 8-g, 4.1 x 4 X 0.5 cm fragment of fibroadipose. tissue. The final margin inked black. Sectioning shows nodule measuring 0.5-cm. Submitted entirely: B1-B3: Serial sections. B4: Nodule. B5: Serial sections. C. SENTINEL LYMPH NODE #1. Received fresh labeled with the patient's identification and designated ""Sentinel lymph node #1"" is a. fragment of fibroadipose tissue, 3 x 2.3 x 1.1 cm showing one possible 2-cm lymph node. Touch. preparation is performed. The lymph node is entirely submitted in cassette C1. D. SENTINEL LYMPH NODE #2. Received fresh labeled with the patient's identification and designated ""Sentinel lymph node #2"" is a. fragment of fibroadipose tissue, 3 x 1.5 x 1 cm, showing a possible 2.3-cm lymph node. Touch. preparation is performed. The lymph node is entirely submitted, D1. E. SENTINEL LYMPH NODE #3. Received fresh labeled with the patient's identification and designated ""Sentinel lymph node #3"" is a. fragment of fibroadipose tissue, 3.1 x 2.2 x 1.1 cm, showing a possible 1.5-cm lymph node. Touch. preparation is performed. The lymph node is entirely submitted, E1. DIAGNOSIS: A. BREAST, RIGHT, WIDE LOCAL EXCISION: - INVASIVE LOBULAR CARCINOMA, SBR GRADE 2, MEASURING 1.5-CM. - LOBULAR CARCINOMA IN SIT√ú. - SURGICAL RESECTION MARGINS NEGATIVE FOR INVASIVE TUMOR. - LCIS PRESENT AT LATERAL AND MEDIAL SURGICAL RESECTION MARGINS AND WITHIN 1 MM. FROM INFERIOR SURGICAL RESECTION MARGIN. - BIOPSY SITE CHANGES WITH FIBROSIS. - FIBROADENOMA. - SEE SYNOPTIC REPORT AND SEE NOTE. B. BREAST, RIGHT, LATERAL MARGIN, EXCISION: - INVASIVE LOBULAR CARCINOMA, SBR GRADE 2, MEASURING 0.6-CM. - LOBULAR CARCINOMA IN SITU. - LCIS PRESENT WITHIN 1 MM FROM FINAL LATERAL MARGIN. - INVASIVE TUMOR PRESENT 2.5 MM FROM FINAL LATERAL MARGIN. - SEE NOTE. C. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. LYMPH NODE, SENTINEL #2, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). E. LYMPH NODE, SENTINEL #3, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). NOTE: The in situ and invasive tumors are negative for E-cadherin, compatible with lobular carcinoma. phenotype. In part A., the main tumor mass is identified in slices #2 and 3. However, additional. scattered foci of invasive lobular carcinoma are identified in slices #4, 5, 6 and 7. Moreover, the. additional submitted lateral margin (part B.) shows invasive lobular carcinoma (0.6-cm). Therefore, this. tumor is considered multifocal. Lobular carcinoma in situ is identified throughout the submitted. sections. The closest surgical resection margin to invasive lobular carcinoma is the lateral (2.5 mm). LCIS is. identified at medial and within 1 mm from inferior and lateral surgical resection margins. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Yes - For mass. Laterality: Right. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive lobular carcinoma 8520/3. Tumor size: 1.5cm. Tumor Site: Not specified. Margins: Negative. Distance from closest margin: 0.25cm. lateral. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: LCIS. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0/3. DCIS not present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative by FISH. Performed on Case: s09-118. Pathological staging (pTN): pT 1c NO. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: .,. Final Review: Pathologist,. Final: "", Pathologist,.",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1mult: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is multifocal, then the T stage is T1mult.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1mult: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is multifocal, then the T stage is T1mult.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",5.0,1137.0,T1c,"The report provides a specific tumor size of 1.5 cm, which falls within the T1 range (<=20 mm) for T1 cancers. However, since the tumor is multifocal, the subclassification 'mult' is used to indicate the multifocality. Therefore, the T stage is T1mult.",85.0,True
TCGA-OL-A5S0.EDF80CFD-4115-48E9-BF76-DDE957A97AEB,"FINAL PATHOLOGIC DIAGNOSIS. A. Breast, right, modified radical mastectomy: - Invasive ductal carcinoma, grade III/III, 5.0 cm in greatest dimension,. present 1.0 mm from posterior inked surgical margin, other margins widely free. (see pathologic parameters and comment below). Ductal carcinoma in-situ, high grade, solid type with associated central. necrosis and calcifications, surgical margins negative. - Previous biopsy site identified. - Metastatic carcinoma involving two of twelve lymph nodes (2/12). B. Breast, right, deep margin re-excision: - Skeletal muscle and fibroadipose tissue, negative for carcinoma. C. Breast, right 'additional tissue under superiomedial skin flap,' excision: - Breast and fibroadipose tissue, negative for carcinoma. D. Skin, right 'chest wall at corner of incision,' excision: - Skin and fibroadipose tissue, negative for carcinoma. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Gross measurement: 5.0 cm. B. Composite histologic (modified SBR) grade: III/III. C. Associated intraductal carcinoma in situ (DCIS). - High grade, solid type with associated central necrosis and. calcifications. - Within main mass. 2. Surgical margins: Free of tumor. - DCIS 3.0 mm from closest margin (posterior). - Invasive carcinoma 1.0 mm from closest margin (posterior) on mastectomy,. separately submitted deep margin re-excision (specimen B) negative for carcinoma. - Additional margins widely free. 3. Blood vessel and lymphatic invasion: Present. 4. Nipple: Uninvolved. 5. Skin: Uninvolved. 6. Skeletal muscle: Focally involved. 7. Axillary lymph nodes: Metastatic carcinoma involving two of twelve lymph. nodes (2/12). - Size of largest metastatic deposit: 1.1 cm. - Extranodal extension: Present (2.0 mm). 8. Special studies . - ER: Weak expression in 30% of invasive tumor nuclei. - PR: No expression in invasive tumor nuclei. - Ki-67: 50% proliferation rate. - Her2/neu antigen (FISH): Amplified (ratio: 3.8). 9. pTNM (AJCC, 7th edition, 2010): pT2, N1a, MX. Clinical History: The patient is a. year-old female with right breast invasive ductal carcinoma. with axillary nodal metastases who undergoes right modified radical mastectomy. Comment. The 5.0 cm mass identified on gross examination is comprised of both invasive. and in-situ carcinoma with extensive necrosis and calcifications. Specimens Received: A: Right breast and axillary contents. B: Additional deep margin. C: Additional tissue under superiomedial skin flap. D: Skin at corner of incision; r chest wall. Gross Description: The specimens are received in four containers each labeled with the patient's. name and medical record number. A. The first container is additionally identified as, 'right breast and. axillary contents'. Received fresh and placed in formalin is a 730 g simple. mastectomy specimen. The specimen is oriented with a double short suture. designating the superior aspect and a double long suture designating the lateral. aspect. The breast measures 23 cm from medial to lateral, 21 cm from superior. to inferior, and 4.5 cm from anterior to posterior. On the anterior surface is. 20 X 8.5 cm ellipse of skin with a 4.2 X 4.0 cm areola and a 1.3 X 1.3 X 0.5 cm. nipple. The nipple-areolar complex reveals no evidence of ulceration or. retraction. There is an attached 6.5 X 5.5 X 1.5 cm portion of apparent axillary. tail on the lateral aspect of the specimen. There is an attached 4.5 X 1.8 X 0.2. cm skeletal muscle consisting of pectoralis at the deep margin at junction of. upper-outer quadrant and lower-outer quadrant in slice3-5 The specimen is. inked as follows: anterior-superior - blue;. anterior-inferior - green;. posterior - black. The specimen is serially sectioned from lateral (slice #1) to medial (slice #11). to reveal a 5.0 X 3.8 X 3.5 cm pink-tan, firm mass (lesion #1) extending from. upper-outer quadrant to lower-outer quadrant in slices 3-7. The mass is 1.6 cm. from the anterior-inferior margin and abuts the posterior margin. Surrounding. the mass is a 10x7x4 cm ill-defined, pink area composing of dilated ducts. and fibrotic tissue in slices 4-9 and the most prominent in slice 7-8. The. ill-defined area (lesion #2) extends towards anterior aspect and is 0.6 cm from. the closest anterior margin and 2.0 cm from the closest posterior margin. The. remainder of the specimen consists of approximately 10% dense gray-white fibrous. breast parenchyma and 90% lobulated yellow adipose tissue. No additional masses. or nodules are grossly identified. Within the axillary tail are identified. several lymph node candidates measuring from 0.3-2.5 cm in greatest dimension. Block summary: A1: Lesion #1, slice 3. A2: Lesion #1, slice 4. A3: Lesion #1 abutting posterior margin, slice 5. A4: Lesion #1, slice 6. A5: Lesion #1, slice 7. A6: Lesion #2, slice 4. A7: Lesion #2, slice 5. A8: Lesion #2, slice 6. A9: Lesion #2, slice 7. A10: Lesion #2, slice 8. A11: Lesion #2, slice 9. A12: Representative adjacent medial to lesion #2, slice 10. A13: Representative adjacent lateral to lesion #2, slice 3. A14: upper-outer quadrant slice 2. A15: lower-outer quadrant slice 1. A16: upper-inner quadrant slice 11. A17: lower-inner quadrant slice 10. A18: nipple. A19: skin. A20: One lymph node. A21-A23: 4 lymph node candidates, each cassette. A24-A26: One lymph node, serial section. B. The second container is additionally identified as, 'additional deep margin;. underlying palpable tumor : Received in formalin is a 3.9 g, 4.2 X 2.2x0.8 cm. yellow-tan, soft tissue fragment with one short stitch designating as new true. deep margin (inked blue) and attached clips on original margin (inked black). The specimen is serially sectioned and entirely submitted as B1-B5. C. The third container is additionally identified as, 'additional tissue under. superiomedial skin flap'. Received in formalin is an unoriented 2.3 g, 4.8 X 1.2. x 1.1 cm portion of yellow-tan fibroadipose tissue, which is serially sectioned. and entirely submitted C1-C2. D. The fourth container is additionally identified as, 'skin at corner of. incision; right chest wall'. Received fresh and placed in formalin is an. unoriented V-shaped ellipse of wrinkled, tan-brown skin measuring 4.5 X 1.5 cm. adjunct with 3.2 X 1.5 cm excised to a depth of 1.3 cm. The specimen is serial. sectioned and review grossly unremarkable parenchyma. The representative section. is submitted as D1. Tissue fixed for at least 6 hours in 10% NBF and no more than 72 hours.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1mult: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is multifocal, then the T stage is T1mult.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1mult: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is multifocal, then the T stage is T1mult.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",5.0,1137.0,T2,"The report provides a specific tumor size of 5.0 cm, which falls within the T2 range (>20 mm but <=50 mm). The type of surgery performed is a modified radical mastectomy, which is a breast surgery other than lumpectomy, wide excision, segmental mastectomy. The tumor size is greater than 20 mm, so the T stage is T2.",100.0,True
TCGA-A8-A08J.C1D59BA7-FC3E-46EA-B095-3B6DF42892B0,"Diagnosis: Ablated (right) breast sample with moderately differentiated invasive and focal ductal. 1. discrete intraductal components, angioinvasion resection ulceration of. the carcinoma skin. Tumor with size at least 7 cm. Paget's disease of the nipple. Dorsal. margin tumor-free. Tumor classification: NOS, G II, pT4bN1aL1 1VORO.",3,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1mult: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is multifocal, then the T stage is T1mult.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1mult: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is multifocal, then the T stage is T1mult.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",5.0,1137.0,T4,"The report mentions 'Tumor with size at least 7 cm' which falls within the T4 range (>50 mm) and provides evidence of invasion of the chest wall or skin ('ulceration of the carcinoma skin'). Therefore, the T stage is T4, regardless of tumor size.",100.0,True
TCGA-S3-AA10.6A981CB0-F551-48B1-AB91-5D5585A7F282,"Temporary Copy. Diagnosis. A. RIGHT BREAST, MASTECTOMY: - HIGH-GRADE INVASIVE DUCTAL CARCINOMA; SEE SYNOPTIC REPORT. - NEGATIVE MARGINS. - SKIN AND NIPPLE WITHOUT SIGNIFICANT PATHOLOGIC ABNORMALITY. - FOUR LYMPH NODES, NEGATIVE FOR TUMOR (0/4); SEE SPECIAL STAINS. (Electronic signature). Verified: Synoptic Report. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Greatest dimension of largest focus of invasion over 0.1 cm: 2.5 cm. Additional dimensions: 2.5 x 1.5 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: Skeietal muscle is present and is free of carcinoma. DUCTAL CARCINOMA IN SITU (DCIS): No DCIS is present. LOBULAR CARCINOMA IN SITU (LCIS): Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTIATION: Score 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape,. occasionally with very large and bizarre forms. MITOTIC COUNT: Score 3. Number of mitoses per 10 high-power fields: 88. Diameter of microscope field: 0.55 mm. OVERALL GRADE: Grade 3: scores of 8 or 9. MARGINS: Margins uninvolved by invasive carcinoma. Distance from anterior margin: 4.0 mm. Distance from posterior margin: 2.0 mm. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE BREAST: No known presurgical therapy. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE LYMPH NODES: No known presurgical therapy. LYMPH-VASCULAR INVASION: Not identified. Temporary Copy. DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Total number of lymph nodes examined (sentinel and nonsentinel): 4. Number of lymph nodes with macrometastases (>0.2 cm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 0. METHOD OF EV /ALUATION OF SENTINAL LYMPH NODES: Hematoxylin and eosin (H&E), one level. Immunohistochemistry. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT2: Tumor >20 mm but less than or equal to 50 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pN0: No regional lymph node metastasis identified histologically. DISTANT METASTASIS (M): Not applicable. ADDITIONAL PATHOLOGIC FINDINGS: Benign breast with calcifications. ESTROGEN RECEPTOR: Performed on this specimen. No immunoreactive tumor cells present. PROGESTERONE RECEPTOR: Performed on this specimen. No immunoreactive tumor cells present. HER2/NEU IMMUNOPEROXIDASE STUDIES: Performed on this specimen. Negative (Score 0). MICROCALCIFICATIONS: Present in non-neoplastic tissue. Specimen Source. A. RT Breast and Axillary Contents. Clinical Information. None. PRE-OP DIAGNOSIS: Right breast CA. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Right modified mastectomy. Gross Description. The specimen is labeled ""RIGHT BREAST AND AXILLARY CONTENTS"" and is received unfixed (the. specimen is in formalin for more than 6 hours and less than 48 hours). It consists of a 420 g right mastectomy. with axillary contents weighing 420 g measuring 18 x 10 x 3.0 cm. The axillary content measures 6.0 x 5.5 x 3.0. cm. The nipple is unremarkable measures 1.3 x 1.3 cm in maximum dimensions. Solar is unremarkable. The left. fascia is smooth and glistening. The anterior margin is inked red and the deep posterior margin is inked black. On sectioning, there is a well-circumscribed lobulated focally hemorrhagic pink-tan mass measuring 2.5 x 2.5 x. 1.5 cm. The mass is close to the deep posterior margin in the outer quadrant close to the axillary contents. The. mass is 0.7 cm from the anterior margin and approximately 12 cm from the nipple. On further sectioning the. breast parenchyma is nodular, there are no other lesions grossly identified. There are four fatty lymph nodes. Temporary Copy. ranging from 0.5-2.0 cm in maximum dimensions. Representative sections are submitted. Section Key: Al - A2 tumor markers with deep margin. A3 tumor. A4 - nipple and skin. A5 - anterior margin close to mass. A6 - upper inner quadrant. A7 - lower inner quadrant. A8 - random sections from central breast. A9 - upper outer quadrant. A10 - lower outer quadrant. All - one lymph node bisected. A12 - one lymph node bisected. A13 - two lymph nodes. Time specimen was removed from the patient (procedure time): Time specimen was placed in formalin: Ischemic time: 1 hour 20 minutes. Special Stains / Slides. IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN RECEPTORS, PROGESTERONE. RECEPTORS, AND HER-2NEU IN INVASIVE MAMMARY CARCINOMA . ESTROGEN RECEPTORS: 0 %, NEGATIVE. PROGESTERONE RECEPTORS: 0 %, NEGATIVE. STAINING INTENSITY: HER-2NEU: SCORE 0, NEGATIVE. Immunohistochemical studies were performed on formalin fixed paraffin embedded tissue (Block A2) using the. following monoclonal antibodies; Estrogen receptor (Clone SP1), Progesterone receptor (Clone 1E2) and. Her-2neu (. Clone 4B5); control sections for HER-2Neu are provided within a kit (score 0 MCF-7, score. 1+ T-47D, score 2+ MDA-MB-453, score 3+ BT-474). Detection system used: polymer. Primary antibodies,. reagents and control sections for HER-2neu are all provided by. All controls show appropriate reactivity. Reactivity of Estrogen and Progesterone receptors is determined based on the percentage of positively. stained nuclei of tumor cells. Reference values (CAP accreditation program checklist 2010 and guidelines on. webpage): Positive: nuclear staining in 1% or greater than 1% of invasive carcinoma cells. Negative : nuclear staining in less than 1% of invasive carcinoma cells. Staining intensity: is reported as weak, moderate or strong. Temporary Copy. HER-2neu reactivity is reported applying the CAP scoring guidelines (CAP accreditation program checklist. 2010 and guidelines on webpage): Score 0 = Negative: No immunoreactivity, or faint weak immunoreactivity in <10% of tumor cells but only a. portion of the membrane is positive.. Score 1 = Negative: Faint weak immunoreactivity in 10% or >10% of tumor cells but only a portion of the. membrane is positive. Score 2+ = Equivocal: Weak to moderate complete membrane immunoreactivity in >10% of tumor cells or. circumferential intense membrane staining in <30% of cells. Score 3+ = Positive: More than 30% of the tumor cells must show circumferential intense and uniform. membrane staining. A homogeneous (chicken wire) pattern should be present. Equivocal results for HER-2neu (Score 2+) will be subsequently followed by a reflex dual-color ISH testing. Additional immunohistochemical studies fpr AE1/AE3 were performed on formalin fixed, paraffin-embedded. tissue (Blocks A11-13) with adequate positive and negative control sections. All stains were negative. The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food. and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical. purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory. Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. Tissue Code.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1mult: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is multifocal, then the T stage is T1mult.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1mult: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is multifocal, then the T stage is T1mult.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",5.0,1137.0,T2,"The report provides a specific tumor size of 2.5 cm, which falls within the T2 range (>20 mm but <=50 mm). The type of surgery performed is a mastectomy, which is a breast surgery other than lumpectomy, wide excision, segmental mastectomy. Therefore, based on the rule '% T2', the T stage is T2.",100.0,True
TCGA-BH-A0C0.53DD68D0-C2BE-4EC2-907E-3F1F11D31052,"FINAL DIAGNOSIS: PART 1: BREAST; LEFT, AT 3 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NOTTINGHAM GRADE 3 (TUBULE FORMATION - 3, NUCLEAR GRADE - 3,. MITOTIC RATE - 3; TOTAL SCORE 9/9). B. INVASIVE TUMOR MEASURES 1.7 CM IN GREATEST DIMENSION (SLIDE 1E). C. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID TYPE, WITH COMEDO NECROSIS AND. CALCIFICATIONS. D. DCIS IS PRESENT ADMIXED WITH INVASIVE COMPONENT AND COMPRISES 40% OF THE TOTAL TUMOR. VOLUME. E. LOBULAR CARCINOMA IN SITU (LCIS) (see comment). F. LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. G. INKED MARGINS OF RESECTION ARE NEGATIVE, INVASIVE TUMOR IS 1MM FROM THE CLOSEST (POSTERIOR). MARGIN (SEE PART 4 FOR ADDITIONAL POSTERIOR MARGIN). H. ATYPICAL LOBULAR HYPERPLASIA (see comment). I. FIBROCYSTIC CHANGES. J. BIOPSY SITE CHANGES. K. BENIGN EPITHELIAL CALCIFICATIONS. L. INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN AND PROGESTERONE RECEPTORS AND WEAKLY. POSITIVE FOR HER2/NEU, AS PER PREVIOUS PATHOLOGY REPORT. PART 2: AXILLARY CONTENTS, LEFT, DISSECTION -. A. ONE OUT OF TWENTY-EIGHT LYMPH NODES POSITIVE FOR CARCINOMA (1/28). B. THE SIZE OF LYMPH NODE METASTASIS IS 1.9 CM. C. BIOPSY SITE CHANGES IN THE POSITIVE LYMPH NODE. PART 3: LEFT AXILLARY LEVEL 3 LYMPH NODE, DISSECTION -. SEVEN LYMPH NODES, NEGATIVE FOR TUMOR (0/7). PART 4: BREAST, LEFT, NEW POSTERIOR MARGIN, EXCISION -. SKELETAL MUSCLE AND FIBROADIPOSE TISSUE, NEGATIVE FOR TUMOR. CAOL JINOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 1.7 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 3. Total Nottingham score: 9. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, benign zones. Yes, malignant zones. TUMOR TYPE, IN SITU: Solid. Comedo. DCIS admixed with invasive carcinoma. LCIS. SURGICAL MARGINS INVOLVED BY INVASIVE Percent of COMPONENT: tumor occupied by in situ component: 40 %. SURG MARGINS INVOLVED BY IN SITU No COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: LYMPH NODES EXAMINED: 1. METHOD(S) OF LYMPH NODE EXAMINATION: 35. SIZE OF NODAL METASTASES: H/E stain. LYMPH NODE METASTASIS(-ES) WITH Diameter EXTRACAPSULAR of largest lymph EXTENSION: node metastasis: 1.9 mm. T NON-NEOPLASTIC BREAST TISSUE: ALH, No FCD. STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pT1c. M STAGE, PATHOLOGIC: pN1a. ESTROGEN RECEPTORS: pMX. PROGESTERONE RECEPTORS: positive. HER2/NEU: positive. 2+.",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1c: If the report provides a specific tumor size within the T1 range (<=20 mm) and evidence of breast surgery other than lumpectomy, wide excision, and the tumor size is between 1.1 and 2.0 cm, then the T stage is T1c.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1c: If the report provides a specific tumor size within the T1 range (<=20 mm) and evidence of breast surgery other than lumpectomy, wide excision, and the tumor size is between 1.1 and 2.0 cm, then the T stage is T1c.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",5.0,1100.0,T1c,"The report provides a specific tumor size of 1.7 cm, which falls within the T1 range (<=20 mm). The type of surgery performed is a segmental mastectomy, which is one of the allowed surgeries for T1 staging. However, the tumor is multifocal, which requires the use of the subclassification 'mult'. The AJCC's TNM Staging System does not have a 'T1mult' category, so we use 'T1' with a subclassification 'c' to indicate the tumor size is between 1.1 and 2.0 cm.",92.0,True
TCGA-EW-A6SD.9FB40DC5-BED9-420E-B334-4D0BE8B8BCF5,"F. Pathologic Interpretation: A. LEFT BREAST LUMPECTOMY: INVASIVE DUCTAL CARCINOMA, poorly differentiated, Nottingham grade 3 (3+3+3=9), 2.1 cm in greatest. dimension. Resection margins are free of tumor; closest is inferior, 0.1 cm. B. LEFT AXILLARY CONTENTS: METASTATIC DUCTAL CARCINOMA to two out of twenty-six lymph nodes (2/26) with extranodal. extension. C. ADDITIONAL LEFT AXILLARY CONTENTS LEVEL 2-3: No malignancy seen in five lymph nodes (0/5). Surgical Pathology Cancer Case Summary. Specimen: Partial breast. Procedure: Excision without wire-guided localization. Lymph Node Sampling: Axillary dissection (partial or complete dissection). Specimen Integrity: Single intact specimen (margins can be evaluated). Specimen Laterality: Left. Tumor Size: Size of Largest Invasive Carcinoma: Greatest dimension of largest focus of invasion over 0.1 cm: 2.1 cm. Additional dimensions: 1.7 x 1.7 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of Tumor: Skin: Skin is not present. Skeletal Muscle: No skeletal muscle present. Ductal Carcinoma in Situ (DCIS): DCIS is present. Architectural Patterns: Solid. Nuclear Grade: Grade III (high). Histologic Type of Invasive Carcinoma: Invasive ductal carcinoma (no special type or not otherwise specified). Histologic Grade: Nottingham Histologic Score: Glandular (Acinar)/Tubular Differentiation. Score 3: < 10% of tumor area forming glandular/tubular structures. Nuclear Pleomorphism. Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and. shape, occasionally with very large and bizarre forms. Mitotic Count. Score 3. Overall Grade. Grade 3. Margins: Margins uninvolved by invasive carcinoma. Distance from closest margin: 1 mm (inferior). Margins uninvolved by DCIS. Lymph Nodes: Number of sentinel lymph nodes examined: 0. Total number of lymph nodes examined (sentinel and nonsentinel): 31. Number of lymph nodes with macrometastases (> 0.2 cm): 2. Largest metastatic deposit: 3.0cm. Extranodal Extension: Present. Method of Evaluation of Sentinel Lymph Nodes: Hematoxylin and eosin (H&E), one level. Pathologic Staging (pTNM): Primary Tumor (pT): pT2: Tumor > 20 mm but 50 mm in greatest dimension. Regional Lymph Nodes (pN): pN1a: Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis greater than 2.0 mm. Distant Metastasis (pM): Not applicable. Ancillary Studies: Estrogen Receptor: Performed on another specimen: Results: Less than 1% immunoreactive cells present. Progesterone Receptor: Performed on another specimen: Results: Less than 1% immunoreactive cells present. HER2/neu Immunoperoxidase Studies: Performed on another specimen: Results: Positive (Score 3+). Clinical History: None Provided. Operation Performed. Left Breast Lumpectomy. Pre Operative Diagnosis: Breast Cancer. Specimen(s) Received/Processing Information: Fee. Codes: A: LEFT BREAST LUMPECTOMY H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E,. Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x. 1. B: LEFT AXILLARY CONTENTS H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E,. Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1, H&E, Initial x 1,. H&E, Initial x 1. C: ADDITIONAL LEFT AXILLARY CONTENTS LEVEL 2-3 H&E, Initial x 1, H&E, Initial x. Gross Description: A. Received in formalin is a yellow tan fibrotic adipose tissue fragment weighing 86 grams and measures 8.0 x. 7.0 x 4.0 cm. The specimen is oriented with a long stitch lateral, short superior and double stitch. Inked as. follows: Superior in Blue - deep black, anterior yellow, inferior green, lateral orange and medial red. Cross. sections of the specimen shows a firm pale tan well circumscribed mass measuring 2.1 x 1.7 x 1.7 cm. It is. within 1 mm from inferior resection margin, all additional margins are uninvolved by tumor. The mass shows. a metallic clip (previous biopsy site). No additional lesions are grossly present. Sections submitted as. follows: Cassette #1-4. Representative section of the mass with relations to the inferior margin (almost in toto). (Cassette #1) -largest dimension of the mass, (Cassette #4) previous biopsy site. Cassette# 5. Superior margin. Cassette# 6. Deep margin. Cassette# 7. Anterior margin. Cassette#8. Lateral margin. Cassette #9. Medial resection margin. B. Received in formalin are multiple yellow tan fibrotic adipose tissue fragments measuring 15.0 x 13.0 x 4.0. cm in aggregate. Twenty-six lymph nodes were grossly identified measuring up to 3.0 x 2.0 cm in greatest. dimension. The two largest lymph nodes show a metastatic tumor. Sections submitted as follows: Cassette #1. Representative section from one large lymph node. Cassette #2. Representative section from the second largest lymph node. Cassettes# 3&4. One lymph node in toto per cassette. Cassettes#5-10. Four lymph nodes in toto per cassette. C. Received in formalin is a yellow tan fibrotic adipose tissue fragment. It measures 10. 0 x 6.0 x 2.0 cm in. aggregate. The five lymph nodes are grossly identified measuring up to 0.4 x 0.3 cm in greatest dimension. Sections submitted as follows: Cassette #1. Two lymph nodes in toto. Cassette# 2. Three lymph nodes in toto.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1c: If the report provides a specific tumor size within the T1 range (<=20 mm) and evidence of breast surgery other than lumpectomy, wide excision, and the tumor size is between 1.1 and 2.0 cm, then the T stage is T1c.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1c: If the report provides a specific tumor size within the T1 range (<=20 mm) and evidence of breast surgery other than lumpectomy, wide excision, and the tumor size is between 1.1 and 2.0 cm, then the T stage is T1c.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",5.0,1100.0,T2,"The report provides a specific tumor size of 2.1 cm, which falls within the T2 range (>20 mm but <=50 mm). The type of surgery performed is a lumpectomy, which is specified in the report. However, since the T stage is already determined to be T2, there is no need to consider the subclassification 'mult' for multifocality. Therefore, the T stage for this patient's cancer is T2.",100.0,True
TCGA-E9-A1R4.AA095896-8217-4BEE-97EC-BC79F5C395BA,"OC ID. Gross Description: Lump with the tumor of 1.2x1.3 cm in size. Fatty tissue lymph nodes demonstrate lipomatosis. Microscopic Description: Infiltrating duct carcinoma; G3. Ten dissected lymph nodes demonstrate focal fibrosis, reactive hyperplasia of the follicles. Diagnosis Details: Tumor Features: Unknown, Tumor Extent: T1 tumor size 2 cm or less, Venous Invasion: Absent, Margins: Absent, Treatment. Effect: Comments: BREAST TISSUE CHECKLIST. Specimen type: Lumpectomy. Specimen size: Not specified. Tumor site: Upper outer quadrant. Tumor size: 1.3 x 0 x 1.2 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Poorly differentiated. Tumor extent: Not specified. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None. Laterality: Left, upper outer quadrant.",0,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1c: If the report provides a specific tumor size within the T1 range (<=20 mm) and evidence of breast surgery other than lumpectomy, wide excision, and the tumor size is between 1.1 and 2.0 cm, then the T stage is T1c.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1c: If the report provides a specific tumor size within the T1 range (<=20 mm) and evidence of breast surgery other than lumpectomy, wide excision, and the tumor size is between 1.1 and 2.0 cm, then the T stage is T1c.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",5.0,1100.0,T1,"The report provides a specific tumor size within the T1 range (1.3 x 0 x 1.2 cm or approximately 1.2 cm) and specifies that the type of surgery performed is a lumpectomy. There is no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy, and the tumor is not multifocal. Therefore, the T stage is T1.",100.0,True
TCGA-BH-A18U.2616F70D-3E15-45BA-8907-65694595F726,"PATIENT HISTORY: The patient is a year-old female. Date of last menstrual period: Not given. PRE OP DIAGNOSIS: Ca left breast. POST OP DIAGNOSIS: Same. PROCEDURE: Sentinel node biopsy, total mastectomy. ADDENDA: Addendum. ESTROGEN/PROGESTERONE AND HER-2/NEU REPORT. Using appropriate positive and negative controls, the test for the presence of these hormone receptor proteins is. performed by the immunoperoxidase method, and reported according to the NIH consensus statement on adjuvant. therapy for breast cancer, of. A positive ER or PR tumor shows any nuclear immunostaining, and is. semiquantitated as indicated below. Semiquantitative Statement. ER positive. Percent cells staining as: (0 20%; 1+ 30%, 2+ 30%, 3+ 20%). PR positive. Percent cells staining as: (0 70%, 1+ 10%, 2+ 10%, 3+ 10%). HER-2/NEU DAKO HERCEPTEST: A STRONG COMPLETE MEMBRANE STAINING IS OBSERVED IN MORE THAN 10% OF. THE TUMOR CELLS. HER-2/NEU IS INTERPRETED AS STRONGLY POSITIVE (SCORE 3+). FINAL DIAGNOSIS: PART 1: LEFT BREAST, TOTAL MASTECTOMY -. A. INFILTRATING DUCT CARCINOMA, TWO LESIONS, 2.6 X 1.7 X 1.5 CM IN THE LOWER OUTER QUADRANT. AND 3.0 x 2.8 X 2.5 CM IN THE UPPER OUTER QUADRANT NOTTINGHAM SCORE 9 OUT OF 9 (TUBULES 3,. NUCLEI 3, MITOSIS 3). B. LYMPHOVASCULAR INVASION IDENTIFIED. C. DUCTAL CARCINOMA IN-SITU, SOLID TYPE, NUCLEAR GRADE 3 WITH COMEDO-TYPE NECROSIS,. COMPRISING LESS THAN 5% OF TUMOR. D. SURGICAL MARGINS NEGATIVE FOR INFILTRATING DUCT CARCINOMA AND DUCTAL CARCINOMA IN-. SITU. E. INFILTRATING DUCT CARCINOMA FOCALLY APPROACHES VERY CLOSELY MARGIN OF EXCISION IN. THE LOWER OUTER QUADRANT (WITHIN 0.2 CM). F. NIPPLE NEGATIVE FOR TUMOR. G. CHANGES CONSISTENT WITH PREVIOUS CORE BIOPSY SITE. H. TWO LYMPH NODES, POSITIVE FOR METASTATIC CARCINOMA (2 OUT OF 2). PART 2: LEFT BREAST, NEW ANTERIOR-INFERIOR MARGIN, EXCISION -. SKIN AND SUBCUTANEOUS TISSUE, NEGATIVE FOR TUMOR. PART 3: LEFT SENTINEL LYMPH NODE #1, BIOPSY -. ONE LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (1 OUT OF 1). PART 4: LEFT SENTINEL LYMPH NODE #2, BIOPSY -. ONE LYMPH NODE NEGATIVE FOR METASTATIC CARCINOMA (0 OUT OF 1). PART 5: LEFT SENTINEL LYMPH NODE #3, BIOPSY -. ONE LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (1 OUT OF 1). PART 6: LEFT AXILLARY CONTENTS, EXCISION -. FIVE OF ELEVEN LYMPH NODES POSITIVE FOR METASTATIC CARCINOMA, THREE WITH EXTRACAPSULAR. EXTENSION. PART 7: RIGHT BREAST TISSUE, EXCISION (396 GRAMS) -. A. FOCAL ATYPICAL DUCTAL HYPERPLASIA ASSOCIATED WITH MICROCALCIFICATIONS. B. CALCIFIED FIBROADENOMA. C. FIBROCYSTIC CHANGES WITH MICROCALCIFICATIONS. D. SCLEROSING ADENOSIS. E. SCLEROSING INTRADUCTAL PAPILLOMA. F. UNREMARKABLE SKIN. COMMENT: Estrogen receptor, progesterone receptor and HER-2/neu immunostains will be ordered and subsequently reported in an. addendum. Immunostaining for e-cadherin and myosin heavy chain confirm the interpretation of changes in the right. breast tissue.",1,True,"% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1c: If the report provides a specific tumor size within the T1 range (<=20 mm) and evidence of breast surgery other than lumpectomy, wide excision, and the tumor size is between 1.1 and 2.0 cm, then the T stage is T1c.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.","% T1: If the report provides a specific tumor size within the T1 range (<=20 mm) and no evidence of breast surgery other than lumpectomy, wide excision, segmental mastectomy, and the tumor is not multifocal, then the T stage is T1.
% T1c: If the report provides a specific tumor size within the T1 range (<=20 mm) and evidence of breast surgery other than lumpectomy, wide excision, and the tumor size is between 1.1 and 2.0 cm, then the T stage is T1c.
% T2: If the report mentions a breast surgery other than lumpectomy, wide excision, segmental mastectomy, or radical mastectomy or if the type of surgery is not specified and provides a specific tumor size within the T2 range (>20 mm but <=50 mm), then the T stage is T2. If the tumor is multifocal, use the subclassification 'mult' to indicate the multifocality.
% T3: If the report mentions a mastectomy or a radical mastectomy and provides a specific tumor size >50 mm, then the T stage is T3.
% T4: If the report provides evidence of invasion of the chest wall or skin, then the T stage is T4, regardless of tumor size.",5.0,1077.0,T2,"The report mentions a total mastectomy and provides a specific tumor size of 2.6 x 1.7 x 1.5 cm and 3.0 x 2.8 x 2.5 cm, both of which fall within the T2 range (>20 mm but <=50 mm). Therefore, the T stage is T2.",99.0,True
